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In Type-2 diabetes, the classic biguanide and sulphonylurea drugs remain first line treatments for 
alleviating chronic insulin resistance and hyperglycaemia. However, newly emerging DPP-4 enzyme 
inhibitors or long acting hormone-based therapeutics provide second line alternatives. The discovery 
of novel peptide therapeutics for the treatment of diabetes and obesity offers simultaneously 
targeting of multiple molecular pathways. Peptide-based therapies provide highly specific 
mechanisms for controlling multiple aspects of glucose dysregulation including improving post-
prandial glycaemia, satiety and gastric emptying.  Dietary proteins must first be hydrolysed to unlock 
their bioactive peptide components.  Investigating the oral efficacy of marine protein hydrolysates 
was a key aim of this research. Initial screening, using BRIN-BD11, GLUTag and STC-1 cell lines, enabled 
bioactivities to be identified from a variety of biological protein sources.  Generally, hydrolysates 
generated using multiple proteolytic enzymes, provided a more effective strategy for enhancing 
insulin, GLP-1 and GIP secretion from cultured cells.   The bioactivity blue whiting, boarfish, salmon 
and Palmaria palmata derived peptides varied significantly, interestingly, even when identical enzyme 
hydrolysis methods were used. Hydrolysates administered orally at 50-150 mg/kg/bw led to an 
improvement in post-prandial glycaemia and insulinotropic responses in normal mice, but 
unfortunately in some instances were less effective at reducing food intake and promoting satiety. 
Long-term oral administration of Palmaria palmata, boarfish and salmon skin hydrolysates resulted in 
improved non-fasting glucose, plasma lipids and terminal glycated haemoglobin in ob/ob or 
Streptozotocin diabetes induced mouse models. Finally, within a double blind placebo controlled 
crossover trial, glucose tolerance in healthy individuals had resulted in no improvement in post-
prandial glucose excursion using 3.5g of boarfish protein hydrolysate, of which had previously shown 
the most promising in vitro and in vivo results. Future study will need to assess the quantity of protein 
hydrolysate required for humans aiming to present the same positive effects seen within the cell and 
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Background & Aims  
Marine protein, hydrolysates and derived small molecular weight peptides, have in recent 
times been investigated for their pleotropic effects upon multiple therapeutic areas. This 
chapter aims to highlight current literature, legislative and therapeutic outcomes. To date, 
the key message for protein intake are still convoluted in regards to recommended intakes 
for health promotion or disease prevention, however with this noted, researchers globally 
are continuing to report anti-cancer, anti-obesogenic or glucoregulatory effects of novel 
proteins and their subquent peptide hydrolysates using well-established models of 
investigation. The role which proteins are involved in above nutrition and metabolism, is still 
a topic of debate due to the unknowns surrounding the effect of liberated peptides after oral 
ingestion. For this reason, this chapter investigates pre-digested proteins or peptides idenfied 
after hydrolysis, and their effect on health.   
1  Introduction 
 
The identification of bioactive compounds has, in more recent times, shifted from terrestrial 
environments to rivers, coasts and oceanic depths. The earth, while covered by 70% oceans 
supports merely 15% of all living organism (Grosberg et al, 2012).   Diverse marine biological 
organisms have adapted, responded to aggressive climate change and thrived in 
environments foreign to terrestrial organisms. The ability to adapt rapidly to temperature, 
salinity, biological and chemical changes has pioneered the search for unique molecular 
compounds contained within living marine organisms.  The oceans are considered one of the 
most abundant sources of bioactives (Lordon et al, 2012) with current environmental efforts 
set in place to increase oceanic sustainability, diminish industrial pollution and promote a 
return of the diverse pelagic fish stock and dwindling coral reefs (Pauly et al, 2005). With this 
being noted, the exploitation of marine organisms for bioactive molecules is underway and 
the race for identifying the next notable biologically active and therapeutic compounds taking 
lead.  
The current costs associated with marine exploration the investigation of bioactive marine  
molecules  requires rigorous characterisation and considerable effort. Unfortunately, in most 
cases the true potential of bioactive compounds are unknown (Nasri et al, 2014). Never-the-
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less this does not hinder the current global approach to discovering bioactive molecules and 
their specific application. Tailored approaches using modern problematic healthcare areas 
such as infection and immunity (Cheung et al, 2015) diabetes and obesity (Lauritano & Ianora, 
2016), neurology (Grosso et al, 2014), cancer and tumorigenesis (Xing, et al, 2017; Suarez-
Jimenez et al, 2012) and cardiovascular disease (Pangestuti & Kim, 2017) are rapidly growing. 
Marine life is vast with molecules of which many are yet to be fully understood. The global 
market for nutraceuticals has increased year on year with annual revenues of US$ 200 billion. 
Current production of nutraceuticals relies heavily on extraction from source followed by 
identification and purification of the compound and ultimately screening of its bioactivity. 
Unfortunately research compounds identified begin with a low cost-per-tonne ratio, 
however, improving a compounds bioactivity can significantly increase market value 
(Cudennec et al, 2012; Martins et al, 2014). Recently. molecules of low cost and in current 
high demand are polysaccharides, polyunsaturated fatty acids (PUFAs),, proteins, enzymes, 
minerals and vitamins, with this noted, large scale removal of protein based compounds 
carries increased cost association versus some of the more traditional extraction 
methods(Grosso et al, 2015).  
Assessment of bioactivity is firstly screened at lab scale, this is noted with marine 
polysaccharides, fatty acids, protein and subsequent hydrolysis to yield smaller novel 
research molecules. Bioactive peptides are of particular interest and contained within larger 
protein molecules and as such need liberated to exert biological activity. Protein extracts are 
initially extracted using acidic or alkaline techniques (Tsugita & Scheffler, 1982), followed by 
further sequential hydrolysis generation via a controllable and adjustable addition of 
proteolytic enzymes (Polanco-Lugo et al, 2014; Martínez-Maqueda, et al, 2013). Peptide-
based nutraceutical or drug design is a specialised endeavour aimed as serving as potent 
pharmacophores. Natural peptide approaches are favoured due to specificity and high 
tolerance profiles (Fosgerau & Hoffmann, 2015). Peptide based therapy approaches is a 
diverse venture with peptides serving as multifunctional signalling molecules or conversely 
very specific cell binding molecules of which can be cell or receptor specific targeting 
molecules, as such promising cell penetrating, uptake and apoptotic properties have been 
reported using in vitro approaches (Boohaker et al, 2012). The oral delivery of nitrogen 
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containing molecules has its limitations, including rapid degradation via endogenous 
intestinal and pancreatic proteolytic hormones.  
Both terrestrial and oceanic environments provide a variety of peptides that are 
expressed in most living species. This has created evolutionary optimised response of 
peptides to bind to cellular receptors with agonistic or antagonistic mechanisms. However, 
the hydrolysis of protein can generate an abundance of less common or completely 
uncharacterised peptides of which signalling mechanisms are to be established (Harnedy et 
al, 2015). Naturally occurring proteins and peptides consist of amino acids typically in their L- 
isoform configuration. Studies involving naturally occurring  peptides with D-amino acids have 
reported resistance to endogenous degradation (Bai et al, 2009).  
Using several proteolytic enzymes may improve sequential hydrolysis outcome. 
Hydrolysis of marine protein using aqueous solution coupled with proteases solution can yield 
a magnitude of small molecular weight peptides (SMWPs). The overall degree of hydrolysis of 
intact protein has several outcomes, a broad pool of fragmented peptides dependent on 
hydrolysis time followed by separation based on fragment size (Hong et al, 2012), mass 
(Gundry et al, 2010), charge (Burgi & Smith, 2001) or  the most commonly used method of 
hydrophobicity separation (Conlon, 2007). This novel approach to generating bioactive 
compounds from marine proteins and their application focused towards current therapeutic 
potential will be the focus of this review.  
 
1.2 Sources of marine protein 
 
With population growth, reduction of arable farming land and fresh water shortages, 
macronutrient sources are becoming ever challenging. There is a global race to provide 
sustainable high quality protein sources. Sustainability efforts and reduction or re-use of 
marine waste has opened a new revenue stream for fisheries (Senevirathne & Kim, 2012). 
Fresh approaches has pioneered government backed research to tackle this area and identify 




Hauls of unwanted ichthyoid species are now landed and stored long-term. This gives 
fisheries the opportunity to wholesale larger quantities of non-marketplace fish that yield 
high quality protein among other constituents. Fish waste, processing by-products or non-
marketable species are often used as fertilizer as well as domestic and livestock animal feed.  
The extraction of potentially upgradable functional food components has recently shifted that 
outlook (Cudennec et al, 2012). Successfully harvesting marine protein rely firstly on 
availability of natural resources of which coastal areas are affected by potentially faltering 
weather conditions and seasonality. Long-term economical and exploitable sources of 
macroalga are being developed with coastal expansion and sustainable livelihoods in mind 
(Rebours et al, 2014). Coastal areas are now one of the most exploitable areas of marine 
harvesting. 
Macroalga production worldwide has a revenue stream estimated to exceed US$ 10 
billion. Seaweeds are consumed by coastal communities across the globe daily and serves as 
a habitual addition to many diets. The demand for seaweed is increasing, especially for 
seaweed protein for ingredients (Černá, 2011).  Asian countries dominate macroalga 
harvesting and production with 80% consumed for nutrition with remaining sold for animal 
feed, fertilizers, pharmaceutical and biotechnological applications. There are over 250 species 
of seaweed worldwide, 150 currently classed as edible and many yet to be fully characterised. 
The nitrogen and protein content has become the focus of applied research for seaweed in 
more recent times (Harnedy et al, 2014). Protein content of seaweed varies between species 
with brown (Phaeophyceae) seaweed having the lowest mean protein content of 
approximately 10% (DW) with red (Rhodophyta) and green (chlorophyta) seaweed  averaging 
13% and 15% total protein (DW), respectively (Černá, 2011). The harvesting period marine of 
macroalga plays an important role in total protein content with protein levels at their highest 
in May and subsequently decline over the summer months (Galland-Irmouli et al, 1999). The 
explanation for lower protein content in the warmer months is factored on decreased water 
nitrogen content accompanied by nitrogen assimilation and energy consumption for growth 
in warmer climates (Kumar et al, 2014). Palmaria palmata (Dulse) a red seaweed native to 
northern coast of the Atlantic and Pacific oceans remarkably reported to contain as high as 
30-45% protein (Galland-Irmouli et al, 1999). Other emerging sources of biomining and 
protein extraction are that of marine fungi and bacteria, shellfish, crustaceans, and a relatively 
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new area utilizing fish industry processing discards and fish waste water. These sources are 
now of considerable importance and potential sources of biologically active compounds and 
source of nutrition.  
 
1.3 Marine protein hydrolysates as potential therapeutics for type 2 diabetes 
Diabetes mellitus is a chronic degenerative disease with high rates of complications 
that are now impacting all areas of specialised healthcare, and as such carries a high morbidity 
and mortality rate (ADA, 2010). Type 2 diabetes mellitus (T2DM) is characterised by 
hyperglycaemia, abnormal insulin levels, lack of insulin secretion and functioning and 
eventually pancreatic beta-cell failure if uncontrolled (Kahn, 1994). Disease aetiology closely 
shadows lifestyle factors such as, excessive nutritional intake and lack of physical activity. In 
obese individuals there is a marked increase in hypertension, cardiovascular disease, non-
alcoholic fatty liver disease (NAFLD), and dyslipidaemia and increase risk of certain cancers. 
Initial treatment methods are being rapidly surpassed for alternative options; however, the 
consensus remains, majority of cases can be completely evaded by the adoption of a healthier 
lifestyle (Chong et al, 2017).  
Chronic hyperglycaemia favours intensive pharmacological treatment approaches. As 
such the use of metformin (Glucophage), a hepatic glucose liberation inhibitor is being 
combined with more exotic oral glucose lowering agents or injectable degradation resistant 
peptide molecules (Marshall, 2017). Oral hypoglycaemic agents such as the family of gliptins 
(sitagliptin, vildaglipin, saxagliptin et al), inhibit the activity of an endogenous enzyme 
dipeptidyl peptidase IV (DPP4) by binding rendering the enzyme redundant (Scheen, 2010). 
Endogenous DPP4, a type II transmembrane glycoprotein cleaves highly active and potent 
postprandial incretin peptide hormones that play vital roles in insulin secretion, specifically 
glucagon like peptide 1 (GLP-1) and glucose-dependant insulinotropic polypeptide (GIP) 
(Matteucci & Giampietro, 2009). Sustained or Increase activity of the incretin hormones have 
glucoregulatory activity including decreased gastric emptying, increased glucose dependant 
insulin secretion, lower glucagon production and increase β-cell proliferation with decrease 
apoptosis (Holst et al, 2009). As such pharmaceutical companies have identified a need for 
longer acting, degradation resistant molecules that act upon endogenous hormone pathways.  
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An indentified peptide molecule from a Gila monster (Heloderma suspectum) venom is 
pharmaceutically available under the name exendin-4 (Byetta) and used in the treatment of 
hyperglycaemia in patients with type 2 diabetes (DeFronzo et al, 2005). The peptide agonist 
binds to the glucagon-like-peptide 1 receptor (GLP-1r) and facilitates the secretion of insulin 
from the pancreatic β-cells, while sharing only 50% similarity in amino acid sequence and 
presents double the half-life over the native GLP-1 hormone. This has promoted researchers 
to further investigate the proteomic approach of improving debilitating conditions such as 
type 2 diabetes (López-Villar et al, 2015). Pharmaceutical approaches to treating disease 
states have the added drawback of accompanied side effects, in particular the cardiovascular 
issues that currently surround the use of DPP4 inhibitors (Sheen, 2013). It is postulated that 
oral bioactives and nutraceuticals carry fewer risks via improved tolerance (McCarty, 2005).   
Anti-diabetic molecule screening approaches of protein hydrolysates have shifted 
from large polypeptides to much shorter peptide chain length (Xia et al, 2017).  Recent 
approaches using marine protein hydrolysates displayed markedly reduced fasting glucose 
concentration using chum salmon (Oncorhynchus kern) in a rat model of type 2 diabetes (Zhu 
et al, 2010). Among the proposed mechanisms for reported antidiabetic potential lays the 
ability of protein hydrolysates to inhibit promoters of T2DM which may lead to disease 
progression. Biopeptides derived from marine hydrolysates have been recently investigated 
for their DPP4 inhibitory activity (Huang et al, 2012; Wang et al, 2015). Extraction of small 
molecular weight peptides from Palmaria palmata protein hydrolysate displayed in vitro 
DPP4 enzyme inhibition (IC50)  at 43.4 (ILAP), 53.67 (LLAP) and 159.37 (MAGVDHI) umol/L 
respectively (Harnedy et al, 2015). A recent study investigating parameters of circulating 
glucose dysregulation in db/db rats reported an improvement in excretion products such as 
glucose and urea content in urine within a group given oral polypeptides from sea cucumber 
(Li et al, 2017). Glucose and lipid regulatory activity was seen in a group of 100 diabetic 
cohorts after treatment with marine collagen peptides (Zhu et al, 2010). Daily oral 
administration resulted in significantly lower fasting blood glucose levels, reduction in 
glycated haemoglobin (HbA1c), fasting blood insulin, improved lipid parameters, notably 
reduced cholesterol, triglycerides and elevated high density lipoprotein (HDL) following 
treatment for 1.5 or 3 months versus control group, respectively.  
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Bioactivity and mechanism of action is one of the more challenging aspects of 
molecule discovery. Oligopeptides from marine salmon skin (OMSS) administered daily (4 
g/kg/d) to diabetic rats for 4 weeks resulted in significantly reduced fasting blood glucose, 
lower circulating serum levels of TNFα and IFNγ and diabetes oxidative stress marker 
malondialdehyde (MDA). Furthermore, resulting antioxidant enzymes measured, specifically 
SOD and GSH were increased (Zhu et al, 2010). The improvement in diabetes status in vivo 
often involves the measurement of oxidative stress markers, weather this is a direct or 
indirect effect of disease status or marine protein hydrolysates ingestion is yet to be 
established. Marine collagen peptides (MCP) administered to a rodent model of type 2 
diabetes reported that 9 g/kg/day significantly improved glucose, insulin and insulin 
sensitivity and subsequently improved the insulin sensitivity index comparative to control, 
respectively. Lower doses of MCP, 4.5 and 2.25 g/kg/d significantly improved liver steatosis 
(Zhu et al, 2017). A similar dose of >4.5 g/kg/d of MCP given to rats partially ameliorated β-
cell apoptosis and apoptosis markers versus a glucotoxic solution alone when studied ex-vivo 
(Zhu et al, 2017). The results demonstrated here have displayed the potential dietary addition 
of marine protein hydrolysates to partially alleviate the negative outcomes of glucoregulatory 
issues using in vitro, in vivo and human models of disease study. Implementing bioactive 
marine peptides as well as the classical and pharmaceutical approaches for the treatment of 
type 2 diabetes may have additive benefits in reducing complications associated with the 
disease.  
 
1.4 Anti-cancer effects of marine protein hydrolysates 
The impact of dietary choices and nutritional status are the most important 
determinants of chronic disease controlling for genetic predisposition. The anticancer and 
cancer preventative potential of marine bioactives has been a focus of great interest over the 
past several decades and as such has focuses on their antiproliferative, antioxidant and 
antimicrotubule actions (Suarez-Jimenez et al, 2012). Countries that habitually incorporate 
marine nutrition into their diet have reported positive health outcomes. Asian countries with 
high intake of seafood have incidence rates lowering in particular cancers, such as breast, 
prostate, lung and colorectal compared to North America and Europe (Key et al, 2004).  
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Identifying the observed trend associated with nutritional intake of seafood and the 
decrease cancer rates has led to extensive research aimed at identifying the beneficial 
compounds present within. Interestingly some local delicacies are also used as ingredients in 
folk medicine in certain areas of Asia (Sho, 2001). Previously interest in consumption patterns 
of fish and fish products, particularly cod and cod liver oil, Eel, of which is a staple of many 
Asian diets and bivalves such as mussels, oysters and clams. Fish consumption is associated 
with health benefits with more recent approaches highlighting the anticancer effect of marine 
protein, hydrolysates and peptides (Suarez-Jimenez et al, 2012). Fish oils, fish meal and 
domestic and livestock applications are shifting attention now towards identification of 
bioactives from marine sources such as fish scales, muscle and organ protein of which as a 
marine product, is only beginning to be appreciated as effective therapeutics (Haefner, 2003). 
Investigations of marine protein hydrolysates and anticancer activity are however, currently 
scarce. Studies involve the use of cancer cell lines and report growth performance or 
antiproliferative activity when incubated with fish protein hydrolysates. There is however a 
major limitation, tracking the direct effect of marine bioactives, either protein hydrolysates 
or biopeptides and their therapeautic effect in humans is a difficult endeavour and currently 
relies heavily on self-reported retrospective data of which tracks prevalence rather than 
causation and prevention (Schüz et al, 2013).  However, as such the use of human cancer cell 
lines and small rodent cancer studies may give insight into the anticancer or therapeutic 
benefits of marine bioactives.  
A study investigating 18 enzymatically digested hydrolysates from various species of 
fish had a spread of peptides from di- to tripeptides to polypeptides of 7 kDa in mass. 
Incubation with several FPH, specifically blue whiting, which contained 96% peptide content 
resulted in up to 30% reduction in cellular proliferation in MDA-MD-231 cancer cells and up 
to 26% proliferation inhibition in MCF-7 human breast cancer cells (Picot et al, 2006). Similar 
reduction was seen when incubated with cod, plaice and salmon protein hydrolysates. The 
observation was concluded that direct cytotoxicity was present when specific peptides were 
exerting an anticancer effect on the cell lines. The mechanism of anti-cancer investigation 
using ultrafiltrated roe hydrolysates (URH) extracted from giant grouper (Epinephelus 
lanceolatus) promoted a dose-response reduced cell viability of two oral cancer cell lines 
using an ATP based activity assay in Ca9-22 and CAL 27 cell lines, respectively (Yang et al, 
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2016). The cellular proliferation reduction and promotion of apoptosis using flow cytometry 
to determine apoptotic changes reported sub G1 accumulation of cells. The apoptotic effect 
was deemed to arise from induced oxidative stress in Ca9-22 cells when incubated with 
ultrafiltrated roe hydrolysates. The bioactivity of marine protein hydrolysates to inhibit 
cellular cancer proliferation or undergo controlled cell death has been noted, the ability of 
MPH to inhibit the metastatic potential of a malignant mesenchymal tumour was described 
using seahorse-derived (Hippocampus kuda) peptides (SP) with a similar amino acid sequence 
of α-enolase, a glycolytic enzyme expressed in most tissues. Using fibrosarcoma cells 
(HT1080) the seahorse peptide decreased interaction of α-enolase and plasminogen, both 
promoters of matastasic potential of cancer cells. The investigation took place by mixing the 
SP, α-enolase and plasminogen together prior to incubation with the HT1080 cell line. The 
decrease in cellular invasion migration over 48 h using the matrigel invasion assay and HT1080 
cells was due to the decreased interaction of α-enolase and plasminogen. Since plasminogen 
and α-enolase interaction are involved in plasminogen activation factors, this signalling was 
inhibited by the use of sea horse-derived peptides (Kim et al, 2014). The anti-cancer activity 
of marine protein hydrolysates and marine bioactive peptides have relied heavily on their 
antioxidant capacity of which is a widely reported trait of small molecular weight peptides 
(Sheih et al, 2009) / (Kumar et al, 2012). Purified cyclic peptides from marine sponges have 
been reported antioxidant and cytotoxic activity on several human cancer cell lines such as 
MCF-7, HeLa, and HepG2 (Zhan et al, 2014). However the anti-cancer activity of orally 
ingested marine protein hydrolysate is more or less unknown with long term intake of marine 
bioactives from intact sources favoured over extracted bioactives. This leaves the true 
potential of bioactive marine peptides and long-term intake and efficacy an increasingly 
difficult outcome to measure.  
 
1.5 Anti-oxidant activity of marine protein hydrolysates 
Many human physiological complications have been related with considerable 
evidence to that of oxidative stress (Uttara et al, 2009)/(Hybertson et al, 2011). As the body’s 
natural anti-oxidant state is overwhelmed this allows an oxidative state to arise. The body is 
constantly fighting to maintain oxidative equilibrium, However, several disease states can 
alter this homeostasis. The oxygen we breathe has undoubtedly obvious benefits to human 
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physiology however it similarly carries potentially damaging side effects for biological 
systems. An evolutionary system in in place to instinctively adapt to a rise in oxidative stress 
and successful attempts are made in counterbalancing this effect (Sies, 1997). Initial minor 
disturbances in oxidative stress may not have any metabolic consequences due to 
homeostatic adaptations, however chronically elevated oxidative state may lead to 
irreparable damage and eventual cell death. This damage arises from reactive oxygen species 
in two major forms, free radicals and their non-radical substrates. Free radicals are molecules 
defined as having one or more unpaired electron and incomplete outer shell that confers their 
highly reactive biological state (Pham-Huy et al, 2008). Biological states that are imperative 
or important to life inadvertently generate reactive oxygen species, such as leakages in the 
electron transport chain, cytochrome P450 and NADPH oxidase. Other sources of oxidative 
stress are drug abuse, toxins and smoking.   
Dietary antioxidants such as ascorbic acid in the form of vitamin C or vitamin E, in the 
form of γ-tocopherol, are extremely potent reactive oxygen species quenchers, and as such 
have imperative dietary roles in reducing oxidative stress (Lobo et al, 2010). Target 
mechanisms of antioxidants are to mop up the molecules of high reactivity by donating an 
electron to reduce reactivity or binding irreversibly to inhibit duration of activity. The 
collective term for superoxide anion radical (O2·–), hydroxyl radical (·OH), singlet oxygen (1O2) 
and perhydroxyl radical (HO2·) is that of reactive oxygen species, and as such are a current 
research target for molecules that can inhibit their damaging capacity or reduce the 
subsequent damage to macromolecules such as lipids, protein and carbohydrates. This 
elevated oxidative state can also result in DNA-protein cross links, double stand breaks, base 
damage, and protein fragmentation (Ray et al, 2012). The first line of innate defence against 
RoS is conversion of the more potent molecules to ones of lesser damaging effect. This is seen 
via the enzyme driven interaction with superoxide (O2·–) with superoxide dismutase (SOD) 
which yields H2O2 a lesser reactive molecule of which on its own cannot damage 
macromolecules. The molecule can however cross cellular membranes and produce the 
highly reactive hydroxyl radical (·OH). On a nutritional level, oxidation causes many problems 
for the food industry particularly reduction in shelf life, loss of wanted sensory characteristics 
and promotion of unwanted as well as production of toxic compounds of which are dangerous 
for health and the consumer. The food industry has an arsenal of synthetic antioxidants which 
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are widely used to inhibit the retardation of foodstuffs and reduce lipid oxidation which yield 
rancid smells (Augustyniak et al, 2010). As such there has been a global interest in gathering 
information on natural antioxidants that may be used in favour over synthetic antioxidants 
which may also present potential to improve health and improve the food we eat.  
Marine research has no shortages of antioxidant compounds that have exploded the 
area of marine protein hydrolysate research and identified peptide compounds (Sheih et al, 
2009)/(Kumar et al, 2012)/(Kang et al, 2012). Low molecular weight proteins that have 
undergone enzymatic hydrolysis to yield peptides and glycoproteins obtained from marine 
sources have been screened for their antioxidant effect, this is now considered an attractive 
way of liberating bioactive molecules without impairing their nutritional value. A study using 
ultrafiltration methods to combine peptides generated from scalloped hammerhead cartilage 
hydrolysate (SHCH) after various methods of proteolytic degradation concluded that protein 
hydrolysates with lower molecular weight showed higher hydroxyl radical (·OH) scavenging 
activity in vitro (Li et al, 2017). As hydrolysate concentration increased subsequent 
antioxidant activity showed linear correlation. Further daily assessment over 7 days had 
shown a dose-dependent decrease in lipid peroxidation with one SHCH fraction showing 
similar antioxidant activity to the synthetic antioxidant Butylated hydroxytoluene (BHT). A 
similar approach was seen in the purification of antioxidant peptides from salmon by-
products and muscle proteins that were subjected to proteolytic degradation using bacterial 
extracellular proteases from Pseudoalteromonas sp. rather than conventional mass 
production proteases (Wu et al, 2017). Bacterial extracellular proteases were cultured in vitro 
and activity assessed at laboratory scale prior to the protein catabolism and subsequent 
generation of various salmon protein hydrolysate for screening. Results showed that 
antioxidant activity was greater from salmon by-product than that of salmon collagen 
hydrolysates generated. Comparing antioxidant peptide sourced from marine muscle protein 
displayed an antioxidant activity (DPPH) IC50 value of 0.51 mg/ml when hydrolysate was 
generated using cultured bacterial extracellular proteases mentioned versus gastrointestinal 
proteases (0.60 mg/ml), neutral serine protease (0.60 mg/ml), trypsin (1.40 mg/ml), pepsin 
and alcalase combination (1.35 mg/ml) and papain (3.06 mg/ml), respectively. The study 
demonstrated that antioxidant activity may be limited by the hydrolysate process and which 
enzyme involved but also the choice of starting raw protein material plays an intrinsic role in 
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antioxidant outcome. Protein hydrolysates and identified peptides from Croceine Croaker 
(Pseudosciaena crocea) were investigated for their antioxidant capacity (Zhao et al, 2016). 
Hydrolysates were generated using alcalase, papain, pepsin and trypsin, respectively. An 
identified hydrolysate fraction was used in several scavenging activity assays and DNA 
damage protective effect assessed. Furthermore the anti-fatigue effect was assessed in 
prolonged exhaustive swimming time in mice. Results concluded that while the identified 
protein fraction with bioactivity in scavenging assays was positive in reducing reactive 
oxidative species activity, particularly as concentration of hydrolysate increased, the study 
highlight was improved protective activity against free radical induced DNA damage and 
improvement in exhaustive swimming time relating to an anti-fatigue effect of marine protein 
hydrolysates extracted and fractioned from Croceine Croaker swim bladder.  
Similar exhaustive swimming duration and anti-fatigue effect was assessed using 
Wistar rats (Huang et al, 2015). Rats were separated into groups (n=10) and assigned either 
dH20 only, dH20 and glutathione or dH20 and different concentrations of Hairtail protein 
hydrolysate (HPH) ranging from 50 to 200 mg/kg bodyweight with or without Fe chelate. 
Assigned treatments were administered orally via gavage for 20 days, prior to 
experimentation assigned treatment was given 1 hour before. Results displayed that rats 
given HPH alone or Fe chelate alone did not perform as well as animals given HPH/Fe 
together. An increase of 60% in exhaustive swimming time was pronounced in HPH/Fe 
(200/12 kg/bw/day) versus negative control (dH20) and 20% increase versus positive control 
group (glutathione (100 mg/kg·bw)), respectively. Furthermore, enhancement of GSH-Px 
activity and significantly lower blood lactic acid were evident in HPH/Fe group versus negative 
control group (dH2O). The study failed to identify the bioactive component producing the 
anti-fatigue effect however future sports related performance enhancing through 
supplementation is reasonable. Many studies have reported the intake of dietary antioxidants 
to alleviate unwanted side effects from cancer therapy. Common side effects include 
anaemia, appetite loss and fatigue to name a few. Research surrounding alternative remedies 
to tackle cancer treatment effects have investigated polyunsaturated fatty acids, intact dairy 
protein, vitamins and minerals. The beneficial effect of marine protein hydrolysate intake 




1.6 Anti-hypertensive activity of marine protein hydrolysates 
A currently active area of marine protein hydrolysate research is that of angiotensin 
converting enzyme inhibition and anti-hypertensive activity and as such will be discussed 
(Harnedy and Fitzgerald, 2013). The aetiology of blood pressure dysregulation and 
subsequent hypertension is believed to play a vital role in other disease states, including 
cardiovascular, heart and kidney disease (Hermansen, 2013). The renal angiotensin system 
regulates blood pressure changes with several pharmaceutical targets identified for issues 
surrounding abnormal or chronically elevated blood pressure.  Inhibition of the enzyme 
angiotensin-I-converting enzyme (ACE) has positive effects on reducing overall hypertension 
(Antonaccio, 1982). ACE functions by controlling and regulating the blood pressure and 
volumes of fluid within the body.   
Angiotensinogen produced by the liver undergoes an enzymatic driven reaction that 
has subsequent effect on blood pressure. The body attempts to maintain homeostatic blood 
pressure, however increased activity of ACE increases sympathetic activity, increased 
reabsorption of Na+ and Cl- with excretion of K+, arteriolar vasoconstriction, H2O retention 
and subsequent elevation of blood pressure. This system undergoes acute changes and is 
counterbalanced with kidney negative feedback signals to promote excretion fluid. 
Antihypertensive drugs such as captopril and enalapril are potent ACE inhibitors currently 
available used in the treatment of hypertension and severe chronic heart failure (Packer et al, 
1986). These work by inhibiting the conversion of angiotensin-I to angiotensin-II a 
vasoconstrictor and regulator of arterial blood pressure. The inhibition mechanism lies in the 
retardation or inhibition of the pepidyl-dipeptidase A, of which drives the angiotensin-I 
conversion. For over a decade now studies have identified foods that reduce hypertension in 
humans.  
Particular interest has been generated for peptides derived from food proteins. 
Seaweed is a staple of Asian cuisine with intake associated with lower rates of hypertension 
(Wada et al, 2011). A study using 17 different kinds of proteases to genrate ACE inhibitory 
hydrolysates from Wakame (Undaria pinnatifida) was assessed (Sato et al, 2002). Detecting 
hippuric acid liberated from Hip-His-Leu by ACE had a broad spectrum of inhibitory activity 
dependant on protease used in the protein hydrolysis process. Identified ACE inhibitors were 
then investigated in vivo using spontaneously hypertensive rats (SPR). Animals were grouped 
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and assigned a product which were comparative to control rats  received dH2O only. Only rats 
of which displayed >200 systolic blood pressure were used. Wakame protein hydrolysates 
were administered (10 - 100 mg/kg bodyweight) and subsequent SBP was measured before 
and up to 6 hours after oral administration of hydrolysates. Captopril (5 mg/kg bodyweight) 
was used as a positive control. Activity was again determined by proteolytic method 
deployed, however all hydrolysates had a somewhat positive effect on acute blood pressure 
lowering. SPH rats displayed markedly elevated systolic blood pressure after a few weeks 
after birth. Dietary addition of 0.1 and 1% wakame hydrolysate was able to significantly 
reduce systolic blood pressure versus standard rodent diet, respectively (Xie et al, 2014). 
Furthermore a study involving oyster protein hydrolysate displayed a reduction in SBP in SHR 
with separated di- and tripeptides inhibiting ACE activity with as little as 16.7, 29 and 51.2 uM 
of peptide in vitro, respectively.  
Further in vitro studies investigating the ACE inhibitory activity of cuttlefish 
wastewater hydrolysates (Amado et al, 2014), skate (Okamejei kenojei) skin gelatin (Ngo et 
al, 2014), thornback ray skin's gelatin (Lassoued et al, 2015) and smooth hound (Mustelus 
mustelus) waste biomass hydrolysates (Sayari et al, 2016), have shown a sweeping approach 
of potential dietary additions of unique and novel protein hydrolysates and biopeptides for 
the therapeutic management or treatment of hypertension.  
 
1.7 Immunoregulatory effects of marine protein hydrolysates 
Itis of no surprise that researchers have a keen interest on immunological regulation 
and development via the use of dietary applications. The increasing aware of dietary 
influences and health are more pronounced now than ever. The therapeutic effect of specific 
foods has gained interested from food manufacturers and consumers, however, more 
importantly clinicians and researchers (Milner, 1999). The valorisation of macronutients and 
their derivatives released during food metabolism is accelerated by the use of chemicals of 
which can digest, modify and potentially upgrade a food source for benefits above purely 
caloric value. Important functionalities include antimicrobial, antihypertensive, antioxidative, 
cytomodulatory and immunomodulatory effects (Lopez et al, 2016). Optimal immune 
functioning is vital for clearance or prevention of infection. This first line of defence against 
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pathogens can be altered according to health status. Growth, development and infection 
control are vital aspects of immune function, especially within the first several years of life 
(Simon et al, 2015). Investigation of immune system adaptation or development is 
investigated using an array of in vitro and in vivo approaches to track the regulation of 
immunomodulatory metabolites and the corresponding effect this may have on health. Very 
recently the area of nutritional intervention of dietary proteins to promote improved health 
and immune related health has improved. Reducing the risk of chronic disease or boosting 
the bodies innate and adaptive immune protection using dietary protein, peptides and amino 
acids has garnered scientific attention (Daly et al, 1990).  Biologically active peptides derived 
from marine protein are now targets of immunomodulatory research.  
Using seaweed protein hydrolysates from Porphyra columbina, researchers displayed 
an inhibition of pro-inflammatory cytokines, namely Interleukin-10 (IL-10), especially under 
lipopolysaccharide stimulation (Cian et al, 2012). On further investigation the hydrolysate did 
not increase production of lactate dehydrogenase with direct promotion of apoptotic 
pathways increased such as JNK, p38 and NF- κB with immunomodulatory effects on 
macrophages and lymphocytes. Furthermore, using a systemic/chronic inflammation study 
using hTNFα mice (C57BL/6 hTNFα), (Bjørndal et al, 2013), this strain expresses chronic 
arthritis of the front and hind paws and a common model of study of chronically elevated 
inflammation. Animals were grouped and assigned a specific dietary regime for 2 weeks. The 
base diet consisted of high-fat (23%, w/w) with alterations to protein source of 20% casein 
(control) or 15% fish protein hydrolysate (FPH) and 5% casein (FPH group). On study 
completion liver, fatty acid composition, gene expression, blood glucose, adipose tissue were 
analysed. Results concluded that mice fed the FPH diet (15% FPH / 5% casein) displayed lower 
hepatic activity of fatty acid synthesis, furthermore INF-γ levels were lower, however levels 
of IL-1β, IL-2, IL-5 and GM-CSF were unaffected by the diets. Inflammation was assessed using 
an antinflammatory index with overall inflammation lower in FPH group versus control group 
after 2 weeks of intervention. Identification of peptides with immunomodulatory activity 
from biomass has shown capability of downregulating allergic responses in vitro. 
Understanding if marine protein hydrolysate administration has a causative negative effect 
on immune system was investigated using BALB/c mice, a strain commonly used for 
immunology and cancer and drug development studies (Duarte et al, 2006). Using a 
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fermentation process to liberate peptides from commercial fish protein was administered to 
animals at various concentrations (20-30 mg/ml) for several consecutive days. The study 
concluded that fish protein hydrolysate enhanced gut specific immunity without a pro-
inflammatory outcome of which demonstrated capacity to enhance host defence systems. 
Peptides identified  from Spirulina maxima were shown to have suppressive effects of 
phospholipase Cγ activation including reactive oxygen species inhibition. Furthermore, both 
identified biopeptides displayed the suppressive effects of IL-4 via nuclear factor-κB 
translocation depression (Vo et al, 2014). The attempt to identify potentially potent bioactive 
marine peptides may be promising candidate for antiallergic therapeutics. Innate immunity 
and prospective disease resistance has its challenges of tracking accurately in humans. Using 
a controlled environment, groups of highly commercial fish species, Red Sea bream (Pagrus 
major) were fed various diets containing marine protein hydrolysates with growth 
performance, innate immunity and disease resistance analysed (Khosravi et al, 2015).  Protein 
sourced from Krill, Shrimp and Tilapia were first hydrolysed. A broad spectrum of peptides 
ranging from 500 – 5000 da were produced. In total five isonitrogenous diets were formulated 
and fed to different groups of juvenile Red Sea Bream. The control diet contained high fish 
meal (HFM), whereas all other diets contained low fish meal (LFM) supplemented with soy 
protein (group B) or soy protein and various marine protein hydrolysates (group C (shrimp / 
Sh), D (Tilapia / TH) and E(Krill / KH)). Fish were hand-fed twice daily (09:00 and 17:00 h) for 
13 weeks. Uneaten feed was subsequently collected and weighed. Growth performance was 
significantly lower in LFM group, whereas groups containing SH, TH and KH had marked 
growth rates, similar to that of the HFM diet group. Antioxidant capacity were significantly 
affected by dietary protein supplementation. Enhanced SOD activity was displayed across all 
hydrolysate groups comparative to LFM group. Several innate immune response parameters 
were significantly elevated versus LFM group such as lysozyme and antiprotease activities 
however there was no variance between the hydrolysate groups and HFM group. The study 
highlighted that a low fish meal diet supplemented with plant protein, specifically in this 
study, soy protein, had an adverse effect on growth, non-specific immune response, disease 
resistance and antioxidative capacity versus groups that were the same diet but addition 
marine protein hydrolysates added. The enhanced growth performance in diets 
supplemented with fish hydrolysates versus that of low fish meal based diet may have been 
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explained by the inclusion of bioactive peptides which were essential for the promotion of 
biological performance of the fish. These studies have demonstrated that protein, specifically 
hydrolysates and subsequent biopeptides have a role regulating or promoting immune 
system functioning and as such have a higher effect beyond merely nutrition.  
1.8 Antimicrobial peptides derived from marine protein hydrolysates 
Since the discovery and development of treatments specific to bacterial eradication 
within human systems the thought of bacteria endangering life was rumoured to be 
dramatically reduced. However, today, encroaching 90 years since the discovery of the first 
antibiotic, bacteria still represents a global threat (Ligon, 2004). The misuse of broad-
spectrum antibiotics threatens to return modern healthcare to the pre-antibiotic era due to 
the rapid rise of multidrug resistant (MDR) bacteria. Therefore, the search for antimicrobial 
inhibiting molecules or antimicrobial peptides (AMPs) is now a priority. A growing class of 
AMPs are naturally occurring or synthetic peptides (Bahar & Ren, 2013)/(da Costa et al, 2015) 
or more recently generated via hydrolysis of protein. These AMPs are considered a new 
exploitable area of alternative hope to conventional antibiotics (Cheung et al, 2015). While 
naturally occurring AMPs represent host defence systems put in place over the course of an 
organisms evolution, it hasn’t faltered researchers from delving into the mechanics of how 
these sequence of amino acids target and ultimately destroy microbes.  
AMPs have diverse interaction and therapeutic use, dysregulation of endogenous 
peptides is notable in the lung disease, cystic fibrosis were the water and salt biofilm coated 
within the tracheobronchial epithelium fails to optimally function resulting in reduced activity 
of its host AMPs. Numerous AMPs have now been discovered with broad-spectrum 
antimicrobial activities that may be developed for therapeutic potential. Sources of current 
natural AMP interest are that of amphibian secretions (Conlon et al, 2009), however, high 
quality sources of marine protein after hydrolysis can yield an abundant quantity of small 
molecular weight peptides that are of current interest. Collagencin, an antibacterial peptide 
isolated from fish collagen was evaluated for its growth inhibitor activity of various different 
strains of bacteria (Ennaas et al, 2016). Collagencin was incubated with an array of G- and G+ 
bacteria at 235 µM and resulted in inhibitory activity in several strains of bacteria including S. 
pyogenes ATCC19615, E. coli MC4100, L. innocua HPB29, L. lactis ATCC11454, and C. divergens 
M35 however failed to have any effect on E coli O157:H7, A. hydrophyla ATCC7966, P. 
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aeruginosa ATCC27853, respectively. Collagenous materials, particular marine collagen are 
thought to be cost effective approach to treating bacterial spread due to containing an array 
of bioactive peptides locked within its primary structure. With this noted, fresh approaches 
of generating AMPs are using knowledge of peptide structure and mechanism of action and 
applying this to generate novel AMPs as potential therapeutic agents. An understanding of 
the hydrolysate optimisation techniques involved in generating large quantity of AMPs from 
novel sources of marine protein is first required.  
 
 
1.9 Nutritional approaches of marine protein hydrolysates 
Improving nutrition status is by far one of the most important aspects of improving 
overall health. The concept of food fortification was first conceived to improve dietary 
nutritional values, in turn this could be used to target areas of poor nutritional status and 
increase macronutrient, micronutrient, minerals or vitamin intake (Quinlivin & Gregory, 
2003)/ (Kuong et al, 2016). The overall goal remains consistent, improvement of perceived 
health for this generation and the generations to come. Supplementation closely followed 
fortification, with the intake of higher quantities of a particular nutrient, particularly seen in 
exercising individuals who increase protein intake to aid in muscle development (Pasiakos et 
al, 2014). The global increase of nutritional knowledge and its impact on human health has 
led to significant discoveries surrounding nutrition, bioactive mining of health promoting 
compounds and mass production on an unprecedented scale to meet demand. The term 
functional food was coined for a food sources ability to improve general health or to ward of 
the risk of disease and illness and as such, has become one of the most expanding areas of 
consumer driven demand (Hesler, 2002).  
This is to say that functional foods, or bioactive components, can also be used to fortify 
foods for additive nutritional value. Marine protein hydrolysates are again in the spotlight for 
their reported ability to improve various aspects of health including increasing bone mineral 
density, improving uptake calcium (Lin et al, 2015) and non-haem iron absorption (Li et al, 
2017) and ability to improve performance and growth (Thuy & Ha, 2016). Using 
ovariectomised rats, orally administered small molecular weight peptides generated from 
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shark gelatine hydrolysate (SGH) resulted in increased femur bone mineral density versus 
control group. Furthermore, the bone content of type I collagen and glycosaminoglycan, 
analysed via western blot, were increased in the SGH group versus control, respectively 
(Nomura et al, 2005). Explaining the bone promoting benefits of marine protein hydrolysates 
has recently evolved. Hydrolysates generated with smaller molecular weight peptides display 
improved mineral and trace element chelating properties (Cai et al, 2017).  
A study investigating hydrolysates derived from microalgae (Schizochytrium sp) tested 
22 fractions separated via RP-HPLC. Of the 22 chromatograph peaks collected, 17 displayed 
calcium chelating properties. In particular a specific peptide Tyr-Leu (YL) displayed calcium 
binding capacity of approximately 130 ug of calcium per mg of peptide and displayed excellent 
thermal stability and solubility. When peptide YL-Ca was incubated in CaCo-2 cell, it improved 
calcium uptake and reduced calcium precipitation due to other reductive nutritional factors. 
Results displayed marine protein hydrolysates can improve calcium uptake and may be used 
in the novel treatment of illnesses such as osteoporosis.  
 
1.10 Discussion & Conclusion 
Marine protein and its subsequent hydrolysed or identified bioactive peptides used in 
this review have displayed insight into their therapeutic potential. Identifying problematic 
areas of modern day health care and its current approach and potential novel incorporation 
of what is essentially food derived molecules that present potent bioactivity across in vitro, in 
vivo and human study’s using various disease states.  Marine protein can contain an almost 
unlimited source of stored bioactive peptides which can be unlocked using various hydrolysis 
approaches. The approach to generating bioactive hydrolysates may use the classical 
extremes of high or low pH solutions, however it is clear that the current general consensus 
is the use of proteolytic enzymes. Furthermore, enzymes used sequentially can yield a great 
number of bioactive peptides within a specific molecular weight target. Delving deeper into 
the crude hydrolysates using identification methods of individual biopeptides, this review 
highlighted the current methods deployed with the target molecule of interest playing a vital 
role in the analytical approaches deployed. Methods such as size exclusion chromatography 
or capillary electrophoresis have their place but the most controllable, high product yielding 
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and further up-scalable approach of separation of crude hydrolysate fractions or single 
peptides is that of RP-HPLC.   
The areas covered within this review are a brief up-to-date insight to the potentially 
rewarding therapeutic areas of marine research, in particular the emerging area of marine 
protein hydrolysates. A large number of generated hydrolysates and their identified peptide 
components have displayed potent anti-hypertensive, anti-obesity, antidiabetic, 
antimicrobial and so forth. Furthermore, expanding areas of marine protein hydrolysates 
research are treatment of hyperlipidaemia, mineral and trace element chelating properties, 
improvement of growth performance and improvement of sports performance in athletes. 
This review aims to serve as a guide and gather information for the bioactive screening 
approach required to successfully generate marine protein hydrolysates with potential 
therapeutic activity.  
Itis noted that several factors must be met in order to streamline the screening 
process. The quality, however not limited by quantity of initial intact protein source, followed 
by the protease/s used in the digestion process. Using several proteases that complement 
each other, particularly protease activity at certain pH and temperature ranges can improve 
the degree of intact protein hydrolysis and finally the separation, fractioning and 
identification methods deployed. Once each of these outcomes are successfully satisfied, 
screening bioactivity using an array of in vitro, in vivo and human study can begin. The study 
highlighted certain therapeutic applications of marine protein hydrolysates favoured certain 
proteases used in the hydrolysis procedure, molecular size and hydrophobicity profile.  
It is understandable that smaller di- and tripeptides have increase absorption rates, 
however using a broad-spectrum of small molecular weight peptides (2 to 20 amino acids) 
may have advantages and via potentially targeting multiple therapeutic areas. Furthermore, 
the ability of bioactives to ultimately improve health can work in two main directions, the 
direct bioactivity reported within in this review via metabolism via hormonal regulation or 
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2.1   Hydrolysates preparation 
Palmaria palmata (Dulse) 
 
Sample preparation by collaborators at Limerick University 
A sample of air-dried milled (5 mm) P. palmata sample was purchased from Irish Seaweeds 
Ltd., Belfast, Co. Antrim, Northern Ireland. The macroalgae was further milled with a 
Cyclotec™ Mill (1 mm screen, FOSS Tecator AB, Hoganas, Sweden) and subsequently stored 
at room temperature. 
 
Extraction and quantification of aqueous and alkaline soluble proteins 
Crude aqueous and alkaline soluble protein extracts were prepared using the method 
described by Harnedy et al. (2013a) with some modifications. In brief, the milled P. palmata 
powder was suspended at a mass:volume ratio of 1:20 ((w/v), 1 kg:20.0 L) and gently stirred 
at room temperature for 3 h. The supernatant containing the aqueous soluble protein was 
obtained following centrifugation at 4,190 x g (Sorvall RC6 Plus, Fisher Scientific, Dublin, 
Ireland) for 15 min at room temperature. The pellet was resuspended in 0.12 M NaOH (1:15 
(w/v)) and gently stirred for 1 h at room temperature and the supernatant containing the 
alkaline soluble protein was obtained following centrifugation as described above. The pellet 
from the above was subjected to a second alkaline extraction using the same conditions and 
both supernatants were combined. The aqueous and alkaline soluble protein components 
were semi-purified and concentrated by a double isoelectric precipitation step at pH 2.5 
(aqueous) and 8.0 (alkaline), respectively using 1.0 M HCl. The precipitated protein pellets 
obtained following the second isoelectric precipitation were resuspended in distilled water 
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(dH20) to a protein concentration of ~ 2.4% (w/v) and combined. The concentration of protein 
in the extracts was determined by the modified Lowry protein quantification method as 
described previously (Harnedy & FitzGerald, 2013b). All samples were analysed in triplicate.  
 
Enzymatic hydrolysis of macroalgal proteins 
Macroalgal protein was hydrolysed by the method described by Harnedy et al. (2013a). A 2% 
(w/v) protein solution was preheated to 50°C and adjusted to pH 7.0 and hydrolysed with 
Alcalase 2.4L, Alcalase 2.4L and Flavourzyme 500L, Bromelain and Promod 144MG at an 
enzyme:substrate (E:S) ratio of 1:100 (w/w or v/w) for 4 h at 50 oC. The hydrolysis reaction 
was maintained at pH 7.0 using a pH-stat (842 Titrando, Metrohm, Switzerland) and 
terminated by heating at 90oC for 20 min. A control protein sample, containing no proteolytic 
enzyme, was treated in the same manner. All samples (control and hydrolysates) were 
subsequently freeze-dried (FreeZone 18L, Labconco, MO, USA) and stored at -20oC. 
 
Simulated gastrointentianal digestion (SGID)  
The unhydrolysed protein control and hydrolysates were subjected to simulated 
gastrointestinal digestion (SGID) as described by Walsh et al. (2004) with modifications. In 
brief, unhydrolysed protein controls and hydrolysates were diluted to 2.0% (w/v) protein in 
water and incubated at 37˚C and pH 2 for 90 min with pepsin at an E:S of 1:40 (w/w). The 
samples were altered to pH 7 and subjected to heat inactivation at 90˚C for 20 min. The 
samples were incubated for a further 150 min at 37˚C with Corolase PP (E:S of 1% (w/w)). This 
simulated gastrointestinal digestion sample was inactivated as described above. All samples 




Atlantic salmon (Salmo salar) gelatin and trimmings 
Sample preparation for both salmon gelatin and trimmings 
Samples of Atlantic salmon (Salmo salar) trimmings and skin were kindly provided by The 
Good Fish Processing Company Ltd., Carrigaline, Co. Cork. The skins were stored at -20oC until 
required. The trimmings were minced using a Meat Mincer equipped with a 1.5 cm diameter 
perforated disk (Breville, Oldham, UK) and were also stored at -20˚C.  
 
Extraction of gelatine from salmon skins 
The thawed skins were cut into pieces (about 5×5 cm) and washed by stirring in distilled water 
(1:5 (w/v)) for 15 min. Salmon skins were separated by filtration using a double layer of cheese 
cloth between each step of the extraction procedure. The fish skins were then soaked in 0.2 
M NaOH (1:5 (w/v)) and stirred at room temperature for 15 min to remove non-collagenous 
proteins. This procedure was repeated three times. NaOH was removed by soaking the skins 
for 15 min in distilled water at a mass:volume ratio of 1:5 (w/v) until the pH was neutral 
(repeated 3 times). The skins were then suspended in distilled water (1:6 (w/v)), the pH was 
altered to pH 3 with 1M HCl, and stirred for 1 h at room temperature. Again the removal of 
HCl was performed by soaking the skins for 15 min in distilled water (1:5 (w/v)) until the pH 
was neutral (repeated 3 times). The gelatine in the swollen skins was then extracted in 
distilled water (1:5 (w/v) at 50°C for 16 h. The supernatant was freeze-dried and stored at -
20oC until required. 
 
Protein quantification 
The protein content of salmon gelatine and purity of the hydrolysates generated were 
quantified using a macro-Kjeldahl procedure (Connolly et al. 2013).  The nitrogen to protein 
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conversion factor used was 5.55 (FAO/INFOODS, 2012). All samples were analysed in 
triplicate. 
 
Enzymatic hydrolysis of salmon skin gelatine 
Salmon skin gelatine was hydrolysed by the method described by Harnedy & FitzGerald 
(2013a) with some modifications. A 7% (w/v) gelatine solution was preheated to 50°C and 
adjusted to pH 7.0 and hydrolysed with Alcalase 2.4L, Alcalase 2.4L and Flavourzyme 500L, 
Bromelain and Promod 144MG at an enzyme:substrate (E:S) ratio of 0.73% (w/w or v/w) at 
50oC. The hydrolysis reaction was maintained at pH 7.0 using a pH-stat (842 Titrando, 
Metrohm, Switzerland). Samples were taken at 1, 2, 3 and 4 h and terminated by heating at 
90oC for 20 min. A control protein sample, containing no proteolytic enzyme, was treated in 
the same manner. All samples (control and hydrolysates) were subsequently freeze-dried 





Generation of salmon trimming meat protein hydrolysates by direct enzymatic hydrolysis  
The minced salmon trimmings were suspended at 1:1.75 (w/v) in distilled water and 
homogenised at 24,000 rpm/min for four x 15 sec durations (Ultra-Turrax® T25 Basic, IKA®, 
Staufen, Germany). Additional water was added following homogenisation to obtain a 6.83% 
(w/v) salmon meat protein suspension. The salmon protein suspension was preheated to 50°C 
and adjusted to pH 7.0 and hydrolysed by three separate means with Alcalase 2.4L, Alcalase 
2.4L and Flavourzyme 500L or Promod 144MG at an enzyme:substrate (E:S) ratio of 1:135 
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(w/w or v/w) at 50oC. The hydrolysis reaction was maintained at pH 7.0 using a pH-stat (842 
Titrando, Metrohm, Switzerland). The hydrolysates were terminated after 4 h by heating at 
90oC for 20 min. A control protein sample, containing no proteolytic enzyme, was treated in 
the same manner. Peptides were then separated by double filtration (Whatman grade 1: 11 
µm). All samples (control and hydrolysates) were subsequently freeze-dried (FreeZone 18L, 
Labconco, MO, USA) and stored at -20oC. 
 
Protein quantification 
The protein content of salmon trimming meat and protein content and purity of the 
hydrolysates generated were quantified using a macro-Kjeldahl procedure (Connolly et al. 
2013).  The nitrogen to protein conversion factor used was 6.25 (Kristinsson and Rasco, 2000). 
All samples were analysed in triplicate. 
 
SGID: Homogenised salmon trimming meat and hydrolysates were subjected to SGID as 
above (section 2.1) 
 
Blue whiting  
Sample preparation 
Samples of minced blue whiting (Micromesistius poutassou) meat were kindly provided by 
Killybegs Fishermen's Organisation, Killybegs, Co Donegal, Ireland through Bord Iascaigh 
Mhara (BIM, Ireland) and stored at -20˚C.  
 
Generation of blue whiting hydrolysate by direct enzymatic hydrolysis  
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The minced blue whiting meat was suspended at 1:1.25 (w/v) in distilled water and 
homogenised at 24,000 rpm/min for four x 15 sec durations (Ultra-Turrax® T25 Basic, IKA®, 
Staufen, Germany). Additional water was added following homogenisation to obtain a 6.00% 
(w/v) blue whiting protein suspension. The suspension was preheated to 50°C and adjusted 
to pH 7.0 and hydrolysed with Alcalase 2.4L and Flavourzyme 500L at an enzyme:substrate 
(E:S) ratio of 1:135 (v/w) at 50oC. The hydrolysis reaction was maintained at pH 7.0 using a 
pH-stat (842 Titrando, Metrohm, Switzerland). The enzymes were inactivated after 4 h by 
heating at 90oC for 20 min. Peptides were then separated by double filtration (Whatman 
grade 1: 11 µm), freeze-dried (FreeZone 18L, Labconco, MO, USA) and stored at -20oC. 
 
SGID: Homogenised blue whiting meat and the hydrolysate were subjected to SGID as 
explained above (Section 2.1). 
 
Protein quantification 
The protein content of blue whiting meat and protein content and purity of the hydrolysates 
generated were quantified using a macro-Kjeldahl procedure (Connolly et al. 2013).  The 
nitrogen to protein conversion factor used was 6.25 (Kristinsson and Rasco, 2000). All samples 
were analysed in triplicate. 
 





Samples of minced boarfish (Capros aper) meat were kindly provided by Killybegs Fishermen's 
Organisation, Killybegs, Co Donegal, Ireland through Bord Iascaigh Mhara (BIM, Ireland) and 
stored at -20˚C.  
 
Generation of a boarfish hydrolysate by direct enzymatic hydrolysis  
The minced boarfish meat was suspended at 1:1 in distilled water and homogenised at 24,000 
rpm/min for four x 15 sec durations (Ultra-Turrax® T25 Basic, IKA®, Staufen, Germany). 
Additional water was added following homogenisation to obtain a 6.83% (w/v) boarfish 
protein suspension. The suspension was preheated to 50°C and adjusted to pH 7.0 and 
hydrolysed with Alcalase 2.4L and Flavourzyme 500L at an enzyme:substrate (E:S) ratio 1:150  
(v/w) at 50oC. The hydrolysis reaction was maintained at pH 7.0 using a pH-stat (842 Titrando, 
Metrohm, Switzerland). The hydrolysates were terminated after 4 h by heating at 90oC for 20 
min. Peptides were then separated by double filtration (Whatman grade 1: 11 µm). All 
samples (control and hydrolysates) were subsequently freeze-dried (FreeZone 18L, Labconco, 
MO, USA) and stored at -20oC. 
 
SGID: Homogenised boarfish meat and the hydrolysate were subjected to SGID as described 
above (Section 2.1). 
 
Kjeldahl nitrogen quantification method  
The protein content of the boarfish meat and protein content and purity of the hydrolysates 
generated were quantified using a macro-Kjeldahl procedure (Connolly et al. 2013).  The 
nitrogen to protein conversion factor used was 6.25 (Kristinsson and Rasco, 2000). All samples 




Boarfish (Semi-pilot scale) 
Sample preparation 
Samples of minced deboned boarfish (Capros aper) meat were kindly provided by Bio-Marine 
Ingredients Ireland Ltd, Killybegs, Co. Donegal, Ireland.  
 
The boarfish protein hydrolysate was generated at semi-pilot scale as per the method used 
to generate the hydrolysate at laboratory scale with modifications. In brief, a boarfish 
suspension (1900 kg) with a protein content of 6.0 % (w/v) incubated at 50oC was adjusted to 
pH 7.0 and hydrolysed with Alcalase 2.4L and Flavourzyme 500L at an enzyme:substrate (E:S) 
ratio of 1:150  (v/w). The hydrolysis reaction was maintained at pH 7.0. After 4 h hydrolysis, 
the enzyme was inactivated at 90oC. The protein/peptide component was separated from the 
sediment and oil by a 2 step decanter/centrifuge process. The oil and sediment were first 
separated from the supernatant using a 3-phase decanter (GEA Westfalia Separator Group 
GmbH). The supernatant was then further clarified using a continuous centrifuge (GEA 
Westfalia Separator Group GmbH) and cooled to <4oC overnight. The hydrolysate was 
pasteurised at 85oC for 85 sec and fed into a 3 stage falling film evaporator and evaporated 
to ~40% total solids. The evaporated hydrolysate was spray dried (80 kg/h water evaporation) 
using an inlet and outlet temperature of 180 oC and 90oC, respectively and stored in an airtight 

























2.2   Materials 
Cell culture materials were obtained from Gibco life technologies (Thermo Fisher Scientific, 
Paisley, UK) including RPMI-1640 cell culture media (BRIN-BD11), DMEM-4500 mg/L glucose 
cell culture media (STC-1)  DMEM-1000 mg/L  cell culture media(GLUTag) and penicillin 
streptomycin (10000 U/ml, 10000 µg/L). Calcium chloride dihydrate (CaCl2.2H2O), D-glucose, 
hydrochloric acid (HCl), magnesium sulphate (MgSO4.7H2O), sodium chloride (NaCl), 
Dimethylsulphoxide (DMSO), biological buffer sodium salt (HEPES), potassium chloride (KCl) 
and sodium hydroxide (NaOH) were obtained from Sigma-Aldrich Chemical Company Ltd. 
(Dorset UK). Controls used for acute secretory activity, glucagon-like peptide-1 (GLP-1 7-
36amide) was obtained from EZbiolabs (Indiana, USA), L-Glutamine (C5H10N2O3) and palmitic 
acid (CH₃(CH₂)₁₄COOH) were obtained from Sigma-Aldrich Chemical Company Ltd. (Dorset 
UK).  
2.1.2   Cell culture 
The maximum hydrolysate concentration of 2.5 mg/ml was used in acute secretory activity in 
all cell lines. This was further serial diluted to assess the dose dependant activity to a 
minimum dose of 0.039 mg/ml of chosen protein hydrolysate.  
2.1.3   BRIN-BD11 rat pancreatic β-cell culture 
BRIN-BD11 cells represent a robust rat insulin secreting cell line which responds 
macronutrients such as glucose and glucose derivatives, peptide hormones and 
pharmacological agents. These cells were established after electrofusion of RINm5f cells with 
New England Deaconess Hospital rat pancreatic islet cells. Morphological study’s established 
that BRIN-BD11 cells grow as monolayers maintaining stability in tissue culture settings for 
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45- 50 passages (McClenaghan et al. 1996). An important immortalised and stable glucose-
responsive cell line. BRIN-BD11 cells were cultured until passage 25 where they were 
cryopressed in 1 ml vials (Sterilin Ltd, Houslow, UK) containing 1 x 106 cells/ml in freezing 
media (10% RPMI-1640 media, 10% DMSO & 80% FBS). Cells were firstly stored at 20oC for 4 
h then transferred to -80oC for 12 h before finally being transferred to liquid nitrogen storage 
(-196oC) for future use. 
 
2.1.4   GLUTag mouse enteroendocrine cell culture 
GLUTag cells generated by the Daniel Drucker laboratory in Toronto and gifted to Ulster 
University via Prof. Gribble at Cambridge University are immortalized. GLUTag cells are a 
relatively well differentiated murine enteroendocrine cell line that express the proglucagon 
gene and secrete glucagon-like peptides in a regulated manner. The GLUTag cell line was 
isolated from a glucagon-producing enteroendocrine cell tumour that arose in glucagon gene-
SV40 T antigen transgenic mice. The production of the large bowel carcinoma expressing the 
glucagon gene was then serially passaged in nude mice which gave rise to glucagonomas that 
exhibit a stable phenotype of glucagon gene expression. GLUTag cells are extensively utilized 
for the analysis of glucagon-like peptide 1 & 2 secretagogues and for investigation of 
enteroendocrine glucagon gene transcription as well as to a lesser extent neurotensin (NT), 
Glucagon, cholecystokinin (CCK) and somatostatin (SST) (Brubaker et al. 1998). This cell line 
was chosen due to its responsiveness to peptides, amino acids, pharmacological agents and 
fatty acids that stimulate secretory activity. GLUTag cells were received from Cambridge 
University at passage 9, cells were cultured by Ulster University until passage 12 where they 
were cryopressed in 1 ml vials (Sterilin Ltd, Houslow, UK) containing 1 x 106 cells/ml in freezing 
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media (90% DMEM media, 10% DMSO).. Cells were firstly stored at -20oC for 4 h then 
transferred to -80oC for 12 h before finally being transferred to liquid nitrogen storage (-
196oC) for future use.  
Experimental GLUTag cells were cultured in Dulbecco’s modified eagle medium (DMEM) 
devoid of glutamine and supplemented with glucose (5 g), fetal bovine serum (10%) and 
penicillin streptomycin (100 mol/ml & 0.1 mg/ml streptomycin) in a sterile breathable 
however filtered 75 cm2 tissue culture flask until a cell confluence of 70% was reached. Cells 
were then gently washed in 10 ml of HBSS prior to incubating with 3 ml of pre-warmed 1% 
trypsin/EDTA at 37oC for 5 – 8 min. Detached cells were observed using a phase contrast 
microscope (Zeiss, Germany). GLUTag cells grow in clusters, thus several aspirations of the 
trypsinized cells are required to gently break clusters to provide single cells for counting. The 
trypsin was neutralized using DMEM media and transferred to a sterile polypropylene tube 
(Sterlin Ltd, Hounslow, UK) vial for centrifugation at 900 rpm for 5 min. Cell supernatant was 
then removed and cells are re-suspended in a known volume of pre-warmed DMEM media. 
A single aliquot of 100 µl of re-suspended cells were mixed with 100 µl of Trypan blue and 
transferred for counting to a Neubauer haemocytometer (Scientific Supplies Co., Middlesex, 
UK). GLUTag cells were either transferred to a T75  tissue culture flask for future use or seeded 
onto a 24 well plate at a cell density of 1.5 x 105 for GLP-1 secretion studies.  
 
2.1.5   STC-1 mouse enteroendocrine cell line 
The STC-1 cell line was derived from a C57B1/6J mouse of which developed an invasive small 
intestinal neuroendocrine carcinoma. The overall cellular morphology of the STC-1 is that of 
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several different enteroendocrine cell types derived from the tumour originally excised from 
the animal. Several studies has vigorously screened the secretory activity of cultured STC-1 
cells and their nutrient sensing capabilities (Kuhre et al, 2016; Gillespie & Green, 2016). The 
STC-1 cell line has the ability to secrete glucose-dependant insulinotropic polypeptide (GIP), 
glucagon-like-peptide 1 (GLP-1), glucagon-like-peptide 2 (GLP-2), Cholecystokinin (CCK), 
Oxyntomodulin and Peptide YY,  making this cell line a favourable source for potentially 
assessing satiating compounds with anti-diabetic activity. STC-1 cells are characterised as 
relatively slow growing cells (45-56 h proliferation time) in standard growth media. STC-1 cells 
were cultured in supplemented DMEM media (DMEM containing 4.5 g/l D-glucose, without 
sodium pyruvate) (GlutaMAX, GIBCO, Paisley, UK) with 17.5 % foetal bovine serum (FBS), 100 
U/ml penicillin, 100 mg/l streptomycin and incubated in a 5% air humidified atmosphere at 
37°C. Cells were passaged at 80–90 % confluence.  
Experimental STC-1 cells were cultured in DMEM (supplementary additions mentioned 
above) in a sterile breathable however filtered T75 tissue culture flask until a cell confluence 
of 90% was reached. Cells were then gently washed in 10 ml of HBSS prior to incubating with 
3 ml of pre-warmed 1% trypsin/EDTA at 37oC for 5 – 8 min. Detached cells were observed 
using a phase contrast microscope (Zeiss, Germany). As STC-1 reach confluence they grown 
in clusters, several aspirations of the trypsinized cells were required to gently break clusters 
to provide single cells for counting. The trypsin was neutralized using DMEM media and 
transferred to a sterile polypropylene tube (Sterlin Ltd, Hounslow, UK) vial for centrifugation 
at 900 rpm for 5 min. Cell supernatant was then removed and cells are re-suspended in a 
known volume of pre-warmed DMEM media. A single aliquot of 100 µl of re-suspended cells 
were mixed with 100 µl of Trypan blue and transferred for counting to a Neubauer 
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haemocytometer (Scientific Supplies Co., Middlesex, UK). STC-1 cells were either transferred 
to a T75 tissue culture flask for future use or seeded onto a 24 well plate at a cell density of 
1.5 x 105 for secreting studies.  
2.2   Cell secretion and analysis  
2.2.1   Determination of insulin secretion from BRIN-BD11 cell cultures 
The insulin radioimmunoassay (RIA) was used for the determination of insulin from both 
insulin secreting cell lines and from ex-vivo blood plasma samples (Flatt & Bailey, 1981). 
Initially BRIN-BD11 cells were seeded onto 24 well plates and incubated with compounds of 
interest for 1 hand subsequently collected for later analysis (described in 2.2.3) using RIA. In 
brief cells are seeded at a cell density of 1.5 x 105 cell/well in 1 ml of RPMI-1640 cell culture 
media and left for 21 h to adhere. On the day of experimentation media was removed and 
replaced with 1 ml of priming KRBB (11 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl2.2H2O, 1.2 mM 
KH2PO4, 1.2 mM MgSO4.7H2O, 10 mM NaHCO3, 25 mM HEPES, 0.1% (w/v) bovine serum 
albumin, pH 7.4) and supplemented with 1.1 mM glucose at 37oC for 40 min. The entire cell 
prepping KRBB (1.1 mmol/L glucose) was then removed and further supplemented with KRBB 
of which contains at least 5.6 mmol/L glucose in all conditions (baseline) with compounds of 
interest used in a dose dependant manner minimum of n=8 replicates. After 20 min of co-
incubation with compounds of interest 900 µl was removed from each well and stored until 





2.2.2    Preparation of iodinated bovine insulin for radioimmunoassay  
Iodination of insulin for use in competitive enzyme binding assays has been in use for several 
decades due to its high sensitivity, low sample volume required and reproducibility. Insulin 
was iodinated according to the protocol by Fracker and Speck (1978). Lyophilised bovine 
insulin (1 mg/ml) was dissolved in 10 mM HCl then diluted (1:8) in 500 mM sodium phosphate 
buffer to a concentration of 125 µg/ml. When needed and directly before use stock iodogen 
(1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril) was first prepared as 2 mg/ml in 
dichloromethane (CH2Cl2). Once dissolved, 20 µl iodogen was then pipetted to the bottom of 
a clear 1.5 ml Eppendorf tube. With the lid left open the bottom of the tube was placed into 
a water bath very briefly (30 – 60 sec) then removed and rotated until a thin coat is remaining 
at the bottom of the tube. Iodogen tubes were stored in a desiccator for up to 1 month, 
however for optimal iodination it is advised to prepare fresh directly before use. Within the 
RIA controlled area (the operator wore 2 pairs of gloves, and lead screening) the reaction 
between 125I and insulin was initiated by first placing 5 µl of 125I (18.5 mbq / 0.5 mCi), followed 
by 20 µl insulin (125 µg/ml) into the iodogen coated Eppendorf tube which was placed on ice. 
Over the next 15 min the Eppendorf underwent gentle agitation using an index finger every 
few min. After the 15 minutes are complete the total 25 µl (125I & insulin) are transferred to a 
fresh Eppendorf tube. The old tube was carefully washed with 500 µl of sodium phosphate 
buffer (50 mM) and mixed into the new tube then subsequently separated by RP-HPLC for 
separation of unbound and insulin bound 125I. 
RP-HPLC was deployed using a TSP Spectra RP-HPLC system (Thermo Finnigan, NJ, USA) 
equipped with a dual gradient TSP P200 solvent proportioning pump, Rheodyne 7125 
injection value with 500 µl loop and a Vydac C18 analytical reverse phase column (250 x 4.6 
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mm) (Hesperia, CA, USA). The Vydac column was equilibrated (1.0 ml/min flow rate) prior to 
injection using a 45 min gradient method consisting of deionized H2O + trifluoracetic acid 
(0.12% v/v (CF3CO2H) (Sigma, Dorset, UK) (Solvent A) and deionized H2O (29.9%), acetonitrile 
(70%) + TFA (0.1% v/v) (Solvent B). The elution of 125I Insulin was completed using the same 
approach, on injection the gradient of solvent B was raised from 0% to 40% over 10 min and 
from 40% to 80% over 40 min and finally from 80% to 100% for 10 min, during this run a Bio-
Rad fraction collector (Model 2110) (Bio-Rad, Hertfordshire, UK) containing 72 x 10 mm 
polypropylene tubes was set at 1 minintervals collecting the entire 60 min run. Unbound 125I 
was typically eluted at fraction 4, whereas the 125I bound Insulin will be eluted within fractions 
20 to 25 with unbound insulin eluted within fraction 27 – 32. An aliquot of each fraction (5 l)  
was finally tested for counts per minute (CPM) from each fraction using a multigamma 
counter (LKB Wallac, Finland). A plot was drawn for CPM versus time (min), with each min 
representing the fraction collected during the RP-HPLC separation process. On completion of 
establishing the count per minute a graph was produced using GraphPad™ Prism 5 with the 
highest CPM counts being stored and diluted in a 1:1 ratio with sodium phosphate buffer (40 
mM, pH 7.4) containing 1% (w/v) BSA and 1.2 mg/ml thimersol. Collected and diluted fractions 
were kept at 2-6oC prior to assessment of antibody binding by radioimmunoassay. Fractions 
with similar percentage binding were pooled for use with desired binding percentage based 
on antibody concentration, typically 1:25000 to 1:65000 with a binding percentage of 40% 
desirable. 
Fig 1. 125I bovine insulin vs unbound bovine insulin 
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2.2.3.   Determination of insulin concentration by radioimmunoassay 
Sample insulin content was measured by dextran-coated charcoal radioimmunoassay (Flatt 
and Bailey, 1981), using crystalline rat insulin standard, guinea-pig anti-porcine antiserum and 
125I bovine insulin standard. Initially stock RIA buffer consisted of 40 mM disodium hydrogen 
orthophosphate containing 0.3% (w/v) sodium chloride and 0.02% thimersol titrated using 40 
mM sodium dihydrogen orthophosphate to pH 7.4. Working RIA buffer included the addition 
of 0.5% bovine serum albumin (w/v). Insulin standard curves were prepared in triplicate (200 
µl) by serial dilution of rat insulin standard from 20 ng/ml stock concentration to 0.039 ng/ml 
in KRBB supplemented with 0.1% (w/v) BSA. Unknown insulin content from cell supernatant 
samples were added in duplicate (200 µl) while insulin standards receive 100 µl of guinea pig 
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anti-porcine (antibody binding concentration determined prior insulin antibody being diluted) 
followed by the addition of 100 µl of 125I bovine insulin (10,000 cpm/ 100 µl). Samples were 
then incubated for 72 h at 4oC.  
Detection of antibody bound insulin was determined by the addition of 1 ml of 5% dextran T-
70 coated charcoal (dilution of 1:5 with stock RIA buffer) to each tube and incubation for 20 
min at 4oC. Following incubation, the samples were centrifuged at 2500 rpm for 20 min. The 
supernatant was decanted and the radioactivity contained within the pellet (corresponding 
to unbound 125I insulin) and the pellet was measured using a 1261 Multigamma counter (LKB, 
Wallac, Finland) linked to DOS-CPM software enabled computer. Insulin concentration in 
unknown samples were determined from the insulin standard curve (prepared using known 
rat insulin concentration standards), created using spline-fitting algorithm.  
 
2.2.4.  Determination of glucagon-like-peptide 1 (GLP-1) concentration by ELISA 
GLP-1 is secreted by intestinal L-cells after oral ingestion of nutrients from food. It plays an 
important role in metabolic homeostasis with the bioactivity of GLP-1 being being reduced in 
obese subjects or those with type 2 diabetes. Using mouse enteroendocrine cell culture 
(GLUTag culturing protocol in detail, 2.1.4) the experimental procedure to determine GLP-1 
content in cell supernatant or biological samples was as follows. Initially GLUTag cells were 
seeded onto 24 well plates and incubated with compounds of interest for 2 hour and 
subsequently collected for later analysis. In brief cells were seeded at a cell density of 1.5 x 
105 cell/well in 1 ml of DMEM 1000 mg/mL glucose cell culture media and left for 48 h to 
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priming KRBB (11 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl2.2H2O, 1.2 mM KH2PO4, 1.2 mM 
MgSO4.7H2O, 10 mM NaHCO3, 25 mM HEPES, 0.1% (w/v) bovine serum albumin, pH 7.4) and 
supplemented with 1.1 mM glucose at 37oC for 40 min. Entire cell prepping KRBB (1.1 mmol/L 
glucose) is then removed and further supplemented with KRBB of which contains at least 2 
mM glucose in all conditions (baseline) with compounds of interest used in a dose-dependant 
manner using n=8 replicate wells. After 2 h of co-incubation with compounds of interest 900 
µl was removed from each well and stored until analysed via ELISA at -20oC. Two different 
GLP-1 ELISAs were used to determine GLP-1 concentration in cell supernatant or ex-vivo 
plasma samples. ELISAs purchased from Millipore (Ontario, Canada) or Mercodia (Uppsala, 
Sweden) were run according to the manufacturer instructions.  






2.2.5.  Determination of glucose-dependant insulinotropic polypeptide (GIP) 
concentration by ELISA 
Similar to GLUTag cell cultures, STC-1 cells differentiate by secreting satiety and glucose 
homeostatic hormones such as cholecystokinin (CCK), glucose-dependant insulinotropic 
polypeptide (GIP), peptide YY (PYY), glucagon-like-peptide 1 (GLP-1) and glucagon-like-
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peptide 2 (GLP-2). The experimental procedure was similar to the GLUTag screening 
procedure. Initially STC-1 cells were seeded onto 24 well plates and incubated with 
compounds of interest for 2 h and subsequently collected for later analysis. In brief cells were 
seeded at a cell density of 1.5 x 105 cell/well in 1 ml of DMEM 4500 mg/mL glucose cell culture 
media and left for 48 h to adhere. On the day of experimentation, media was removed and 
replaced with 1 ml of priming KRBB (11 mM NaCl, 4.7 mM KCl, 1.28 mM CaCl2.2H2O, 1.2 mM 
KH2PO4, 1.2 mM MgSO4.7H2O, 10 mM NaHCO3, 25 mM HEPES, 0.1% (w/v) bovine serum 
albumin, pH 7.4) and supplemented with 1.1 mM glucose at 37oC for 40 min. Entire cell 
prepping KRBB (1.1 mmol/L glucose) was then removed and further supplemented with KRBB 
of which contained 2 mM glucose in all conditions (baseline) with compounds of interest used 
in a dose dependant manner in n=8 replicates. After 2 h of co-incubation with compounds of 
interest 900 µl  of the supernatant was removed from each well and stored until analysed via 
ELISA at  -20oC. Analysis of GIP from cell supernatant or biological samples using a GIP ELISA 
(Rat/Mouse) from Millipore (West Lothian, UK) was carried out as instructed by the 
manufacturer.  












2.2.6 Measurement of GLP-1 (7-36amide) degradation during co-incubation with 
dipeptidyl peptidase 4 (DPP4)  
The known degradation of GLP-1 (7-36amide) relies on its interaction with a ubiquitous serine 
protease hormone, dipeptidyl peptidase-4 (DPP-4). DPP-4 catalyses the cleavage of the 
penultimate N-terminus amino acid, namely Ala2 of the peptide chain. The metabolic 
effectiveness was rendered obsolete when this cleaveage takes place. Active GLP-1 (7-
36)amide has several important roles in glucose and satiety regulating homeostasis. GLP-1(7-
36)amide in its active form is secreted from intestinal L-cells and has a half-life of 
approximately 2 min due to the abundance of DPP-4 present in the gut and blood steam. 
Increasing the active GLP-1 concentration beyond its inactive cleavage molecule GLP-1(9-36) 
has many advantageous anti-diabetic effects, including increased insulin biosynthesis, 
increased β-cell survival, glucose dependant reduction of plasma glucose and decreased food 
intake.  Inhibiting the activity of DPP-4 (described in 2.2.8) highlights the potential of enzyme 
inhibition for the treatment of type 2 diabetes.  
 
2.2.7 Glucose uptake assay via 3T3-L1 transdifferentiated adipocyte cells 
3T3-L1 cells were first cultured in DMEM growth medium until reaching 70% confluence. Cells 
were split and further seeding into a 96 well plate at a seeding density of 5x105 and left 
overnight to attach. The next day (day 0) growth media was aspirated and fresh pre-warmed 
grown media containing IBMX (0.5 mM) and dexamethasone (1 m). Plates are returned to 
tissue culture incubator where on day 3, differentiation media was aspirated and fresh growth 
medium was added containing 10 g/mL Insulin. Plates were incubated for a further 3 days, 
were insulin containing growth media was aspirated and replaced with fresh DMEM culture 
44 
 
media. On day 7 – 10 plates were observed under a microscope where if successful, fully 
differentiated adipocyte-like cells were obtained for experimentation.  Glucose uptake assay 
was preformed directly onto the 96 well plates after aspirating the growth media, 
replacement of media with KRBB containing necessary test conditions either in the presence 
of insulin or without insulin. A fluorescently tagged glucose is used to test the glucose uptake 
efficiency and added to each subsequent well at a fixed concentration.  
 
2.2.8   Direct inhibition of dipeptidyl peptidase 4 (DPP-4) activity in vitro 
The substrate (H-Gly-Pro-7-amino-4–methyl coumarin, standard (7-Amino-4-methyl 
coumarin (AMC) and inhibitor control (Diprotin A) were obtained from Bachem 
Feinchemikalien (Bubendorf, Switzerland). Human recombinant DPP-4 enzyme was obtained 
from Sigma-Aldrich (Dorset, UK). DPP-4 inhibitory activity was determined by measuring free 
AMC (7-amino-4-methyl-coumarin) (Kato et al. 1978) liberated from the fluorogenic 
substrate Gly-Pro-AMC. Using a Costar, black 96 well plate, 30 µl of 100 mM TRIS-HCl (pH 7.4) 
buffer was added into each well. Following this 10 µl sample or controls was added (n=3) 
followed by 50 µl of 200 µM H-Gly-Pro-AMC. The plate was then incubated at 37oC for 10 min. 
The reaction was finally started by adding 10 µl of DPP-4 (8 mU/ml) and incubated for a 
further 30 min.The plate was read using excitation (360 nm) and emission (460 nm) 
florescence wavelength using a Flex Station 3 (Molecular Devices, CA, USA). A calibration 
curve was plotted using the standard florescent compound 7-amino-4-methylcoumarin from 













2.2.9  Assessing the GLP-1 activity in the presence of DPP-4 using RP-HPLC 
chromatography 
Preserving GLP-1 (7-36)amide from degradation to GLP-1 (9-36) in the presence of DPP-4 was 
achieved by co-incubating with synthetic peptides of marine origin first isolated from 
Palmaria palmata. A 100 mM triethanolamine (TEA) buffer (pH 7.4) was used. In brief, 30 µl 
of GLP-1(7-36)amide (106 M) was added to a low bind Eppendorf tube (Sigma-Aldrich, Dorset, 
UK) followed by 30 µl of sample, DPA control (106 M) or blank. Following this 430 µl of TEA 
buffer was added. The reaction was started by adding 10 µl of human DPP-4 (5 mU). Several 
tubes (n=??) containing the same additions were prepared and subsequently incubated for 0 
h, 2 h, 4 h, 8 h and 24 h respectively. The reaction was stopped by adding 50 µl of 10% TFA. 
Samples were then stored at -20oC until RP-HPLC analysis.  
 
Analysis of samples was by a  RP-HPLC system (Thermo Finnegan, Surveyor) equipped with a 
UV/VIS detector (Thermo Finnigan Surveyor UV-VIS Plus Detector), 4 port gradient inlet 
solvent proportioning pump (Thermo Finnigan Surveyor LC Pump), Rheodyne 7125i injector 
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with a 1000 µl loop, multi-sampler (Thermo Finnigan Surveyor Autosampler) equipped with a 
250 µl reservoir and 100 µl column loop. Using a Phenomenex  Aeris Peptide C18 (250 x 46 
mm / 3.6 µm) solvents (solvents description 2.2.2) starting at 0% solvent B and and increased 
to 30% Solvent B after 10 min then a further increase to 70% solvent B over the next 40 min 
and finally increasing to 100% solvent B over 5 min and retaining 100% for a further 10 min 
before returning to starting conditions (100% solvent A). Eluted peaks were collected and 
stored at -20oC in low bind Eppendorf tubes (Sigma-Aldrich, Dorset, UK) and later analysed 
using MALDI-TOF MS (PerSeptive Biosystems Voyager-DE Biospectrometer, Hertfordshire, 
UK).  
2.2.10 Compound mass determination using Matrix assisted laser desorption 
ionisation time of flight mass spectrometry (MALDI-TOF MS) 
MALDI-TOF MS was performed using a PerSeptive Biosystems Voyager-DE Biospectrometer 
(Hertfordshire, UK) equipped with a 1 m time-of-flight tube.  A 10 mg/ml solution of α-cyano-
4-hydroxycinnamic acid (CHCA) (Sigma Aldrich, UK) was prepared in 80% acetonitrile, 20% 
water with 0.1% trifluroacetic acid. The matrix was vortexed thoroughly to mix, then spun in 
a microcentrifuge for 2 min to ensure any undissolved matrix settled to the bottom of the 
tube; only the supernatant was used. A 10 µL aliquot of each sample was mixed with 10 µL of 
matrix and a 1.5 µL aliquot pipetted onto a predefined well of a 100-well stainless steel plate. 
Once the test mixtures had dried on the plate, the plate was inserted into the MALDI-TOF. 
An internal mass calibration of the instrument was performed prior to sample analysis using 
Peptide Calibration Mix 2 (LaserBio Labs, Spohia-Antipolis, Cedex, France) containing four 
individual peptides; Neurotensin, ACTH fragment 18-39, Insulin bovine β-chain oxidised and 
Insulin bovine with monoisotopic masses of 1672.9176, 2465.1989, 3494.6514 and 
5730.6087, respectively.   
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All sample measurements were collected in linear positive ionisation mode using 50 laser 
shots/spectrum.  The accelerating voltage was maintained at 20,000V, the grid voltage and 
guide wire voltages were set at 93% and 0.05% respectively, of the accelerating voltage.  The 
nitrogen laser set at 337 nm was directed toward the densest area of the sample / matrix spot 
and the laser intensity adjusted to obtain the best spectral response.  The mass/ charge ratio 
(m/z) was plotted against relative abundance.   
 
 
2.2.11 Cell signalling events 
 
2.2.12 Measurement of Adenosine 3,5-cyclic monophosphate (cAMP) production after 
coincubation with marine protein hydrolysates  
The signalling cascade of marine protein hydrolysates on total cAMP release was determined 
using a commercially available cAMP Parameter assay kit (R&D Systems, Minneapolis, USA). 
The assay measured cAMP in various samples with cAMP being one of the most important 
cellular signalling events promoted by the conversion of ATP to cAMP and is imperative to 
biological functioning. BRIN-BD11 cells were cultured as described in section 2.1.3. Cells were 
seeded on 24 well plates at a cell density of 50,000 cells per well with the addition of 1 ml of 
RPMI-1640 media (10% FBS, 1% PenStrep). Cells were placed into an modified atmosphere 
incubator (95% air, 5% CO2 ) at 37oC for 21 h. Following this the media was removed and 1 ml 
of prepping KRBB was added (described in 2.2.1) for 1 h. Protein hydrolysates were prepared 
in working KRBB (described in 2.2.1) with the addition of 5.6 mmol/L glucose and 200 µl of 
IBMX in the presence of control or control and hydrolysate and incubated for 20 min. Cells 
were then lysed after removal of supernatant using 100 µl of cell lysis buffer for 30 minat 
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37oC. Cells were visually inspected to verify cell lysis using a phase contrast microscope (Zeiss, 
Germany). Samples were stored at -20oC until analysis.  
 
Using the cAMP Parameter assay kit (R&D Systems, Minneapolis, USA) samples were brought 
to room temperature before being diluted with calibrator diluent RD5-55 from the assay kit. 
A control serial dilution was prepared from 240 pmol/L to 3.45 pmol/L using the stock 2400 
pmol/L standard (Fig 4). The remaining assay was carried out specific to manufacturing 
protocol instructions. Optical density was read at 450 nm with wavelength correction set to 







2.2.13 Measurement of membrane potential signalling after co-incubation with 
marine protein hydrolysates 
  
BRIN-BD11 cells were seeded at a cell density of 90,000 cells per well in Costar, black walled, 
clear bottom 96 well plates (Appleton-Woods, Birmingham, UK) and incubated for 21 h at 
37oC (95% air, 5% CO2). A fluorometric membrane potential assay was purchased from R&D 
Systems (Minneapolis, USA). This is a homogenous assay with fast read times. Using a 
proprietary long wavelength membrane indicator to detect the membrane potential change 
that is caused by the opening and closing of ion channels. A red indicator was used to minimise 
interference from compounds or cellular auto-fluorescence. The protocol was run as 
indicated in the manufacturer guidelines. In brief, 100 µl of working KRBB buffer (described 
in 2.2.1) supplemented with 5.6 mmol/L glucose was added to each well after removal of 
media. The plate was then incubated for 10 min. After incubation, the KRBB buffer was left in 
each well and 100 µl of the FLIPR membrane potential buffer (11 ml of KRBB (5.6 mmol/L) 
added to R&D premade FLIPR membrane buffer vial) was added to the first column (n=8) of 
the 96 well plate. The plate was incubated again for 5 min and the 100 µl of the FLIPR buffer 
was added to the second column of the 96 well plate and incubated again for 5 min. This 
process was repeated until all columns had received 100 µl of the FLIPR membrane potential 
buffer and finally transferred to a FlexStation 3 plate reader (Molecular devices, CA, USA) 
which had its plate compartment pre-warmed to 37oC. Using an excitation and emission 
wavelength (Ex 360 nm, Em 460 nm), the software had been programmed to read the first 
column for 5 minutes after it added 10 µl of  sample to each well. After 5 min the plate reader 
automatically added the same samples to the next column and read for a further 5 min. This 
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was continued until all columns had been aliquoted with sample and read for 5 min. The data 
was combined and later analysed using Graphpad™ Prism 5 statistical software.  
 
2.2.14 Measurement of Intracellular calcium (Ca2) signalling after co-incubation 
with marine protein hydrolysates  
The FLIPR calcium assay (Molecular Devices, CA, USA) measures changes in intracellular 
calcium only via its proprietary fluorescent dye. This represents a robust, sensitive assay for 
use with a broad range of compounds including food derived and pharmaceutical. The kit 
delivers a pre-optimized, homogenous, fluorescent-based formulation of which is vital for 
GPCR and ion based channel activation. BRIN-BD11 cells were seeded at a cell density of 
90,000 – 100,000 cells per well in Costar, black walled, clear bottom 96 well plates (Appleton-
Woods, Birmingham, UK) and incubated for 21 hat 37oC (95% O2, 5% CO2). A fluorometric 
membrane potential assay was purchased from R&D Systems (Minneapolis, USA). This is a 
homogenous assay with fast read times. Using a proprietary long wavelength membrane 
indicator to detect the membrane potential change that is caused by the opening and closing 
of ion channels.  
 
The protocol was run as indicated by the manufacturer guidelines. In brief, 100 µl of working 
KRBB buffer (described in 2.2.1) supplemented with 5.6 mM glucose was added to each well 
after removal of media. The plate was then incubated for 10 min. After incubation, the KRBB 
buffer was left in each well and 100 µl of the FLIPR membrane potential buffer (11 ml of KRBB 
supplemented further with 10 mM calcium chloride (CaCl2) and 100 X probenecid) added to 
R&D premade FLIPR membrane buffer vial) was added to the first column (n=8) of the 96 well 
plate. The plate was incubated again for 5 min and the 100 µl of the FLIPR buffer was added 
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to the second column of the 96 well plate and incubated again for 5 min. This process was 
repeated until all columns had received 100 µl of the FLIPR membrane potential buffer and 
finally transferred to a FlexStation 3 plate reader (Molecular devices, CA, USA) of which had 
its plate compartment pre-warmed to 37oC. Using an excitation and emission wavelength (Ex 
315 nm, Em 400 nm), the software was programmed to read the first column for 5 min after 
it added 10 µl of  sample to each well. After 5 min the plate reader automatically added the 
same samples to the next column and read for a further 5 min. This was continued until all 
columns had been aliquoted with sample and read for 5 min. The data was combined and 
later analysed using Graphpad™ Prism 5 statistical software.  
2.2.15 Cellular viability assay using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide).  
Investigating cellular redox reactions is used a tool to identify potential cellular stability, 
toxicity or proliferation in various cell lines when challenged with various molecules. While 
the overall reaction converts a water soluble MTT compound to an insoluble formazan, the 
rate at which this is carried out can be accurately used to investigate cellular functionality and 
potential cytotoxicity issues that may arise from a compound of interest.  
Experimental conditions require cells to be seeded at a cell density of 10 – 100 x 10-4. Cells 
were left to adhere overnight in culture medium suited for optimal growth. On day of 
experimentation, test conditions were prepared in KRBB buffer with various concentrations 
of glucose which match the test conditions seen in the acute secretory activity study (refer to 
section 2.1.2/3 for test condition preparation).  
On completion of compound co-incubation with KRBB, this was removed and cells were 
carefully washed with HBSS. Furthermore 100 µl of growth media was added back to each 
well of the 96 well plate and further supplemented with 20 µl of MTT solution (5 mg/ml stock). 
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The 96 well plate was then incubated for 2 – 4 hours (dependent on cell density) in a modified 
atmosphere (95% air, 5% CO2) tissue culture incubator at 37oC. 
The plates were visually inspected with MTT growth media aspirated and washed for a final 
time with 100 µl of HBSS. On completion of the final wash, 100 µl of DMSO was added, which 
dissolves the insoluble formazan crystals. The 96 well plate is placed onto an orbital shaker at 
RT for 5 min. Finally using a spectrophotember, the plate wass read at absorbance 570 nm 
with 630 nm correction. Results were then generated and analysed using Graphpad Prism 5.  
 
 
2.2.16 Identifying cellular toxicity using cytotox 96 non-radioactive cytotoxicity 
assay 
Lactate dehydrogenase (LDH) is a relatively stable and expressed intracellular enzyme which 
catalyses the conversion of lactate to pyruvic acid and vice versa (interconversion). LDH acts 
upon hydrides (single hydrogen accepting molecule) allowing NAD+ to convert to NADH and 
back again. This vital cellular respiratory activity makes LDH detection a valuable tool for 
cellular viability and toxicity. As LDH is an intracellular metabolite, the detection of this 
enzyme on the outside of the cell is a common marker of cellular injury and damage 
Using the cytotox 96 non-radioactive cytotoxicity assay (Promega, UK), cellular investigation 
was carried out using cultured cell lines at a cell density of 150 x10-5. Experimentation was 
carried out exactly as described in 2.1.2 with a final step of testing 50 µl of collected 
supernatant alloquoted into 96 well plates using test conditions (n=3) for released LDH 
concentration. Using the assay kit, 50 µl of cell supernatant was mixed with 50 µl of Promega 
LDH substrate solution and incubated at RT protected from UV light for 30 min. Once 
complete, 50 µl of stop solution (NaOH) was added and finally read at absorbance 595 nm 
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using a spectrophotometer 96 well plate reader. Results are then generated and analysed 
using Graphpad Prism 5.  
 
2.3.   Animal models 
2.3.1   Normal mice (NIH Swiss) 
NIH Swiss mice (Harlan UK Ltd., Blackthorne, UK) derived from a nucleus colony obtained from 
the National Institute of Health, Bethesda, Maryland were used for acute glucose lowering 
experiments. Prior to experimentation mice were acclimatized for 1 week on arrival on a 
standard rodent diet (10% fat, 30% protein, 60% carbohydrate; percentage of total energy 
12.99 kJ/g; Teklad Natural diet for rodents) (Envigo, Blackthorn, UK).  
Mice were housed in an air conditioned room maintained within a narrow temperature range 
of 22 ± 2oC with a 12 h light: 12 h dark cycle. Mice were used as a model of euglycemic. Mice 
were grouped depending on their body weight and non-fasting blood glucose concentration. 
Drinking water and standard rodent diet was freely available. All animal studies were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1986.  
 
2.3.2   Genetically-induced obese-diabetic (Ob/Ob) mice (B6.Cg-Lepob/J) 
Ob/Ob mice carry the homozygous gene for spontaneous mutation of the Lepob autosomal 
recessive chromosome 6 (Harris et al. 1998). Subsequently this model exhibits rapid onset of 
obesity (4 – 6 weeks) and obesogenic conditions commonly studied in metabolic research 
such as hyperphagia, glucose intolerance, elevated plasma insulin levels including 
hyperglycaemia making this rodent an good model for type 2 diabetes and potential 
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treatment of glucose lowering compounds and dietary related metabolic changes (Bailey and 
Flatt, 1982). Mice (10-12 week old) were ordered from Envigo, Blackthorn, UK.  
Mice were housed in an air conditioned room maintained within a narrow temperature range 
of 22 ± 2oC with a 12 h light: 12 h dark cycle. Mice were used as a model of insulin resistant 
type 2 diabetes Mice were grouped depending on their weight and non-fasting blood glucose 
concentration. Drinking water and standard rodent diet was freely available. All animal 
studies were performed in accordance with the UK Animals (Scientific Procedures) Act 1986.  
 
2.3.3   Multiple low-dose Streptozotocin induced diabetes model 
A large one-off dose of Streptozotocin (STZ) in fasted mice are typically used for the study of 
non-insulin resistant, insulin-dependent type 1 diabetes (Wu & Huan, 2008). Streptozotocin 
has a toxicity affinity toward the pancreatic β-cell causing a cascade of downstream effects 
including direct DNA methylation and eventual cell death via its high affinity for the GLUT2 
protein receptor, of which are in abundance on β-cells (Bolzán & Bianchi, 2002). 
Streptozotocin has no cross reactivity for other GLUT protein receptors explaining its potency 
for pancreatic β-cells. Doses used for type 1 diabetes are typically 165 – 220 mg/kg 
bodyweight in mice and 40 – 50 mg/kg in rats, however lower doses have been used 
successfully to partly inhibit insulin secretion via reduced cellular damage of the pancreatic 
β-cells (McEvoy et al. 1984; Deeds et al. 2011). This in-turn causes moderately elevated blood 
glucose concentrations. Insulin production was still evident in this model without the insulin 
resistance seen in other obesity derived diabetes rodent models.  
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HsD:Ola T0 mice (10 weeks old) were obtained from Envigo, Blackthorn, UK. Mice were 
housed in an air conditioned room maintained within a narrow temperature range of 22 ± 2oC 
with a 12 h light: 12 h dark cycle. Mice were grouped depending on their body weight and 
non-fasting blood glucose concentration. Drinking water and standard rodent diet was freely 
available. All animal studies were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986.  
Animals were injected with Streptozotocin (40 mg/kg bodyweight), which was prepared in a 
citrate buffer containing sodium citrate dehydrate (0.08 M) and citric acid (0.018 M) and pH 
to 4.5 with 1 M HCl. Drinking water was changed for sucrose water to reduce the potential 
overnight hypoglycaemia commonly seen with STZ injections. On the third day after the 
injection blood glucose was obtained from a tail bleed sample using a Bayer Contour 
glucometer (Bayer, Leverkusen, Germany). This process was repeated twice more for a total 
of 3 x 40 mg/kg bodyweight injections. Animals were given 9 days of acclimatization 
subsequent hyperphagia, polydipsia and hyperglycaemia to develop before they were 







2.3.4   Satiety and appetite study in 3 h fed trained animals 
Metabolic hormone homeostasis is controlled within narrow ranges in healthy individuals, 
however these regulatory mechanisms can be altered in conditions of severe obesity or in 
subjects with type 2 diabetes. Food intake and satiety hormones such as leptin and ghrelin 
present a diminished biological triggers when obesity, hyperglycaemia and hyperinsulimia are 
present (Klok et al. 2007). Using healthy animals which have controlled satiety after oral 
ingestion of nutrients can be used for assessing appetite for compounds that may promote 
satiety. Several hormones have been shown to play a role on promoting alterations to food 
intake such as leptin, ghrelin and more recently peptide YY (PYY 3-36) (Batterham & Bloom, 
2003) and cholecystokinin (CCK-8) (Little et al. 2005). When PYY or CCK is administered via 
intraperitoneal (ip) injection, food intake is reduced whereas the opposite is observed with 
ghrelin.   
HsD:Ola T0 mice (8 weeks old) were obtained from Envigo, Blackthorn, UK. Mice were housed 
in an air conditioned room maintained within a narrow temperature range of 22 ± 2oC with a 
12 h light: 12 h dark cycle. Drinking water and standard rodent diet was freely. All animal 
studies were performed in accordance with the UK Animals (Scientific Procedures) Act 1986.  
On arrival animals had access to food 24 h per day for 1 week. This was reduced to 10 h of 
food availability on week 2 with further reduction to 6 h by week 3. Finally, on week 4 and for 
the remaining duration of the animal satiety study, food availability was 3 hours per day from 





2.4   Acute animal studies 
2.4.1 Establishing the acute oral dose required for glucose lowering effect of 
marine protein hydrolysates 
A working hydrolysate dose was initially established using several interchangeable dosing 
approaches depending on the protein hydrolysate used. An initial hydrolysate dose of 100 
mg/kg bodyweight was used in experiments and further titrated to 50 mg/kg and 25 mg/kg 
until effect, if any was evident. The animal model used were NIH Swiss mice (section 2.3.1). 
Each group (n=8) were fasted for 8 h prior to experimentation and housed as described in 
2.3.1. Food was withheld during experimentation however access to water was available. 
Prior to compound administration a fasting tail blood sample was analysed for glucose 
concentration using a handheld glucometer (Bayer Contour, Leverkusen, Germany). A fixed 
dose (25 – 100 mg/kg bodyweight) of hydrolysate was then mixed with a dose of glucose (18.8 
mmol/kg bodyweight) and administered orally via gavage. The effectiveness of each 
hydrolysate was then established by further testing blood glucose concentration at various 
timepoints up to 2 h (15, 30, 60, 90 and 120 min).  After experiments were complete mice 
were given access to food and given a 72 hour washout period before any further 
experimentation was carried out on the same group of animals.  
 
2.4.2 Establishing the acute duration of biological action of marine protein 
hydrolysates 
Hydrolysates that were identified as having an oral glucose lowering effect were then carried 
onto further investigation using a delayed glucose tolerance test. This was investigated via 
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oral compound administration during fasting, followed by glucose (18.8 mmol/L) 
administration either 4, 8 or 12 h later to identify if a lasting glucose lowering effect was 
evident from the hydrolysate of choice. The glucose lowering dose of the hydrolysate was 
previously identified, mice were then fasted for 4 h and then administered a dose of 
hydrolysate depending on its glucose lowering effect. Animals were given access to only water 
and at 4, 8 or 12 h the animals were then given glucose (18.8 mmol/L) via oral gavage. Tail 
blood glucose concentrations were recorded using a handheld glucometer (Bayer Contour, 
Leverkusen, Germany). Similar to acute animal study, blood glucose concentration were 
established prior (0 min) and after oral glucose administration (15, 30, 60, 90 and 120 min). 
Animals were then given access to food and given 72 hwashout before further experiments 
could commence. 
2.4.3 Assessing the anti-diabetic efficacy of marine protein hydrolysates in obese 
diabetic ob/ob mice after chronic twice daily oral administration 
The acute and delayed glucose lowering effect of various marine protein hydrolysates were 
previously established using healthy NIH Swiss mice with homeostatic control of blood 
glucose concentrations. Using an animal model described in 2.3.2, 8 week old (n=32) ob/ob 
mice were given several weeks to fully establish markers of spontabeous type 2 diabetes, 
including obesity, hyperglycaemia, hyperphagia and polydipsia before being grouped 
according to bodyweight and non-fasting blood glucose concentration. Animals were grouped 
and assigned either a MPH compound or control. All animal groups were given twice daily 
oral saline to acclimatize for 3 days (day -3 to 0) and the assigned treatment started twice 
daily (09.00 h am & 17.00 h) from day 0 to day 27 after which some terminal analysis 
commenced. Mice were maintained on the twice daily treatment regime from day 27 until 
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the completion of the study (day 30).  During the study duration (30 day total) animals were 
assessed every third day with  blood glucose concentration, weight and food intake recorded 
alongside collection of blood plasma for future analysis. Collected blood plasma was 
centrifuged at 13,000 rpm for 5 min and stored in low-bind Eppendorf tubes at -20oC until 
analysed.  
 
2.4.2  Terminal parameters assessed in ob/ob animals 
 
2.4.3   Glucose tolerance tests (intraperitoneal and oral)  
Blood samples were measured from a minor tail vein bleed in fasted (8 h) ob/ob mice. Blood 
glucose was measured using a handheld glucometer (Bayer Contour, Leverkusen, 
Germany),prior (t=0) to administrating a glucose challenge (18.8 mmol/kg/bodyweight). Once 
administered, blood glucose was further analysed at 15, 30, 60, 90 and 120 min. At each 
timepoint a quantity of blood (approx. 50-80 l) was collected into fluoride coated 
microcentrifuge tubes (Starstedt, Mimbrecht, Germany) and immediately centrifuged at 
13,000 rpm for 5 min and stored frozen at -20oC in a fresh Eppendorf tube prior to insulin 
determination.. Plasma insulin concentration was determined by insulin radioimmunoassay 
(described in 2.2.3).  
 
2.4.4   Insulin sensitivity test  
Blood glucose concentrations of animals were measured from a minor tail vein bleed in non-
fasted mice using a handheld glucometer (Bayer Contour, Leverkusen, Germany). Blood 
glucose concentrations were measured prior to (t=0) and at 30 and 60 min post injection 
60 
 
following ip administration of bovine insulin as 25 U/kg bodyweight (normal NIH Swiss / 
HsdOlaT0 / C57Blk) or 50 U/kg bodyweight (ob/ob mice).  
 
2.4.5   Measurement of indirect calorimetry  
Mice were housed individually in a Complete Laboratory Animal Monitoring System (CLAMS) 
metabolic chambers (Columbus Instruments, Columbus, Ohio, USA). Consumption of 02 and 
production of CO2 was measured for 30 sec at 15 min intervals for a total of 20 h. Animals 
were housed within the CLAMS apparatus for 24 h prior to analysis to reduce anxiety related 
result bias. Respiratory exchange ratio (RER) was calculated by dividing VCO2 by VO2. Energy 
expenditure was calculated using RER with the following equation (3.815 + 1.232 x RER) x VO2. 
Ambulatory locomotor activity of each mouse was measured simultaneously using optimal 
beams (Opto M3, Columbus Instruments, Columbus, Ohio, USA). A breakage of photo-beams 
(X, Y and Z directional plane) was measured as physical movement recorded every min for a 
20 h period. 
 
2.4.6   Tissue excision 
On completion of all terminal experiments mice were fasted (4 h) and sacrificed. Mice were 
placed unconscious via oral inhalation of a general anaesthetic (Isoflurane) and euthanatized 
via cervical dislocation. The pancreas from each animal was excised removing any extraneous 
material. The pancreas was sectioned in half from the pancreas head to tail with half being 
wrapped in aluminium foil and snap frozen in liquid nitrogen and later stored at -70oC and the 
remaining half being placed into tissue fixative solution (4% paraformaldehyde) for later use 




2.4.7   Pancreatic hormone content  
Thawed tissue was rinsed in cold PBS before being weighed and transferred to a bijou where 
2 ml of ice cold acid ethanol (1.5% (v/v) HCL, 75% (v/v) ethanol, 23.5% (v/v) H20) was added. 
The bijou was then placed on ice for 30 min before being homogenized for 30 sec. The bijou 
was blitzed using a high-speed Homogenizer for 30 sec intervals for a total of 2 min per 
pancreas and placed back onto ice. The homogenate-containing bijou was kept on ice until 
centrifuged at 4000 rpm for 20 min with the resulting supernatant transferred to a fresh tube. 
Total volume was then increased by addition of 5 ml of TRIS-HCl (pH 7.4) and placed into a 
speed vac concentrator (45oC for 4 h) until all liquid was evaporated. The remaining sample 
was reconstituted in 500 µl of TRIS-HCl (pH 7.4) and stored in 1.5 ml polypropylene Eppendorf 
tubes at -80oC until analysis.  
 
2.4.8   Assessment of pancreatic insulin and glucagon content  
The pancreatic homogenate was diluted to a range of concentrations (1:100, 1:200, 1:500 and 
1:1000) using stock RIA buffer prepared in section 2.2.2 and tested for insulin content using 
the RIA described in section 2.2.3. Pancreatic glucagon content was assessed using a 
chemiluminescent sandwich ELISA (Millipore, Ontario, Canada) and run according to 
manufacturer instruction. Insulin and glucagon content were then calculated and further 
compared to total pancreatic protein content using the Bradford assay method for 









2.4.9  Total pancreatic protein content  
Insulin RIA and glucagon ELISA were used to determine total pancreatic hormone content. In 
order to quantify detected hormone percentage it was compared to total pancreatic protein 
concentration from tissue homogenate described in 2.4.7. The Bradford assay is a robust 
assay for its sensitivity and linear protein quantification using diluted samples. The assay was 
run at room temperature and results were generated using a microplate reader. Protein 
standards were prepared using a fixed concentration of bovine serum albumin (BSA) and 
diluted in a serial dilution.  Initially 10 µl of pancreatic homogenate was diluted with deionized 
H20 (1:10). The diluted sample was then pipetted onto a 96 well plate in duplicate (10 µl per 
well) with the addition of 250 µl of Bradford reagent added (Sigma-Aldrich, Dorset UK). The 
plate was then placed on an orbital shaker at 300 rpm for 5 min at room temperature. Finally 
the plate was read at wavelength 595 nm using a microplate reader (Flex Station 3, Molecular 
devices, CA, USA). Bradford reagent only was used as the blank control and was used to 
subtract the baseline absorbance. Results were plotted against the absorbance of the BSA 















2 1.942993537 1.997109257 
1.5 1.368010583 1.306675103 
1.125 1.066143515 1.014222876 
0.84375 0.821293029 0.769505098 
0.6328125 0.599225069 0.57879704 
0.474609375 0.43763023 0.41146972 
0.355957031 0.317086195 0.319783487 
0.266967773 0.223337896 0.239100276 
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2.4.10   Assessment of terminal plasma lipid profile  
Terminal blood plasma lipid profile was determined using an I-Lab 650 clinical chemistry 
system (Instrumentation Laboratory, Warrington, UK). The analysis consisted of assessing 
total triglycerides, total cholesterol, high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) concentration. Reagents for triglyceride analysis were obtained from 
Instrumentation Laboratory (Warrington, UK) and reagent for LDL cholesterol were obtained 
from Randox Healthcare (Randox, Co, Antrim, NI). 
 
2.4.1 Assessing the anti-diabetic effect of marine protein hydrolysates in 
Streptozotocin diabetes induced mice after twice daily oral administration 
Using an animal model described in 2.3.3, 10 week old (n=32) HsdOla:TO mice were 
administered several low doses of  Streptozotocin (40 mg/kg bodyweight x 3 over 6 days and 
monitored daily for 9 days total, (day 0, 3, 6 & 9), which causes β-cell damage with partial 
insulin secretion still observable. Animals were given 9 further days to acclimatize after the 
last STZ injection. Animals were monitored for signs of hyperglycaemia, weight loss, 
hyperphagia and polydipsia. Once the acclimatization period ended mice were grouped (n=7-
8) according to non-fasting blood glucose concentration and bodyweight. Each group was 
assigned a treatment and prior to treatment commencing animals were further acclimatized 
for 6 days (study day -6 to day -1) with twice daily oral saline (0.9% NaCl) gavage (09.00 h and 
17.00 h) to mimic the treatmentwhich started on study day 0. During the study duration (18 
day total) animals were assessed every third day with  blood glucose concentration, body 
weight and food intake recorded alongside collection of blood plasma for future analysis. 
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Collected blood plasma was centrifuged at 13,000 rpm for 5 min and stored in low-bind 
Eppendorf tubes at -20oC until analysed.  
2.4.2  Assessment of food intake in 3 hour trained feeding HsdOla:TO mice  
 
HsD:Ola:T0 mice (8 weeks old) were obtained from Envigo, Blackthorn, UK. Mice were housed 
in an air conditioned room maintained within a narrow range of 22 ± 2oC with a 12 h light: 12 
h dark cycle. Drinking water and standard rodent diet was freely available on arrival. Mice 
were trained to eat for 3 h per day as described in section 2.3.4. Before animals were given 
access to food for 3 h, food averaging 10 g was weighed. Animals (n=8) were administered a 
chosen compound by oral gavage dissolved in saline or a saline vehicle (0.9% NaCL) with food 
presented and weighed subsequently every 30 min up to 3 h. Food would then be removed 
until the following day.  Food intake was calculated and compared to the saline only (0.9% 




2.5   Human study 
2.5.1  Materials 
Rapilose™ OGTT solution (orange flavour, WHO recommended 75 g of glucose) were 
purchased from Galen Pharmaceuticals (Portadown, Co. Armagh, NI). Blood collection tubes 
were purchased from BD Biosciences (Oxford, UK) including serine protease inhibitors for the 
preservation of GLP-1 (P800 clear cap, 2 ml), fluoride oxalate tubes for the preservation of 
plasma glucose (grey cap, 2 ml) and anti-coagulation tubes for the preservation of whole 
blood plasma (lavender cap, 6 ml). Plasma collected was stored in Low-Bind© Eppendorf 
tubes purchased from Sigma-Aldrich (Poole, Dorset, UK). Hydrolysate (Boarfish) was obtained 
from University of Limerick following processing described in section 2.1. A tomato based 
chilli flavoured soup was produced and supplied by Ulster Catering College (Belfast, NI) and 
stored at -20oC until required then heated to °C and cooled before serving. 
 
2.5.2 Rescreening acute antidiabetic effect of Boarfish (Capros Aper) after scaling 
up of hydrolysate production  
Production of boarfish protein hydrolysate generated and sent to Ulster University from 
University of Limerick (as described in section 2.1 / semi-pilot scale) was scaled up and 
required subsequent re-screening for retention of bioactivity in cell cultures (as described in 
section 2.2.1) and in acute in vivo setting (described in section 2.4.1).  
 
2.5.3  Recruitment of study participants 
Ethical approval was sought via Ulster University Research Governance of research involving 
human participants (UREC). Approval for research with 20 participants was granted on 20th 
September 2016 (See appendix ?). The study required 20 participants of which were recruited 
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from within the University campus or neighbouring Causeway coast area. A mixed cohort of 
males and females (10 male 10 female) with body mass index below 25 kg/m2 were screened 
using anthropometric analysis before being confirmed as eligible for participation on the 
study.  
 
2.5.4  Acute effect of Boarfish (Capros aper) hydrolysate on markers of obesity, 
diabetes and satiety in healthy individuals 
 
The study was designed as a double-blind placebo controlled crossover trial that required two 
separate visits to the Ulster University, Human Intervention Study Unit (HISU) at Coleriane. 
Participants were randomly assigned to either placebo or control by a member of staff who 
was independent from the research team. Participants were required to fast from 22.00 h (if 
they were required to attend a 07.30 h session) or 23.00 h (if a 08.30 h session was attended). 
On arrival, a fasting blood sample was obtained via cannulation of the medial cubital vein on 
the non-dominant arm. A short questionnaire (visual analogue scale, VAS) was completed on 
feelings of hunger and current taste perception. The participant was then asked to consume 
a tomato based chilli soup (60 ml) which was or was not supplemented with 3.5 g of boarfish 
protein hydrolysate. Following this the participant was then asked to consume the Rapilose™ 
OGTT solution (300 ml) within 5 - 10 min. Blood samples were subsequently taken at set 
timepoints after completion of the OGTT solution (15, 30, 60, 90, 120, & 180 min) with further 
VAS on hunger and satiety completed by the participant at each blood collection timepoint.  
 
2.5.5  Collection of blood plasma for later analysis 
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Blood collected was processed immediately on withdrawal from each participant. Vials were 
first placed onto an orbital blood roller for 5 min before centrifugation. Vials were centrifuged 
at the manufacturers recommended instructions (P800 tube at 2000 g for 10 min, grey and 
lavender vials 3000g for 15 min). Separated plasma were finally labelled and aliquoted into 
smaller volumes in low-bind Eppendorf tubes and stored at -80oC until further use.  
 
2.5.6    Plasma analysis of glucose homeostasis and satiety hormones 
The study outcome aimed to analyse acute short-term markers that may indicate oral food 
derived antidiabetic compounds within the boarfish protein hydrolysate. Initially blood 
glucose concentration from 0 min to 180 min was measured using an I-Lab 650 clinical 
chemistry system (Instrumentation Laboratory, Warrington, UK). Blood plasma collected via 
BD P800 serine protease inhibitor blood collection tubes were analysed for glucose 
homeostasis metabolites and metabolites of satiety using Meso Scale Discovery (MSD) 4-plex, 
GLP-1 (7-36)amide, insulin, glucagon and leptin (Kit - K15174C, Meso Scale Discovery, 
Maryland, USA). Meso Scale Discovery uses a sandwich immunoassay with proprietary MSD 
SULFO-TAG™ technology allowing each labelled hormone to bind to their specific working 
surface electrode. Any unbound surface electrodes are blocked by the use of bovine serum 
albumin (MSD Blocker) and when read using the MSD Sector Imager, this correlates surface 
electrochemiluminescence to plasma metabolite concentration via linear calibration curves. 
Accuracy was assessed using a single pooled plasma sample and plate variance reported as 





2.5.7  Analysis of self-reported satiety and food preference using visual analogue 
scales 
Participants were required to attend both sessions fasted with perceived hunger and food 
preference assessed using visual analogue scales at each blood collection time point, prior 
and post consumption of the assigned compound. Each visual analogue scale was rated from 
0 to 10, with 0 as the lowest score of perceived hunger and 10 the highest score of perceived 
hunger. Similarly, food preference during the study was investigated determining if food 
preference was altered with the intake of each assigned compound. Each VAS was measured 
to the closest mm and scores were entered into IBM™ SPSS© statistical software and 
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Proteins are nitrogen-containing compounds consisting of amino acids joined together by 
peptide or covalent amide bonds. For aspects of life, protein serve as vital structural 
compounds in muscle and tissue within all living organisms (Hoffman & Falvo, 2004). In 
addition to making up integral structural components of an organism, proteins act as 
physiological messengers, signalling molecules, enzymes and hormones that play imperative 
roles for biological functioning (Walther  & Sieber, 2011). The energy that can be supplied via 
proteins are the same as carbohydrates however only when the protein is degraded to its 
simplest form, an amino acid. Unlike its caloric rival glucose, protein is regulated within tight 
requirement basis with protein being required on a day-to-day basis. This information leaves 
protein, one of the 3 main macronutrients, ruled out as a direct cause of obesity during 
protein imbalance, however increased protein intake without the requirement may affect fat 
balance (Galgani & Ravussin, 2008).  The makeup of a protein consists of a large number of 
amino acids in series (≥80-400+), which can contain any one of the 21 amino acids identified 
that are needed for human growth, repair and metabolism. The adult human body can 
synthesize 11 of the 20 amino acids under normal physiological conditions termed non-
essential, however, requirements must be met from exogenous sources for the remaining 9 
essential amino acids required. Additionally the non-essential amino acids can be further 
categorized into conditionally essential when higher than average requirements are needed 
which can be seen in a disease state or in an exercising individual (Lacey & Wilmore, 1990) 
Intake of protein at above recommended levels is widely accepted for those with athletic 
goals or competing in resistance and endurance sports (Phillips & Van Loon, 2011). Protein 
intake levels typically exceed the recommended daily amount in a healthy, active individual. 
Recent trends in weight loss have led to a marked increase in protein intake globally, the 
recommendations of 0.8 g/kg BW/d is contrived in individuals that have renal impairment and 
as such should closely monitor protein intake (Martin et al, 2005). The renal impairment, the 
ability of the kidneys to remove the amino acid metabolites and urea waste from the blood 
in hindered and as such accumulates.  
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There is concern over increased protein intake and the promotion of renal impairment 
in otherwise healthy individuals, however, with this noted the question relies on sufficient 
evidence provided to assess such a statement. Protein intake is a reported modulator of renal 
function and as such has spawned the ongoing controversy over compensatory renal 
hypertrophy and thus the changes seen in renal function (Calderon et al, 2004). At this 
moment, elevated intakes of protein are not cause for global concern with several studies 
providing beneficial study outcomes of increased protein intake, mainly the offset of other 
macronutrients such as carbohydrates, cause increased secretion of satiety hormones 
(Leptin, GIP and GLP-1) (Karamanlis et al, 2007), while having the opposite effect on the 
orexigenic hormone ghrelin (Leidy et al, 2007) with acute improvement in glycaemic profile 
in non-insulin dependent type 2 diabetes patients (Pomerleau et al, 1993). 
The incorporation of protein with carbohydrates has led to researchers investigating 
the link between glucose excursions or decreased post-prandial glucose elevation. In patients 
with type 1 diabetes, high protein dietary incorporation increased glucose excursion however 
had a protective effect lowering hypoglycaemic events (Smart et al, 2013). Using 
macronutrient comparisons, on a gram to gram basis, protein has the ability to elevate post-
prandial glucose concentration as efficiently as carbohydrates alone. This was seen in high-
protein low carbohydrate diets in untreated type 2 diabetic patients, overall glycaemia was 
chronically improved suggesting enhanced gluconeogenesis and reduced fasting glucose 
concentration due to carbohydrate reduction with insulin sensitivity enhancement (Gannon 
& Nuttal, 2004). With this noted, proteins combined with carbohydrates displayed attenuated 
glucose elevation when observed and overall acute glucose lowering effect having 2 to 3 fold 
greater effect than fat supplementation (Moghaddam et al, 2006). The mechanism of this is 
now understood as the post-prandial incretin effect accompanied with reduced gastric 
emptying. The intestinal nutrient sensing cells are also involved via secretion of potent insulin 
secreting hormones of which will be discussed later in greater detail (Karamanlis et al, 2007).  
The source and type of protein affects the displayed therapeutic effect, otherwise 
described in layman’s as fast or slow proteins, of which display various effects on blood 
glucose spikes in both healthy individuals or those mild to moderate glucose dysregulation. 
The digestion rate and appearance of amino acids within the blood stream describe the 
characteristics of the protein (Deutz & Wolfe, 2013). The impact of post-prandial glycaemia 
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on health and disease prevention related to metabolic syndrome and diabetes is an area of 
wide academic interest. Chronically increased nutritional intake in relation to 
hyperinsulinemia and lipidaemia is implicated in the development of obesity, cardiovascular 
disease and type 2 diabetes mellitus (Ley et al, 2014). Carbohydrates are the most important 
macronutrient within the human diet as a fuel source, however interest in protein, protein 
hydrolysates and its peptide and amino acid degradation products have directed research to 
rethink the overall goal of high protein intake for attenuation of health and disease states 
especially those related to glucose homeostasis and diabetes (Manders et al, 2006; Van loon 
et al, 2003; Clemmensen et al, 2013). 
Common protein sources 
Exogenous proteins are available from a wide array of dietary sources. Typically the human 
diet consists primarily of protein from animal and plant origin (Bilsborough & Mann, 2006). 
More recently dietary patterns and the incorporation of protein from supplemental sources 
have become increasingly popular (Wolfe, 2000). Nitrogen based supplements take full 
advantage of industry by-products, such as whey protein during cheese manufacturing. By-
products are often resold and processed, powdered and flavoured for addition to food 
matrixes or high quality food replacement or addition supplements for nutritional 
improvement, sports and exercise use and bioengineering (Kapoor et al, 2017). Dietary 
incorporation of complete proteins, those of which contain all the essential and non-essential 
amino acids is accomplished easily from animal sources whereas proteins of plant origin lack 
several amino acids that must be obtained from several sources, i.e. a vegetarian can obtain 
all amino acids more efficiently via dietary incorporation of several different plant sources 
rather than relying on a single biological source of protein (Young & Pellett, 1994)  
Dairy derived protein types 
In recent years data from epidemiological studies has shown that dairy consumption is 
associated with a decrease prevalence of metabolic related disorders with experimental 
studies pointing towards dairy protein as holding the key to this success (McGreggor and 
Poppitt, 2013). Increasing dietary intake of dairy derived proteins are now widely available 
from many sources of dairy. Whey is described as the transient liquid part of milk that is left 
over following the coagulation and curd removal in cheese making abundant in beta-
73 
 
lactoglobulin and alpha-lactalbumin. Proteins within the liquid can be separated using various 
techniques and purified to the desired protein concentration afterwards. Whey is described 
as one of the 2 main milk derived proteins with whey accounting for approximately 20-25% 
of total protein content with casein accounting for the remainder. Milk protein sources 
provide a large quantity of readily available amino acids of which makes whey protein a 
valuable product worldwide. Nowadays It’s not surprising that the idea surrounding milk and 
milk products having a beneficial metabolic effect as its complex in nature, containing all the 
vital nutritional components to sustain and support life and nutritional development (Pasin & 
Comerford, 2015). 
The processing of whey has several advantages, whey powder with minimal 
processing can be used as a food additive seen in snacks, confectionary and bakery items. Its 
sensory characteristics vary which can be used to alter the taste of a product making it a 
valued product in food manufacturing. Concentrate whey however involved hands-on 
processing of which aims to remove unwanted lactose, lipids and various minerals. This 
intermediate processing step between whey and whey isolate is favoured in sports due to its 
biologically active components, micronutrient and trace elevment profile (Geiser, 2003). 
Lastly whey isolate involved rigorous processing and yields the highest protein content of all 
whey variants described, however with intensive processing denaturation of the protein 
structure removing peptide bonds and lowering protein activity, this product still generally 
remains safe for those with lactose intolerance.  
 
Plant derived protein types 
Plant proteins have reduced essential amino acid diversity and lack methionine, lysine and 
tryptophan however when combined from various sources still provide vital nourishment to 
individuals who abstain from animal products or for those who may have hypersensitivity 
allergies to animal products such as lactose intolerance or cow milk protein allergy (CMPA). 
The benefits of plant proteins were once based upon population based studies regarding 
volume of plant based food intake versus animal derived products. It’s now considered that 
the constituents of plant based foods, such as soya protein, the most widely consumed source 
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of plant protein may have more than a purely nutritional role in disease prevention (Hasler, 
2002) 
 Higher intakes of non-essential amino acids are reported among vegetarians and as 
such offset intakes of essential amino acids. Lower levels of lysine and methionine are 
reported in individuals which consume protein from plant sources and as such 
hyperproteinaemia is a concern (Krajcovicova-Kudlackova et al, 2005). This condition displays 
abnormally low blood protein concentration may become commonplace without adequate 
nutritional knowledge (Key et al, 2006). The benefits on consuming plant based proteins and 
reducing cardiovascular health risk is well documented within the literature (Richer et al, 
2015). Plant protein hydrolysates yield abundant small molecular weight peptides that in 
experimental settings have displayed prevention of hypertension (Yang et al, 2004), promote 
heart health (Erdman, 2000) and have less total lipid and carbohydrate content which may 
promote weight loss, improve insulin sensitivity and promote glucose homeostasis (Tian et al, 
2017). There is an overall interest for knowledge of the diet and the way in which the protein 
is consumed. However, dietary alternations such as abstaining from animal protein sources 
in favour of plant based protein sources that contain other beneficial components remain a 
difficult factor to control for.  
 
Animal meat protein 
Proteins obtained from animal sources (i.e Poultry, meat & fish) provide the largest selection 
and quantity of amino acids due to the completeness of the protein source. The overall 
quantity of amino acids obtained from these sources are significantly greater than the plant 
variants.  While these protein sources contain valuable dietary protein, other constituents are 
present that have contrived sustenance for regularly dietary intake such as saturated fat, 
cholesterol and increased sodium content involved in processing.  
 Animal proteins act as connective tissue and structural components to support 
movement and activity. These proteins known as myofibrillar proteins that consist mainly of 
actin, myosin and titin. Stromal proteins consisting of collagen, elastin and reticulins as well 
as sarcoplasmic proteins containing biologically active proteins such as myoglobin (colour of 
muscle) and haemoglobin (oxygen transfer protein). 
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 Protein content varies between species, with the average protein content averaging 
20-25% of with remaining consisting of water, lipids and intramuscular energy stores. 
Controversy surround animal products extend primarily to their lipid, sodium and cancer 
promoting heterocyclic amine compounds when overcooked (Zheng and Lee, 2009), however 
as a protein source it is favoured in many situations. When comparing plant base protein to 
animal, animal protein favours anabolic response. In a healthy active individual the improved 
amino acids profile of animal protein which contain higher quantity of methonine, lysine and 
leucine have beneficial effects for recovery, endurance and performance (Van Vilet et al, 
2015). 
 
Novel protein sources 
As the global population expands the search for sustainable macronutrient sources have 
proven a worthwhile endeavour. The ability to produce mass amounts of carbohydrates, lipids 
and protein from novel sources has also unearthed sources of minerals and macronutrients 
that may be exploited for health promotion. Ancestral dietary patterns are re-emerging and 
coined as possible ways of improving nutritional health and wellbeing over current dietary 
applications (Cerna, 2011). Current production of animal protein sources is seen as 
problematic due to mass greenhouse gas production and direct impact on environmental 
hygiene. Novel sourced food by-products that yields desirable macronutrients, especially 
protein, are of interest in a bid to reduce overall food waste and improved food utilization 
and as such has taken the front seat for driving research and industry to work together to 
identify new food sources (Batista, 1999)  
Table 1.4 Seaweed (Dulse) Insects (Crickets) Brewers spent 
grain 
Protein 10 – 35 % >55 % ≥20 % 
Lipids <1 % 25 % nd 





Protein structure  
Within the protein complex are a combination of amino acids connected in series via peptide 
bonds. The structure of proteins vary due to their amino acids and the amino acid sequence 
however rules regarding protein characteristics follow a special arrangement that define its 
bioactivity. Proteins contain several structural units, primary, secondary, tertiary and 
quaternary. For the purpose of amino acid and/or peptide liberation the primary structure of 
the protein contains the amino acid sequence of interest. The remaining structural 
characteristics define the protein shape (secondary), folding capacity (tertiary) and 
protein/protein interaction (quaternary). 
Protein bioactivity 
Nutritional approaches describe protein bioactivity as the duration it takes from protein being 
ingested to the amino acids being found in circulating systems. Newer approaches describe 
bioactivity as the affect seen on biological process directly or via substrates that have an 
impact on bodily systems (Jeewanthi et al, 2017). Unlike carbohydrates and lipids the 
bioactivity of proteins including functionality and biological activities can be improved via 
hydrolysis to release peptides or amino acids (Pouliot et al, 2009). The intake of protein in the 
general population may be for exercise, growth and repair of tissue or for recovery from 
illness that requires higher nutritional intake however underlying mechanisms are involved in 
more than a caloric role. The history of increased protein intake via supplementation is a short 
one however the industry continues to innovate searching for novel sources of protein and 
markets for these value added products. More recently hydrolysis of protein to form smaller 
bioactive peptides targeting exercise and endurance and furthermore health promotion has 
become increasingly popular. Evidence exists that di- and tri-peptides are absorbed more 
rapidly than free amino acid, of which a magnitude have been identified having potent 
bioactivity using experimental approaches (Webb, 1990; Geissler et al, 2010) 
 The term bioactivity is derived from foods and food components that can affect 
biological processes, endogenous substrates or produce subunits that have an impact on 
health, physical condition and bodily functions. Protein bioactivity relating to its degradation 
products also encompass the peptides that are liberated during digestion. Peptides from 2 to 
20 amino acids in sequence are of interest due to their specific receptor affinity, agonistic or 
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antagonistic signalling characteristics and ability to affect biological processes (Daliri et al, 
2017). Identifying the urgent need for cost effective methods for the production, screening 
and application of bioactive proteins that that may yield further bioactive peptides applicable 
to health promotion is more important now than ever before.  
Hydrolysis of protein occurs when bonds between adjacent amino acids are broken. 
The process of hydrolysis, meaning hydro “water” and lysis “break” is the use of water 
molecules to uncouple and liberate amino acids or peptides from the primary protein 
complex. However there is a limiting caveat that only certain proteins can under hydrolysis 
using water. Protein structure including the tertiary portion of the protein or the folding 
capacity of the protein dictates its water interaction and thus the hydrolysis. As such 
specialised proteolytic enzymes can be used in order to overcome this hydrolysis limitation, 
of which will be discussed (Adler-Nissen, 1976). 
 
Protein degradation using proteolytic enzymes 
Proteolytic enzymes are capable of hydrolysing peptide bonds within a protein complex 
liberating peptides and amino acids. Commonly referred to as peptidases, proteases and 
proteinases can be found in all living organisms (Motyan et al, 2013; Barrett & McDonald, 
1986). Enzymes are vitally important for physiological functioning and as such have great 
medical and pharmalogical roles (Park & Breckenridge, 1981). The role of enzymes in 
biological lifecycles are now more apparent than ever with research attempting to take 
advantage of these enzymes and evaluate their application for industry and biotechnology. 
From a researching aspect, enzymes serve as imperative applications for improved life 
sciences from tissue dissociation, peptide synthesis, and digestion of unwanted proteins for 
diagnostics and therapy with the market currently worth an estimated $3 billion in value 
(Sarrouh et al, 2012).  
 The classification of the enzymes relies on origin and target, ranging from microbial or 
plant derived to animal and human origin. These enzymes are further categorized based on 
their protein molecule interaction. The classifications can be derived due to the site of action 
that the enzyme interacts with the protein. Endopeptidases cleave specific peptide bonds 
between amino acids whereas exopeptidases target peptide bonds near the C- or N- terminus 
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of the peptide chain. Enzymes such as carboxypeptidases cleave single amino acids from the 
peptide chain whereas aminopeptidases can be used to liberate dipeptides (dipeptidyl 
peptidases) or tri-peptides (tripeptidyl peptidases). The application of these enzymes can be 
individual or used in combination or sequential hydrolysis of the intact protein. Partial 
hydrolysis describes when a certain molecular weight target or certain cleavage site is 
exhausted is achieved using 1 or more enzymes during the hydrolysis process.  Complete 
hydrolysis described when all peptide bonds are cleaved leaving only free amino acids behind.  
Partial and complete hydrolysis of protein can be utilized for applications for health 
promotion.   
The role of liberated free amino acids are well documented within the literature. It 
was considered that the fate of all proteins ingested orally would result in absorption via the 
intestinal in their individual amino acid state and while it’s debated we know small peptides 
are able to pass through into circulation and may stimulate a biological response. Amino acids 
have momentous health promotion effects and regulatory roles while acting as biological 
catalysts affecting appetite, metabolic regulation, endocrine status, body composition, cell 
signalling, protein synthesis, reproduction and lactation, respectively. The process of 
liberating free amino acids from exogenous protein sources, while mentioned above, heavily 
relies endogenous enzyme activity, primarily produced within the gastric tract, mainly 
stomach, small intestines and pancreas following intake of food.  
 
Summary of food derived marine peptides,  
To date there has been a significant development of biologically active food proteins with 
clinical, therapeutic and health promoting effects beyond pure nutritional requirement. This 
has promoted researchers to look upon protein as a resource for potential development of 
protein derived molecules that may have intrinsic health promoting effects. The development 
of identified peptides that hold metabolic regulatory effects has expanded exponentially, 
however these often require injection to unlock the full potential of the molecule once a 
disease target has been identified.  
Many of these peptide molecules that are liberated from longer protein chains have similar 
properties, relatively short (eg. 2 – 20 aa) and contain hydrophobic amino acids residues as 
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well as arginine, lysine and proline groups which are resistant to digestion when ingested 
orally.  Smaller peptide molecules are of interest for their ability to act upon signalling 
mechanisms similar to larger specific molecules as well as being cheaper to manufacture. 
Crude bioactive peptides taken orally are of interest due to their resistance to intestinal 
digestion enzymes. These small molecular weight peptides are thought to pass the intestinal 
brush boarder and have circulatory signalling activity, as well as displaying potent post-
prandial incretin effect in vivo.  
Food derived peptides from gluten or casein may act as an antihypertensive with properties 
that can inhibit angiotensin I converting enzyme (Ibrahim et al, 2017), milk proteins containing 
anti-inflammatory peptides activing upon opioid receptors (Chatterton et al, 2013) and soy 
peptides acting upon superoxide anions and antioxidant peptides containing 
immunomodulatory activity (Sanchez & Vazquez, 2017).  Marine proteins will however be the 
focus of the remainder of this chapter and further chapters. Using marine protein as a 
therapeutic for type 2 diabetes has been a relatively novel endeavour. The oceans are 
considered the richest and most untapped source of bioactive compounds (Khan et al, 2016). 
As population increases the need for new novel protein sources is vital and as such has led to 
underutilized pelagic ichthyoid species being used to generate new and novel protein and 
subsequent peptide hydrolysates.  It is hypothesized that marine protein has the ability to 
yield a greater quantity of bioactive peptides that are resistant to gastrointestinal digestion, 
making them a potential source of nutraceutical with meaningful metabolic regulating effects.  
Studies involving marine peptides have displayed anti-carcinogenic and antihypertensive 
abilities while further regulating circulating lipids and glucose making them of interest to 
metabolism and diabetes research.  The typical procedure for discovery of novel bioactive 
peptides involves protein extraction from source, enzymatic digestion using a wide array of 
proteases, further fractioned using analytical machinery such as RP-HPLC or electrophoresis 
then assessed using bioassays and finally purified as a single bioactive peptide for further 
investigation. With this noted, the work presented in this chapter will contain only that of the 
crude protein fractions obtained via enzymatic digestion. Bioactive molecules from the crude 
peptide hydrolysates have been identified and as such is an area that is being actively pursued 
and discussed in later chapters.   
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The effects of the crude protein hydrolysates was first investigated using in-vitro bioassays. 
Using a concentration of protein hydrolysates (2.5 mg/ml) from various marine sources that 
have undergone enzymatic digestion the research was able to target diabetes specific states 
using tailored assays that may give a broad overview of the therapeutic potential of marine 
protein hydrolysates when ingested orally.  In this present study, cell lines of interest were 
the insulin secreting BRIN-BD11, Glucagon-like-peptide 1 (GLP-1) secreting GLUTag cell line, 
and finally the glucose-dependant insulinotropic polypeptide (GIP) secreting STC-1 cell line. 
Furthermore, glucose uptake studies were performed on differentiated 3T3-L1 fibroblast cells 
as well as the investigation of protein/protein interaction using amylase and DPP4 enzyme 
bioassays while finally the toxicity of the marine protein hydrolysates were tested on each 
cell line mentioned using cellular proliferation and intracellular molecule production assays. 
Background & Aims 
There are many methods available to hydrolyize proteins into smaller peptide fractions of the 
parent protein molecule. The previous chapter elaborated on the hydrolysis methods used to 
generate numerous protein hydrolysates from novel biological marine sources using various 
enzyme combinations. The enzymes used ranged from single use endopeptidases, targeting 
specific amine groups within the protein, to sequential hydrolysis using a mixture of more 
than one endopeptidases and exopeptisases. The current hypothesis is that the use of a single 
peptidase will not yield bioactivity similar to using more than one peptidase in the generation 
of the protein hydrolysates. The rationale for this relies on the greater number, and variance 
of peptides that can be unlocked using multiple peptidases rather than a single peptidase. In 
order to test the hypothesis, a range of diabetes specific assays will be deployed across 
multiple cell lines, including the insulin secreting BRIN-BD11, GLP-1 secreting GLUTag and GIP 
secreting STC-1 cells. Furthermore, protein-protein interactions investigating endogenous 
enzyme activity in the presence of the generated protein hydrolysates such as DPP4 and 
Amalayse activity will be investigated. Finally, the effect on toxicity at the cellular level using 
the well established LDH and MTT assays will assess any adverse effects during acute co-
incubation with various hydrolysates in vitro. Once the bioactivity ranges across the 
aforementioned experiments have been assessed, the most promosing hydrolysates will be 




3.2 Materials and Methods 
Sample preparation of crude marine peptide hydrolysates 
As discuss and detailed in chapter 2 (2.1 hydrolysate preparation), hydrolysates from several 
sources were screened for bioactivity in vitro. The hydrolysate were produced from boarfish 
(Capros aper), blue whiting (Micromesistius poutassou), salmon (Salmonidae) including 
separated skin and muscle trimmings and finally Dulse (Palmaria palmata). On extraction of 
intact protein subsequent hydrolysis was carried out using various proteases, outlined in 
section 2.2.  
 
Acute insulin secretory activity in BRIN-BD11 cells 
Insulin radioimmunoassay (RIA) was used for the determination of insulin from both insulin 
secreting cell lines and from ex-vivo biological plasma samples (Flatt & Bailey, 1981). Initially 
BRIN-BD11 cells are seeded onto 24 well plates and incubated with compounds of interest for 
1 hour and subsequently collected for later analysis (described in 2.1.3) using RIA. In brief cells 
are seeded at a cell density of 1.5 x 105 cell/well in 1 ml of RPMI cell culture media and left 
for 21 hours to adhere.. After 20 minutes of co-incubation with compounds of interest 900 µl 
is removed from each well and stored until analysed via insulin radioimmunoassay at -20oC. 
A detailed outline is described in 2.2.1 
 
GLP-1 secretion from GLUTag mouse enteroendocrine cells 
On experimentation day DMEM culture media is removed, cell prepping KRBB (1 mmol/L 
glucose) is added for 2 hours then removed and further supplemented with KRBB of which 
contains 2 mmol/L glucose in all conditions (baseline) with compounds of interest used in a 
dose dependant manner in n=4 wells minimum. After 2 hours of co-incubation with 
compounds of interest 900 µl is removed from each well and stored until analysed via ELISA 
at -20oC. A detailed outline is described in 2.2.2 including ELISA protocol in section 2.2.4. 
GIP secretion from STC-1 mouse enteroendocrine cells 
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As outlined in section 2.2.3 cells were seeded on 24 well plates as described in 2.2.1. Removal 
of experimental supernatant were stored at -20oC until analysis. For an in-depth protocol 
including the GIP ELISA used see section 2.2.10. 
 
Acute Intracellular Ca2+ mobilization  
BRIN-BD11 cells were seeded at a cell density of 90,000 cells per well in Costar, black walled, 
Clear bottom 96 well plates (Appleton-Woods, Birmingham, UK) and incubated for 21 hours 
at 37oC (95% O2, 5% CO2). A fluorometric membrane potential assay was purchased from R&D 
Systems (Minneapolis, USA). Refer to section 2.2.11 for full experimental protocol. 
 
Acute cellular membrane potential  
A fluorescent membrane potential assay was purchased from R&D Systems (Minneapolis, 
USA). Using a proprietary long wavelength membrane indicator to detect the membrane 
potential change that is caused by the opening and closing of ion channels. The protocol was 
run as indicated in the manufacturer guidelines. Protocol in brief, 100 µl of working KRBB 
buffer supplemented with 5.6 mmol/L glucose was added to each well after removal of media. 
Refer to section 2.2.12 for full experimental protocol.  
 
Cellular toxicity using LDH cytotox assay 
Experimentation was carried out exactly as described in 2.1.2 with a final step of testing 50 µl 
of collected supernatant aliquoted into 96 well plates using test conditions (N=3) to 
determine LDH concentration. Using the assay kit, 50 µl of cell supernatant is mixed with 50 
µl of Promega LDH substrate solution and incubated at RT protected from UV light for 30 
minutes. Refer to 2.2.16 for full experimental procedure.  
 
Cellular viability using MTT proliferation assay 
Test conditions are prepared in KRBB buffer with various concentrations of glucose of which 
match the test conditions seen in the acute secretory activity study’s, refer to section 2.1.4 





Data was expressed as mean ± SEM with values compared using one-way analysis of variance 
(ANOVA) followed by post-hoc students T-test. Data between groups were considered 




Insulinotropic activity of Marine protein hydrolysates 
 
Fig 3.1 A/B - The acute insulinotropic activity during co-incubation with known insulin 
secretagogues in BRIN-BD11 cells.  
Insulin secretion was determined over a 20 minute co-incubation with various MPH and 
glucose. Baseline insulin secretion was established using KRBB buffer online containing a fixed 
dose of glucose at 5.6 mmol/L (Fig 3.1-A) or 16.7 mmol/L (Fig 3.1-B). All other test conditions 
contained addition compounds from positive insulinotropic controls to a dose dependant 
concentration of MPH. The positive controls deployed KCL (30 mM) and GLP-1 (10-6) displayed 
8 –fold (p<0.001) and 5 -fold (p<0.001) insulin secretion versus baseline (5.6 mmol/L) glucose, 
respectively. 
 
Fig 3.2 – 4 & 3.6 - 8 - Insulinotropic marine protein hydrolysates generated from Palmaria 
palmata 
Using a fixed dose of palmaria palmata (ULPH018, 0.0195 – 2.5 mg/ml) in KRBB buffer 
containing 5.6 mmol/L glucose, the aqueous alkaline protein hydrolysate caused significant 
insulin secretion at 1.25 and 2.5 mg/ml MPH (P<0.01 to P<0.001; Fig Fig 3.2-A) respectively. 
This hydrolysate is used as a bioactive baseline as the peptides were generated using only 
aqueous hydrolysis. Subsequent hydrolysates have further undergone enzymatic hydrolysis 
or/and simulated gastrointestinal digestions (SGID).  
The SGID variant ULPH042 had improved insulinotropic activity showing significant 
dose dependent insulin release from 0.312 to 2.5 mg/ml (P<0.05 to P<0.001; Fig 3.2 B). The 
enzymatically produced ULPH019 (Alcalase) similarly displayed insulin secretory activity from 
0.312 to 2.5 mg/ml (P<0.001; Fig 3.2 C), however after SGID, the insulinotropic activity was 
84 
 
lost with only 1.25 and 2.5 mg/ml showing bioactivity (P<0.05 to P<0.01; Fig 3.2 D). 
Hydrolysate ULPH020 (Alcalase/Flavourzyme) displayed cellular bioactivity and insulin 
secretion from 0.156 to 2.5 mg/ml of MPH (P<0.01 to P<0.001; Fig 3.3 A). The SGID variant, 
ULPH036 had lost its insulinotropic activity at 0.156 and 0.312 mg/ml, however remained 
potent at 0.625 to 2.5 mg/ml (P<0.001; Fig 3.2 B).  
The Bromelain produced hydrolysate, ULPH021 had promising insulin section activity 
displaying dose dependent bioactivity ranging from 0.078 mg/ml to 2.5 mg/ml (P<0.05 to 
P<0.001; Fig 3.3 D) however this activity was reduced after further SGID was carried out with 
activity seen from 0.312 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.3 D), respectively. Finally the 
Promod produced hydrolysate, ULPH022 had insulinotropic activity from 0.625 to 2.5 mg/ml 
(P<0.01 to P<0.001; Fig 3.4 A) and had retained this activity after SGID production of ULPH040 
with activity remaining from 0.625 to 2.5 mg/ml (P<0.05 to P<0.001; Fig 3.4 B).  
 
The Palmaria palmata hydrolysates were similarly tested in supra-physiological glucose 
concentrations tested in KRBB supplemented with 16.7 mmol/L glucose, respectively. The 
positive controls deployed KCL (30 mM) and GLP-1 (10-6) displayed 11 -fold and 6 -fold insulin 
secretion versus baseline (16.7 mmol/L) glucose (Fig 3.1 B). The aqueous produced 
hydrolysate, ULPH018 resulted in significant insulin secretion from 0.312 to 2.5 mg/ml 
(P<0.01 to P<0.001; Fig 3.6 A) whereas, similarly seen with the SGID variant, ULPH042 
displayed improved potency and dose-dependent insulinotropic activity from 0.156 to 2.5 
mg/ml (P<0.01 to P<0.001; Fig 3.6 B), seen also when tested at 5.6 mmol/L glucose, 
respectively.  
The enzymatically produced hydrolysates, ULPH019 (Alcalase) resulted in significant 
insulin secretion from 0.625 to 2.5 mg/ml (P<0.001; Fig 3.6 C), whereas some activity was lost 
in the SGID variant (Alcalase + SGID) were elevated insulin secretion was only reported at 1.25 
to 2.5 mg/ml (P<0.001; Fig 3.6 D). The Alcalase/Flavourzyme hydrolysate, ULPH020 displayed 
dose-dependent secretory activity from 0.312 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.7 A) and 
retained insulinotropic potency after SGID processing, were ULPH036 resulted in activity from 
0.625 to 2.5 mg/ml (P<0.001; Fig 3.7 B). The Bromelain produced ULPH021 hydrolysate 
similarly returned insulinotropic activity from 0.625 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.7 
C) and further activity was observed after SGID processing and generation of ULPH038 were 
bioactivity was observed from 0.312 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.7 D). Finally, of 
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the Palmaria palmata hydrolysates, the Promod generated ULPH022 displayed insulinotropic 
activity from 0.625 to 2.5 mg/ml (P<0.001; Fig 3.8 A), however after further SGID processing 
and generation of ULPH040, dose-dependent activity was improved upon with potent 
insulinotropic activity displayed from  
0.156  2.5 mg/ml (P<0.001: Fig 3.8 B), respectively.  
 
Fig 3.9 - Insulinotropic marine protein hydrolysates generated from Blue whiting 
Blue whiting protein hydrolysate generated using Alcalase and Flavourzyme, ULPH063, 
displayed dose dependant insulinotropic activity during 20 minute co-incubation in BRIN-
BD11 cells. Activity was displayed from 0.078 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.9 A). The 
insulinotropic activity was retained after SGID processing, however only from 0.156 to 2.5 
mg/ml (P<0.01 to P<0.001; Fig 3.9 B). Blue whiting ULPH072 protein of which only underwent 
SGID processing similarly displayed potent insulinotropic activity from 0.078 to 2.5 mg/ml 
(P<0.001; Fig 3.9 C), respectively.  
 
Fig 3.10 - Insulinotropic marine protein hydrolysates generated from Boarfish (Capros aper) 
Boarfish hydrolysate generated using Alcalase and Flavourzyme enzymatic digestion, 
ULPH062, resulted in a 1.3 to 4 –fold insulin secretion versus baseline glucose control. The 
activity was displayed from 0.078 to 2.5 mg/ml (P<0.01 to P<0.001, Fig 3.10 A). Using only 
SGID hydrolysis, ULPH066 displayed 1.8 to 5.5 –fold insulin secretion versus basal glucose 
control. Activity was seen from 0.156 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.10 B). Using both 
enzymatic digestion (Alc/Flav) and further SGID digestion, potency of hydrolysate ULPH068 
was retained at higher concentrations however reduced at the previously significant lower 
concentrations. 1.2 to 5.8 –fold activity was displayed from 0.156 to 2.5 mg/ml (P<0.01 to 
P<0.001; Fig 3.10 C), respectively. The production of Boarfish protein hydrolysate on large 
scale was subsequently retested for bioactivity.  
 
Fig 3.11 - 13 - Insulinotropic marine protein hydrolysates generated from Salmon Trimmings 
(Capros aper) 
Using Alcalase, Alcalase and Flavourzyme in combination or Promod proteases with or 
without SGID processing, several hydrolysates were generated from Salmon muscle 
trimmings. The Salmon trimming hydrolysate generated using Alcalase only, ULPH051, had 
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displayed 2 –fold insulinotropic activity at 0.625 and 2.5 mg/ml only (P<0.05 and P<0.01; Fig 
3.11 A). Further processing of ULPH051 using SGID yielded ULPH057 of which displayed 
improved insulin secretion of 2.5 to 2.8 –fold increase versus basal control. Insulin secretion 
was displayed from 0.625 to 2.5 mg/ml (P<0.05 to P<0.01; Fig 3.11 C). Furthermore, ULPH052 
generated using Alcalase and Flavourzyme in combination had shown similar secretory 
activity ranging from 2 to 2.5 –fold higher insulin secretion versus basal glucose control. The 
activity was seen from 0.312 to 2.5 mg/ml (P<0.05 to P<0.001; Figure 3.11 B), however after 
SGID processing activity of ULPH059 was improved upon with 4 to 4.5 –fold increase in insulin 
secretion versus basal glucose control, respectively. Dose-dependent insulin secretion was 
seen from 0.625 to 2.5 mg/ml (P<0.01 to P<0.001; Fig 3.3.1-AI). Finally, hydrolysate ULPH053 
generated using Promod, insulin secretion ranging from 1.8 to 3 –fold versus basal glucose 
control was displayed from 0.312 to 2.5 mg/ml (P<0.05 to P<0.001; Fig 3.12 A). The same 
hydrolysate had undergone SGID with similar activity seen ranging from 1.8 to 3.8 –fold versus 
basal glucose control from concentration 0.156 to 2.5 mg/ml (P<0.05 to P<0.001; Fig 3.12 B), 
respectively.  
 
Incretin secretion (GLP-1) during co-incubation with marine protein hydrolysates 
 
Fig 3.14 A - Marine protein hydrolysate incretin effect from the GLP-1 secreting 
enteroendocrine    GLUTag cell line 
The enteroendocrine GLUTag cell line was investigated for its GLP-1 secreting ability. Positive 
controls, Glutamine (10 mM), Forskolin (10 mM) and GIP (10-6) returned from 2 to 4 –fold 
increased GLP-1 secretion versus 2 mM basal glucose control (P<0.05 to P<0.001; Fig 3.14 A), 
respectively. Using 2.5 mg/ml, all hydrolysates were subsequently co-incubated with 2 mM 
glucose.  
 
Fig 3.14 - 15 - Incretin effect of marine protein hydrolysates generated from Palmaria 
palmata 
During the 2 hour MPH co-incubation with 2 mM glucose, ULPH018 generated using aqueous 
hydrolysis only had reported 3 –fold GLP-1 secretion versus basal glucose control using 2.5 
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mg/ml (P<0.001; Fig 3.14 B), after SGID processing, potency of ULPH042 was reduced, 
however elevated GLP-1 secretion was still evident (P<0.001; Fig 3.14 B). Using Alcalase, 
ULPH019 displayed 2 fold (P<0.001) GLP-1 secretion whereas its SGID variant, ULPH034 failed 
to increase GLP-1 secretion over the basal glucose control (Fig 3.14 C). Similarly ULPH020 
promoted 2.2 fold GLP-1 secretion (P<0.001) however after SGID activity was lost in ULPH036 
(Fig 3.14 D). The Bromelain generated hydrolysate, ULPH021, resulted in 2 –fold (P<0.001) 
GLP-1 secretion and retained 1.4 fold (P<0.05) secretory activity after SGID generation of 
ULPH038 (Fig 3.15 A). Finally the Promod generated hydrolysate, ULPH022, displayed 1.6 –
fold (P<0.001) and SGID ULPH040, 1.4 fold (P<0.05) GLP-1 secretion versus basal glucose 
control, (Fig 3.15 B), respectively.  
 
Fig 3.15 C - Incretin effect of marine protein hydrolysates generated from Blue whiting 
Under the same experimental conditions, blue whiting hydrolysate generated using Alcalase 
and Flavourzyme, ULPH063 promoted a 1.4 fold (p<0.01) increase of GLP-1 secretion over 
basal glucose control, however after SGID processing of ULPH063 and generation of ULPH063, 
potency was improved upon and 1.8 –fold (P<0.001) GLP-1 secretion was displayed (Fig 3.15 
C).  
 
Fig 3.15 D - Incretin effect of marine protein hydrolysates generated from Boarfish (Capros 
Aper) 
Boarfish hydrolysate generated using Alcalase and Flavourzyme in combination, ULPH062 
returned 0.5 -fold lower GLP-1 secretion than basal glucose control, however no effect was 
displayed from its SGID, ULPH068 variant. Protein hydrolysate generated using SGID only 
however stimulated 2.5 –fold (P<0.001) increase of GLP-1 secretion over the basal glucose 
control (Fig 3.15 D), respectively.  
 
Fig 3.16 - Incretin effect of marine protein hydrolysates generated from Salmon trimmings 
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The Alcalase generated hydrolysate, ULPH051 had no effect on cellular secretion. After 
further SGID processing, its ULPH057 hydrolysate caused 2.2 –fold (P<0.001) increase in GLP-
1 secretion. The Alcalase and Flavourzyme combination, ULPH052 and its SGID variant 
ULPH059 both displayed potent GLP-1 secretion of 2.4 (P<0.001) and 2.2 –fold (P<0.001) 
increase versus basal glucose control, respectively. Hampered GLP-1 secretion was displayed 
from the Promod generated hydrolysate ULPH053 and its SGID ULPH053 Variant with 0.5 fold 
and 0.4 fold reduction in GLP-1 secretion (Fig 3.16 A).  
 
Incretin secretion (GIP) during co-incubation with marine protein hydrolysates 
 
Fig 3.17 A - Marine protein hydrolysate incretin effect from the GIP secreting 
enteroendocrine STC-1 cell line 
The STC-1 cell line was investigated for its glucose-dependant insulinotropic polypeptide (GIP) 
secretion. Using the same experimental conditions as the GLUTag investigation, positive 
controls, Palmitic acid (500 uM) and Glutamine (10 mM) reported a 4 –fold increase (P<0.001) 
of glucose-dependant insulinotropic polypeptide (GIP) versus basal glucose control 
respectively (Fig 3.17 A). All test conditions contained 2.5 mg/ml of various marine protein 
hydrolysates within a 2 mM glucose supplemented KRB buffer co-incubated for 2 hours.  
 
Fig 3.17 B – 3.18 - GIP secretion during acute co-incubation of marine protein hydrolysates 
generated from Palmaria palmata 
In the presence of ULPH018, a 4 –fold (P<0.001) increase of GIP secretion was displayed 
whereas the SGID, ULPH042 variant improved upon this stimulating a 5.8 –fold (P<0.001) 
increase in GIP secretion versus basal glucose control (Fig 3.17 B). The Alcalase generated, 
ULPH019 reported a 6 –fold (P<0.001) increase in GIP furthermore, the SGID variant, ULPH034 
promoted a 8 –fold (P<0.001) increase in GIP secretion under the same conditions (Fig 3.17 
C). The secretory activity reported from ULPH020 was mildly elevated (P<0.01) above basal 
glucose control, whereas the SGID variant reported a reduction (P<0.01) in GIP secretion (Fig 
3.17 D). The bromelain produced ULPH 021 and Bromelain/SGID, ULPH038 increased GIP 
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secretion by 5 –fold (P<0.001) and 4 – fold (P<0.001), respectively (Fig 3.18 A). Finally, the 
Promod, ULPH022 and Promod/SGID ULPH040 improved GLP-1 secretion by 6 –fold and 3.8 
–fold versus basal glucose control (Fig 3.18 B).  
 
 Fig 3.19 A - GIP secretion during acute co-incubation of marine protein hydrolysates 
generated from Blue whiting  
During co-incubation with ULPH063 no GIP secretion above basal glucose control was 
reported, however ULPH070 and ULPH072 reported a 2 –fold (P<0.001) and 6 –fold (P<0.001) 
increase in GIP (Fig 3.19 A).  
 
Fig 3.19 B - GIP secretion during acute co-incubation of marine protein hydrolysates 
generated from Boarfish (Capros aper) 
The boarfish hydrolysates generated using Alcalase and Flavourzyme, ULPH062 and its SGID 
variant, ULPH068 caused no elevation of GIP versus basal glucose control, however when 
hydrolysed with only SGID, ULPH066 promoted a 5 –fold increase above basal levels(P<0.001) 
of GIP (Fig 3.19 B). 
 
Fig 3.19 C -  D - Incretin effect of marine protein hydrolysates generated from Salmon 
trimmings 
Salmon trimming hydrolysate ULPH generated using SGID promoted a 3.8 –fold increase 
(P<0.001) in GIP secretion versus basal glucose control (Fig 3.19 C). Salmon skin gelatine, 
ULPH032 caused a 2 –fold increase in GIP secretion, whereas ULPH 24/26/28 & 30 caused no 
significant elevation of GIP above basal glucose control, respectively (Fig 3.19 D).  
 
Establishing glucose update in transdifferentiated adipocytes during co-incubation with 




Fig 3.20 A - Glucose uptake investigation during acute co-incubation using marine protein 
hydrolysates on differentiated 3T3-L1 fibroblast cells 
The 3T3-L1 cell line was investigated after it had undergone trans-differentiation from 
fibroblast to adipocyte cells. This was done over a period of 9 days, for more information 
please refer to section 2.2.3. The positive control apegenin results in significant reduction 
(P<0.001) of glucose uptake via the inhibition of the GLUT1 receptor whereas insulin (1 nm & 
100 nM) had the opposite effect causing 1.4 (P<0.001) and 1.8 (P<0.001) fold glucose uptake 
versus the basal glucose control (Fig 3.20 a). The remainder of the test conditions remained 
consistent with marine hydrolysates used at 2.5 mg/ml on their own or in the presence of 
insulin (1 nM) for the duration of the experiment.  
 
Fig 3.20 B – 3.21 B - Glucose uptake assessment during acute co-incubation using Palmaria 
palmata hydrolysate 
ULPH018 caused no significant uptake of glucose on its own, however in the presence of 
insulin had displayed a 1.5 –fold increase (P<0.05). The SGID variant ULPH042 caused a 
significant uptake of glucose on its own, however this effect was lost in the presence of insulin 
(Fig 3.20 B). When co-incubated, ULPH019 and ULPH042 both caused a similar 1.5 –fold 
(P<0.001) increase in glucose uptake, however the same result was shown when combined 
with insulin with no additive effect displayed (P<0.001; Fig 3.20 C).  Additionally ULPH020 
caused a 1.8 fold increase (P<0.001) in glucose uptake whereas in combination with insulin 
results in a 1.7 fold increase (P<0.001) versus basal glucose control (Fig 3.20 D). Similar results 
were displayed with ULPH036 with and without insulin present, with a 1.38 –fold  (P<0.05) 
seen from both test conditions . The ULPH021 failed to improve glucose uptake by when 
incubated alone, with improvement in glucose uptake seen when incubated with insulin with 
a 1.5 –fold increase (P<0.01; Fig 3.21 A). The ULPH038 SGID variant resulted in no 
improvement in glucose uptake with and without insulin. (Fig 3.21 A). Finally ULPH022 when 
in the presence of insulin improved glucose uptake by 1.5 –fold increase (P<0.05) while the 




Fig 3.21 C - Glucose uptake assessment during acute co-incubation using Boarfish 
hydrolysate 
Glucose uptake was promoted with ULPH062 (P<0.05) however in the presence of insulin the 
uptake was diminished. Improvement in uptake was seen with ULPH068 with (P<0.01) and 
without (P<0.05) insulin causing similarly significant 1.3 –to 1.4 –fold increase in glucose 
uptake (Fig 3.3.4G). Finally both ULPH066, with (P<0.001) and without (P<0.01) insulin 
promoted a 1.4 to 1.5 –fold increase of glucose uptake (Fig 3.21 C), respectively. 
 
 
Fig 3.21 D - Glucose uptake assessment during acute co-incubation with Blue whiting 
hydrolysate 
Glucose uptake using ULPH063 and ULPH072 was promoted with (P<0.01) and without insulin 
(P<0.05 to P<0.01). In the presence of both hydrolysates, uptake was increase on average 1.4 
to 1.5 fold during co-incubation, However ULPH070 failed to promote glucose uptake in 
adipocyte cells under any test condition, (Fig 3.21 D), respectively. 
 
Establishing amylase activity during co-incubation with marine protein hydrolysates 
 
Fig 3.22 A - Inhibition of start digestion using various marine protein hydrolysates 
Starch, a long chain polysaccharide, digested in the presence of amylase (2 U/ml). In the 
presence of the positive control, Acarbose, of which inhibits amylase activity, starch digestion 
was reduced by over 95% (p<0.001).   Further test conditions used 2.5 mg/ml of hydrolysate 
of interest in the presence of amylase (2 U/ml) and starch (2 mg/ml) (Fig 3.22 A).   
 
Fig 3.22 B - Inhibition of amylase using Palmaria palmata protein hydrolysates 
Hydrolysates generated from palmaria palmata displayed a similar reduction in start digestion 
across ULPH 042 (-18%) 019 (-20%) 034 (-21%) 020 (-21%) 036 (-19%) 021 (-21%) 038 (-15%)  
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022 (-15%)  040 (-18%)  (P<0.001) with the ULPH018 generated using aqueous hydrolysis 
resulting in 28% reduction (P<0.001) of amylase activity (Fig 3.22 B), respectively.  
 
Fig 3.22 C - Inhibition of amylase using Blue whiting protein hydrolysates 
Hydrolysate ULPH 063 and ULPH 072 had no effect on reducing amylase activity whereas 
ULPH070 reduce amylase activity by 18% (p<0.01; Fig 3.22 C). 
 
Fig 3.22 D - Inhibition of amylase during co-incubation with Boarfish hydrolysates 
Comparative to the amylase online control, none of the boarfish hydrolysates investigated 
reduced amylase activity (Fig 3.22 D) 
 
 
Fig 3.23 - Inhibition of amylase during co-incubation with Salmon trimmings 
Comparative to the amylase online control, none of the salmon trimmings hydrolysates 
investigated reduced amylase activity (Fig 3.23 A) 
 
Establishing DPP-4 activity during co-incubation with marine protein hydrolysates 
 
 
Fig 3.24 A - Inhibition of Dipeptidyl peptidase IV (DPP4) using various marine protein 
hydrolysates 
Marine protein hydrolysates were investigated for their ability to interact and potential inhibit 
the enzymatic activity of the serine protease, DPP4. The positive control, Diprotin A (DPA, Ile-
Pro-Ile) was used due to the interaction and reduction of activity between the molecule and 
DPP4. A dose dependant reduction of DPP4 activity was displayed from 2.5 to 200 uM of DPA 
ranging from 10% to 95% reduction (P<0.01 to P<0.001) in DPP4 activity (Fig 3.24 A). Similar 
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experimental controls were used, and all other marine hydrolysates were investigated using 
2.5 mg/ml in the presence of 8 mU/ml DPP4 and the DPP4 luminescent substrate Gly-Pro-
AMC (200 uM). 
 
Fig 3.24 B – 3.25 B - Inhibition of Dipeptidyl peptidase IV (DPP4) using Palmaria palmata 
protein hydrolysates 
The DPP4 activity was reduced by 32% (P<0.001) during co-incubation with ULPH018 and 
similarly its SGID variant, ULPH042, displayed a 30% (P<0.05) reduction in enzyme activity (Fig 
3.24 B). Similarly, ULPH019 and reduced enzyme activity by 34% (P<0.001) and to a lesser 
extent, ULPH034 reduced activity by 17% (P<0.001; Fig 3.24 C). Enzyme activity during 
ULPH020 co-incubation was reduced by 35% (P<0.001) whereas its SGID variant displayed a 
17% reduction (P<0.05; Fig 3.24 D). While ULPH021 had shown a 10% reduction (P<0.01) in 
enzyme activity, the SGID variant improved upon DPP4 enzyme inhibition with activity 
reduced by 20% (P<0.001; Fig 3.25 A). Finally ULPH022 displayed a 14% reduction (P<0.001) 
while ULPH040 inhibited DPP4 by 19% (P<0.001; Fig 3.25 B), respectively.  
Fig 3.25 C - Inhibition of Dipeptidyl peptidase IV (DPP4) using Boarfish protein hydrolysates 
Boarfish protein hydrolysate, ULPH062 reduced DPP4 enzyme activity by 15% (P<0.01) 
reduction in DPP4 activity (Fig 3.25 D).  
Fig 3.25 D - Inhibition of Dipeptidyl peptidase IV (DPP4) using Blue whiting protein 
hydrolysates 
Blue whiting hydrolysate, ULPH063 displayed a 15% reduction (P<0.05) in DPP4 enzyme 
activity (Fig 3.25 C). 
 
Fig 3.26 A / B - Inhibition of Dipeptidyl peptidase IV (DPP4) using Salmon hydrolysates 
Salmon gelatine hydrolysate, ULPH026 and Salmon trimmings, ULPH052 and displayed a 22% 




Measurement of cAMP during co-incubation with marine protein hydrolysates 
 
Fig 3.27 A - Measurement of intracellular cAMP production during co-incubation with 
various MPH 
Using BRIN-BD11 cells, the signalling mechanism of action was assessed via the production of 
intracellular cAMP. Using positive controls, elevated intracellular cAMP was reported using 
16.7 mmol/L glucose (P<0.05) and GLP-1 (P<0.001) comparative to the glucose only basal 
control of 5.6 mmol/L glucose only (Fig 3.27 A). The remaining test conditions used a fixed 
dose of 2.5 mg/ml of marine protein hydrolysates in KRBB supplemented with 5.6 mmol/L 
glucose. Results are comparative to basal glucose control, respectively.  
Fig 3.27 B - Measurement of intracellular cAMP production during co-incubation with Blue 
whiting MPH 
Across the blue whiting hydrolysates investigate, ULPH63, ULPH070 and ULPH072 increased 
intracellular cAMP production similarly by 60% (P<0.001; Fig 3.27 B ) versus the basal glucose 
control, respectively. 
Fig 3.27 C - Measurement of intracellular cAMP production during co-incubation with 
Boarfish MPH 
Investigating ULPH066, ULPH062 and ULPH068 increased (P<0.001) cAMP production 
similarly by 50% above  basal glucose control (Fig 3.27 C).  
Fig 3.27 D - Measurement of intracellular cAMP production during co-incubation with 
Salmon gelatine MPH 
The Salmon gelatine generated ULPH026 failed to stimulate cAMP production during 
experimentation, however ULPH026, 030 and 053 increased cAMP production by 
approximately 80% (P<0.001) across each hydrolysate versus basal glucose control (Fig 3.27 
D).  
Fig 3.28 A - Measurement of intracellular cAMP production during co-incubation with 
Salmon trimming MPH 
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Salmon trimming hydrolysate, ULPH051 while displaying an upward trend of cAMP 
production failed to display a significant increase. The remaining hydrolysates, ULPH052, 053, 
055, 057, 059, 061 and 064 significantly increased intracellular cAMP production above basal 
glucose control (P<0.05 to P<0.001; Fig 3.28 A). 
Fig 3.28 B - Measurement of intracellular cAMP production during co-incubation with 
Palmaria palmata MPH 
Elevated cAMP production was evident in several of the Palmaria palmata hydrolysates. 
There was approximately 25% increase (P<0.05 to P<0.001) in cAMP production across all 
hydrolysates, except ULPH018 and ULPH040 where no significant elevation of cAMP was 
recorded. Hydrolysate ULPH020 and its SGID variant ULPH036 increased intracellular cAMP 
production by 80% (P<0.001) versus the basal glucose control (Fig 3.28 B).  
 
Measurement of intracellular Ca2+ during co-incubation with marine protein hydrolysates 
 
Fig 3.29 A - Measurement of intracellular calcium mobilization during co-incubation with 
various MPH 
Using a fluorescent-based assay for detecting changes in intracellular calcium was deployed 
to establish further mechanisms involved in cellular signalling.  Positive controls of which 
effect calcium mobilization were deployed such as alanine (10 mM). During co-incubation 
Alanine acts a calcium-specific agent that is essential to membrane binding.  During 
experimentation, Alanine caused a 15 –fold increase (P<0.001) in calcium mobilization versus 
glucose only control (Fig 3.29 A), respectively.  
Fig 3.29 B - Measurement of intracellular calcium mobilization during co-incubation with 
Palmaria palmata MPH 
During investigation, Palmaria palmata generated with Alcalase and Flavourzyme in 
combination calcium mobilization was increased 80 –fold (P<0.001; Fig 3.29 B) versus the 
glucose only control.  
96 
 
Fig 3.30 A - Measurement of intracellular calcium mobilization during co-incubation with 
Salmon trimmings MPH 
During investigation, Salmon trimmings generated with Alcalase and Flavourzyme in 
combination calcium mobilization was increased 15 –fold (P<0.001; Fig 3.30 A) versus the 
glucose only control.  
Fig 3.30 B - Measurement of intracellular calcium mobilization during co-incubation with 
Boarfish MPH 
During investigation, Boarfish generated with Alcalase and Flavourzyme in combination 
calcium mobilization was increased 22 –fold (P<0.001; Fig 3.30 B) versus the glucose only 
control.  
Fig 3.31 A - Measurement of intracellular calcium mobilization during co-incubation with 
Blue whiting MPH 
During investigation, Blue whiting generated with Alcalase and Flavourzyme in combination 
calcium mobilization was increased 40 –fold (P<0.001; Fig 3.31 A) versus the glucose only 
control.  
 
Measurement of membrane potential during co-incubation with marine protein 
hydrolysates 
 
Fig 3.32 A - Membrane potential activation during co-incubation with various MPH 
Signalling effects that cause membrane potential are carried out via ion channel sensitivity 
and activation. The positive control for investigation of BRIN-BD11 insulin secreting cells was 
potassium chloride (KCL) a potent membrane potentiating insulinotropic electrolyte.  Under 
experimental conditions, KCL caused a 75 –fold peak increase (P<0.001) in membrane 
potential during acute co-incubation (Fig 3.32 A).  




During acute co-incubation with salmon skin gelatine returned a 50 –fold peak increase 
(P<0.001) in membrane potential versus glucose only control in BRIN-BD11 cells (Fig 3.32 A).  
Fig 3.32  B - Acute membrane potential activity during co-incubation with Palmaria palmata 
MPH 
During acute co-incubation with Palmaria palmata returned a 125 –fold peak increase 
(P<0.001) in membrane potential versus glucose only control in BRIN-BD11 cells (Fig 3.32 B).  
Fig 3.33 A - Acute membrane potential activity during co-incubation with Salmon trimmings 
MPH 
During acute co-incubation with salmon trimmings returned a 55 –fold peak increase 
(P<0.001) in membrane potential versus glucose only control in BRIN-BD11 cells (Fig 3.33 A).  
Fig 3.33 B - Acute membrane potential activity during co-incubation with Boarfish MPH 
During acute co-incubation with Boarfish returned a 25 –fold peak increase (P<0.001) in 
membrane potential versus glucose only control in BRIN-BD11 cells (Fig 3.33 B).  
Fig 3.34 A - Acute membrane potential activity during co-incubation with blue whiting 
MPH 
During acute co-incubation with blue whiting returned a 25 –fold peak increase (P<0.001) in 




Measurement of cellular toxicity during co-incubation with marine protein hydrolysates 
 
Fig 3.35 A - Investigation of LDH release and cellular toxicity during acute co-incubation 
with various MPHs 
Intracellular LDH release was investigated using the Promega cytotox-96 non-radioactive 
LDH assay. Using various positive controls the supernatant was used to test LDH 
concentration versus a basal glucose control. During investigation, none of the positive 
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controls used displayed elevated LDH release versus the basal control (Fig 3.35 A). The 
target marine protein hydrolysate for LDH release used was 2.5 mg/ml and comparative to 
the basal glucose control, respectively.  
 
Fig 3.36 A - Cellular LDH release during co-incubation with Palmaria palmata MPH 
During investigation, all hydrolysates derived from Palmaria palmata caused apparent 
significant cellular LDH release (P<0.001; Fig 3.36 A) suggesting cellular toxicity, however 
this will be further investigated using MTT cellular respiration assay.  
 
Fig 3.36 B - Cellular LDH release during co-incubation with Boarfish, blue whiting, salmon 
gelatine and salmon trimmings MPH 
During co-incubation, marine protein hydrolysates generated from boarfish, blue whiting, 
salmon gelatine or salmon trimmings caused no increased LDH release versus the basal 
glucose control, respectively (Fig 3.36 B).  
 




Fig 3.37 A - Cellular viability and function investigation using MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) assay at 5.6 mmol/L glucose 
Using the redox potential in actively respiring cells to investigate cell functionality was 
deployed as a further measure to test Palmaria palmata MPH toxicity seen during the LDH 
release assay. Positive controls used were 20 mmol/L glucose of which acutely increased 
cellular viability (P<0.05) whereas potent cellular toxicity was seen during co-incubation 




Fig 3.37 BCellular viability and function investigation using MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide) assay at 16.7 mmol/L glucose  
During investigation, none of the Palmaria palmata hydrolysates caused any decrease in 
cellular viability versus the glucose only basal control at 5.6 mmol/L (Fig 3.3.11-A) or at 16.7 
mmol/L glucose (Fig 3.37 B). 
 
Fig 3.38 A - Cellular viability during co-incubation of Palmaria palmata MPH in GLUTag 
cells 
During investigation, none of the Palmaria palmata hydrolysates caused any decrease in 
cellular viability versus the glucose only basal control at 2 mmol/L (Fig 3.38 A). 
Fig 3.38 B - Cellular viability during co-incubation of Palmaria palmata MPH in STC-1 cells 
During investigation, none of the Palmaria palmata hydrolysates caused any decrease in 
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Fig 3.1.A Effects of KCL (30 mM) and GLP-1 (10-6) on insulin secretion from BRIN-
BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated test conditions for 
20 min and insulin release measured by RIA. Values are expressed as mean  
S.E.M. (n=8). ***p<0.001 compared to respective glucose control.  
 
Fig 3.1.B. Effects of KCL (30 mM) and GLP-1 (10-6) on insulin secretion from BRIN-
BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated test conditions 
for 20 min and insulin release measured by RIA. Values are expressed as mean  












Fig 3.2 A B 
C D 
Fig 3.2.C/F. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with either ULPH018 
(Panel C), ULPH042 (Panel D), ULPH019 (Panel E) orULPH034 (Panel F) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. 





















Fig 3.3. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with either ULPH020 
(Panel A), ULPH036 (Panel B), ULPH0021 (Panel C) orULPH038 (Panel D) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. 














Fig 3.4. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with either ULPH022 
(Panel A) or ULPH040 (Panel B) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed as mean  S.E.M. 
















Fig 3.5 Dose-dependent effects of Blue whiting on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with either ULPH063 (Panel A),  
ULPH070 (Panel B) or ULPH072 (Panel C) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed as mean 
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C D
 
Fig 3.6. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated with either ULPH018 
(Panel A), ULPH042 (Panel B), ULPH019 (Panel C) orULPH034 (Panel D) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. 































Fig 3.7. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated with either ULPH020 
(Panel A), ULPH036 (Panel B), ULPH0021 (Panel C) orULPH038 (Panel D) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. 

















Fig 3.8. Dose-dependent effects of Palmaria palmata on insulin secretion from BRIN-BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated with either ULPH022 
(Panel A) or ULPH040 (Panel B) using a range of concentrations (2.5 to 0.039 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed as mean  S.E.M. 
























Fig 3.9. Dose-dependent effects of Blue whiting on insulin secretion from BRIN-BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated with either ULPH063 (Panel 
A), ULPH070 (Panel B), or ULPH072 (Panel C) using a range of concentrations (2.5 to 0.0195 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed as 




















Fig 3.10 A B 
C 
Fig 3.10. Dose-dependent effects of Boarfish on insulin secretion from BRIN-BD11 cells at 16.7 mM glucose. BRIN-BD11 cells were incubated with either ULPH062 (Panel A), 
ULPH066 (Panel B), or ULPH068 (Panel C) using a range of concentrations (2.5 to 0.0195 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed as 


























Fig 3.11. Dose-dependent effects of Salmon trimming protein hydrolysates on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with 
either ULPH051 (Panel A), ULPH052 (Panel B), ULPH057 (Panel C) or ULPH059 (Panel D) using a range of concentrations (2.5 to 0.0195 mg/ml) for 20 min and insulin release 






















Fig 3.12 Dose-dependent effects of Salmon trimming protein hydrolysates on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with 
either ULPH053 (Panel A) or ULPH061 (Panel B) using a range of concentrations (2.5 to 0.0195 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed 

















































































































































































Fig 3.13 B 
C 
D 
Fig 3.13. Dose-dependent effects of Salmon trimming protein hydrolysates on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with 
either ULPH053 (Panel A) or ULPH061 (Panel B) using a range of concentrations (2.5 to 0.0195 mg/ml) for 20 min and insulin release measured by RIA. Values are expressed 



































B Fig 3.14 
Fig 3.14. Secretory effects of incretin secreting hydrolysates on GLP-1 secretion from GLUTag cells at 2 mM glucose. GLUTag cells were incubated with a range of incretin 
secreting positive controls (Panel A), ULPH018/042 (Panel B), ULPH19/034 (Panel C) or ULPH020/036 using a fixed concentrations of hydrolysate (2.5 mg/ml) for 2 hours and 

















Fig 3.15. Effects of GLP-1 secreting marine protein hydrolysates from GLUTag cells at 2 mM glucose. GLUTag cells were co-incubated with ULPH021/038 (Panel A), ULPH022/040 (Panel B), 
ULPH063 (Panel C) or ULPH062/068/066 (Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 2 hours and GLP-1 release measured by ELISA. Values are expressed as 
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Fig 3.16. Effects of GLP-1 secreting marine protein hydrolysates from GLUTag cells at 2 mM glucose. GLUTag cells were co-incubated with 
ULPH051/057/052/059 or 053 (Panel A), using a fixed concentrations of hydrolysate (2.5 mg/ml) for 2 hours and GLP-1 release measured by ELISA. 





Fold increase of GLP-1 secretion summary of GLUTag cells 
Hydrolysate Source Glucose/hydrolysate Fold increase at max concentration Significance SGID 
18 P.palmata 2 mM / 2.5 mg/ml 3 ***p<0.001 n 
42 P.palmata 2 mM / 2.5 mg/ml 1.6 ***p<0.001 y 
19 P.palmata 2 mM / 2.5 mg/ml 2 ***p<0.001 n 
34 P.palmata 2 mM / 2.5 mg/ml 0 ns y 
20 P.palmata 2 mM / 2.5 mg/ml 2.2 ***p<0.001 n 
36 P.palmata 2 mM / 2.5 mg/ml 0 ns y 
21 P.palmata 2 mM / 2.5 mg/ml 1.9 ***p<0.001 n 
38 P.palmata 2 mM / 2.5 mg/ml 1.2 *p<0.05 y 
22 P.palmata 2 mM / 2.5 mg/ml 1.6 ***p<0.001 n 
40 P.palmata 2 mM / 2.5 mg/ml 1.3 *p<0.05 y 
63 Blue whiting 2 mM / 2.5 mg/ml 1.31 **p<0.01 n 
70 Blue whiting 2 mM / 2.5 mg/ml 1.71 ***p<0.001 y 
62 Boarfish  2 mM / 2.5 mg/ml -0.4 **p<0.01 n 
68 Boarfish  2 mM / 2.5 mg/ml 0 ns y 
66 Boarfish  2 mM / 2.5 mg/ml 2.5 ***p<0.001 y 
51 Salmon Trimming 2 mM / 2.5 mg/ml 0 ns n 
57 Salmon Trimming 2 mM / 2.5 mg/ml 2.1 ***p<0.001 y 
52 Salmon Trimming 2 mM / 2.5 mg/ml 2.4 ***p<0.001 n 
59 Salmon Trimming 2 mM / 2.5 mg/ml 2.2 ***p<0.001 y 
53 Salmon Trimming 2 mM / 2.5 mg/ml -0.5 ***p<0.001 n 
61 Salmon Trimming 2 mM / 2.5 mg/ml -0.4 **p<0.01 y 
32 Salmon gelatine 2 mM / 2.5 mg/ml 2 ***p<0.001 y 
24 Salmon gelatine 2 mM / 2.5 mg/ml 3 ***p<0.001 y 
26 Salmon gelatine 2 mM / 2.5 mg/ml 3.4 ***p<0.001 y 
28 Salmon gelatine 2 mM / 2.5 mg/ml 3.8 ***p<0.001 y 


















3.17 A B 
C D 
Fig 3.17. Secretory effects of incretin secreting hydrolysates on GIP secretion from STC-1 cells at 2 mM glucose. STC-1 cells were incubated with a range of incretin secreting 
positive controls (Panel A), ULPH018/042 (Panel B), ULPH19/034 (Panel C) or (Panel D) ULPH020/036 using a fixed concentrations of hydrolysate (2.5 mg/ml) for 2 hours and 




















Fig 3.18. Effects of GIP secreting marine protein hydrolysates from STC-1 cells at 2 mM glucose. STC-1 cells were co-incubated with ULPH021/038 (Panel A) or ULPH022/040 (Panel B) 
using a fixed concentrations of hydrolysate (2.5 mg/ml) for 2 hours and GLP-1 release measured by ELISA. Values are expressed as mean  S.E.M. (n=3).  *p<0.05,**p<0.01,***p<0.001 
















Fig 3.19. Effects of incretin secreting hydrolysates on GIP secretion from STC-1 cells at 2 mM glucose. STC-1 cells were incubated with either blue whiting ULPH063/070/072 
(Panel A), Boarfish ULPH0062/068/066 (Panel B), Salmon trimmings ULPH055 (Panel C) or Salmon skin gelatin ULPH032/024/026/028/030 (Panel D) using a fixed 
concentrations of hydrolysate (2.5 mg/ml) for 2 hours and GLP-1 release measured by ELISA. Values are expressed as mean  S.E.M. (n=3).  **p<0.01,***p<0.001 compared 










Fold increase of GIP secretion summary of STC-1 cells 
Hydrolysate Source Glucose/Hydrolysate Fold increase at max concentration Significance SGID 
18 P.palmata 2 mM / 2.5 mg/ml 4.4 ***p<0.001 n 
42 P.palmata 2 mM / 2.5 mg/ml 6.1 ***p<0.001 y 
19 P.palmata 2 mM / 2.5 mg/ml 5.7 ***p<0.001 n 
34 P.palmata 2 mM / 2.5 mg/ml 8.1 ***p<0.001 y 
20 P.palmata 2 mM / 2.5 mg/ml 1.5 **p<0.01 n 
36 P.palmata 2 mM / 2.5 mg/ml -0.5 *p<0.05 y 
21 P.palmata 2 mM / 2.5 mg/ml 5.2 ***p<0.001 n 
38 P.palmata 2 mM / 2.5 mg/ml 3.6 ***p<0.001 y 
22 P.palmata 2 mM / 2.5 mg/ml 5.8 ***p<0.001 n 
40 P.palmata 2 mM / 2.5 mg/ml 3.5 ***p<0.001 y 
63 Blue whiting 2 mM / 2.5 mg/ml 0 ns n 
70 Blue whiting 2 mM / 2.5 mg/ml 2.2 ***p<0.001 y 
72 Blue whiting 2 mM / 2.5 mg/ml 6 ***p<0.001 y 
62 Boarfish  2 mM / 2.5 mg/ml 0 ns n 
68 Boarfish  2 mM / 2.5 mg/ml 0 ns y 
66 Boarfish  2 mM / 2.5 mg/ml 5.1 ***p<0.001 y 
55 Salmon Trimming 2 mM / 2.5 mg/ml 3 ***p<0.001 n 
32 Salmon gelatine 2 mM / 2.5 mg/ml 2 **p<0.01 y 
24 Salmon gelatine 2 mM / 2.5 mg/ml 0 ns y 
26 Salmon gelatine 2 mM / 2.5 mg/ml 0 ns y 
28 Salmon gelatine 2 mM / 2.5 mg/ml 0 ns y 
30 Salmon gelatine 2 mM / 2.5 mg/ml 0 ns y 
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Fig 3.20. Effects of marine protein hydrolysates on glucose uptake individually, or in combination with insulin in trans-differentiated 3T3-L1 adipocyte cells. Adipocyte cells were incubated with either 
Apigeninin (50 uM), Insulin (1nM or 100 nM) (Panel A), ULPH018 or 042(with or without 1 nM insulin, (Panel B), ULPH019 or 034 (With or without 1nM insulin, Panel C) or ULPH020 or 036 (with or 
without 1 nM insulin, Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 1 hour with 3 mM fluorescent glucose. Values are expressed as mean  S.E.M. (n=3).  8p<0.05, 
























Fig 3.21. Effects of marine protein hydrolysates on glucose uptake individually, or in combination with insulin in trans-differentiated 3T3-L1 adipocyte cells. Adipocyte cells were incubated with either 
ULPH021 or 038 (With or without 1 nM insulin, Panel A), ULPH022 or 040 (with or without 1 nM insulin, Panel B), ULPH062, 068 or 066 (With or without 1nM insulin, Panel C) or ULPH063 or 070 or 072 
(with or without 1 nM insulin, Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 1 hour with 3 mM fluorescent glucose (2-NBDG). Values are expressed as mean  S.E.M. (n=3).  

































3.22 A B 
C D 
Fig 3.22. Effects of marine protein hydrolysates on amylase activity in the presence of starch. Starch (2 mg/ml) was were incubated with Amylase (2 U/ml) with either Acarbose (Panel A), ULPH018. 042, 
019, 034, 020, 036, 021, 038, 022 or 040 (Panel B), ULPH063, 070 or 072 (Panel C) or ULPH062 or 068 or 066 (Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 1 hour with liberated 










Fig 3.23. Effects of marine protein hydrolysates on amylase activity in the presence of starch. Starch (2 mg/ml) was were incubated with Amylase (2 U/ml) only or ULPH055 or ULPH064 (Panel A), using a 


























3.24 A B 
C 
D 
Fig 3.24. Effects of marine protein hydrolysates on DPP4 activity and liberation of the flurogenic AMC substrate. Gly-Pro-AMC (200 µM)was incubated with DPP4 (8 mU/ml) alone or with either a dose 
dependant concentration of Diprotin A (2.5 – 200 µM, Panel A), ULPH018 or 042 (Panel B), ULPH019 or 034 (Panel C) or ULPH020 or 036 Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) 
























Fig 3.25. Effects of marine protein hydrolysates on DPP4 activity and liberation of the flurogenic AMC substrate. Gly-Pro-AMC (200 µM) was incubated with DPP4 (8 mU/ml) alone or with either ULPH021 
or 038 (Panel A), ULPH022 or 040 (Panel B) or ULPH063 (Panel C) or ULPH074 (Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 30 min with liberated AMC analysed using EX/EM 
















A B 3.26 
Fig 3.26. Effects of marine protein hydrolysates on DPP4 activity and liberation of the flurogenic AMC substrate. Gly-Pro-AMC (200 µM) was incubated with DPP4 (8 mU/ml) alone or with either ULPH026 
(Panel A), ULPH052 (Panel B) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 30 min with liberated AMC analysed using EX/EM 360/460 nm wavelength. Values are expressed as mean  S.E.M. 

























3.27 A B 
C D 
Fig 3.4.27. Effects of marine protein hydrolysates on cAMP production in BRIN-BD11 cells during acute co-incubation with glucose  alone or with glucose (16.7 mM) or GLP-1 (10-7) (Panel A) or ULPH063 
070 or 072 (Panel B), ULPH066, 062 or 068 (Panel C) or ULPH026, 030, 032 or 053 (Panel D) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 20 min. Cells were lysed using cAMP assay lysis 























Fig 3.28. Effects of marine protein hydrolysates on cAMP production in BRIN-BD11 cells during acute co-incubation with glucose  alone or with ULPH051, 052, 053, 055, 057, 059, 061, or 064 (Panel A) or 
ULPH018, 042, 019,034, 020, 036, 021, 038, 022, 040 (Panel B) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 20 min. Cells were lysed using cAMP assay lysis buffer with cAMP concentration 
























Fig 3.3.7.E&F. Effects of marine protein hydrolysates on cAMP production in BRIN-BD11 cells during acute co-incubation with glucose  alone or with ULPH051, 052, 053, 055, 057, 059, 061, or 064 (Panel 
E) or ULPH018, 042, 019,034, 020, 036, 021, 038, 022, 040 (Panel F) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 20 min. Cells were lysed using cAMP assay lysis buffer with cAMP 




Fig 3.29. Effects of marine protein hydrolysates on intracellular calcium mobilization in BRIN-BD11 cells during acute co-incubation with glucose alone or alanine (10 Mm) or ULPH055 (Panel A) or ULPH020 
(Panel B) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent Ca2+ and read using a spectrophotometer. Values are expressed as 















Fig 3.30. Effects of marine protein hydrolysates on intracellular calcium mobilization in BRIN-BD11 cells during acute co-incubation with glucose alone or alanine (10 Mm) or ULPH055 (Panel A) or ULPH066 
(Panel B) using a fixed concentrations of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent Ca2+ and read using a spectrophotometer. Values are expressed as 












Fig 3.31. Effects of marine protein hydrolysates on intracellular calcium mobilization in BRIN-BD11 cells during acute co-incubation with glucose alone or alanine (10 Mm) or ULPH063, using a fixed 
concentrations of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent Ca2+ and read using a spectrophotometer. Values are expressed as mean  S.E.M. (n=3).  

















Fig 3.32. Effects of marine protein hydrolysates on membrane potential in BRIN-BD11 cells during acute co-incubation with glucose alone or KCL (10 Mm) or ULPH055 (Panel A) or ULPH020 (Panel B) using 
a fixed concentrations of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent membrane potentiating electrolyte and read using a spectrophotometer. Values are 
















Fig 3.33. Effects of marine protein hydrolysates on membrane potential in BRIN-BD11 cells during acute co-incubation with glucose alone or KCL (10 Mm) or ULPH055 (Panel A) or ULPH062 (Panel B) using 
a fixed concentrations of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent membrane potentiating electrolyte and read using a spectrophotometer. Values are 














Fig 3.34. Effects of marine protein hydrolysates on membrane potential in BRIN-BD11 cells during acute co-incubation with glucose alone or KCL (10 Mm) or ULPH063 (Panel A) using a fixed concentrations 
of hydrolysate (2.5 mg/ml) for 300 sec. Cells were incubated prior with a proprietary florescent membrane potentiating electrolyte and read using a spectrophotometer. Values are expressed as mean  








Fig 3.35. Effects of secretagogues on cellular toxicity and LDH release in cells during acute co-incubation with glucose alone or glucose (20 mM), Glutamine (10 mM), GIP (10-6) or Forskolin (10 mM) (Panel 
A). Cells were incubated acutely (20 minutes) with test conditions with supernatant tested for LDH release from cultured cells during experimental investigation. Values are expressed as mean  S.E.M. 



















Fig 3.36. Effects of marine protein hydrolysates on cellular toxicity and LDH release in cells during acute co-incubation with glucose alone or ULPH018, 034, 019, 036, 020, 038, 021, 040, 022 or 042 (Panel 
B). Cells were incubated acutely (20 minutes) with test conditions with subsequent supernatant tested for LDH release from cultured cells during experimental investigation. Values are expressed as mean 




















Fig 3.3.10 C. Effects of marine protein hydrolysates on cellular toxicity and LDH release in cells during acute co-incubation with glucose alone or glucose and ULPH062, 066, 068, 063, 070, 072, 024, 026, 
028, 030, 055, 064 (Panel C). Cells were incubated acutely (20 minutes) with test conditions with subsequent supernatant tested for LDH release from cultured cells during experimental investigation. 
Values are expressed as mean  S.E.M. (n=3).  Values are compared to respective glucose only control.  
 
Fig 3.37. Effects of marine prot in hydrolysates on cellular viability and respiration BRIN-BD11 cells at 5.6 mmol/L (Panel A) and 16.7 mmol/L glucose (Panel B) during acute co-incubation with glucose 
alone or glucose and ULPH018, 034, 019, 036, 020, 038, 021, 04 , 022, 042 (Panel A/B). Cells were inc ated acutely (20 mi ut s) with test conditions f which were apirated and r placed with growth 














Fig 3.38. Effects of marine protein hydrolysates on cellular viability and respiration GLUTag cells at 2 mmol/L (Panel A) and STC-1 cells at 2 mmol/L glucose (Panel B) during acute co-incubation with 
glucose alone or glucose and ULPH018, 034, 019, 036, 020, 038, 021, 040, 022, 042. Cells were incubated acutely (20 minutes) with test conditions of which were aspirated and replaced with growth 




3.4 Discussion  
Initially a cell based approached was used to investigate bioactivity of crude protein 
hydrolysates generated from marine sources using cell specifically tailored to glycaemic 
regulation that may have potential to be a target for therapeutic benefit. The role of dietary 
proteins has in the past been focused primarily on caloric need rather than additive to health, 
however several decades of bioactive food derived peptide investigation has become 
increasingly acknowledged (Nasri, 2017). Proteins of interest are becoming ever novel, 
typically dairy or plant sourced that have undergone aqueous hydrolysis were the highpoint 
of bioactive peptide research, however new approaches are developed aiming to optimise 
the hydrolysis processes and characterise the biomolecules generated.  This approach has 
yielded further bioactivity but also enhanced development of collaborations within industry 
and research communities (Hernández-Ledesma et al, 2014).  
 Understanding the benefits of the hydrolysis process has improved targeted outcomes 
of crude protein hydrolysates. This has advanced recently due to the ever expanding list of 
proteases and peptidases that have specific amino acid interactions and if used correctly has 
the ability to yield new and exciting peptide molecules of which may be screened for health 
promoting effects (Shimizu & DO, 2013). To date food derived peptides have been shown to 
exert various activities on the immune system, cardiovascular and nervous system along with 
improving blood pressure and digestive health (Daliri et al, 2017). The technologies 
surrounding the identification of novel bioactive peptides has progressed and become 
increasingly optimised. The application of peptides for health and in particular for improving 
insulin secretion via incretin hormone secretion, direct insulin secretion via pancreatic 
interaction or the activation of satiety centres is not uncommon. Peptide-based treatment 
approaches is leading the revolution in highly specific diabetes therapeutics due to their 
multifunctional properties.  
 Within this chapter, in order to evaluate if marine protein hydrolysates presented 
bioactivity at the cellular level we employed several secretory cell lines tailored towards 
diabetes biomarkers. Initially an insulin secreting cell line, BRIN-BD11 was used to investigate 
the insulinotropic activity of the small molecular weight peptides. Pancreatic β-cell secretion 
of insulin responds well to nutrient stimuli, specifically glucose, amino acids and free fatty 
acids (Torres et al, 2009). New approaches acknowledge that peptide hormone-based insulin 
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secretion may be the most potent approach to improving insulin secretion in those with 
pancreatic dysfunction. Peptide cellular receptors, specifically the GLP-1r is known to be 
glucose dependent, and a safe approach to lowering elevated glucose levels via optimised 
insulin secretion (Meloni et al, 2013). Here we screened a wide array of crude peptides within 
cultured beta cells, and for the first time displayed several potent insulinotropic dose-
dependent hydrolysates. Furthermore, hydrolysates of particular interest were p.palamata 
and boarfish, of which were biologically active at lower concentrations versus that of other 
sources of hydrolysates. Oral intake of proteins and their insulinotropic actions are commonly 
reported to firstly arise from gut activation of incretin hormones GLP-1 and GIP including the 
anorexogenic hormone PYY (Van der Klaauw, 2012). Gut base cells and nutrient sensing 
hormones are becoming increasingly acknowledge for its potent effect upon glycaemic 
regulation and promotion of satiety (Salehi et al, 2012). We tested the cellular activation of 
both GLP-1 secreting L-cells and GIP secreting K-cells using in vitro cultured cells. This is a 
nutritional look-and-see approach to understand the interaction of small molecules and their 
post-prandial incretin effect (Marathe et al, 2013). Intestinal cell lines respond well to 
nutrients, in particular amino acids and free fatty acids.  
Interestingly, when incubated with a fixed concentration of hydrolysate, secretion of 
GLP-1 and GIP was general elevelated above basal level, however under the same 
experimental conditions, incretin hormone secretion was lower across all SGID generated 
hydrolysates, with exceptions of a few. This was rather surprising, as the hydrolysates firstly 
generated using enzymatic hydrolysis yielded the most potent incretin effect, whereas the 
further digested SGID hydrolysates resulted in lowered incretin secretion. This reaffirms that 
these cells respond well to peptides, and less so to amino acids liberated from the peptides 
after SGID which is contrary to reported work (Lindgren et al, 2015). We further investigated 
how orally administered peptides would affect endogenous enzyme activity. Two viable 
approaches currently used within obesity and diabetes management is that of amylase 
inhibitors and DPP-4 inhibitors. The former decreased the rate of which glucose molecules 
are liberated from dietary polysaccharide molecules, whereas the latter inhibits a molecule, 
which shortens the post-prandial incretin effect of GLP-1 and GIP (DiNicolantonio et al, 2015; 
Plosker, 2014). Investigation enzyme kinetics using an in vitro assay approach highlighted that 
peptide hydrolysates used within, and potentially in general have little effect is any towards 
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amylase activity, and more specific molecules, such as acarbose are extremely effective. With 
this noted, peptide based approaches for inhibiting DPP-4 are very exciting, especially food 
derived approaches (Harnedy et al, 2015; Lacroix & Li-Chan, 2016). The DPP-4 enzyme 
destroys both GLP-1 and GIP rendering them inactive via cleavage of the first two N-terminus 
amino acid chains. Inhibiting the enzyme has many advantages, especially towards improved 
post-prandial glycaemic parameters, satiety promotion and reduction of gastric emptying.  
Interestingly, SGID hydrolysates had a lesser effect upon inhibiting the enzyme activity using 
a florescence based assay. The hydrolysates prior to SGID had shown as much as a 25% 
reduction in enzyme activity, which may prolong the incretin effect if used correctly such as 
preloading prior to meal intake. This affirmed that the interaction and inhibition of DPP-4 was 
peptide derived, rather than free amino acid derived which would be more prominent within 
the SGID hydrolysates.  
The explanation for peptide bioactivity and its potential beneficial health effects is 
based upon the inherent amino acid composition and subsequent sequence (Moughan, 
2009). This has led researchers to identity an optimised hydrolysis method that is tailored for 
the protein source, rather than the protein. However, many of these beneficial health effects 
are contributed from predesigned peptide interactions of which has evolved over millennia. 
With this being said, targeted peptide discovery from novel sources is an endeavour that has 
surprising payoffs from overall low drug developmental costs (Zhang et al, 2005).  
 Investigating bioactive peptides has changed course from larger molecules to small 
molecular weight molecules ranging from 2 to 20 amino acids in length. Smaller peptide 
fragments have been shown to exert multifunctional properties and improved intestinal 
absorption with dietary sources of these being the most important source available (Catnach 
et al, 1994). In short, we are learning not only that large molecules such as proteins can yield 
smaller molecules which exert beneficial health effects. In order to assess the bioactivity of 
protein hydrolysates cellular based signalling pathways were investigated. This involved 
membrane depolarization, calcium mobilization and generation of cAMP which together 
allow a general overview of activity to be displayed without delving deeper into specific 
receptor activation or expression. The hydrolysates were potent towards membrane 
depolarisation and internal calcium mobilization suggesting cell based activity, however in 
order to asses if this was potentially via unwanted compounds used within the hydrolysis 
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process such as electrolytes used for pH ranges, particular focus was spent investigating 
cAMP. The adenylyl cyclase pathway suggests that small molecular weight peptides may be 
activating secretion of the aforementioned hormones such as insulin, GLP-1 and GIP via g-
coupled protein receptors. These receptors are only activated by extracellular stimuli and can 
have potent cellular activation via promoting of internal signalling cascades. For example, 
activation of the GLP-1r via GLP-1 promotes a significant increase in cAMP production and 
glucose dependent insulin secretion (Ramos et al, 2008). Generally, cAMP was increased 
across several of he hydrolysates with he exception of salmon trimmings and gelatine. 
Interestingly, the p. palmata aqueous hydrolysate had shown no increase of cAMP, whereas 
fractions 20 and 36 presented an almost 80% increase during acute co-incubation in BRIN-
BD11 cells. This would suggest that within the crude hydrolysates, small molecular weight 
peptides are activating peptide based GPCRs and furthermore may have further pleotropic 
effects that are not solely confined within the pancreas. Lastly, cellular integrity and viability 
was not effected during acute incubation with each of the hydrolysates. One thing to note 
however was the misleading results from the LDH assay carried out after incubation with 
p.palmata based hydrolysates. Unfortunately the chlorophyll pigment interfered with the 
absorbance values of the assay meaning further investigating using the well-established MTT 
assay was needed. The results confirmed however that no effect upon cellular respiration and 
viability was present.   
We had hypothesized that activity would rely greatly on the hydrolysis process, length 
of hydrolysis and which protease was used in the generation of the small molecular weight 
peptides. Initial investigation using BRIN-BD11 cells was initially investigated for insulinotropic 
activity during co-incubation with test hydrolysates.  
Improved insulinotropic activity seen after enzymatic hydrolysis and/or retained 
activity after SGID is related to the initial peptide fragment length and amino acid sequence, 
the observed bioactivity of the parent fragment and subsequent fragments that can be 
produced by further proteolytic digestion. This had reaffirmed that subsequent additional 
hydrolysis seen yields further smaller peptides that are reported to have multifunctional 
activity of which improves overall activity of the biopeptides. During oral digestion, protein 
undergoes rapid digestion with endogenous proteases produced in the stomach such as 
pepsin, the pancreas such as trypsin and within the small intestines which produce 
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carboxypeptidases. The aim is to digestion protein molecules into their amino acid mono-
macronutrient form for absorption, however peptides from 2 to 5 amino acids have been 
shown to actively pass the intestinal brush boarder and into circulation of which will be 
investigated in latter chapters. The beneficial effect of crude peptides that are absorbed 
within the duodenum, jejunum or ileum is speculative as assuming the peptides arrive or get 
absorbed intact is at this stage unknown, however using cells that originate in these areas 
such as GLP-1 secreting GLUTag cells and GIP secreting STC-1 cells allowed researchers to 
approach the antidiabetic potential of marine protein hydrolysates using a nutritional “look 
and see” approach while measuring incretin hormone release.   
The ability of smaller molecules interacting with exponentially larger ones, such as 
peptide/protein or protein/protein interaction has been of interest for the past decade. Small 
molecules that can antagonise or agonise an enzyme, cell receptor or cause cellular signalling 
are of vital importance and can be biologically potent while remaining cost effective to 
produce over larger increasingly complex molecules. As mentioned previously the enzyme 
DPP4, a serine peptidase of which preferentially cleaves dipeptides from the N-terminus of a 
peptide chain and is one of the only endogenous enzyme with the ability to cleave a proline  
beside the penultimate amino acid. This has challenged researchers to make this enzyme a 
pharmaceutical target and one that has been hugely successful in the treatment of type 2 
diabetes. Understanding that proteins are potential bioactive peptide precursors makes them 
particularly attractive for the development of functional foods or further identifying specific 
inhibitory peptides.  
The study identified several signalling pathways of interest, each potentially 
complimentary to how crude unknown molecules interact at the cellular level. Further 
questions need to be addressed regarding multifaceted signalling of a potentially potent 
singular peptide molecule within the crude hydrolysate mixture or if the diverse signalling 
properties is derived from synergistic mechanisms, meaning peptides work in tandem to 
achieve a desired effect, this work displayed the latter. During signalling mechanism studies, 
several hydrolysates from Palmaria palmata, boarfish, blue whiting and salmon derivatives 
caused an increase in the intracellular messenger cAMP including potent membrane potential 
followed by intracellular calcium mobilization. Each of these assays are suggestive of receptor 
activation via direct signalling effects or signalling transduction. Extracellular signals are 
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internalized via the form of secondary messengers, production of hormones and other 
biological molecules of which can be represented here using increased cAMP production as a 
basis of general cellular activation. These are used to upregulate transcription and secretory 
signalling factors that has been displayed in this study via insulin, GLP-1 and GIP secretion that 
was clearly evident throughout. However, while we assume the secretory activity is derived 
from extracellular signalling there are potential for false positives or increased bioactivity that 
has been derived from unwanted mechanisms. An example seen within this study is that of 
Palmaria palmata. The protein source, while it had been assumed it is of high quantity and 
quality may contain numerous cellular signalling molecules that are contained within the 
micronutrient and trace element profile of the source. Palmaria palmata contains a high 
concentration of calcium, sodium, potassium and chloride as expected from its coastal 
origination. In order to control for this further desalting approaches may be deployed in 
future studies, however until now it is assumed that any additive effect of these unwanted 
electrolytes and trace elements is minimal.  
Palmaria palmata presented a further challenge during initial hydrolysate cellular 
toxicity screening. High concentration of chlorophyll caused false toxicity during lactate 
dehydrogenase assay investigation. It was initially assumed that the concentration of 
hydrolysate used caused adverse effects, however until further investigation using the well-
established MTT cellular viability assay reaffirmed the safety of the hydrolysate during acute 
incubation in all cell lines investigated. No toxicity was present in any of the hydrolysates at 
the chosen experimental concentration.  
 
Conclusion 
Using a rapid high throughput approach to test potentially bioactive hydrolysates has 
its limitation. This approach fails to provide definitive answers on the potential of proteins 
and those which serve as bioactive precursors. It also fails to answer which peptides are 
having the bioactivity displayed and if identifying these peptides is beneficial to the study aim. 
With this noted, this study has attempted to provide a comprehensive screening model for a 
disease target including the approach best deployed for generating a marine protein 
hydrolysate with specific or multifaceted bioactivity. The knowledge surrounding enzymatic 
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digestion of proteins to yield a product with targeted therapeutic bioactivity is improving. We 
set out to test the acute in vitro effects of marine protein hydrolysates from novel sources 
using various proteolytic methods. The results are thus far promising with positive 
insulinotropic and incretin secretion activity including enzyme interaction and signalling 
mechanisms and cellular toxicity, furthermore identifying several standout hydrolysates of 
which will be further investigated using acute and chronic in vivo assessment. To date, there 
is a gap in the knowledge for the application of protein hydrolysates in general. This study has 
attempted to rapidly screen marine protein hydrolysates for potential anti-diabetic potential 
of which will be the sole focus for the remaining of this work.  
 
Trajectory of work from herein 
Using the data generated from in vitro experimentation, identify which of the hydrolysis 
methods provides and promotes the most promising secretory activity of insulin, GLP-1 and 
GIP via in vitro experimentation.  
Disseminate which source of protein and the subsequent hydrolysates present the highest 
level of biological activity at the lowest concentrations between each enzymatic method. 
Consider combinational treatments due to some hydrolysates showing greater activity than 
others in particular cell lines.  
Identifying if the biological activity presented within chapter 3 is from the peptides generated 
from protein hydrolysis via the use of synthetically produced peptides identified from a 
previously generated hydrolysate (Chapter 4).  
Identify the dose required to firstly improve postprandial glucose excursion in non-diabetic 
mice, including oral administration of hydrolysates on satiety and delayed glucose tolerance 
(chapter 5).  
The effect of the most promising hydrolysates identified on markers of diabetes and obesity 
in genetic and diabetes induced models of diabetes (chapter 6/7).  
Finally, identify if the dose used within mice models is translatable to human study and the 





Screening multifunctional bioactivities of synthetic peptides 

















4.1  Introduction 
Obesity and related co-morbidities present challenges that have in recent years spiralled out of control 
becoming a global epidemic. Treatment costs now affect health care centres across multiple 
departments, which pose to further stretch healthcare budgets worldwide (Seuring et al, 2015). The 
most common, yet avoidable outcome of chronic obesity is type 2 diabetes mellitus (T2DM), which 
accounts for 90% of global diabetes prevalence and characterised by obesity, chronic hyperglycaemia 
and dyslipidaemia (Shaw et al, 1999). During obesity related progression of T2DM, pancreatic 
dysfunction disrupts intrinsic glucose homeostatic mechanisms of which are tightly controlled via 
peptide hormones, insulin, glucagon and somatostatin from β, α and δ cells within the islet of 
Langerhans (Zyromski, 2015). Cells which are most adversely altered by chronic over-nutrition are the 
β-cell which accounts for 90% of total islet cell mass within the endocrine tissue, however represent 
only 1 -  2 % of total cells within the pancreas, in turn this leads to β-cell dysfunctions and subsequent 
insulin resistance when the disease is established (Mingyu et al, 2014; Gupta et al, 2012).  
 Dietary intake has a profound effect on blood glucose concentrations and disease progression, 
as such, modern strategies implemented focus on reducing carbohydrates and lipids, however no 
reduction in protein necessary (Frans, 2014). New evidence suggesting classical dietary modification 
approaches may be enhanced by incorporation of bioactive food components or foods with 
multifunctional properties that extend further than purely caloric requirements (Oh & Jun, 2014). 
These approaches however, aim to highlight novel molecules of which constitute only a micronutrient 
portion of the food of which it is contained within. Newer approaches unlocking bioactive peptides 
from food-derived proteins within in the last decade has highlighted the importance of food 
components that may be exploited for therapeutic gain (Patil et al, 2015; Xia et al, 2017).  
Using proteolytic enzymes which unlock small molecular weight peptides with a targeted 
range of 2  to 20 amino acids has been underlined as a researching aim with huge nutraceutical 
potential (Oseguera-Toledo et al, 2014). Screening of food derived protein by-products has spanned 
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across several modern key research areas with research highlighting the anti-cancer (Lefranc et al, 
2017), hypotensive (Rong et al, 2014), and anti-obesity properties (Pan et al, 2016). Anti-diabetic 
properties of small peptide molecules is a new endeavour for their intrinsic interaction with 
endogenous enzymes, signalling and regulatory pathways of which have the ability to display 
advantageous health outcomes. Endogenous food proteins are vital for health with their smaller 
degraded peptide molecules and amino acids full-filling vital metabolic roles improving health prior to 
being utilized in metabolic or cellular respiratory roles (Jain & Chawrai, 2005).  
Its proposed that oral nutrient sensing, hormone secreting cells within the intestinal tract are 
currently a key target area of diabetes therapy (Sanyal, 2013). Improving the action or increasing the 
circulating concentration of intestinal hormones both glucagon-like-peptide 1 (GLP-1) secreted from 
intestinal L-cells and glucose-dependant insulinotropic polypeptide (GIP) secreted from intestinal K-
cells have numerous beneficial effects including improved post-prandial glucose excursion, glucose-
dependent insulin secretion, reduction of gastric emptying, improvement of glycated haemoglobin 
(HbA1c) (Kim and Egan, 2008) and effects which are seen beyond the pancreas, such as the more-
recently highlighted, potential improvement of cognitive function. Both GLP-1 and GIP are rapidly 
degraded by the transmembrane cell surface expressed serine protease, dipeptidyl-peptidase 4 
(DPP4) also known as CD26. The 101 amino-acid enzyme targets the N-terminus di-peptide from the 
peptide chain of both GLP-1 and GIP analogues rendering the incretin hormones inactive in regards to 
glucose homeostasis (Dicker, 2011).  
DPP4 is overly expressed in several disease states including inflammatory conditions, cancer, 
obesity and diabetes (Röhrborn et al, 2015). Inhibition of the enzymes has been a therapeutic target 
since the development of the first small synthetic molecule that interacts and renders the enzyme 
inactive, sitagliptin. Approval of sitagliptin use was granted on October, 2006 and since, several 
improvements have been made in both biological activity and duration of action of newer DPP4 
enzyme antagonist molecules. The biological half-life of saxagliptin (Onglyza) ranges from 2 – 4 hours, 
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sitagliptin (Januvia ) from 8 – 15 hours, were as more modern enzyme antagonists, linagliptin (trajenta) 
boasts a 24 hour half-life with the aim of improving patient compliance and improvement of post-
prandial glucose regulation. Currently 13 DPP4 inhibitors are in use or awaiting approval via FDA 
regulatory bodies. The efficacy and safety of DPP4 inhibitors has improved and recently evolved into 
combinational drug approaches in a single tablet form, such as the sitagliptin/metformin combination 
(5mg / 500 mg w/w), marketed as Janumet.  
The mechanism, specificity and duration of DPP4 inhibitors rely on enzyme interaction, with 
each having diverse structural protein binding sites with several functional areas across the enzyme 
promoting decreased kinetic activity. A few of the most potent molecules target the proline mimetic, 
cyanopyrrolidine P1 group which increases enzyme inhibitory potency over other targeted protein 
regions (Thornberry & Gallwitz, 2009)  
The DPP4 enzyme was first reported as having the ability of being able to cleave a proline or 
alanine residue from the penultimate N-terminus amino acid, denoting the name, di-peptidyl 
peptidase, however more recently the interaction of the enzyme to cleave other amino acids has been 
reported (Matteucci & Giampietro, 2009). With this noted, several studies have reported DPP4 
inhibition using animal and plant derived compounds including peptides obtained via enzymatic 
hydrolysis of proteins from various biological sources (Jao et al, 2015; Liu et al, 2017; Harnedy et al, 
2015). Enzymatic hydrolysis of proteins yields abundant small molecular weight peptides of which 
have reported multifunctional properties, including incretin hormone secretion and intrinsic enzyme 
interaction with various biological enzymes such as ACE (Iwaniak et al, 2014) and DPP4 (Power et al, 
2014), respectively. Oral intake of specific food compounds for therapeutic health gain is a relatively 
new approach for the treatment of diabetes, however as DPP4 is expressed highly within the intestine, 
oral treatment approaches have been the pharmacotherapy target, this in turn has promoted research 
to identify novel compounds with DPP4 inhibitory action.  
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Peptides yielded post-hydrolysis are diverse with various molecular weight, structure and 
amino acid sequence variations that can result in diverse molecular bioactivity that is translated into 
effects that are, A.) challenging to characterise in their crude state and B.) require increasing quantities 
of crude product to display bioactivity over an identified synthetic peptides that may have specific 
therapeutic capabilities. Oral intake of crude peptides are hypothesised to remain bioactive and 
resistant to digestion while able promote cellular signalling firstly via the gastrointestinal hormone 
secreting cells and secondly have more specific cellular interaction based upon the assumption that 
the smaller peptides of interest will be absorbed intestinally, again proving problematic to establish 
the source of bioactivity (Sable et al, 2017).  
This leads researchers to verge from crude peptide screening to targeted identification of the 
individual peptide/s that may promote a therapeutic effect of interest. Peptides are important natural 
products, which are present in many terrestrial and aquatic species, which have in more recent times 
displayed nutraceutical and medicinal properties due to a broad spectra of reported bioactivities (Jo 
et al, 2016). With this being noted, certain peptides can fulfil more than a singular biological role, 
however their primary use is that of a targeted therapeutic effect. In regards to health, peptides have 
the ability to regulate cellular proliferation (Nekhai et al, 2000), inflammation (Ialenti et al, 2001), cell 
migration and wound repair (Yamada, 2000), and targeted drug delivery (Bruno et al, 2014). This 
approach has lead researchers and industry to produce peptide analogues, which has opened a new 
door to a generation of targeted healthcare. Peptides can be highly specific with over 60 approved by 
the FDA and a further 200 in clinical trials and now estimated 800+ in pre-clinical trials. Peptides are 
now recognised as being highly selective, well tolerated and effective, of which is contrived versus 
current diabetes therapy approaches reporting potential hypoglycaemic, pancreatitis and increased 
cardiovascular events.  
Chapter 3 characterised the acute bioactivity of crude protein hydrolysates from various 
biological marine sources. These nitrogenous sources were carefully chosen based on source 
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sustainability, availability, protein content, as well as utilizing various processing waste discard 
sources. The assumption that each of the hydrolysates investigated in the previous chapter present 
bioactivity via similar cell signalling, hormone secretory activity and enzyme interaction via the same 
mechanisms or via a single peptide is considered in this case, inaccurate with effects seen from a wide 
array of unknown peptides having a multifaceted effect. In order to test this hypothesis, several 
peptides had been identified from protein obtained from palmaria palmata protein hydrolysate 
generated using the proteolytic enzyme, promod. The peptides were firstly identified via hydrolysate 
RP-HPLC fractioning, Tandem LCQ/MS-MS de-novo sequencing and finally synthesized. Peptides 
identified ranged from 4 to 11 amino acids in length of which several have been previously identified 
as potent DPP4 inhibitors (Harnedy et al, 2015b). Three of the most potent DPP4 inhibitor peptides, 
ILAP (ILE-LEU-ALA-PRO) , LLAP (LEU-LEU-ALA-PRO) and MAGVDHI (MET-ALA-GLY-VAL-ASP-HIS-ILE) , 
were deployed to investigate signalling activity other than the already reported DPP4 inhibitory action, 
using a range of cell pancreatic and intestinal cell lines with specific antii-diabetes potential including 
in vivo animal models.  
Background & Aims 
A major limitation to protein hydrolysate investigation is establishing the bioactive 
component/s contained within a sample. A common approach used is fractionation of peptide 
components followed by mass spectrometry and peptide structure/amino acid comformity 
using proteomic tools. Futhermore this allows peptide synthesis and administration of pure 
idenitified peptides using similar experimental protocols. Here, three peptides previously 
identified from Palmaria palmata protein hydroysates, are known to reduce the activity of 
DPP4, a current pharmaceutical target for the treatment of type 2 diabetes. We aim to further 
investigate the biological activity of these peptides across multiple cell cultures including the 
administration to small rodent models alone, or in combination with GLP-1, a hormone 
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typically cleaved to its inactive form by DPP4 rendering its effect upon glucose excursion 
redundent. We hypothesize that the idenitified synthetic peptides will present in vitro 
bioactivity and furthermore the improve the effect upon glucose excusion in mice after being 
injected alone, or in combination with GLP-1 if these peptides posses the ability to inhibit 


















4.2 - Materials and Methods 
HPLC elution properties of peptides from crude Palmaria palmata protein hydrolysate 
Using a fixed dose of 2.5 mg/ml, hydrolysate sample was first reconstituted in dH20 (1 ml) 
and briefly vortexed. Prior to RP-HPLC, sample was centrifuged at 3000 rpm for 20 minutes 
and supernatant finally filtered using a 0.45 µm whatman filter. The HPLC column equipped 
was a C18 preparative LUNA (250 x 10 mm, 10 µM particle size) with the flowrate set to 5 
ml/min. Solvents consisting of (solvent A) 100% deionized HPLC grade water (dH20) 
supplemented with 0.12% TFA increasing over 60 minutes to 70% of (Solvent B) 70% 
acetonitrile, 30% dH20 (70/30 v/v) supplemented with 0.1% TFA. For full RP-HPLC protocol 
refer to section 2.2.9.  
 
Acute insulin secretory activity in BRIN-BD11 cells 
In brief, cells are seeded at a cell density of 1.5 x 105 cell/well in 1 ml of RPMI cell culture 
media and left for 21 hours to adhere. Insulin radioimmunoassay (RIA) was used for the 
determination of insulin from both insulin secreting cell lines and from ex-vivo biological 
plasma samples (Flatt & Bailey, 1981), described in 2.1.3. 
GLP-1 secretion from GLUTag mouse enteroendocrine cells 
On experimentation day DMEM culture media is removed, cell prepping KRBB (1 mmol/L 
glucose) is added for 2 hours then removed and further supplemented with KRBB of which 
contains 2 mmol/L glucose in all conditions (baseline) with compounds of interest used in a 
dose dependant manner in n=4 wells minimum. A detailed outline is described in 2.2.2 




GIP secretion from STC-1 mouse enteroendocrine cells 
As outlined in section 2.2.3, cells were grown until 80–90 % confluence. Cells were trypsinized 
and seeded onto 24 well plates at a seeding density of 15 x10-5 for 24 hours. A detailed outline 
is described in 2.2.3 including ELISA outline in section 2.2.5.  
Cellular toxicity using LDH cytotox assay 
Experimentation was carried out exactly as described in 2.1.2 with a final step of testing 50 µl 
of collected supernatant aliquoted into 96 well plates using test conditions (N=3) for released 
LDH concentration. Refer to section 2.2.16 for full experimental protocol.  
 
Acute Intracellular cAMP production 
BRIN-BD11 cells were cultured as described in section 2.1.3. Cells were seeded on 24 well 
plates as described in 2.2.1. Cells were then lysed after removal of supernatant using 100 µl 
of cell lysis buffer for 30 minutes at 37oC. Cells were visually inspected to verify cell lysis using 
a phase contrast microscope (Zeiss, Germany). Samples were stored at -20oC until analysis. 
For an in-depth protocol including the cAMP ELISA used see section 2.2.10. 
 
Investigating GLP-1 activity in the presence of DPP4 using RP-HPLC chromatography 
Preserving GLP-1 (7-36amide) from degradation to GLP-1 (9-36) in the presence of DPP4 was 
achieved by co-incubating with synthetic peptides of marine origin first isolated from 
Palmaria palamta. A 100mM Triethanolamine (TEA) buffer (pH 7.4) was used as a biological 
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buffer of which all reagents would be dissolved in. Protocol in brief, 30 µl of GLP-17-36amide (106 
M) is added to a low bind Eppendorf tube (Sigma-Aldrich, Dorset, UK) followed by 30 µl of 
sample, control (106 M) or blank. Following this 430 µl of TEA buffer is added. The reaction is 
started by adding 10 µl of DPP4 (5 mU). Several tubes containing the same additions are 
prepared and subsequently incubated for 0 h, 2 h, 8 h and 24 h respectively. The reaction is 
stopped by adding 50 µl of 10% TFA. Samples are then stored at -20oC until RP-HPLC analysis.  
Refer to section 2.2.9 for HPLC and solvent protocol information.  
 
Compound massda determination using Matrix assisted laser desorption ionisation time of 
flight mass spectrometry (MALDI-TOF MS) 
For full MALDI-TOF MS experimental protocol, refer to section 2.2.10.  
 
 
Acute glucose lowering effect of peptides via intraperitoneal injection (IPGTT) 
The animal model used were NIH Swiss mice (section 2.3.1). Each group (n=8) were fasted for 
8 hour prior to experimentation and housed as described in 2.3.1. Food was withheld during 
experimentation however access to water was available. Prior to compound administration a 
fasting blood sample was analysed for glucose concentration using a handheld glucometer 
(Bayer Contour, Leverkusen, Germany). A fixed dose (25 nmol/kg bodyweight) of peptide was 
then mixed with a dose of glucose (18.8 mmol/kg bodyweight) and administered via IP 
injection. Effect of the peptides was then established by further testing blood glucose 
concentration at various timepoints over 2 hours (15, 30, 60, 90 and 120 min). After 
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experimentation was complete animals were given access to food and given a 72 hour 
washout period before experimentation could be carried out on the same group of animals.  
Investigating reduction of food intake in 3 hour trained feeding HsdOla:TO mice  
 
HsD:Ola:T0 mice (8 weeks old) were obtained from Envigo, Blackthorn, UK. For housing and 
animal conditioning please refer to section 2.3.4. Before animals were given access to food 
for 3 hours, Food averaging 10 g was weighed. Animals (n=8) were given a chosen compound 
within a saline vehicle (0.9% NaCL) with food given and weight subsequently every 30 minutes 
for 3 hours total. Food is then be removed until the following day.   
 
Statistical analysis 
Data was expressed as mean ± SEM with values compared using one-way analysis of variance 
(ANOVA) followed by post-hoc students T-test. Data between groups were considered 












Fig 4.1  - RP-HPLC separation of crude peptides after enzymatic digestion. 
Using the method described in 4.2.1, 4 mg/ml of crude hydrolysate was injected with subsequent 
peaks analysed over a 60 minute solvent gradient elution period. The chromatograph (Fig. 4.1) 
displayed was not used in the generation of the peptides identified of which gives an understanding 
of the hydrophobicity profile of peptides generated using the Alcalase/flavouzyme enzyme 
combination with protein from palmaria palmata. (Fig. 4.1) 
 
Fig 4.2 - Insulinotropic activity of peptides during acute (20 min) co-incubation in BRIN-BD11 cells  
Insulin secretion was determined over a 20-minute co-incubation period with each peptide 
incubated in the presence of a fixed glucose concentration (5.6 mmol/L). Baseline insulin 
secretion was established using KRBB buffer alone containing 5.6 mmol/L glucose (Fig 4.1 A). 
All other test conditions contained addition peptide compounds or known insulinotropic 
agents. The positive controls used were KCL (30 mM) and GLP-1 (10-6) displayed 4.2 –fold 
(p<0.001) and 3.2 -fold (p<0.001) insulin secretion versus baseline (5.6 mmol/L) glucose, 
respectively. Peptide LLAP and ILAP displayed a 2 – fold increase in insulin secretion at 10-6 M 
(p<0.001; Fig 4.2 B) and a 1.5 – fold activity in a dose dependant manner to 10-9 M and 10-11 
M (p<0.01 Fig 4.2 C).. Under the same incubation conditions, peptide MAGVDHI (Fig 4.2 D) 
failed to promote insulin secretion beyond the basal glucose control, respectively.  
 
Fig 4.3 A - Glucagon-like-peptide-1 (GLP-1) secretion of peptides during acute (2 H) co-incubation in 
enteroendocrine GLUTag cells  
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GLP-1 secretion was determined over a 2 H co-incubation period with each peptide incubated 
in the presence of a fixed glucose concentration (2 mmol/L). Basal GLP-1 secretion was 
established using KRBB buffer alone containing 2 mmol/L glucose (Fig 4.3 A). All other test 
conditions contained addition peptide compounds or known GLP-1 secreting agents. The 
positive control used was forskolin (10 mM) which displayed 10 -fold GLP-1 concentration 
versus the basal glucose control, respectively. Under the same incubation conditions, peptide 
ILAP (10-6 M; ), LLAP (10-6 M) and MAGVDHI (10-6 M) failed to promote any GLP-1 secretion 
above the basal control from the concentrations used, respectively. (Fig 4.3 A). 
 
Fig 4.3 B - Glucose-dependent insulinotropic-polypeptide (GIP) secretion of peptides during acute (2 
H) co-incubation in enteroendocrine STC-1 cells  
GIP secretion was determined over a 2 H co-incubation period with each peptide incubated 
in the presence of a fixed glucose concentration (2 mmol/L). Basal GIP secretion was 
established using KRBB buffer alone containing 2 mmol/L glucose. All other test conditions 
contained addition of a fixed peptide concentration. Co-incubation with peptide ILAP (10-6 M) 
displayed 2 – fold GIP secretion, LLAP (10-6 M) 1.5 – fold secretion while peptide MAGVDHI 
(10-6 M) failed to promote any GIP secretion with 0.4 fold reduction in GIP secretion versus 
basal control, respectively (Fig 4.3 B).  
 
Fig 4.3 C - Cellular toxicity of peptides during co-incubation in BRIN-BD11 cells 
During acute insulinotropic experimentation supernatant from the highest concentration of 
peptides (10-6 M) were investigated for extracellular lactate dehydrogenase (LDH) 
concentration using the cytotox non-radioactive LDH assay. Each of the experimental 
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conditions investigated returned no-increase in LDH concentration over basal glucose control, 
respectively (Fig 4.3 C).  
 
Fig 4.3 D - Acute intracellular cyclic adenosine monophosphate (cAMP) produced during 
acute peptide co-incubation in BRIN-BD11 cells.  
Post-insulinotropic experimentation, BRIN-BD11 cells were further lysed and collected for 
cAMP concentration determination using a cAMP elisa assay (as described in 4.2.8). Results 
were comparative to basal glucose control (5.6 mmol/L) with positive controls, 16.7 mmol/L 
glucose and GLP-1 returning 20% and 30% increase in intracellular cAMP concentrations. 
Peptide ILAP and LLAP returned a 70% and 30% increase in intracellular cAMP concentration, 
however MAGVDHI displayed no increase versus basal control, respectively (Fig 4.3 D).  
 
Fig 4.4 Investigating DPP-4 activity using a GLP-1 based RP-HPLC assay 
DPP4 (5 mU) was co-incubated with GLP-1 (10-6 M) alone, or with the further addition of either 
Diprotin A (10-6 M), ILAP (10-6 M), LLAP (10-6 M), or MAGVDHI (10-6 M). GLP-1 alone in the 
presence of DPP4 resulted in 1.5 H half-life, whereas the known small peptide molecule DPP4 
inhibitor Diprotin A resulted in a 24 hour half-life (p<0.001). Subsequently the peptides ILAP, 
LLAP and MAGVDHI extended the GLP-1 half-life from 1.5 h to 8 h (P<0.001, Fig 4.4 B), 9 h 






Fig 4.5 – 4.11 - Glucose lowering effect of peptides co-administered with glucose via 
intraperitoneal injection 
Peptides were tested in-vivo via intraperitoneal injection. Blood glucose of each animal was measured 
prior to administration (0 min) with each peptide (25 nmol/kg bw) co-administered with glucose (18.8 
mmol/kg bw) and subsequent blood glucose concentration measured at various timepoints (15, 30, 
60, 90 & 120 min; Fig 4.5 - 9) with blood plasma collected for insulin RIA over a 2 hour period after 
administration. Blood glucose concentrations were reduced overall via analysis by area under the 
curve (AUCmin120) after administration of both ILAP and LLAP with a blood glucose AUC reduction of 
43-52% reduction (P<0.05; fig 4.8 A)  and accompanied by a 2.9 to 4.4-fold rise (p<0.01; Fig 4.8 B) in 
plasma insulin (AUC0-120 min, P<0.01 to p<0.001), compared to the glucose control. No improvement in 
glucose homeostasis was noted with MAGVDHI (Fig 4.8).   When peptide LLAP and ILAP were co-
administered with GLP-1 a further glucose reduction of 13% (P<0.01, Fig 4.9 B) and 16% (P<0.01, Fig 
4.10 B) below GLP-1 injection alone when analysed via blood glucose area under the curve (AUC0-120 
min). No improvement was noted during the glucose challenge and co-administration of peptide 
MAGVDHI with and without GLP-1, respectively (Fig 4.11 B).  
Fig 4.12 - Satiety promoting effects of marine derived peptides 
Groups of mice (n=8) trained to eat for 3 H per day were administered peptides (25 nmol/kg bw) via 
intraperitoneal injection. Food was weighed with mice only allowed access to food post-injection. 
Food was weighed at 30 minute intervals up until 180 minutes. Peptide ILAP displayed a food intake 
reduction at 180 min only (p<0.05,) whereas peptide MAGVDHI reduced food intake from 90 min to 
180 min (p<0.05 – p<0.001) versus saline control group. Peptide LLAP had no effect on food intake 
over the 180 minute period (Fig 4.12).  
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Fig 4.1 - A. Chromatograph displays a RP-HPLC elution of palmaria palmata hydrolysates generated using Alcalase and Flavourzyme combination (4h). 
Using a prep luna C18 column (250 x 10 mm, 10 µm particle size) a 4 mg injection using a rheodyne 7725i injector attached to a thermo surveyor RP-
HPLC machine equipped with a UV/VIS detector set to 214 nm wavelength. Solvent proportioning changed from dH20 w/v 0.12% TFA to a maximum of 
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Fig 4.2. Dose-dependent effects of Palmaria palmata derived peptides on insulin secretion from BRIN-BD11 cells at 5.6 mM glucose. BRIN-BD11 cells were incubated with either LLAP 
(Panel B), ILAP (Panel C) or MAGVDHI (Panel D) using a range of concentrations (10-12 M to 10-6 M) for 20 min and insulin release measured by RIA. Values are expressed as mean  
























A.  Secretory effects of peptides on GLP-1 secretion from GLUTag cells at 2 mM 
glucose. GLUTag cells were incubated with ILAP, LLAP or MAGVDHI using a fixed 
concentrations of peptide (10-6 M) for 2 hours and GLP-1 release measured by 
ELISA. Values are expressed as mean  S.E.M. (n=3).   
 
 
B. Secretory effects of peptides on GIP secretion from STC-1 cells at 2 mM 
glucose. GLUTag cells were incubated with ILAP, LLAP or MAGVDHI using a fixed 
concentrations of peptide (10-6 M) for 2 hours and GIP release measured by 
ELISA. Values are expressed as mean  S.E.M. (n=3).   
 
 
C. LDH release from BRIN-BD1 cells during co-incubation with ILAP, LLAP or 
MAGVDHI using a fixed concentrations of peptide (10-6 M) for 20 min with LDH 
measured by cytotox assay. Values are expressed as mean  S.E.M. (n=3).   
 
 
D. Effects of marine peptides on cAMP production in BRIN-BD11 cells during acute co-incubation with 
glucose  alone or ILAP, LLAP or MAGVDHIusing a fixed concentrations of hydrolysate (10-6 M) for 20 min. 
Cells were lysed using cAMP assay lysis buffer with cAMP concentration established using a cAMP specific 
ELISA. Values are expressed as mean  S.E.M. (n=3).  *p<0.05, **p<0.01,***p<0.001 compared to respective 
glucose only control. 
 















Fig 4.4 - Graphs displays a graphical depiction of a RP-HPLC elution of active GLP-1 (10-6 M 7-36 amide) after incubation with DPP4 (5 mU) at 0, 2, 8 and 24 H 
in a TEA buffer (pH 7.4).  Using an analytical kinetix C18 column (250 x 10 mm, 3.6 µm particle size) a 200 µl injection using a rheodyne 7725i injector 
attached to a thermo surveyor RP-HPLC machine equipped with a UV/VIS detector set to 214 nm wavelength. Panel A represents GLP-1 and DPP4 only, 
panel B represented the addition of LLAP with panel C addition of ILAP and panel D displaying the addition of MAGVDHI. Each graph also contained the 
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Fig 4.5 - A. Acute actions of ILAP on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to (t=0) 
and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with ILAP (25 nmol/kg body weight; IP). Values are expressed as mean  S.E.M. for 6 mice. 
 
Fig 4.5 - B. Acute actions of ILAP on plasma insulin concentrations in NIH Swiss mice. Plasma insulin was 
measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body 



















Fig 4.6 - A. Acute actions of LLAP on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to (t=0) 
and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with LLAP (25 nmol/kg body weight; IP). Values are expressed as mean  S.E.M. for 6 mice. *p<0.05 
versus glucose only control group 
 
Fig 4.6 B. Acute actions of ILAP on plasma insulin concentrations in NIH Swiss mice. Plasma insulin was measured 
prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) 

















Fig 4.7 A. Acute actions of MAGVDHI on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to 
(t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with MAGVDHI (25 nmol/kg body weight; IP). Values are expressed as mean  S.E.M. for 6 mice. 
 
Fig 4.7 B. Acute actions of MAGVDHI on plasma insulin concentrations in NIH Swiss mice. Plasma insulin was 
measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body 
weight; IP) or in combination with MAGVDHI (25 nmol/kg body weight; IP). Values are expressed as mean  



























Fig 4.8 A/B. AUC values for 0-120 min post-injection compared to glucose alone with panel G representing blood 
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Fig 4.9 A. Acute actions of LLAP on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to (t=0) 
and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with LLAP with and without GLP-1 in combination(25 nmol/kg body weight; IP). Values are 
expressed as mean  S.E.M. for 6 mice. 
 
Fig 4.9 B. Mean AUC values for 0-120 min post-injection compared to glucose alone with panel B representing 
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Fig 4.10 A. Acute actions of ILAP on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to (t=0) 
and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with ILAP with and without GLP-1 in combination(25 nmol/kg body weight; IP). Values are expressed 
as mean  S.E.M. for 6 mice. 
 
Fig 4.10 B. Mean AUC values for 0-120 min post-injection compared to glucose alone with panel D representing 
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Fig 4.11 A. Acute actions of MAGVDHI on IP glucose tolerance in NIH Swiss mice. Glucose was measured prior to 
(t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; IP) or in 
combination with ILAP with and without GLP-1 in combination(25 nmol/kg body weight; IP). Values are expressed 
as mean  S.E.M. for 6 mice. 
 
Fig 4.11 B. Mean AUC values for 0-120 min post-injection compared to glucose alone with panel D representing 
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Summary of analysis 
Fig 4.12. Food intake data for mice with restricted food availability (3 hours per day). Each group was 
given an IP injection with a compound of interest. A weighed amount of food is given (T 0 min) and 
amount eaten weighted every 30 minutes for 180 minutes. Marine peptides were administered via IP, 
(ILAP, LLAP and MAGVDHI) with food eaten calculated accumulatively and comparative to non-treated 
saline control. Panel C represents oral palmaria palmata hydrolysates and panel D, boarfish 
hydrolysates effect on food intake. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05 









4.4  Discussion 
 
To date there has been a wealth of knowledge applied to the field of potential therapies based 
upon peptides, which display antidiabetic properties (Billyard et al, 2007). This applies to 
classical and more recently identified approaches that aim to exploit homeostatic 
mechanisms, which in turn has concomitant application for improved health and physiological 
regulation. Diabetes research is firmly established in developing new approaches of which 
regulate endogenous hormones or more recently the exploitation of existing therapeutic 
pathways for medicinal advantage (Todd & Bloom, 2007). Due to the rapid global rise of type 
2 diabetes, approaches have shifted from classical lifestyle alterations and the well-
established biguanide and sulphonylurea treatments targeting pancreatic and hepatic cell 
signalling to peptide based approached which have shown sustained improvement of 
pancreatic functioning (Lau & Dunn, 2018). The utilization of peptides of all classes have 
evolved and changed dramatically, including peptides isolated from natural sources. New 
therapies such as DPP4 inhibition mentioned earlier of which lengthens the post-prandial 
incretin effect. This in turn allows hormones such as GLP-1 and GIP to cause potent glucose 
dependent insulin secretion, thus lowering overall circulating plasma glucose concentrations. 
Furthermore, hormones of interest have over the past decade diversified and now include 
interest in numerous gut related hormones such as leptin, ghrelin, peptide YY, obestatin and 
oxyntomodulin to name a few (Sala et al, 2014).  
Overall, these approaches of exploiting the later hormones (excluding DPP4 and GLP-
1 therapies) of which may promote improved glucose, insulin and glucagon homeostasis has 
yet to fully materialise and opens the questions to researchers, what prompts the intestines, 
or specifically, certain intestinal cells to fail to counteract the rapid increase in global 
hyperglycaemia?. This chapter attempts to expose the multifaceted properties of identified 





diet, Palmaria palmata. Each of the assays deployed aim to expand on the crude hydrolysates 
results presented in the previous chapter. As such verging from the crude hydrolysate co-
incubation to the identified peptides, ILAP, LLAP and MAGVDHI presented interesting results 
within the in vitro assays and in vivo animal investigation. Bioactive peptides from seaweed 
protein in the past was unfortunately not given the attention it require, and more recently 
taken forefront towards increasing sustainability of the nitrogen source (Admassu et al, 2018).  
Firstly, elaborating on previous crude work carried out the same screening approach 
was taken using the insulin secreting BRIN-BD11 cell line with each of the peptides 
investigated for bioactivity and potency. Initially, MAGVDHI displayed no increase in basal 
insulin secretion, interestingly peptide ILAP stimulatory effect was below 10-9 M was not 
above basal glucose control whereas a single amino acid change in the form of  ILAP resulted 
in similar secretory potency from 10-6 M through to 10-10 M and as low as 10-11 M still resulting 
in elevated insulin secretion. The interest in small molecule receptor agonists is at the 
forefront of diabetes research with particular interest with incretin specific receptor 
activation such as the GLP-1 receptor (Willard et al, 2012). Its unclear if the insulinotropic 
activity of LLAP and ILAP are receptor based, however the increased cAMP reported would 
suggest a downstream cascade effect which is likely due to membrane based activation, 
however further work is needed to elucidate the mechanism of action.  
Furthermore, the insulin secretory effect of these synthetic peptides is lower 
compared to its crude hydrolysate counterpart of which they were identified suggesting a 
synergistic effect of multiple peptide compounds within the crude hydrolysate, however ILAP 
appears to be insulinotropic at considerably lower concentrations that LLAP and MAGVDHI. 
Rationale for this may arise from the protease used bromelain. Bromelains cleavage site 
converts protein carboxyl groups into uncharged amides which can impede effect towards 





cells, each of the peptides failed to stimulate GLP-1 secretion above the basal glucose control, 
again adding to the hypothesis that cellular receptor/peptide interaction may be hindered 
using this digestion process. With this being noted, ILAP and LLAP, similar to the secretory 
activity within the BRIN-BD11 cell line, resulted in elevated GIP secretion within STC-1 cells, 
whereas fascinatingly, MAGVDHI inhibited the relative GIP secretion versus the basal glucose 
control; however, the reason for this is unknown. Oral protein intake is considered beneficial 
due to the incretin effect which may have beneficial glucose lowering effects in type 2 diabetes 
(Jakubowicz et al, 2014). With this noted, as these peptides were injected rather than orally 
administered, their insulinotropic effect may be derived from the pancreas.  
The toxicity profile of these peptides returned favourable results within eukaryotic 
cells. The immunogenicity of peptide-based therapeutics is a cause for concern; however, no 
adverse effects were noted during acute co-incubation with the algal derived peptides (Gupta 
et al, 2015). During acute intracellular signalling investigation, cAMP concentration was 
established after acute incubation within culture cells; interestingly ILAP presented a potent 
rise in intracellular cAMP production with LLAP resulting in similar levels to that of GLP-1. The 
activation of cAMP dependent pathways may shed light on why both ILAP and LLAP presented 
secretory activity in both BRIN-BD11 and STC-1 cells, as under the same experimental 
conditions MAGVDHI resulted in the same intracellular cAMP as the basal glucose control. This 
result would correspond with, up until now, the cellular secretory pattern seen with peptide 
MAGVDHI, as GLUTag and STC-1 trigger hormone secretion from cellular cAMP signalling 
pathways being activated prior to hormone exocytosis concluding that MAGVDHI is relative 
inert towards cellular based receptors (Simpson et al, 2007).  
Protein-protein interaction was investigated using an RP-HPLC assay approach. Under the 
experimental conditions, GLP-1 and DPP-4 incubated alone yielded a 1.5 h half-life of the 





the half-life of GLP-1 was significantly extended across all three peptides of interest, this time 
highlighting that MAGVDHI using this approach was successful at inhibiting the action of DPP4 
resulting in a 13 h half-life versus 8 h and 10 h for peptides LLAP and ILAP, respectively. These 
algal peptides have been previously reported within the literature for their DPP-4 inhibitory 
action (Harnedy et al, 2015). However, with this noted, the study mentioned that peptides 
with ile at the penultimate position having a negative effect on DPP4 activity. Our own work 
corroborated this finding, furthermore we confirmed that the mechanism of which MAGVDHI 
inhibits DPP4 in unknown at present, however we hypothesize that the intact peptide chain 
may not itself present the inhibitory activity seen, more-so its further degraded amide bonds 
that may be released during DPP4 interaction. 
During IPGTT investigation, we identified in the previous chapters that therapeutic 
gain from crude peptides might be exhibited primarily via the gut, however with peptides ILAP 
and LLAP eluding effects upon cultured pancreatic cells, that the delivery of the identified 
synthetic marine peptides may also present glucose lowering effects via intraperitoneal (IP) 
injection. This method aimed to assess that bypassing the intrinsic intestinal signalling via 
post-prandial pathways may also be advantageous for glucose regulation in the fed state such 
as that of current peptide mimetics via injection of GLP-1 mimetics (Gupta, 2013). Delivery of 
peptides via injection avoids the harsh proteolytic intestinal environment. In order to test this 
approach, mice were giving an IP glucose challenge including 25 nmol/kg/bw of each peptide 
to assess their efficacy as potential anti-diabetic peptides. Interestingly, after injection, overall 
plasma glucose was lower post-injection when analysed via area under the curve over the 2 H 
period in both ILAP and LLAP groups with an increase in circulating plasma insulin during the 
same investigation period. It was unclear if the mechanism of which circulating insulin was 
elevated, either via DPP-4 inhibition and improvement in GLP-1 action upon the pancreas, or 
direct pancreatic interaction and promotion of insulin secretion. Expanding on the knowledge 





injection of peptide ILAP or LLAP with GLP-1 further improved the glucose lowering effect 
versus the GLP-1 only injected group, when challenged via the same glucose concentration; 
however, improvement beyond GLP-1 only was marginal when analysed via AUC. The in-vitro 
investigating displayed a lack of activity for peptide MAGVDHI, exceptions being the decrease 
in DPP4 activity via RP-HPLC assessment; furthermore, no improvement in glucose 
homeostasis was seen in-vivo during the IPGTT of MAGVDHI alone or in combination with GLP-
1. Blood glucose levels after the IPGTT however increased in the latter experiment when co-
injected with GLP-1, eluding to the peptides potential antagonistic effect upon biological 
pathways. This antagonistic effect was presented within the STC-1 cells and lack of secretory 
effect upon BRIN-BD11 and GLUTag cells, respectively.  
Finally, groups of trained mice of which had access to food for 3 H per day were used 
to assess the effect upon food intake during food availability at 30 min intervals. Concluding 
this, peptide LLAP had no effect upon food intake, whereas ILAP presented a reduction at the 
180 min time point only. Interestingly, peptide MAGVDI resulted in a significant reduction in 
food intake from 90 min through 180 min with overall food reduction across the entire group 
of mice averaging 45% versus the control group. In order to assess the rationale for this we 
must assume the peptides ILAP and LLAP are true DPP4 inhibitors due to their lack of effect 
upon food intake. Dietary protein intake and improvement in satiety via a reduction in food 
intake is commonly reported (Paddon-Jones, 2008), however injection of peptide based 
molecules and their effect on food intake is less known towards satiety.  
Conclusion 
Identifying several novel peptide hormones of which present multifaceted effects upon 
cultured cells, ability to elevate intrinsic intracellular signalling mechanisms, interact with 
large complex endogenous enzymes and finally improve glucose homeostasis and promote 





hydrolysed form can elicit effects that have more than a purely nutritional role. Protein is vital 
for life; however the form of which it is ingested may alter the therapeutic effects displayed. 
Here we presented three peptides hormones of which were identified from a marine protein 
source, Palmaria palmata. On completion of the protein isolation, food grade enzymes were 
deployed to yield abundant small molecular weight peptides of which were subsequently 
separated, identified and synthesized for investigational purposes. Each peptide presented 
unique interactions upon in-vitro and in-vivo experimentation, which concluded that while the 
protein source was identical, each individual peptide may present unique therapeutic effects 
of which might be exploited for medical gain. Concluding this work, the research agrees that 
ILAP and LLAP are DPP4 inhibitors, which also elicit additional properties, most likely 
dependent on its cellular surroundings. Peptide MAGVDHI however will need further 
characterisation to fully elucidate its potential as a satiety promoting peptide. Each of the 
peptides individually however, are modest DPP4 inhibitors comparative to synthetic 
molecules presently prescribed to treat type 2 diabetes, however this does not neglect the 
findings that these are food derived molecules with high safety and tolerance profiles and 
incorporation of the crude protein hydrolysate of which they were identified may prove 
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5.1 - Introduction 
 
The overwhelming rise of obesity related diabetes and associated co-morbidities has 
in recent years presented one of the greatest public health threats to both developed and the 
developing world (Wang, 2012; Ng et al, 2014). Increased rates of morbidity and mortality 
have unearthed further personal, economic and societal outcomes with devastating impact 
on health related wellbeing, thus there is an urgent need for direct and effective tools to 
prevent weight gain within the population and approaches to maintain weight loss (Lenz et 
al, 2009).  
Non-insulin dependent diabetes mellitus is the most common obesity related 
endocrine disorder expected to affect more than 640 million people by 2040 (Marín-Peñalver 
et al, 2016). To date, classical approaches of controlling type 2 diabetes via conventional 
weight loss using lifestyle modifications with the aim of successful weight and hormonal 
homeostasis is rapidly surpassed in favour of intensive pharmacological strategies due to 
insulin resistance, weight loss plateau and the progression of diabetes complications 
(Bramante et al, 2017). Long term weight loss for treating obesity related diabetes 
unfortunately have a low successes rate at higher body mass indexes (BMI) (Monteso et al, 
2016), however with nutritional guidance dramatically improves diabetes disease-associated 
outcomes.  Western food environments are currently dominated by energy dense, highly 
processed and relatively inexpensive foods (Mattes & Foster, 2014), however a modest 10% 






Furthermore, the only sustainable weight loss approach in the super-morbidly obese 
is achieved by gastrointestinal surgery in the form of gastric sleeve, bypass, banding or balloon 
(Golzarand et al, 2017). Researchers have now questioned the importance of the of the 
intestine as surgery procedures, such as the Laparoscopic Roux-en-Y gastric bypass (RYGBP), 
completely reverses type 2 diabetes in almost 80% of cases well before significant weight loss 
is displayed. This improvement is initially due to improvements in insulin sensitivity and 
metabolic improvements that are considered humoral in nature (Pajecki et al, 2007; Goldfine 
& Patti, 2014).  
Gut hormone changes are noted, specifically with foregut surgery, which decreases 
the appetite promoting hormone ghrelin while increasing post-operative cholecystokinin 
(CCK) levels while hindgut surgery advances GLP-1 and PYY secretion (Beckman et al, 2010). 
The importance of protein, carbohydrates and lipid ratios within foodstuffs for weight 
management has been relatively consistent within the literature; defining that reduction total 
caloric intake can ultimately, lead to improvement in weight associated disease outcomes 
(Finer, 2001). Conversely, high protein intake in childhood and adolescents can be a factor 
leading to childhood obesity; however, protein intake is generally higher across many ages 
ranges leaving the direct association of the protein source and weight gain challenging to 
elucidate (Del Mar Bibiloni et al, 2015; Wallace & Frankenfeld, 2017). This association is a 
puzzling primarily due to the associated complexities of macronutrients within the foodstuff 
that ultimately need to be factored in. Controversial outcomes has unfortunately left 
researchers shy to fully clarify the importance of protein including the source which may 
display more than a caloric role for health and disease via the use of large scale studies with 





  Nutritional promotion of humoral factors and have proved invaluable for 
understanding the mechanisms for ameliorating glycaemic and appetite control. Satiating 
factors via low glycaemic index foods or hormonal promotion of CCK, PYY, GLP-1 , GIP and 
leptin have reported concurrent glucose lowering capabilities via satiation, reduction of 
gastric emptying or direct stimulation of insulin secretion via β-cell activation (Anderson & 
Woodend, 2003; Klok et al, 2007; Cheung et al, 2009; Gault et al, 2011; Joshi et al, 2013).  
 In overweight and obese patients with established T2DM, glucose homeostasis is 
achievable prior to weight loss with recent advances in hormone alteration via endogenous 
highly specific molecules, such as DPP-4 and SGLT2 inhibitors or GLP-1 mimetics (Chaudhury 
et al, 2017). Obesity and type 2 diabetes presents abnormal hormones concentrations such 
as cholecystokinin (CCK), leptin, ghrelin, adiponectin and peptide tyrosine-tyrosine (PYY) 
(Breen et al, 2013). Several rapid biochemical changes occur following intestinal bypass 
surgery; however, these hormonal changes are acutely amendable via post-prandial food 
intake (Coll et al, 2007). As such over several decades of nutritional research has highlighted 
this as a potential therapeutically viable approach to identifying foods and food components, 
which may act as vital glycaemic, appetite and metabolic regulators.  
 Oral intake of several sources of protein involve interaction with gut hormone 
secreting cells are directly involved in improved β-cell functionality, satiety, reduction of 
gastric emptying and insulin secretion, It is not clear however, the source or quantity needed 
of protein that leads to this outcome (Jakubowicz et al, 2014). Peak plasma amino acid 
circulation is considered the classical approach for describing protein metabolism, 
furthermore several decades of intestinal signalling and transport research has identified 





Protein administration however has several major limitations; firstly, of the 
administered protein of interest, which aspect of the protein or peptides display the beneficial 
effect and secondly, during digestion of the protein, which degraded hydrolysate product 
remains bioactive after oral ingestion? Albeit, extraction of protein from diverse biological 
sources has reaffirmed that protein possess beneficial biological properties that are yet to be 
fully understood. 
 Proteins sources including cod ,salmon, herring and blue whiting are several species 
of ichthyoids of which present promising nutraceutical, anti-obesity and anti-diabetic 
potential (Hoyle & Merritt, 1994; Vik et al, 2015 Godinho et al, 2016; Harnedy et al, 2018). 
Protein extracted and hydrolysed from these sources have offered the ability to ameliorate 
weight gain and increase insulin sensitivity while promoting satiety, anti-inflammatory and 
lower adiposity in vivo. Our own hydrolysate research displayed potent insulin, GLP-1 and GIP 
secretion and finally improved glucose uptake in cultured adipocytes from a range of 
hydrolysates from marine sources, however bioactivity between each protein source varied 
leaving an understanding that the source of protein is a leading factor for potential targeted 
therapeutic effect. This work aims to answer if the source of protein and hydrolysis method 
play a role in the biological effect using altered doses of marine derived protein hydrolysates. 
Each of which, will be investigated for their effect upon glucose tolerance during acute and 
delayed glucose tolerance tests including effect upon food intake in mice.  
Background & Aims 
 
Within the literature, the optimal dose required to promote a positive effect from oral intake 





effect upon glucose lowering or satiety also vary. Unfortunately, a large proportion of the 
currently literature focuses on dietary protein sources from food stuffs or in the form of 
supplemental intact proteins such as those derived from dairy or plant based sources. For this 
reason, this chapter aims to identify the optimal dose required to promote a beneficial effect 
in regards to post-prandial glucose excusion, such as blood glucose levels pre- and post-oral 
administration of protein hydrolysates, including the delayed anti-glycaemic effect. Finally, 
the effect upon satiety in mice trained to eat for 3 hours per day using a similar protein 
concentration that promoted a reduction in post-prandial glucose elevation will be deployed. 
With this noted the translation of bioactivity from in vitro to in vivo study would be a main 
investigative outcome. The hypothesis for this chapter is in line with current literature of 
which is in agreement with protein promoting both direct and delayed improvements in post-
prandial glucose excursion and a positive effect upon satiety and food intake, however the 














5.2 Materials and methods 
 
Acute glucose tolerance screening of marine protein hydrolysates 
 
ice were grouped depending on their weight and non-fasting blood glucose concentration. 
Drinking water and standard rodent diet was freely available. All animal studies were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1986. For 
experimental and animal information refer to section 2.4.3.  
Glucose tolerance tests  
Blood samples were measured from a minor tail vein bleed in fasted (8 h) ob/ob mice. Blood 
glucose was measured using a handheld glucometer (Bayer Contour, Leverkusen, Germany)  
prior (t=0) to administrating a glucose challenge (18.8 mmol/kg/ bodyweight). Once 
administered, blood glucose was further analysed at 15, 30, 60, 90 and 120 min. Plasma 
insulin concentration was determined using insulin radioimmunoassay (described in 2.2.3).  
 
Delayed glucose lowering effect In vivo 
 
Hydrolysates that were identified as having an oral glucose lowering effect were then carried 
onto further investigation using delayed glucose tolerance test. This was investigated via oral 
compound administration during fasting, followed by glucose (18.8 mmol/L) administration 
either 4, 8 or 12 h later to identify if a lasting glucose lowering effect was evident from the 
hydrolysate of interest. The glucose-lowering dose of the hydrolysate were previously 
identified, animals were then fasted for 4 hours and then administered a dose of hydrolysate 





or 12 hour hours the animals were then given glucose (18.8 mmol/L) via oral gavage. Further 
experimentation procedures can be found at section 2.3.1.  
 
 
Satiety and appetite study in 3 hour fed trained animals 
Male HsD:Ola T0 mice (8 weeks old) were obtained from Envigo, Blackthorn, UK. Mice were 
housed in an air conditioned room maintained within a narrow range of 22 ± 2oC with a 12 h 
light: 12 h dark cycle. Drinking water and standard rodent diet was freely available on arrival. 
All animal studies were performed in accordance with the UK Animals (Scientific Procedures) 
Act 1986.  
On arrival animals had access to food 24 hours per day for 1 week. This was reduced to 10 
hours of food availability on week 2 with further reduction to 6 hours by week 3. Finally on 
week 4 and for the remaining duration of the animal satiety study, food availability was 3 




Data was expressed as mean ± SEM with values compared using one-way analysis of variance 
(ANOVA) followed by post-hoc students T-test unless otherwise stated. Data between groups 
were considered statistically significant if p≤0.05. Data was plotted and analysed using 








Fig 5.1 / 2 - Establishing the dose required to improve glycaemic parameters after oral 
administration of Boarfish protein hydrolysate and glucose 
Groups of animals (n=8) were fasted for 12 h prior to an oral glucose challenge. Fasting blood 
glucose was established prior to administration of glucose and various concentrations of 
boarfish protein hydrolysate (BPH) ranging from 10 to 100 mg/kg/bw. Blood glucose was 
concentration was subsequently measured at intervals over a 120 min period. Initially 
concentrations of BPH administered at 10 and 25 mg/kg/BW had no effect on glycaemic 
parameters (fig 5.1 A). Furthermore, an improvement was reported with concentrations of 
50 mg/kg/bw and above. The 50 mg/kg/bw had reported a significant improvement in 
glycaemic parameter at 15 min (p<0.05), 30 min (p<0.001) and 60 min (<0.05) versus the 
glucose only control (Fig 5.1 B). Interestingly, at higher administered doses, both 75 mg/kg/bw 
and 100 mg/kg/bw had only shown a significant glucose reduction at 30 min (p<0.01) over 
the 120 min time period (Fig 5.1 C). The SGID variant had no effect upon improving glycaemic 
control when administered compared to the glucose only control (fig 5.2). 
Fig 5.3 - Establishing the dose required to improve glycaemic parameters after oral 
administration of Blue whiting protein hydrolysate (BWPH) and glucose 
Initially concentrations of BWPH administered at 10 and 50 mg/kg/BW had no effect on 
glycaemic parameters (Fig 5.3 A / B). An improvement was reported however, with a 
concentration of 100 mg/kg/bw (Fig 5.3 C). The 100 mg/kg/bw had reported a significant 
improvement in glycaemic parameter at 90 min (p<0.01), and 120 min (p<0.01) versus the 





Fig 5.4 - Establishing the dose required to improve glycaemic parameters after oral 
administration of P.palmata protein hydrolysate (PPPH) and glucose 
An improvement was reported with concentrations of 50 mg/kg/bw and above. The 50 
mg/kg/bw had reported a significant improvement in glycaemic parameter at 90 min 
(p<0.01), and 120 min (P<0.001) versus the glucose only control (Fig 5.4 B). At higher 
administered doses, 100 mg/kg/bw had shown an further improved glucose reduction at 60 
min (p<0.01), 90 min (p<0.001) and 120 min (P<0.001) versus the glucose only administered 
control (Fig 5.4 C).  
Fig 5.5 - Establishing the dose required to improve glycaemic parameters after oral 
administration of Salmon gelatine protein hydrolysate (SGPH) and glucose 
Concentrations of SGPH administered at 10 mg/kg/BW had no effect on glycaemic 
parameters (Fig 5.5 A). Furthermore, an improvement was reported with concentrations of 
50 mg/kg/bw only (Fig 5.5 B) and not at 100 mg/kg/bw (Fig 5.5 C). The 50 mg/kg/bw had 
reported a significant improvement in glycaemic parameter at 30 min (p<0.05), 60 min 
(p<0.05), 90 min (p<0.01) and 120 min (p<0.05) versus the glucose only control. At higher 
administered dose, 100 mg/kg/bw no improvement in glycaemic parameters were noted 
versus the glucose only control, respectively (Fig 5.5 A – C).  
Fig 5.6 - Establishing the dose required to improve glycaemic parameters after oral 
administration of Salmon trimmings protein hydrolysate (STPH) and glucose 
A Concentration of STPH administered at 10 mg/kg/BW had no effect on glycaemic 
parameters (Fig 5.6 A). An improvement was reported with concentrations of 50 mg/kg/bw 





parameter at 60 min (p<0.05), 90 min (p<0.05), and 120 min (p<0.05) versus the glucose only 
control (Fig 5.6 B). At a higher administered dose of 100 mg/kg/bw glycaemic parameters 
were improved upon at the same time points with a modest improvement over 50 mg/kg at 
90 min (p<0.01) versus the glucose only control, respectively (Fig 5.6 C).  
Fig 5.7 A - Establishing the mechanism of improved glycaemic parameters after oral 
administration of Boarfish protein hydrolysate (BPH) via circulating insulin concentration 
Circulating plasma insulin levels were measured over the same time period of 120 min. When 
analysed via insulin area above the curve (AAC), BPH reported a significant total increase of 
circulating insulin levels (p<0.05) versus the glucose only control (Fig 5.7 A).  
Fig 5.7 B - Establishing the mechanism of improved glycaemic parameters after oral 
administration of P.palmata protein hydrolysate (PPPH) via circulating insulin 
concentration 
When analysed via insulin area above the curve (AAC), PPPH reported a significant total 
increase of circulating insulin levels (p<0.05) versus the glucose only control (Fig 5.7 B).  
Fig 5.8 A - Establishing the mechanism of improved glycaemic parameters after oral 
administration of Blue whiting protein hydrolysate (BWPH) via circulating insulin 
concentration 
When analysed via insulin area above the curve (AAC), BWPH reported no significant total 





Fig 5.8 B - Establishing the mechanism of improved glycaemic parameters after oral 
administration of Salmon Trimmings protein hydrolysate (STPH) via circulating insulin 
concentration 
When analysed via insulin area above the curve (AAC), STPH reported a significant total 
increase of circulating insulin levels (p<0.05) versus the glucose only control (Fig 5.8 B).  
Fig 5.9 A - Establishing the mechanism of improved glycaemic parameters after oral 
administration of Salmon gelatine protein hydrolysate (SGPH) via circulating insulin 
concentration 
When analysed via insulin area above the curve (AAC), SGPH reported a elevated insulin trent 
however a non-significant increase versus the glucose only control (Fig 5.9 A).  
Fig 5.10 A - Establishing the delayed glycaemic effect duration after oral administration of 
Salmon gelatine protein hydrolysate (SGPH) over a 12 hour period 
An oral glucose challenge was carried out however; animals were administered SGPH at 4 h, 
8 h or 12 h prior. Blood glucose levels were measures prior to glucose challenge (T=0 min) and 
at intervals to 120 min post glucose challenge. Administration of SGPH had no improvement 
in glycaemic parameters over the 120 min period post 8 and 12 h administration of SGPH, 
however an improvement at 15 min (p<0.05) was noted 4 h post SGPH. There was a glucose 
trend reduction for both 4 h and 8 h which both returned an overall glucose reduction when 
analysed via area under the curve (p<0.05) compared to the glucose only control (Fig 5.10 A).  
Fig 5.10 B - Establishing the delayed glycaemic effect duration after oral administration of 





Administration of STPH had no improvement in glycaemic parameters over the 120 min 
period post 4 and 8 h administration of STPH. There was no glucose trend reduction for both 
4 h and 8 h when analysed via area under the curve compared to the glucose only control (Fig 
5.10 B).  
5.11 A - Establishing the delayed glycaemic effect duration after oral administration of 
Boarfish protein hydrolysate (BPH) over a 8 hour period 
Administration of BPH had no improvement in glycaemic parameters over the 120 min period 
post 8 h administration of BPH, however an improvement at 15 min (p<0.05) was noted 4 h 
post BPH. There was a glucose trend reduction for 4 h which both returned an overall glucose 
reduction when analysed via area under the curve (p<0.05) compared to the glucose only 
control (Fig 5.11 A).  
5.4.11 B - Establishing the delayed glycaemic effect duration after oral administration of 
Blue whiting protein hydrolysate (BWPH) over a 8 hour period 
An oral glucose challenge was carried out however; animals were administered SGPH at 4 h 
and 8 h prior. Blood glucose levels were measures prior to glucose challenge (T=0 min) and at 
intervals to 120 min post glucose challenge. Administration of BWPH had no improvement in 
glycaemic parameters over the 120 min period post 4 h or 8 h administration of BWPH. 
5.12 B - Establishing the delayed glycaemic effect duration after oral administration of 





Administration of PPPH had no improvement in glycaemic parameters over the 120 min 
period post 4 h, 8 h or 12 h administration of PPPH versus glucose only treated control (Fig 
5.12 B). 
Fig 5.13 A / B– Investigating the reduction in food intake post IP administration of satiety 
promoting peptide hormones in animals trained to eat for 3 h per day  
Animals trained to eat for 3 h/day were administered via IP injection, saline only, or saline 
with either Exendin-4 or CCK-8, both of which are known to be potent promoters of satiety 
causing a reduction of food intake. Food was weighed prior to availability and subsequently 
measured at 30 min intervals over a 180 min period. Both Exendin-4 and CCK-8 resulted in a 
significant reduction post-injection from 30 min through 180 min (p<0.001, 30 min – 0.001, 
180 min) versus the saline only control group (Fig 5.13 A/B).  
Fig 5.13 C – Investigating the reduction in food intake post oral administration of P.palamata 
protein hydrolysate (PPPH) in animals trained to eat for 3 h per day 
A reduction of food intake was only evident within the group administered 100 mg/kg bw 
PPPH which resulted in a significant reduction at 60 min through 120 min (p<0.05 – p<0.01) 
versus the saline only control (Fig 5.13 C).  
Fig 5.13 D – Investigating the reduction in food intake post oral administration of Boarfish 
protein hydrolysate (BPH) in animals trained to eat for 3 h per day 
No reduction of food intake was evident within the group administered BPH versus the saline 





Fig 5.14 A – Investigating the reduction in food intake post oral administration of Blue 
whiting protein hydrolysate (BWPH) in animals trained to eat for 3 h per day 
No reduction of food intake was evident within the group administered BWPH versus the 
saline only control (Fig 5.14 A).  
Fig 5.14 B – Investigating the reduction in food intake post oral administration of Salmon 
gelatine protein hydrolysate (SGPH) in animals trained to eat for 3 h per day 
A reduction in food intake was only evident at 90 min (p<0.001) after 50 mg/kg/bw whereas 
after 100 mg/kg/bw a significant reduction of food intake was evident from 90 min through 
180 min (p<0.05 – p<0.001) versus saline control group (Fig 5.14 B.  
5.14 C – Investigating the reduction in food intake post oral administration of Salmon 
trimmings protein hydrolysate (STPH) in animals trained to eat for 3 h per day 
A reduction of food intake was evident within both groups administered STPH at 50 mg/kg/bw 
and 100 mg/kg/bw versus the saline only control. A reduction at both administered 
concentrations was reported from 30 min through 180 min (p<0.05 – p<0.001) versus saline 
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Fig 5.1. Acute actions of Boarfish hydrolysates on oral glucose tolerance in NIH Swiss mice. 
Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with extract (Panel A 
10 / 25 mg/kg  bw, Panel B 50mg/kg bw, Panel C 75-100 mg/kg body weight; oral gavage). 
Integrated panels (Right) show glucose AUC values for 0-120 min post-oral administration. Values 
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Fig 5.2. Acute actions of SGID Boarfish hydrolysate on acute oral glucose tolerance in NIH Swiss 
mice. Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with boarfish (Panel A) 
50 mg/kg  bw; oral gavage). Integrated panels (Right) show glucose AUC values for 0-120 min 
post-injection. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, **p<0.01 and 
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Fig 5.3. Acute actions of blue whiting hydrolysates on oral glucose tolerance in NIH Swiss mice. 
Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with extract (Panel A 
10 mg/kg  bw, Panel B 50mg/kg bw, Panel C 100 mg/kg body weight; oral gavage). Integrated 
panels (Right) show glucose AUC values for 0-120 min post-oral administration. Values are 
expressed as mean  S.E.M. for 8 mice. *p<0.05, **p<0.01 compared to glucose alone. 
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Fig 5.4. Acute actions of palmaria palmata hydrolysates on oral glucose tolerance in NIH Swiss 
mice. Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with extract (Panel A 
10 mg/kg  bw, Panel B 50mg/kg bw, Panel C 100 mg/kg body weight; oral gavage). Integrated 
panels (Right) show glucose AUC values for 0-120 min post-oral administration. Values are 
expressed as mean  S.E.M. for 8 mice. *p<0.05, **p<0.01 compared to glucose alone. 
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Fig 5.5. Acute actions of salmon gelatine hydrolysates on oral glucose tolerance in NIH Swiss 
mice. Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with extract (Panel A 
10 mg/kg  bw, Panel B 50 – 100 mg/kg bw; oral gavage). Integrated panels (Right) show glucose 
AUC values for 0-120 min post-injection. Values are expressed as mean  S.E.M. for 8 mice. 
*p<0.05, **p<0.01 compared to glucose alone. 
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Fig 5.6. Acute actions of salmon trimming hydrolysates on oral glucose tolerance in NIH Swiss 
mice. Glucose was measured prior to (t=0) and 15, 30, 60, 90 and 120 min after administration of 
glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with extract (Panel A 
10 mg/kg  bw, Panel B 50 mg/kg bw; Panel C 100 mg/kg bw oral gavage). Integrated panels 
(Right) show glucose AUC values for 0-120 min post-oral administration. Values are expressed as 
mean  S.E.M. for 8 mice. *p<0.05, **p<0.01 compared to glucose alone. 
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Fig 5.7. Acute insulinotropic action of marine hydrolysates generated using Alcalase/Flavourzyme 
combination, Boarfish (Panel A) and Palmaria palmata (Panel B) during oral glucose tolerance in 
NIH Swiss mice. Plasma insulin concentration was measured via RIA prior to (t=0) and 15, 30, 60, 
90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; oral gavage) or 
in combination with hydrolysates. Integrated panels (Right) show glucose AUC values for 0-120 
min post-oral administration. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, 
compared to glucose alone. 
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Fig 5.8 
Fig 5.8. Acute insulinotropic action of marine hydrolysates generated using Alcalase/Flavourzyme 
combination, Blue whiting (Panel A) and Salmon trimmings (Panel B) during oral glucose tolerance 
in NIH Swiss mice. Plasma insulin concentration was measured via RIA prior to (t=0) and 15, 30, 60, 
90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; oral gavage) or 
in combination with hydrolysates. Integrated panels (Right) show glucose AUC values for 0-120 
min post-oral administration. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, 
compared to glucose alone. 
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Fig 5.9. Acute insulinotropic action of marine hydrolysates generated using Alcalase/Flavourzyme 
combination, Salmon skin gelatine (Panel A) during oral glucose tolerance in NIH Swiss mice. 
Plasma insulin concentration was measured via RIA prior to (t=0) and 15, 30, 60, 90 and 120 min 
after administration of glucose alone (18 mmol/l kg body weight; oral gavage) or in combination 
with hydrolysates. Integrated panels (Right) show glucose AUC values for 0-120 min post-oral 
administration. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, compared to glucose 
alone. 
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Fig 5.10. Delayed actions of salmon gelatine (Panel A) or salmon trimming (Panel B) hydrolysates 
on oral glucose tolerance in NIH Swiss mice. Hydrolysates were administered 4, 8 or 12 h prior to 
glucose. Blood glucose was then measured prior to (t=0) and 15, 30, 60, 90 and 120 min after 
administration of glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with 
pre-admininstered extract (Panel A SSG 50 mg/kg  bw 4, 8 & 12h prior to glucose Panel B ST 50 
mg/kg  bw 4 & 8 hours prior to glucose oral gavage). Integrated panels (Right) show glucose AUC 
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Fig 5.11. Delayed actions of boarfish (Panel A) or blue whiting (Panel B) hydrolysates on oral 
glucose tolerance in NIH Swiss mice. Hydrolysates were administered 4, 8 or 12 h prior to 
glucose. Blood glucose was then measured prior to (t=0) and 15, 30, 60, 90 and 120 min after 
administration of glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with 
pre-admininstered extract (Panel C BF 50 mg/kg  bw 4 & 8 H prior to glucose Panel D  BW 50 
mg/kg  bw 4 & 8 hours prior to glucose oral gavage). Integrated panels (Right) show glucose AUC 
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Fig 5.12. Delayed insulinotropic actions of palmaria palmata (Panel A) hydrolysates on oral 
glucose tolerance in NIH Swiss mice. Hydrolysates were administered 4, 8 or 12 h prior to 
glucose. Blood glucose was then measured prior to (t=0) and 15, 30, 60, 90 and 120 min after 
administration of glucose alone (18 mmol/l kg body weight; oral gavage) or in combination with 
pre-admininstered extract (Panel E 50 mg/kg  bw 4, 8 & 12h prior to glucose oral gavage). 
Integrated panels (Right) show glucose AUC values for 0-120 min post-oral administration. Values 
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Fig 5.13. Food intake data for mice with restricted food availability (3 hours per day). Each group was 
given a compound (oral or IP). A weighed amount of food is given (T 0 min) and weighed every 30 
minutes for 180 minutes. . Marine Hydrolysates were administered orally, except panel A (IP) and 
Panel B (IP) with food eaten calculated accumulatively and comparative to non-treated saline control. 
Panel C represents oral palmaria palmata hydrolysates and panel D, boarfish hydrolysates effect on 
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Fig 5.14. Food intake data for mice with restricted food availability (3 hours per day). Each group was 
given a compound (oral or IP). A weighed amount of food is given (T 0 min) and weighed every 30 
minutes for 180 minutes. . Marine Hydrolysates were administered orally, (Panel A, Blue whiting, Panel 
B, Salmon gelatine, Panel C, salmon trimming) with food eaten calculated accumulatively and 
comparative to non-treated saline control. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05 








5.4 Discussion  
Several decades of dietary research have highlighted that high protein diets can be 
successfully deployed to aid weight loss through improvements in body weight via humoral appetite 
regulation, however the overall outcome is neither consistent nor conclusive (Lepe et al. 2011). 
Protein loading prior to post-prandial food ingestion has shown improved satiety control without 
direct alteration of dietary macronutrients (Chambers et al, 2015). Here, we studied whether co-
ingestion of marine protein hydrolysates (MPH) from various biological sources showed 
improvements towards acute and delayed glucose tolerance including reducing food intake in trained 
mice. The oral glucose tolerance test still remains the gold standard for assess post-prandial glycaemic 
status.  Upon challenging mice with glucose alone, or combined with protein hydrolysates including 
investigating the physiological dose required to promote improved glucose tolerance was assessed 
including detecting changes in plasma insulin concentration. Finally, analysis of food intake post-
administration of MPH investigated which may hint at mechanisms that are insulin independent via 
satiety hormone or incretin hormone secretion mechanisms.  
Within our own acute glucose tolerance tests, administration of hydrolysates at either 10 or 
25 mg/kg/bw had no effect upon glycaemia. Interestingly, the dose required to improve post-prandial 
glucose tolerance was different throughout the biological sources. For example, Boarfish administered 
orally at 50 mg/kg/bw with glucose was the optimal dose required to promote a significant 
improvement in glycaemia over the 120 min observation duration. Furthermore, at higher doses of 75 
and 100 mg/kg/bw, the positive effects within the later stages of observation at 60 min were lost. This 
may be due to the nature of protein source, still within a rather crude state including unwanted 
compounds, which may affect the outcome such as free fatty acids or triglycerides that were not 
removed in total during the delipidating process. In order to assess if the bioactivity and glucose 
lowering effect was derived from peptides or amino acids, the boarfish hydrolysate was further 





After administration of the SGID boarfish protein hydrolysate at the same dose that had promoted the 
most potent glucose tolerance improvement, the glucose lowering effect was lost. This had indicated 
the effects upon insulin dependent of independent mechanisms were peptide derived, as the SGID 
variant would have contained a significantly higher proportion of its nitrogen source as amino acids 
rather than peptides. The optimal dose required for boarfish, salmon and algal hydrolysates was 50 
mg/kg/bw and while further glycaemic improvements were seen with 100 mg/kg, this equates to 7 g 
for human consumption and may present issues around food incorporation, especially within western 
food stuffs. With this noted, blue whiting required the highest dose investigated to promote improve 
glucose tolerance within mice.  
Protein intake has significant effect on insulin and glucagon, including liberated amino acids, 
specifically branch chain amino acids Val, Ile and Leu being potent predictors for insulin and glucagon 
response (Yoon, 2016; Chartrand et al, 2017). This study focused on peptides derived from marine 
protein after hydrolysis using proteolytic enzymes yielding an abundance of small molecular weight 
peptides. Recent review outcomes have showed advantages of high protein intake that is consistent 
with weight loss and lowered fat mass via humoral improvements (Pesta & Samuel, 2014), however, 
studies focusing on novel marine sources of protein hydrolysates and metabolic changes relating to 
post prandial glucose regulation and satiety are limited. The insulinotropic actions of orally 
administered hydrolysates within this study returned interesting results. The analysis was suggestive 
post-analysis of the lowest dose required to promote improved glucose tolerance of increased 
circulating plasma insulin however, this was only deemed significant when analysed via insulin area 
above the curve (AAC). Furthermore, blue whiting hydrolysate had not reported any effects upon 
increase insulin secretion versus the glucose only administered control group. This is suggestive of 
potentially non-insulinotropic mechanisms involved; however, without further investigation the effect 





Finally, within this study investigating the effect upon food intake in trained animals was 
assessed. Satiety studies focus primarily on food-derived protein or supplemental dairy or plant based 
protein, showing lesser interest to liberated protein by-products in the form of peptides (Bendtsen et 
al, 2013). Nowadays however, the bioactive screening of novel proteins and peptides is one of the 
most exciting therapeutic directions aimed at tacking some of the most prevalent diseases within 
society (Giri & Ohshima. 2012; Jo et al, 2017). To date the evidence that oral intake of peptides and 
exogenous biopeptides can stimulate glucoregulatory and satiating effect present a consistent 
relationship (Steinert et al, 2009). This link between satiety and improved glucose regulation is due to 
the diverse mechanisms that are displayed when a protein is digested, liberating small molecular 
weight peptides (SMWP) and amino acids. An increasing number of fish protein hydrolysates and 
derived peptides to date have exposed a range of anti-diabetic activity with improved glucose 
utilization in vivo promoting hyperglycaemic management however the precise mechanisms 
underlying these action are still to be determined (Zhu et al, 2017; Saleh et al, 2018).  
Throughout this investigation, not all glucose lowering doses of marine hydrolysates 
translated into a reduction in food intake suggesting different insulin dependent and independent 
pathways being activated dependant on the peptide fragments generated via hydrolysis. Blue whiting 
hydrolysate generated promoted improved glucose excursion, however, only after 100 mg/kg oral 
administration, whereas the same dose had no effect on food intake. Furthermore, studies 
investigating the satiating effect of blue whiting hydrolysates have reported beneficial effects of 1.4 
and 2.8 g increasing CCK and GLP-1 secretion in healthy volunteers (Nobile et al, 2016). Throughout 
our food intake investigation post-oral administration of hydrolysates at 50 or 100 mg/kg/bw, the 
lowest quantity of hydrolysate needed to promote a reduction in food intake was 100 mg/kg/bw. 
Furthermore, this was only evident after administration of the algal and salmon gelatine hydrolysate, 
however interestingly the salmon trimmings hydrolysate was equally potent at both 50 and 100 mg/kg 





We hypothesis the mechanism of which food intake was reduced is primarily intestinal 
derived. Interaction of small marine peptides with large complex molecules have Identified peptides 
from marine biomass, palmaria palmata (Dulse) which have  also presented dipeptidyl-peptidase-IV 
(DPP4) inhibitory effect in vitro (Harnedy et al, 2015). Peptides derived and sequenced from the crude 
protein hydrolysate ranging from 4 to 11 amino acids long, presented DPP4 IC50 inhibition at 
concentrations ranges of 43 - 139 µM, with 3 short protein fragments in particular showing promising 
activity, namely, Ile-Leu-Ala-Pro, Leu-Leu-Ala-Pro and Met-Ala-Gly-Val-Asp-His-Ile. Small peptides play 
advantageous metabolic roles versus their intact protein counterpart. Generally, the acute effect of a 
product leading to amelioration of post-prandial spikes in blood glucose or reduction in overall food 
intake is considered an advantageous approach to obesity and diabetes management.  
Work involving multifaceted effects of marine protein hydrolysates acutely using in vitro and 
in vivo investigation has been promising (Harnedy et al, 2018). The aforementioned study had shown 
modest GLP-1 secretion from cultured murine enteroendocrine cells; however the SGID variant of blue 
whiting presented increased bioactivity regarding GLP-1 secretion over the non-SGID version of which 
was investigated within. Furthermore, this may explain the rationale towards requiring a larger 
administrated dose of blue whiting while other hydrolysates such as boarfish and salmon were more 
promising at lower doses, however post-oral investigation of circulating plasma GLP-1 concentrations 
are needed.  
Post-prandial incretin secretion and satiety hormone biomarkers were not established within 
this study however is warranted in future work, especially post-administration of salmon protein 
hydrolysate. This confirmed that the protein source and method used to generate the hydrolysate and 
liberate peptides fragments are the most important factors when producing a product with bioactivity 
after oral intake. Understanding the prolonged effects of protein and hydrolysate intake is widely 





homeostasis or perceived hunger with subsequent meals after the pre-loading stage however, some 
suggest that the satiety response is independent to CCK, GLP-1 and PYY secretion (Oesch et al, 2005).  
The work presented within agrees with concerns and questions raised over protein and 
protein by-products that may promote therapeutic benefits for the treatment of obesity and type 2 
diabetes. Firstly, the source of protein may be a major factor in producing a bioactive product and 
secondly the hydrolysis method used to liberate the bioactive components such as small molecular 
weight peptides may directly dictate the bioactivity. Furthermore, the in vitro activity does not always 
translate to in-vivo, seen with work published on blue whiting hydrolysates of which promote dose 
dependent secretion of insulin in BRIN-BD11 cells and GLP-1 secretion in GLUTag cells (Harnedy et al, 
2018); however, no satiating effect was displayed when administered orally to mice.  
Surprisingly with protein sources, such as salmon skin gelatine and trimmings, in vitro 
secretory activity was not as potent as other sources such as P.palmata or boarfish hydrolysates seen 
in cultured cells within previous chapters while salmon hydrolysates continued to prove very effective 
at improving glucose tolerance and promoting a potent reduction of food intake in vivo. We conclude 
that more importantly the hydrolysis method is most likely a vital step, with hydrolysates that are 
abundant in peptides less than 2kDa as this yield a higher concentration of peptides and free amino 
acids. This approach to glucoregulatory and effect on appetite was limited due to the full 
understanding of mechanisms behind the effects seen; however, with the insulinotropic and satiating 
effect displayed we can confirm that oral intake of hydrolysed marine protein has pleotropic actions 











Investigating efficacy of long-term twice-daily oral intake of 
Boarfish and Salmon skin gelatine protein hydrolysates in 























6.1 – Introduction 
 
Dietary advice for obese individuals with type 2 diabetes (T2D) recommend reducing 
foodstuffs containing refined carbohydrates and saturated fats as well as increasing fibrous foods may 
be useful in disease management (Asif, 2014; Gray, 2015). Overnutrition is currently the leading cause 
of type 2 diabetes globally with serious impacts on quality of life and life expectancy (Gupta et al, 
2012). Type 2 diabetes, the most common endocrine disorder is expected to affect over 640 million 
people by 2040, and represents 100% rise from today’s diagnosed rates (Marín-Peñalver et al, 2016). 
Once an issue faced primarily in western countries, it is now an environmental disaster of epidemic 
proportions. Weight gain is now regrettably a primary reality globally with ready access to highly 
processed, low cost convenience foods that are calorie dense (Mozaffarian et al, 2011). Weight loss 
approaches and maintenance of weight loss needs major and modern revitalization in order to 
improve weight associated disease outcomes (Champagne et al, 2012).  
Overweight and obese individuals may present with unsuccessful weight loss attempts 
accompanied by compensatory homeostatic glucose regulation prior to the diagnosis of T2D directly 
related to over-nutrition (Chui et al, 2010). In those with T2D, hyperglycaemia, insulin resistance, 
hyperinsulinaemia and elevated glycated haemoglobin A1c (HbA1c) are invaluable diagnostic 
biomarkers which allows strategic management using an arsenal of hypoglycaemic agents (Meigs, 
2009; Lorenzati, et al, 2010). Dietary modification mentioned, including an increase in physical activity 
allow individuals to successfully manage and potentially prevent further progression of T2D (Sigal et 
al, 2006). Furthermore, with this noted, weight loss plateau and failure to adhere to the classical diet 
and lifestyle management approaches unfortunately are very often surpassed in favour of 
pharmacological treatment (Gibson & Sainsbury, 2017). In the past several decades alone, the 
effective use of metformin has been joined by eight classes of highly specific glucoregulatory drugs 





pharmacological agents have diverse interaction with glucose homeostatic systems.  Advances using 
Gliptins, known as DPP-4 inhibitors, prolong post-prandial incretin hormone action of GLP-1 and GIP, 
both potent glucose-dependant insulinotropic hormones with advantageous effects towards satiety 
and gastric emptying (Ahren, 2007; Pathak & Bridgeman, 2010). Improving upon endogenous 
hormones using modified incretin mimetics via injectable GLP-1 analogues act upon endogenous 
hormone pathways and receptors with increased half-lives and resistance to endogenous DPP-4 
proteolytic digestion and are quickly becoming a viable second choice option for type 2 diabetes 
treatment, especially within the elderly due to their safety profile (Gupta, 2013; NICE NG28 2015, 
McBrayer & Tal-Gan, 2017;). Finally, in keeping with the gastrointestinal theme, alpha-glucosidase 
inhibitors (-GIs) reduce post-prandial carbohydrate degradation within the intestine reducing 
glucose excursion from exogenous food polymers, inevitably lowering the post-prandial elevation of 
glucose (Van De Laar et al, 2005; Van De Laar, 2008).  
There are many viable approaches to treating hyperglycaemia, insulin resistance and T2DM 
via the use of oral or injectable hypoglycaemic agents (Evans et al 2016); the few approaches listed 
above are of particular interest due to their post-prandial potency. Recently, several exciting 
approaches for attempting to exploit hormonal pathways via food derived biomolecules that exert 
direct or indirect interaction with satiety centres or improvement of gastrointestinal transitioning and 
signalling have become increasingly popular, however these have bioavailability limitations (Rekha & 
Sharma, 2013). Current evidence investigating total fibre or cereal fibre being inversely associated 
with the risk of developing type 2 diabetes has made its way into dietary recommendations for obese 
or pre- or post T2D. Rather than focus on bioavailability and absorption of biomolecules, studies have 
suggested that a high intake of fibre is associated with a 33% reduction of T2DM over those with lower 
fibre intake (The InterAct Consortium, 2015). The rationale being that both soluble and insoluble fibre 
components present effects for delaying the rate of which carbohydrate polymers are liberated into 





and investigatory work have shown that food derived or supplemented fibre improves fasting blood 
glucose concentrations and improves glycated haemoglobin A1c (HbA1c) (Post et al, 2012).  
Nutritional recommendations such as reduction of overall carbohydrate and fat intake help 
support approaches to nutritional management of hyperglycaemia (Carreriro et al, 2016). 
Furthermore, newer approaches to obesity management are now being explored with high protein 
intake becoming increasingly popular with potential for offsetting other macronutrient intake by 
improving satiety. Dietary proteins are vital modulators of glucose metabolism, however, only a 
limited number of studies to date have attempted to unravel long-term protein intake and effect on 
satiety and glycaemia with renal function usually a key aim of investigation (Kamper & Strandgaard, 
2017).  Nethertheless, protein in maintenance of energy balance has considerable support however; 
several variable arise at present, such as the protein source, type and quantity required (Griffioen-
Roose et al, 2012). Furthermore, short-term trials investigating various macronutrient loading upon 
glycaemia favoured high protein over high carbohydrate and thus have been suggestive for a viable 
nutritional approach for T2D prevention (Nuttal et al, 1984). Additionally, many studies up until now 
focus primarily on food derived protein which leaves many unanswered questions for other sources 
of protein and in particular, dietary supplemented protein or hydrolysed protein products and amino 
acids.  
This present study aims to investigate bioactive protein by-products generated using 
enzymatic hydrolysis.  Bioactive peptides are molecules derived from the intact proteins and consist 
of amino acids chains linked together by peptide bonds. In nature free-living peptides are known, but 
the overwhelming majority are contained within the protein structure (Herbst et al, 2004; Conlon & 
Mechkarska, 2014, Sarbon, 2017). Hydrolysis of protein yields an abundant source of small molecular 
weight peptides, which can be further characterised for bioactivity using a range of in vitro or in vivo 
investigation. Small molecular weight peptides generated using enzymatic hydrolysis are now of 





with systems that control metabolism, satiety, including interaction with large endogenous proteases 
that are of pharmacological relevance for hypertension, obesity and diabetes treatment (Hayes & 
Tiwara, 2015; Patil et al, 2015). There are many examples of biologically active food proteins however; 
evidence now supports that liberation of small molecular weight peptides (SMWP’s)  may presents 
advantageous biological effects over the parent proteins (Kitts & Weiler, 2003).  
A study investigating DPP-4 inhibitory properties of peptides derived from protein extracted 
from an algal source (Palmaria palmata) after enzymatic hydrolysis. The peptides were generated 
using enzymatic digestion and fractioned using solid phase extraction (SPE) combined with semi-
preparative high pressure liquid chromatography (HPLC). In total, 13 peptides were identified; three 
novel DPP-4 inhibitors returned IC50 values in the range of 42 – 159 µM. These peptides, varying from 
four to seven amino acids in length liberated from parent protein molecule may have potential in the 
management or prevention of T2D as part of a functional food approach (Harnedy et al, 2015).  
Protein, peptides and amino acids can regulate glycaemic control via a wide range of internal 
signalling mechanisms dependent on the primary sequence of the peptides or amino acids generated 
following digestion (Harnedy & Fitzgerald, 2011). Hydrolysates deployed within the present study 
were screened initially using acute in vitro and in vivo small rodent models to assess which enzymatic 
preparation presented promising effects prior to long-term administration in a diabetic mouse model. 
Other work investigating acute administration of marine protein hydrolysates generated using 
Alcalase and Flavourzyme in combination (2.4L/500L) from blue whiting (Micromesistius poutassou) 
presented potent and promising in vitro and in vivo data. The hydrolysate returned a DPP-4 IC50 value 
of 1.28 mg/ml, including dose-dependent insulin secretion from cultured BRIN-BD11 cells ranging 
from 0.039 to 2.5 mg/ml (Harnedy et al, 2018). A limitation for any nitrogen containing biomolecule 
is the ability to survive in the harsh proteolytic conditions of the gastrointestinal (GI) environment and 
something that researchers must acknowledge (Renukuntla et al, 2013). Interestingly, laboratory 





comparable or improved insulinotropic actions in culture cells including improved glucose tolerance 
in mice following post-prandial insulinotropic actions (Harnedy et al, 2018b). Studies investigating 
long-term administration of marine protein hydrolysates have similarly returned anti-diabetic 
potential. Using a cohort of Chinese patients with T2D, a total of 100 diabetic patients and 50 health 
controls were recruited. The diabetic subjects received 13 g of marine collagen peptides for 1.5 or 3 
months daily,  and subsequently returned reduced levels of fasting blood glucose, glycated 
haemoglobin (A1c), improved fasting insulin, lipid parameters including lowered triglycerides and low-
density lipoprotein and importantly increased levels of insulin sensitivity during both treatment 
durations, respectively (Zhu et al, 2010). Similarly, studies investigating markers of inflammation 
related to the development of insulin resistance and T2D have shown that fish protein hydrolysates 
were able to attenuate and produce a sharp decrease in levels of serum high-sensitivity C-reactive 
protein (hs-CRP), free fatty acids and cytochrome P450 (Asfandiyarova et al, 2016).  
The translation of biological activities between in vitro and in vivo situations can present 
challenges, especially towards oral bioavailability of peptides. The studies highlighted here present a 
directed approach to tackling obesity and diabetes using hydrolysed marine proteins with 
multifaceted physiological activity. This study aims to identify if the source of protein including the 
hydrolysis method affects the bioavailability using a genetic model of obesity and diabetes. Here we 
deployed a twice daily oral administration of either boarfish or salmon skin gelatine (50 mg/kg bw) 
hydrolysate that were hydrolysed using the same enzymatic preparation, Alcalase and Flavourzyme in 
combination (2.4L/500L). Groups of ob/ob mice were administered physiological saline alone or in 
combination with boarfish, salmon skin gelatine (SSG) or metformin and assessed over 30 days. 
Additionally, the effects of the treatments on glucose homeostasis and markers of obesity and 
diabetes status were examined.  
Background & Aims 
Longterm intake of supplemental protein, or dietary modification increasing protein intake from 





anthropometric outcomes. More recently, the effects of longterm protein intakes on satiety and post-
prandial glucose excursion have been investigated for the effect upon incretin hormone secretion, 
protein-protein interactions within the GUT, and secretion of hormones that control GUT-brain satiety 
centres. The effect of protein hydrolysates on these biological outcomes is poorly undertood, with no 
definitive outcomes in place to make firm nutritional recommendations. For this reason, the aim of 
this chapter is to assess the effect of chronic twice-daily oral intake of two protein hydrolysate sources 
identified from previous chapters, and their effect upon food intake and non-fasting blood glucose 
parameters over a 30 day period in genetically obese, diabetic mice. Finally, terminal analysis 
investigating longterm markers of obesity, diabetes and bone health will be investigated. This 
chapter’s hypothesis suggests that food intake will be reduced over the duration of the study, 
















6.2 Materials and Methods 
 
6.2.1  Genetically-induced obese-diabetic (Ob/Ob) mice (B6.Cg-Lepob/J) 
Mice (12 week old) were orders from Envigo, Blackthorn, UK. Mice were housed in an air 
conditioned room maintained within a narrow range of 22 ± 2oC with a 12 h light: 12 h dark 
cycle. Drinking water and standard rodent diet was freely available. All animal studies were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1986.  
 
6.2.2  Glucose tolerance tests (intraperitoneal and oral)  
Blood samples were measured from a minor tail vein bleed in fasted (8 h) ob/ob mice. Blood 
glucose was measured using a handheld glucometer (Bayer Contour, Leverkusen, Germany)  
prior (t=0) to administrating a glucose challenge (18.8 mmol/kg/ bodyweight). Once 
administered, tail blood glucose was further analysed at 15, 30, 60, 90 and 120 min.  
 
6.2.3 Insulin sensitivity test  
Blood glucose concentrations of animals were measured from a minor tail vein bleed in non-
fasted mice using a handheld glucometer (Bayer Contour, Leverkusen, Germany). Blood 
glucose concentrations were measured prior (t=0) and following intraperitoneal 
administration of bovine insulin as 25 U/kg bodyweight (normal NIH Swiss / HsdOlaT0 / 
C57Blk) or 50 U/kg bodyweight (ob/ob mice) at 30 and 60 minute post injection.  
 





Following the various treatments for 30 days mice (at day 40) were housed individually in a 
Complete Laboratory Animal Monitoring System (CLAMS) metabolic chambers (Columbus 
Instruments, Columbus, Ohio, USA). For more information on CLAMs refer to section 2.4.5. 
 
6.2.5 Tissue excision 
On completion of terminal experimentation mice were fasted (4 h) and sacrificed. Mice were 
placed unconscious via oral inhalation of a general anaesthetic (Isoflurane) and euthanatized 
via cervical dislocation. The pancreas from each animal was excised removing any extraneous 
material. The pancreas was sectioned in half from the pancreas head to tail with half being 
wrapped in aluminium foil and snap frozen in liquid nitrogen and later stored at -70oC and the 
remaining half being placed into tissue fixative solution (4% paraformaldehyde) for later use 
in tissue processing and for immunohistochemistry.  
 
6.2.6 Pancreatic hormone content  
Thawed tissue was rinsed in cold PBS before being weighed and transferred to a Bijou tube 
where 2 ml of ice cold acid ethanol (1.5% (v/v) HCl, 75% (v/v) ethanol, 23.5% (v/v) H20) was 
added. The Bijou was then placed on ice for 30 min before being homogenized for 30 sec. The 
Bijou was blitzed again for 30 second intervals for a total of 2 minutes per pancreas. The 
homogenate containing Bijou was kept on ice until spun at 4000 rpm for 20 min with the 
resulting supernatant transferred to a fresh tube. Total volume was then increased by 
addition of 5 ml of TRIS-HCL (pH 7.4) and placed into a speed vac concentrator (45oC for 2 h) 
until complete liquid evaporation. The remaining sample extract was reconstituted in 500 µl 






6.2.7 Assessment of pancreatic insulin and glucagon content  
Pancreatic homogenate was diluted to a range of concentrations (1:100, 1:200, 1:500 and 
1:1000) using stock RIA buffer prepared in section 2.2.2 and 2.2.3. Pancreatic glucagon 
content was assessed using a chemiluminescent sandwich ELISA (Millipore, Ontario, Canada) 
and run according to manufacturer instructions as per section 2.4.8. 
 
 
6.2.8 Total pancreatic protein content  
The Bradford assay was used for protein quantification using diluted samples. Bradford 
reagent was used as the blank control and is used to subtract the baseline absorbance as 
described in section 2.4.9. 
6.2.9 Assessment of terminal plasma lipid profile  
Terminal plasma sample lipid profiles were determined using an I-Lab 650 clinical chemistry 
system (Instrumentation Laboratory, Warrington, UK). The analysis consisted of assessing 
total triglycerides, total cholesterol, high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) concentration. Reagents for triglyceride analysis were obtained from 
Instrumentation Laboratory (Warrington, UK) and reagent for LDL cholesterol were obtained 
from Randox Healthcare (Randox, Co. Antrim, NI). 
 
6.2.10 Statistical analysis 
Data was expressed as mean ± SEM with values compared using one-way analysis of variance 
(ANOVA) followed by post-hoc students T-test unless otherwise stated. Data between groups 
were considered statistically significant if p≤0.05. Data was plotted and analysed using 







Fig 6.1 – Grouping of mice prior to long-term hydrolysate investigation  
Genetically obese and diabetes mice (ob/ob) were initially grouped depending on non-fasting 
blood glucose taken in the morning and on the basis of bodyweight. There was no significant 
difference in either parameter between each group of mice (Fig. 6.1).   
 
Fig 6.2 – Effect of twice daily treatment on non-fasting blood glucose parameters 
Mice were administered their assigned treatments twice daily, once in the morning (9.00 am) 
and once in the afternoon (5.00 pm). Every third day non-fasting blood glucose (NFBG) was 
measured via a handheld glucometer (Bayer, UK). Treatments consisted of orally 
administered physiological saline only (as control) or saline containing Boarfish protein 
hydrolysate (BPH, 50 mg/kg/bw), or Salmon skin gelatine (SGPH, 50 mg/kg/bw) or Metformin 
(200 mg/kg/bw). Metformin initially resulted in a significant reduction of NFBG at day 3 
(p<0.05) however the effect was lost until day 12 (p<0.05) and was sustained throughout the 
study up until day 27 (p<0.05 – p<0.001). BFPH significantly lowered NFBG at day 6 (p<0.05) 
and this was sustained throughout up until completion at day 27 (p<0.05 – p<0.001). The 
salmon skin gelatin (SSG) protein hydrolysate showed sustained lowered NFBG from day 9 
(p<0.05) and throughout the study until completion at day 27 (p<0.05 – p<0.001), compared 
to the ob/ob saline only treated control group. All groups resulted in a significant total 
reduction of total NFBG when analysed via AUC, with each ob/ob treatment group on average 
causing a 40% reduction (p<0.01 – p<0.001) compared to the saline treated ob/ob control 






Fig 6.3 – Effect of twice daily treatment on non-fasting plasma insulin parameters 
Every third day non-fasting plasma insulin (NFGB) was measured via RIA. Generally, there was 
an overall increasing trend in plasma insulin concentrations, however only Boarfish at day 12 
has shown a significant increase (p<0.05) versus the ob/ob saline control. When analysed via 
total insulin area aunder the curve (AUC), again only the BPH group resulted in a significant 
increase in NF-plasma insulin concentrations versus the ob/ob saline control group, however 
it is noted, while non-significant for the other treatment groups such as SSG and metformin, 
there was an increased plasma insulin trend. (Fig 6.3). 
Fig 6.4 – Effect of twice daily treatments on weight parameters 
Mice were weighed every third day. On completion of the study, no intergroup significance 
was reported in weight gain. On average, each ob/ob treatment group had weight increases 
of approximately 11 – 14%, which was not significantly differently to the ob/ob saline control 
(Fig 6.4).  
Fig 6.5 A – Effect of twice daily treatments on dietary energy intake 
 Food was measured every 3 days of which animals had ad-lib access to. The weight of the 
food was measured and cumulatively scored with each gram of food eaten consisting of 12.99 
Kj. The metformin group showed a significant reduction of energy intake from day 9 through 
completion of the study at day 27 (p<0.05 – p<0.001). The Boarfish and SSG groups showed a 
significant energy intake reduction from day 12 throughout the remaining of the study at day 
27 (p<0.05 – p<0.001), with except for the SGPH group at day 15. (Fig 6.5 A). 





Following twice daily treatments, animals were fasted for 8 h and blood glucose 
concentrations determined using a handheld glucometer from a tail vein bleed. No significant 
difference in fasting blood glucose concentration was noted in SGPH or Metformin treated 
animals, however a significant improvement was noted within the BPH treated animals with 
an 8 mmol/L reduction (40% ?? p<0.05) versus the ob/ob saline treated control group. (Fig 
6.5 B). 
Fig 6.6 – Effects of twice daily treatment on terminal oral glucose tolerance in mice 
Following 27 days of treatment glucose tolerance was investigated after fasting animals for 8 
h. Fasting blood glucose levels were established prior to oral glucose administration (t=0 min) 
and at regular intervals up to 120 min. Significant blood glucose improvements were noted at 
15 min post glucose challenge in the metformin group (p<0.05), BPH (p<0.05) and the SGPH 
(p<0.001) compared to the ob/ob saline control. The effect was lost in each group from 30 
min and 60 min, however at 90 min a significant reduction in blood glucose levels were 
reported in the metformin (p<0.05) and SGPH (p<0.01) compared to the ob/ob saline control. 
Interestingly, all treatment groups at 120 min had improved glucose parameters (p<0.05) 
versus ob/ob saline treated control, respectively. When analysed via total blood glucose AUC, 
only SGPH (p<0.001) and Metformin (p<0.05) groups presented a significant total reduction 
versus ob/ob saline control. (Fig 6.6). 
Fig 6.7 – Effects of twice daily treatment on terminal ip glucose tolerance  
Following treatment analysis on ip glucose tolerance (ip GGT) was investigateds after fasting 
mice for 8 h. Fasting blood glucose levels were established prior to oral glucose administration 
(t=0 min) and at regular intervals up to 120 min. There was no improvement in glucose 





and 90 min. However, the BPH group resulted in a significant reduction in blood glucose 
concentration at both 90 min (p<0.05) and 120 min (p<0.001), furthermore, metformin also 
had shown reduction in blood glucose levels at 120 min (p<0.001) versus the ob/ob saline 
control group. Using analysis of total blood glucose from AUC data, only boarfish (p<0.01) and 
metformin (p<0.01) showed a significant improvement in total glucose reduction over the 120 
min versus the ob/ob saline control, respectively. (Fig 6.7) 
 
Fig 6.8 – Effect of twice daily treatment on terminal insulin sensitivity 
Each group was fasted for 4 h prior to insulin injection (50 U/kg/bw bovine insulin). Blood 
glucose concentration was established prior to insulin injection (t=0 min) and at 30 min and 
60 min post-injection. There was no significant improvements in insulin sensitivity noted 
between any of the ob/ob treatment groups compared to the ob/ob saline control, however 
a rend towards an improvement was noted in the BPH group, but this failed to reach 
significance. (Fig 6.8). 
 
Fig 6.9 B – Effects of twice daily treatments on long-term markers of glucose regulation via 
glycated haemoglobin analysis (HbA1c) 
Using a HbA1c assay (A1cNow), glucose control was established using this long-term marker. 
Each of the treatment groups had shown a significant reduction in HbA1c versus the ob/ob 
saline treated control group. A reduction within the BPH of 2.7 % (p<0.001), SGPH of 2.2 % 






Fig 6.10 – Effects of twice daily treatment on non-fasting circulating total GLP-1 
concentration 
Terminal plasma circulating GLP-1 was established using the chemiluminescent MSD 
mesoplex assay. There was no change found between the SGPH treatment group and the 
ob/ob saline control group. However, there was a significant increase in circulating total GLP-
1 concentration in the BPH (p<0.001) whereas the opposite effect was noted within the 
Metformin group, which displayed a significant reduction (p<0.001) versus the ob/ob saline 
control. (Fig 6.10). 
 
Fig 6.11 A – Effects of twice daily chronic treatment on circulating plasma cholesterol  
Plasma lipids were analysed using a clinical lab 650 analyser. Cholesterol concentrations were 
significantly lower in both the SSGPH (p<0.05) and the metformin (p<0.01) treatment groups 
versus the ob/ob saline control.  The Boarfish treatment group failed to reach significance 
(P>0.05). (Fig 6.11 A). 
 
Fig 6.11 B – Effects of twice daily chronic treatment on circulating plasma HDL cholesterol  
Plasma lipids were analysed using a clinical lab 650 analyser. High-density lipoprotein 
cholesterol concentrations within the three ob/ob treatment groups were unchanged versus 
the ob/ob saline control. As expected the lean saline treated control group, had a marked 
reduction of circulating HDL versus that of the ob/ob saline treated control group (p<0.001). 






Fig 6.12 A – Effects of twice daily chronic treatment on circulating plasma triglycerides  
Triglyceride concentrations were normalised towards the lean control values and were 
significantly lower in the BPH (p<0.05), SSGPH (p<0.01) and the metformin (p<0.001) 
treatment groups when compared to the ob/ob saline treated control group. (Fig 6.12 A) 
 
Fig 6.12 B – Effects of twice daily treatment on circulating plasma low-density lipoprotein 
levels analysed post-study 
LDL concentrations were normalised towards the lean control values and were significantly 
lower in the BPH SGPH and the metformin (all p<0.001) treatment groups when compared to 
the ob/ob saline control group. (Fig 6.12 B). 
 
Fig 6.13 A/B – Effects of twice daily chronic treatment on acute insulin secretion from 
isolated pancreatic islets and islet insulin content 
Pancreatic functionality was assessed after isolating pancreatic islets from each treatment 
group and testing insulin secretion and insulin content following acute treatment with known 
insulin secretagogues. Isolated islets responded to know secretagogues in a glucose 
dependent manner (Fig. 6.13A). Analysis showed a similar functionality between each 
treatment group, as well as similar insulin content as assessed via RIA analysis. No significant 
differences were reported between the various ob/ob treatment groups. (Fig 6.13 A/B) 






Pancreatic hormone changes were established using acid-ethanol extraction and 
homogenisation of pancreatic tissue and subsequently analysed using a Bradford protein 
assay. A significant reduction of ptotein content was evident within the BPH (p<0.01) and 
SSGPH (p<0.05) versus the ob/ob saline control group. No changes in total ptotein content 
were noted within the metformin group, respectively. (Fig 6.14 A) 
Fig 6.14 B – Total pancreatic insulin content expressed per mg of wet tissue 
Followin acid ethanol extraction, insulin content was analysed using RIA, no changes in 
pancreatic insulin content was noted between ob/ob treatment groups compared to the 
ob/ob saline control group. (Fig 6.14 B). 
Fig 6.19 B – Immunohistochemistry analysis of average islet cell area of excised pancreas in 
ob/ob treatment groups 
Islets were stained for glucagon, insulin and cellular nuclei stain DAPI. Based on total cell 
morphology, islets were assessed for size via cell area analysis. A significant reduction in cell 
area was reported within the BPH (p<0.001) and the metformin (p<0.001) treatment groups 
versus the ob/ob saline control group. (Fig 6.19 B). 
 
Fig 6.20 A – Immunohistochemistry analysis of average insulin -cell area of excised 
pancreas in ob/ob treatment groups 
Islets were stained for insulin. Based on total insulin cell area morphology, islets were 
assessed for total insulin cell area. A significant reduction in insulin cells were reported in the 
BPH (p<0.01) and metformin (p<0.001) whereas the SSGPH displayed a significant increase in 





Fig 6.20 B – Immunohistochemistry analysis of average glucagon -cell area of excised 
pancreas in ob/ob treatment groups 
Pancreatic islets were stained for glucagon. Based on total glucagon cell area morphology, 
islets were assessed for total glucagon cell area analysis. A significant reduction in glucagon 
cells were reported in the BPH (p<0.001) and SGPH (p<0.001) versus the ob/ob saline 
treatment group. No change in glucagon cell area was reported within the metformin group 
versus the ob/ob saline control group. (Fig 6.20 B). 
 
Fig 6.21 A - Immunohistochemistry analysis of total insulin cell area of excised pancreas in 
ob/ob treatment groups 
Pancreatic islets were stained for insulin and quantified based on total pancreatic insulin cell 
area. A significant increase in total insulin cells were shown in the BPH (p<0.001) whereas a 
reduction was noted within the SSGPH (p<0.001) and metformin (p<0.01) treatment groups 
versus the ob/ob saline treatment group. (Fig 6.21 A). 
 
Fig 6.21 B - Immunohistochemistry analysis of total glucagon cell area of excised pancreas 
in ob/ob treatment groups 
Pancreatic islets were stained for glucagon and quantified based on total pancreatic glucagon 
cell area. A significant reduction in total glucagon cell area were reported in the BPH 
(p<0.001), SGPH (p<0.001) and metformin (p<0.001) versus the ob/ob saline treated group. 





Fig 6.22 - Immunohistochemistry analysis of total alpha-cell to beta-cell ratio in ob/ob 
treatment groups 
Total glucagon to insulin cell ratio were analysed to complete the pancreatic cell morphology 
changes post-treatment. A significant reduction in α- to β- cell ratio was noted within the BPH 
(p<0.001) and SSGPH (p<0.001) whereas interestingly a significant increase in this ratio was 
noted within the metformin (p<0.001) treatment group compared to the ob/ob saline treated 
control group. (Fig 6.22) 
 
Fig 6.23 A – Bone mineral density parameter changes post-treatment analysed using DEXA 
No changes in BMD were reported in any of the ob/ob treatment groups versus the ob/ob 
saline control group. (Fig 6.23 A) 
 
Fig 6.23 B – Bone mineral content parameter changes post-treatment analysed using DEXA 
Using DEXA analysis, a significant increase in BMC was noted in both the BPH (p<0.01) and 
SSGPH (p<0.01), whereas a reduction was noted in the metformin (p<0.05) group versus the 
ob/ob saline control group, respectively. Fig 6.23 B). 
 
Fig 6.24 A – Body composition changes in total lean mass post-treatment analysed via DEXA 
No changes in total body lean mass were noted between each of the ob/ob treatment groups 






Fig 6.24 B – Body composition changes in total fat mass post-treatment analysed via DEXA 
No changes in total body fat mass were noted between each of the ob/ob treatment groups 
compared to the ob/ob saline treated control group. As expected in the lean saline treated 
control group, total fat mass was significantly lower than each of the ob/ob treatment groups 
(p<0.001) (Fig 6.24 B). 
 
Fig 6.25 A - Body composition changes in total fat % post-treatment analysed via DEXA 
No changes in total % body fat were noted between each of the ob/ob treatment groups 
compared to the ob/ob saline treated control group. (Fig 6.25 A). 
 
6.25 B - Body composition changes in total lean mass versus fat mass post-treatment 
analysed via DEXA 
No changes in total lean mass were noted between each of the ob/ob treatment groups 
compared to the ob/ob saline control group. (Fig 6.25 B).  
6.26-30 – Changes in oxygen exchange (VO2, VCO2) and respiratory exchange ratio (RER) 
analysed post-treatment using CLAMS 
No changes in oxygen exchange of O2 or VO2 including RER were noted post-treatment when 
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Fig 6. 1 – Animals were given an acclimatization period before being grouped. Groups consisted of 
evenly matched non-fasting blood glucose (A) and body weight (B). Both blood glucose and weight 
were significantly elevated versus lean control group. Results are Mean ± SEM for 8 observations 
per group. ***p<0.001 versus lean control group. No differences displayed between the various 
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Fig 6.2. Effects of twice-daily administration of marine hydrolysates on blood glucose in ob/ob mice 
(A). Parameters were measured 3 days prior to and 27 days twice daily treatment with marine 
hydrolysates (50 mg/kg bw), metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). Values 
represent mean ± SEM for 8 mice.  ***p<0.001 vs ob/ob saline, ∆p<0.05, ∆∆p<0.01, ∆∆∆p<0.001 
compared to salmon skin gelatine; ɸp<0.05, ɸɸp<0.01, ɸɸɸp<0.001 compared to boarfish; 
Ωp<0.05, ΩΩp<0.01, ΩΩΩp<0.001 compared to metformin. (B) represents Mean ± SEM blood 
glucose area under the curve (AUCday 0-27). ***p<0.001 versus ob/ob saline control and ΔΔΔp<0.001 
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Fig 6.3. Effects of twice-daily administration of marine hydrolysates on circulating plasma insulin in ob/ob mice (A). 
Parameters were measured 3 days prior to and 27 days during twice daily treatment with marine hydrolysates (50 
mg/kg bw), metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). Values represent mean ± SEM for 8 mice. 
*p<0.05, **p<0.001 vs ob/ob saline, (B) represents Mean±SEM plasma area above the curve (AAC). **p<0.01, 
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Fig 6.4. Effects of twice-daily administration of marine hydrolysates on weight gain (A) and 
percentage weight change (B) in ob/ob mice. Weight measured 3 days prior to every 3 days 
during a twice daily treatment (for 2 days) with marine hydrolysates (50 mg/kg bw), metformin 
(200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). Values represent mean ± SEM for 8 mice.  
***p<0.001 versus ob/ob saline control group. (B) represents Mean ± SEM weight change over 
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Fig 6.5. (A) Effects of twice-daily administration of marine hydrolysates on food intake in ob/ob 
mice. Food was measured 3 days prior to and 27 days during twice daily treatment with marine 
hydrolysates (50 mg/kg bw), metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). 
Values represent mean ± SEM for 8 mice.  8p<0.05, **p<0.01 and ***p<0.001 versus ob/ob 
saline control group.  
Fig 6.5 (B). Effects of twice-daily administration of marine hydrolysates on fasting blood glucose. 
Mice were fasted for 12 hours prior to measurement of glucose. Values represent mean ± SEM 
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Fig 6.6. Effects of twice-daily administration of marine hydrolysates on (A) terminal oral glucose tolerance and 
(B) integrated AUC values. Parameters were measured prior to (t=0) and 15, 30, 60, 90 and 120 min after 
administration of glucose alone (18 mmol/l kg body weight; oral gavage). B - Glucose AUC values for 0-120 min 
post-injection. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, **p<0.01 and ***p< 0.001 compared 
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Fig 6.7. Effects of twice-daily administration of marine hydrolysates on (A) terminal IP glucose tolerance and (B) 
integrated AUC values. Parameters were measured prior to (t=0) and 15, 30, 60, 90 and 120 min after 
administration of glucose alone (18 mmol/l kg body weight; IP Injection). Panel B - Glucose AUC values for 0-
120 min post-injection. Values are expressed as mean  S.E.M. for 8 mice. *p<0.05, and ***p< 0.001 compared 
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Fig 6.8. Effects of twice-daily administration of marine hydrolysates on (A) Insulin sensitivity and (B) Mean AAC 
values. Parameters were measured prior to (t=0) and 30 and 60 min after administration of insulin alone (50 
U/kg body weight; IP Injection, Bovine Insulin). Insulin AAC values for 0-60 min post-injection. Values are 
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Fig 6.9 (A). Effects of chronic administration of marine hydrolysates on fasting blood glucose. Mice 
were fasted for 12 hours prior to measurement of glucose. Values represent mean ± SEM for 8 
mice.  *p<0.05 versus ob/ob saline treated control group.  
Fig 6.9 B. Effects of chronic administration of marine hydrolysates on terminal glycated 
haemoglobin (HbA1c). Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, ***p<0.001 
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Fig 6.10. Effects of twice-daily administration of marine hydrolysates on terminal total plasma 
GLP-1 concentration. Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, ***p<0.001 
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Fig 6.11 A. Effects of chronic administration of marine hydrolysates on terminal plasma cholesterol 
concentration. Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, ***p<0.001 versus 
ob/ob saline treated control group.  
Fig 6.4.11 B. Effects of chronic administration of marine hydrolysates on terminal plasma HDL 
concentration. Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, ***p<0.001 versus 
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Fig 6.12 (A). Effects of chronic administration of marine hydrolysates on terminal plasma 
triglyceride (mmol/L) concentration. Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, 
***p<0.001 versus ob/ob saline control group.  
 
Fig 6.12 (B). Effects of chronic administration of marine hydrolysates on terminal plasma LDL 
(mmol/L) concentration. Values represent mean ± SEM for 8 mice.  ***p<0.001 versus ob/ob saline 
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Fig 6.13. Effects of chronic administration of marine hydrolysates on isolated islet insulin secretion 
(A) and islet insulin content (B). Isolated islets were harvested from mice after the treatment 
period was passed (day 40). Islets were treated with various concentrations of glucose and known 
insulin secretagogues. A represents islets (10 islets per treatment per group) treated acutely for 
secretory activity. B represents the insulin content after acid ethanol extraction of islet tissue 
produced after the acute insulin secretory study was completed. The supernatant was removed, 
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Fig 6.14 (A). Effects of chronic administration of marine hydrolysates on excised pancreata 
protein content. Whole pancreata were excised, weight and processed via acid ethanol 
extraction of tissue hormones. Hormone protein content was analysed using the Bradford 
protein assay. Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, versus ob/ob saline 
control group.  
Fig 6.14 (B). Effects of chronic administration of marine hydrolysates on excised pancreati 
protein content. Whole pancreata were excised, weight and processed via acid ethanol 
extraction of tissue hormones. Hormones content was analysed using the Bradford protein assay. 


























Fig 6.15. Effects of chronic administration of physiological saline on excised pancreatic islet morphology 
via immunohistochemistry analysis. Post-antigen retrieval slides were stained for (A) DAPI, (B) Insulin 






















GLUCAGON  Merged 
Fig 6.16. Effects of chronic administration of Boarfish protein hydrolysate on excised pancreatic islet 
morphology via immunohistochemistry analysis. Post-antigen retrieval slides were stained for (A) DAPI, 
(B) Insulin and (C) Glucagon. Greater than 50 islets were analysed per slide with analysis carried out using 







































Fig 6.17. Effects of chronic administration of Salmon gelatine protein hydrolysate on excised pancreatic 
islet morphology via immunohistochemistry analysis. Post-antigen retrieval slides were stained for (A) 
DAPI, (B) Insulin and (C) Glucagon. Greater than 50 islets were analysed per slide with analysis carried 









































Fig 6.18. Effects of chronic administration of Metformin on excised pancreatic islet morphology via 
immunohistochemistry analysis. Post-antigen retrieval slides were stained for (A) DAPI, (B) Insulin and 
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Fig 6.19 (A). Effects of twice-daily administration of marine hydrolysates on pancreata 
morphology. Graph represents total tissue section (µm2) Values represent mean ± SEM for 8 mice. 
Fig 6.19 (B). Effects of twice-daily administration of marine hydrolysates on pancreatic islet 
morphology. Graph represents average islet cell area (µm2). Values represent mean ± SEM for 8 
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Fig 6.20 (A). Effects of twice-daily administration of marine hydrolysates on pancreatic islet 
morphology. Graph represents average insulin/beta cell area (µm2). Values represent mean ± SEM 
for 8 mice.  *p<0.05, ***p<0.01, versus ob/ob saline control treated group,  
 
Fig 6.20 (B). Effects of twice-daily administration of marine hydrolysates on pancreatic islet 
morphology. Graph represents average glucagon/alpha cell area (µm2). Values represent mean ± 
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Fig 6.21 (A). Effects of twice-daily administration of marine hydrolysates on pancreatic islet 
morphology. Graph represents total insulin stained cell area for all islets (µm2). Values represent 
mean ± SEM for 8 mice. ***p<0.001, versus ob/ob saline treated control group.  
 
Fig 6.21 (B). Effects of twice-daily administration of marine hydrolysates on pancreatic islet 
morphology. Graph represents total glucagon stained area for all islets imaged (µm2). Values 
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Fig 6.22 (A). Effects of twice-daily administration of marine hydrolysates on pancreata morphology. 
Graph represents alpha to beta cell ratio (%). Values represent mean ± SEM for 8 mice.  *p<0.05, 
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Fig 6.23 (A). Effects of twice-daily administration of marine hydrolysates on bone mineral density 
analysis assessed via PIXImus DEXA. Graph represents total body bone mineral density (BMD 
g/cm2). Values represent mean ± SEM for 8 mice.  **p<0.01, versus ob/ob saline treated control 
group.  
 
Fig 6.23 (B). Effects of twice-daily administration of marine hydrolysates on bone mineral density 
as assessed via PIXImus DEXA. Graph represents total body bone mineral content (BMD g/cm2) 
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Fig 6.24 (A). Effects of twice-daily administration of marine hydrolysates on total lean mass as 
assessed via PIXImus DEXA. Graph represents total body lean mass (grams) Values represent mean 
± SEM for 8 mice.   
 
Fig 6.24 (B). Effects of twice-daily administration of marine hydrolysates on total fat mass as 
assessed via PIXImus DEXA. Graph represents total body fat mass (grams) Values represent mean 
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Fig 6.25 (A). Effects of twice-daily administration of marine hydrolysates on % body fat mass as 
assessed via PIXImus DEXA. Graph represents total body fat (%) Values represent mean ± SEM for 
8 mice.  ***p<0.001 versus ob/ob saline treated control group.  
 
Fig 6.25 (B). Effects of twice-daily administration of marine hydrolysates on anthropometric 
analysis assessed via PIXImus DEXA. Graph represents total body lean mass percentage. Values 
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Fig 6.26 (A). Energy expenditure after twice daily boarfish hydrolysate administration in ob/ob mice. The 
mice were single housed and energy expenditure was normalized for 12 h prior to 12 more consecutive 
analysis h (n = 6). Gas exchange (Volume O2) was measured at post-27 days of treatment. The data are 
expressed as mean ± SEM. Black bar represents the dark room cycle with area without representing light 
room cycle (12 h:12 h). 
 
Fig 6.26 (B). Energy expenditure after chronic salmon gelatine hydrolysate administration in ob/ob mice. 
The mice were single housed and energy expenditure was normalized for 12 h prior to 12 more 
consecutive analysis h (n = 6). Gas exchange (Volume O2) was measured at post-27 days of treatment. 
The data are expressed as mean ± SEM. Black bar represents the dark room cycle with area without 
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Fig 6.27 (A). Energy expenditure after twice-daily metformin administration in ob/ob mice. The mice were 
single housed and energy expenditure was normalized for 12 hours prior to 12 more consecutive analysis 
hours (n = 6). Gas exchange (Volume O2) was measured at post-27 days of treatment. The data are 
expressed as mean ± SEM. Black bar represents the dark room cycle with area without representing light 
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Fig 6.27 (B). Mean energy expenditure post study in ob/ob mice. The mice were single housed and energy 
expenditure was normalized for 12 hours prior to 12 more consecutive analysis hours (n = 6). Graph 
represents average VO2 (Volume O2) exchanged at post-27 days of treatment. The data are expressed as 
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Fig 6.28 (A). Energy expenditure after twice-daily boarfish administration in ob/ob mice. The mice were 
single housed and energy expenditure was normalized for 12 h prior to 12 more consecutive analysis hours 
(n = 6). Gas exchange (Volume CO2) was measured at post-27 days of treatment. The data are expressed 
as mean ± SEM. Black bar represents the dark room cycle with area without representing light room cycle 
(12 h:12 h).  
 
Fig 6.28 (B). Energy expenditure after twice-daily salmon skin gelatine administration in ob/ob mice. The 
mice were single housed and energy expenditure was normalized for 12 h prior to 12 more consecutive 
analysis hours (n = 6). Gas exchange (Volume CO2) was measured at post-27 days of treatment. The data 
are expressed as mean ± SEM. Black bar represents the dark room cycle with area without representing 
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Fig 6.29 (A). Energy expenditure after twice-daily metformin administration in ob/ob mice. The mice were 
single housed and energy expenditure was normalized for 12 hours prior to 12 more consecutive analysis 
hours (n = 6). Gas exchange (Volume CO2) was measured at post-27 days of treatment. The data are 
expressed as mean ± SEM. Black bar represents the dark room cycle with area without representing light 
room cycle (12 h:12 h).  
 
Fig 6.29 (B). Mean energy expenditure post study in ob/ob mice. The mice were single housed and energy 
expenditure was normalized for 12 hours prior to 12 more consecutive analysis hours (n = 6). Graph 
represents average VCO2 (Volume VCO2) exchanged at post-27 days of treatment. The data are expressed 
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Fig 6.30 (A). Respiratory exchange ratio after twice-daily boarfish administration in ob/ob mice. The mice 
were single housed and energy expenditure was normalized for 12 h prior to 12 more consecutive analysis 
h (n = 6). Respiratory exchange (RER) was measured at post-27 days of treatment. The data are expressed 
as mean ± SEM. Black bar represents the dark room cycle with area without representing light room cycle 
(12 h:12 h).  
 
Fig 6.30 (B). Respiratory exchange ratio after twice-daily salmon skin gelatine administration in ob/ob 
mice. The mice were single housed and energy expenditure was normalized for 12 h prior to 12 more 
consecutive analysis h (n = 6). Respiratory exchange (RER) was measured at post-27 days of treatment. 
The data are expressed as mean ± SEM. Black bar represents the dark room cycle with area without 
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Fig 6.30 (A). Respiratory exchange ratio after twice-daily metformin administration in ob/ob mice. The 
mice were single housed and energy expenditure was normalized for 12 h prior to 12 more consecutive 
analysis hours (n = 6). Respiratory exchange (RER) was measured at post-27 days of treatment. The data 
are expressed as mean ± SEM. Black bar represents the dark room cycle with area without representing 
light room cycle (12 h:12 h). 
Fig 6.30 (B). Average respiratory exchange ratio post study in ob/ob mice. The mice were single housed 
and energy expenditure was normalized for 12 h prior to 12 more consecutive analysis hours (n = 6). Graph 
represents average VCO2 (Volume VCO2) exchanged at post-27 days of treatment. The data are expressed 
as mean ± SEM. Black bar represents the dark room cycle with area without representing light room cycle 










It is well established that dietary protein components can act as vital regulators of glycaemia 
through mechanisms that are directly involved in pancreatic insulin secretion or via nutritional 
stimulation of GLP-1 and GIP via intestinal mechanisms (Thorens, 1995; Shah & Vella, 2015). The port-
prandial incretin effect is one of the most important regulators of glucose homeostasis with oral 
protein hydrolysates acting as moderate inhibitors of DPP-4 of which may well prolong the incretin 
effect (Tulipano et al, 2011). One of the major limitations encountered via the screening of marine 
protein hydrolysates using in vitro and small animal models was the hydrolysis method. Work has 
shown that sequential hydrolysis of proteins using more than one proteolytic enzyme preparation 
yields an abundant amount of small molecular weight peptides. This screening approach has resulted 
in improved bioactivity using cultured cell lines with potent insulin and GLP-1 secretion (Harnedy et 
al, 2018). In small animal models during an oral glucose tolerance test, the co-administration of marine 
hydrolysates were able to improve post-prandial glucose excursion via the increase of circulating 
plasma insulin. It is unknown for now, if this effect was via direct pancreatic interaction or via intestinal 
hormone stimulation or inhibition of endogenous proteolytic enzymes such as DPP-4.  
In order to test the oral bioavailability, administration of various marine protein hydrolysates 
was deployed, the study acknowledges that to exert a systemic effect the peptides much reach their 
target sites intact (Muheem et al, 2016). Previous studies have shown that lab based simulated 
gastrointestinal digestion (SGID) of blue whiting or boarfish hydrolysates has modest effect on overall 
bioactivity, and in some cases improved cellular secretion in GLP-1 in cultured cells. However, this 
approach, not in all cases, provided encouraging results however several enzymatic hydrolysis 
approaches may hinder bioactivity post-SGID. Hydrolysis using two enzymatic preparations can 
potentially yield smaller peptides ranging from 2 to 10 amino acids in length, which in-vitro 
investigations demonstrate resistance to further degradation and may therefore improve oral 
bioavailability. This study investigated boarfish and salmon skin gelatine protein hydrolysates 





Genetically obese diabetic mice (C57BL/6 ob/ob) were grouped based upon their non-fasting 
blood glucose and body weights. No significance difference in either parameter was present between 
the groups prior to beginning the study. Animals were assigned either physiological saline (0.9% NaCl) 
or saline containing the treatment that consisted of either boarfish or salmon skin hydrolysate (50 
mg/kg bw) or metformin (200 mg/kg).  
Non-fasting blood glucose (NF-BG) 
Animals were acclimatized using physiological saline from day -3 to -1 and from day 0 treatments were 
started and administered orally twice daily, once in the AM (e.g. time 09.00 h) and once in the PM 
(17.00 h). Non-fasting blood glucose (NF-BG) including weight, food intake and plasma were recorded 
and collected for analysis. During the study, metformin resulted in a significant reduction of non-
fasting blood glucose at day 3, however this effect was lost but returned from day 15 onwards until 
day 27. Both hydrolysate treatment groups showed sporadic improvements in NF-BG levels with 
boarfish presenting a significant reduction at day 6 initially, and returning from day 15 onwards until 
completion. Salmon skin gelatine however, resulted in a reduction in NF-BG from day 9 and 
throughout until day 27 with an overall significant reduction of NF-BG ranging from 20 mmol/L at day 
9, reducing to 14 mmol/L by day 27. Similarly, both metformin and boarfish presented reductions in 
NF-BG concentrations similar to that of salmon skin gelatine, with the saline treated control ob/ob 
group unsurprisingly averaging 31 mmol/L by day 27. Its unclear presently if the peptide components 
or indeed the further degraded smaller peptides or indeed amino acids generated from the further 









Non-fasting (NF) plasma insulin concentration 
As mentioned, protein components have insulinotropic activities, which may be immediate or delayed 
(Park et al, 2015). This may be in part due to the liberated amino acids or indeed the peptide 
components of protein itself. Our in vitro analysis after solid phase and RP-HPLC fractioning, which 
attempted to remove polar compounds and free amino acids, had yielded potent dose-dependent 
insulinotropic action in cultured cells (refer back to section in thesis). When administered twice daily, 
both the boarfish and salmon skin gelatine group displayed an increasing trend of NF-blood insulin 
concentrations. Boarfish presented the only significant increase of plasma insulin at day 12 versus the 
saline control group, but this effect was lost thereafter. When each group was analysed via area under 
the curve for NF-insulin through the study, the increasing trend of circulating insulin was significantly 
elevated within the boarfish hydrolysate treatment group only. This may be explained by an overall 
improvement of insulin secretion and action from the hydrolysate treatment, In speculating on 
potential mechanisms in a mouse model that expresses insulin resistance from early stages of life the 
NF-BG reduction suggests an insulin independent mechanism may be involved. Insulin secretion study 
in ob/ob mice suggest that leptin injections improved glucose-stimulated insulin secretion including a 
reduction of triglyceride levels in islets, which is further discussed by Khan and colleagues (2001).   
 
Weight changes and food intake during administration of treatments 
As previously mentioned, animals were grouped using non-fasting blood glucose concentration and 
body weight. Throughout the administration of treatments, improvement in NF-BG and modest 
elevation of NF-insulin concentration, particularly within the boarfish treatment group, were noted. 
Neither weight reduction or weight gain were not evident in any of the treatment groups. Weight 
variances between animal groups remained consistent with overall weight gain of each ob/ob 
treatment group averaging between 12 – 14%. Interestingly, an overall reduction in food intake was 





did not translate into weight loss for any of the animal groups, however studies investigating weight 
regain in RYGB-ob/ob mice concluded that leptin may prevent weight regain and diabetes recurrence 
and finally mice continued to gain weight after RYGB surgery was performed (Hao et al, 2016). 
Interestingly, the reduction of food intake and satiety improvements was leptin independent; 
however, the mechanism by which the hydrolysate treatments reduced food intake is unknown and 
requires further investigation. Furthermore, protein hydrolysates from many biological sources have 
reported potent cholecystokinin (CCK) secretion from cultured cells, suggesting CCK release from 
enteroendocrine cells are nitrogen compound sensing that may elude to the satiety effect within both 
hydrolysate groups (Foltz et al, 2008) 
 
Cumulative food intake and satiety 
The effect of protein and increased feeling of fullness and promotion of satiety is well established 
(Paddon-Jones et al, 2008), an effect that varies widely however between protein sources (Du et al, 
2018). Activation of satiety centres via the promotion of CCK and leptin including reduction of the 
appetite hormone ghrelin is often considered a viable approach in food studies for combatting weight 
gain and obesity, with studies suggesting these cannot yet serve as a tool for the satiating effect of 
foods (De Graaf et al, 2004). While limitations have been highlighted, the overall effect of promoting 
satiety is much more complex with pleotropic effects of incretin hormones such as GLP-1, which is a 
potent insulinotropic peptide, that also aids in reducing food intake via promoting a reduction of food 
intake and improved feeling of fullness. Out of the three main macronutrients including fibre, only 
protein and fibre have been regarded as potentially viable approaches for obesity prevention (Astrup, 
2005; Clark & Slavin, 2013).  
During our analysis of food intake in mice, metformin, which is reported to decrease food 
intake and promote weight loss (Lee & Morley, 1998), had shown a significant reduction in overall 





versus the saline control ob/ob group.  Metformin may act as a DPP-4 inhibitor (Lindsay et al. 2005;     
Green et al. 2006; Duffy et al. 2007; Cuthbertson 2009) among many other activities. Both boarfish 
and salmon skin gelatine resulted in a reduction in food intake from day 12, but the effect was lost at 
day 15 for SSG, but regained from day 18 onward until study completion (day 27). Once a significant 
reduction of food intake was established with boarfish at day 12, the effect was sustained until 
completion of the study at day 27. With regards to the overall reduction of total food intake, boarfish 
resulted in 16% less food intake within the group whereas SSG, while still significantly lower versus 
the saline control, lowered food intake at 12%. The reduction in overall food intake between each of 
the treatment groups was not translated into reduction in total bodyweight, however the limitations 
of using this model for weight reduction studies has been mentioned earlier (Hao et al, 2016). Both 
sources of protein hydrolysate have not been reported within the published literature for their effects 
upon food intake until now. However, there are several salmon protein hydrolysate products on the 
market aimed at reducing body mass index in humans but it is unclear how this assumption is made 
without human investigation (Hofseth BioCare AS).  
 
Fasting blood glucose and oral glucose tolerance (OGTT) and intraperitoneal glucose tolerance (ip-
GTT) 
Post-treatments, each group was subsequently fasted for 12 h prior to assessing oral glucose tolerance 
tests at the end of the 27 day treatment regime. Interestingly, each treatment group averaged a 
fasting blood glucose concentration of 18 mmol/l (±2 mmol/L) with the interesting exception of the 
boarfish hydrolysate treatment group. The boarfish group showed a significant reduction in fasting 
blood glucose concentration versus the saline control group and returned to almost normoglycaemia 
with fasting glucose concentrations of 10 mmol/l (±3 mmol/L). Interestingly, when investigating the 
acute delayed glucose tolerance effect of boarfish, of all the hydrolysates investigated, only boarfish 





both acute and longer acting but the associated mechanisms and mode of action are still to be fully 
elucidated. Studies investigating protein pre-loading may enhance glucose-lowering efficacy of the 
DPP-4 inhibitor, suggesting the improved fasting glucose levels within the boarfish group may be 
incretin mediated (Wu et al, 2016). Each of the groups after chronic exposure were challenged with 
18.8 mmol/kg glucose to test acute glucose tolerance over 120 min. Both hydrolysate treated groups 
and metformin treated mice had shown significant improvements of glucose concentration at 15 min 
post-glucose challenge. Improvements were lost from 30 min to 60 min, however both metformin and 
the salmon skin gelatine treatment groups resulted in significant reduction of blood glucose at both 
90 min and 120 min versus the saline control group. The Boarfish hydrolysate treatment group 
returned to similar levels of both metformin and salmon skin gelatine, however not until 120 min. 
During analysis of blood glucose area under the curve, again both metformin and salmon skin gelatine 
hydrolysate group had significantly lower total circulating blood glucose versus the ob/ob saline 
control group. Using a similar approach, administration of the glucose challenge was altered from oral 
to IP injection using the same concentration of glucose. Initial glucose elevation was similar across all 
ob/ob treatment groups, however by 90 min the boarfish group displayed a significant reduction in 
circulating blood glucose which was maintained until 120 min, while metformin presented a significant 
reduction at 120 min only. No improvement in ipGTT was evident within the salmon skin gelatine 
group with glucose area under the curve showing the same outcome. This approach may suggest that 
the insulinotropic and delayed effect of glucose tolerance improvements seen with boarfish may be 
beyond that of the post-prandial incretin effect and potentially via internalised systems, while salmon 
skin gelatine hydrolysate relies on post-prandial incretin effect via oral intake to achieve biological 
activity by direct effects within the gut. Future work investigating glucose tolerance may require pre-
loading with hydrolysates prior to glucose challenge. A study investigating protein preloading had 
shown enhanced glucose lowering, improved C-peptide and insulinotropic actions after a high-






Insulin sensitivity  
Classically leptin deficient ob/ob mice present insulin resistance, rapid weight gain, obesity and 
diabetes from early life (Muzzin et al, 1996). In these animals, insulin sensitivity was only assessed 
post-treatments. Each animal was administered via an ip injection a dose of 50 U/kg bodyweight of 
bovine insulin. Blood glucose concentrations were then measured post-injection (t=0 min) and at 30 
min and 60 min. Results indicate that specifically metformin or salmon skin gelatine did not show 
improvements in insulin sensitivity over the 60 min duration. The boarfish hydrolysate group however 
did display a modest trend in lowered glucose levels post-insulin injection, however this was non-
significant. Its apparent that improvements in insulin sensitivity are derived from changes in body 
weight, with those who are diabetic at higher BMI ranges requiring larger doses of insulin to get a 
desired hypoglycaemic effect over those at lower BMI ranges. This approach to insulin sensitivity in 
ob/ob mice was partly expected, due to the relatively large amount of centralised adiposity even after 
improvements of non-fasting blood glucose and reduction of food intake. To see a marked 
improvement of insulin sensitivity in this animal model, a significant reduction in body weight or 
particularly, adipose reduction, is required (Meade, 1978). This was not evident within the present 
study and with the caveat for a potential limitation of using this mouse model for weight change and 
insulin sensitivity analysis (Hao et al, 2016).  
Terminal glycated haemoglobin A1c (HbA1c) 
The relevance of HbA1c is now known to be an invaluable diagnostic tool for monitoring long-term 
glycaemic control (Weykamp, 2013). The measurement of glycated haemoglobin A1c is now the gold 
standard for establishing long term glycaemic control and commonly deployed alongside glucose 
tolerance prior to a T2D diagnosis. Typical ranges of HbA1c vary between 4% to 6.5%, with ranges 
between 5.7% and 6.4% categorised as pre-diabetes or over 6.5% as diabetes (WHO, 2011).  Post-
treatment analysis of each of the hydrolysate treatment groups including the metformin group 





(±1%) whereas better improvement of HbA1c, resulted from boarfish returning 5.6% versus 6.1% for 
that of the salmon skin gelatine treated group. The metformin treatment group averages a HbA1c score 
of 6.2%. These HbA1c scores for the metformin and SSG are still elevated, however in comparison to 
the control mice HbA1c was dramatically improved over the ob/ob saline treated control group. 
Interestingly, the boarfish HbA1c score of 5.6% would classify the group as having well-controlled long-
term blood glucose and falling within non-diabetic range. Interestingly, high protein diets have 
beneficial effects on weight loss, which can be translated to improvement in HbA1c concentrations; 
however, the effect is seen mainly with long-term intake of protein, at significantly higher amounts 
than administered within the present study (Dong et al, 2013). It is perhaps not surprising that each 
of the ob/ob treatment groups resulted in improved HbA1c compared to the ob/ob saline control group 
due to the reduction of food intake including the improved non-fasting blood glucose profiles.  
 
Terminal plasma GLP-1 concentrations 
Glucagon-like-peptide 1 (GLP-1), a hormone secreted from the intestinal enteroendocrine L-cells 
following nutrient stimulation is a potent insulin secretagogue, as well as having notable effects upon 
satiety, delaying gastric emptying and β-cell proliferation. The hormone is unfortunately rapidly 
degraded via the serine peptidase, dipeptidyl peptidase-IV (DPP-4). Several pharmacological 
approaches for treating T2D have been mentioned, however in short, the promotion of GLP-1 using 
nutritional factors could be a highly beneficial approach to better management of glucose 
homeostasis in individuals with T2D (Bodnaruc et al, 2016). Following the chronic treatment of mice 
over a 30-day period, a one off fasting sample of total GLP-1 was analysed. Interestingly, the boarfish 
hydrolysate treated group had a 46% increase in circulating plasma insulin concentration compared 
to the saline treated ob/ob control group. There was no change in total GLP-1 present within the SSG 
hydrolysate treatment group, however rather surprisingly the metformin group showed a 25% 





GLP-1 levels versus the lean saline control group, however this is not surprising due to the nature of 
post-prandial GLP-1 secretion, where ob/ob groups averaged 25 – 40% additional food intake per day. 
Within the total GLP_1 analysis it is not possible to distinguish between the bioactive isoforms of GLP-
1(7-36)amide of GLP-1(7-37) versus the assumed inactive truncated GLP-1(9-37) degration product.  
The elevated GLP-1 levels however might partically explain the food intake reduction that was evident 
within the boarfish group. Glucagon-like-peptide 1 has been associated with pancreatic β-cell CCK 
secretion including elevated levels of GLP-1 involved in a reduction of abnormal hepatic lipid retention 
(Linnemann et al, 2015). Rather surprisingly, metformin-induced GLP-1 secretion is reported within 
the literature (Cuthbertson et al. 2009) with duel combination therapies taking advantage of this by 
combining metformin with DPP-4 inhibitors within a single pill.  Again, without establishing which GLP-
1 isoforms are predominantly present within the blood circulation system makes the consequences of 
a reduction of GLP-1 noted with metformin treatment group difficult to predict.  
Circulating plasma lipids 
Screening of of circulating plasma lipids is  now commonplace in diabetes, obesity and inflammatory 
related diseases, with hyperlipidaemia frequently present among poorly controlled T2D sufferers 
(Daniel, 2011). Blood plasma lipids were analysed for cholesterol, high density lipoprotein (HDL), low 
density lipoproteins (LDL)  and triglycerides. Each of the ob/ob treatment groups had significantly 
elevated cholesterol over the lean saline control animals; however, but wnen compared to the ob/ob 
saline treated group, both SSG and metformin both resulted in a significant reduction of total plasma 
cholesterol. A potentially misleading outcome noted, after HDL analysis, showing an almost 1.5- fold 
increase in total circulating HDL versus the lean control group across all ob/ob treatment groups. It is 
important to note that studies looking specifically at HDL turnover are advised to investigate using a 
more appropriate animal model as leptin deficient mice as such, present defective HDL particle uptake 
with hindered recycling and degradation of HDL resulting in abnormally plasma HDL concentrations 





concerns. The boarfish, SSG including metformin treatment groups showed significantly reduced 
plasma triglycerides versus the saline treated ob/ob controls. The plasma triglyceride concentration 
from each of the treatment groups matched that of the lean saline control group indicating marked 
improvement in diabetic status. Furthemore, HbA1c could be correlated with triglyceride status and a 
predictor of diabetic control, since treatment groups had shown a significant improvement of both 
HbA1c and circulating triglycerides post treatment (Naqvi et al, 2017). A study investigating salmon 
protein hydrolysates generated via adjusted hydrolysis approaches had shown very different effects 
of oral administration of the hydrolysate source on hepatic enzymes. The peptides generated were 
from different regions of the salmon body with molecular weights averaging 200 – 1200da or above. 
That study concluded that improvements in plasma lipid concentrations was due to interaction with 
various hydrolysate peptide fractions and their effect on enzyme desaturases which in turn resulted 
in altered lipid parameters including weight loss (Vik et al, 2015). Furthermore, a study investigating 
the mechanism by which protein hydrolysates affect lipid metabolism concluded that lipid-
independent atherosclerotic activity was present in ApoE-deficient mice with the ability to attenuate 
risk factors relating to atherosclerotic risk that were independent to changes in plasma lipids or fatty 
acids (Parolini et al, 2014).  
Isolated pancreatic islet β-cell functionality tests performed post-study 
Alterations to both islet cell morphology including density and secretory capability is adversely 
affected in the diabetic state, including severe pathognomonic changes (Gepts & lecompte, 1981). 
Within our own analysis of islet functionality post-treatment of isolated pancreatic islets, we reported 
comparable insulin secretion when compared to effects of cellular secretagogues. In particular, during 
insulin secretion investigations, there no increase of insulin secretion over that of lean mice islets, 
with cells responding to potassium chloride (KCl), and GLP-1 in a similar manner. However when 
analysed for insulin content post-acute analysis, the ob/ob mice indeed presented elevated 





or in combination with KCl or GLP-1 showing a 3-fold rise in insulin content versus the lean control 
mice, but no significant differences between the ob/ob treated saline controls or treatment groups, 
respectively. On subsequent analysis of pancreatic hormone content investigated using 20 mg of 
pancreas and acid ethanol hormone extraction, protein analysis returned significantly lower 
pancreatic protein content within the boarfish and SSG treatment groups. Using the same approach 
for determining total pancreatic insulin content yielded similar insulin content between each of the 
ob/ob animal models with lean control animals on average showing 30% less insulin content. Without 
identifying total pancreatic hormone content, in particular, glucagon and pancreatic polypeptide (PP) 
it is unclear at present, how the decreased total protein content represented within hydrolysate 
groups with overall similar insulin content to other groups was of benefit to the general diabetes 
status. Comparing this however, the total hormone content versus total insulin would represent 
significantly higher pancreatic insulin content within these ob/ob mice.  
 
Cellular morphology analysed using immunohistochemistry  
Changes within the pancreatic islets were analysed using florescent microscopy. Excised pancreata 
were stained with primary mouse antibodies for insulin and glucagon, and her was particular interest 
in α to β-cell ratio. Impaired insulin secretion is a consequence of functional and survival defects at 
the cellular level, hallmarked by abnormal basal insulin secretion and loss of first-phase insulin 
secretion (Del Prato & Marchetti, 2004). Studies suggest that both pancreatic defects including a lower 
number of beta cells and alteration to alpha cell mass may contribute to diabetic progression (Henquin 
& Rahier, 2011). As the diabetic state progresses, studies have reported increased cellular 
differentiation and cellular survival via α to β-cell trans-differentiation (Lui & Habener, 2009). 
Correcting both beta- and alpha cell dysfunction becomes an attractive therapeutic approach. Firstly, 
the average cell area was assessed between the ob/ob mice groups. The ob/ob mouse model has 





lean animals are significantly smaller, and yet possess the same secretory capacity. On analysis, both 
boarfish and metformin treated groups had significantly smaller islet volume versus the saline ob/ob 
control and SSG groups. Analysis of insulin cell area within total islet area returned various results, 
again with boarfish and metformin groups with lower insulin cell area, whereas SSG with significantly 
elevated insulin cell area. Analysis of the average glucagon cell islet area showed that boarfish and 
SSG had lower average glucagon cell area, whereas no change was noted with metformin compared 
to the saline ob/ob control. Finally, the alpha cell to beta cell ratio of both boarfish and SSG were both 
significantly lower, resulting in less alpha cells within the islet. The ob/ob control group alpha cells 
consisted of 6% of the total islet mass, whereas boarfish and SSG averaged 4% and 4.2%. These small 
changes in α-cell to β-cell ratios may suggest a protective mechanism involved via protecting β-cells 
from damage causing cellular transdifferentiating to α-cells, however more mechanistic investigations 
are warranted.  
Anthropometric and body composition analysis using DEXA 
Animals were analysed for intergroup changes of body composition including fat mass, lean body mass 
and bone mineral density (BMD) and bone mineral content (BMC). DEXA analysis of total body BMD 
had shown no changes within each of the ob/ob mouse groups, with elevated BMD within the lean 
control animals. Interestingly however, total BMC was significantly improved within both the boarfish 
and SSG hydrolysate treatment groups and BMC was comparable to the lean saline control group; 
however, a significant reduction of BMC was noted in the metformin group compared to the ob/ob 
saline treated control group. Studies investigating metformin using ovariectomy rodent models 
reported no differences in bone architecture compared to a saline control over an 8-week treatment 
period (Jeyabalan et al, 2013). Within the literature, BMD is reportedly affected within the diabetic 
state (Ma et al, 2012). The increase of BMC within the hydrolysate groups maight possibly be explained 
via dietary calcium binding properties of small molecular weight peptides. Indeed the calcium 





been reported (Sun et al, 2016; Zhao et al, 2014). Increased calcium binding affinity has been noted 
with peptides such as Gly-Leu and Gly-Gly which are abundant in marine collagen (Tang & Skibsted, 
2016).  Analysis of lean mass revealed that no changes between treatment and non-treatment groups 
including no change recorded within the lean control mice. Furthermore, as expected with genetically 
obese animal models, fat mass was over 4-fold elevated between ob/ob animals and the lean control 
group. The fat mass between the ob/ob treatment and ob/ob control group displayed no differences 
indicating that the reduction of food intake, including the improvement of non-fasting blood glucose 
parameters had no effect on adipocyte turnover and utilization as a fuel source with similar results 
found with total body fat content. The body composition of the ob/ob animals still consisted primarily 
of fat mass, with each of the ob/ob group’s post-study maintaining body weight based upon 50% 
contributed solely from fat mass alone. This was reflected when identifying how lean body mass was 
affected with all ob/ob animal models with a similar return of 50% lean mass, whereas due to the 
relatively low fat mass of the lean control animals, their total lean mass percentage was 80%.  
 
Oxygen exchange ratios analysed using CLAMS 
Pre-loading of particular macronutrients for improved oxygen exchange in athletes is commonly 
investigated (Woodward & Bird, 1991). Within this study, the elevated body mass of the ob/ob mice 
resulted in significantly lower VO2 score, VCO2 score and average respiratory exchange ratio (RER) 
compared to the lean control group. Group variances between ob/ob treatment groups were not 
significantly different in comparison to the ob/ob saline control group. No improvements in 
respiratory exchange ratios where noted, which may reflect the relative lack of weight loss noted 








The results presented herein report a high throughput hydrolysis screening approach using both in 
vitro to in vivo aiming to unravel the multifaceted effects and importantly the oral efficacy of protein 
hydrolysate intake from two different marine sources and assess their anti-diabetic effects. Further 
mechanistic analysis using acute and long-term biomarker approach is acknowledged; however, the 
research has highlighted glucoregulatory activity of marine protein hydrolysates, which will be 
summarised. This study was not designed to directly compare food derived biomolecules against a 
known and highly regarded oral hypoglycaemic agent, however the incorporation of metformin was 
for control purposes only from a tried and tested anti-diabetic pharmaceutical. With this noted, the 
study has highlighted several key aspects of small molecular weight peptides from marine sources and 
their ability to promote satiety and lowering of food intake, improvement of non-fasting and fasting 
blood glucose including better circulating plasma lipid profiles and HbA1c. Furthermore, outcomes 
and results relating to bone mineral content, pancreatic cell morphology and inflammation are aspects 
that the researcher will aim to unravel within a future study. Finally, the most bioactive hydrolysate 
from the study is boarfish, with the work generated on its lasting effects over the shorter lived salmon 
skin gelatine (SSG) hydrolysate has indicated that boarfish protein hydrolysate is a target that would 












Investigating long-term twice-daily oral intake of Algal protein 
hydrolysates derived from Palmaria palmata (Dulse) in 















 The last several decades have seen the most dramatic changes in dietary intake 
patterns. Access to food, including foodstuffs from different continents has become easier to 
obtain. Unfortunately, free movement of food across global networks has not improved 
population health with controversially the opposite is often the case (Marlow et al., 2009; 
Popkin & Kenan, 2016). Nevertheless, the opportunity to alter dietary intake based upon 
dietary needs is now available with a vast array of food varieties. Climate change and the rise 
in global population and has unfortunately placed tremendous strain on the food chain, with 
access to high quality protein being a priority in the need to meet ever growing global 
demands (Luber & Prudent. 2009; Hall et al., 2017).  The ability to exploit all potential food 
sources and nutrients requires sunstantial economic investment and support (Proietti et al., 
2015).  
Underutilized nitrogen sources such as marine waste byproducts are classically 
incorporated within low-cost animal feed or fertilizers (Sranacharoenpong et al., 2015). 
Similarly, demand for protein and its peptide components has seen an exponential growth 
within the cosmetics industry (Secchi, 2008). Furthermore, sustainable protein sources are 
abundant, such as animal and plant-based being readily available albeit, these sources are not 
without their economic costs (Rosi et al., 2017). The financial cost of protein food choices 
between biological sources are noted with aim to reduce the environmental footprint 
worldwide. This includes dietary protein source changes to prevent the prevalence of non-
communicable diseases such as obesity and diabetes (Musaiger & Al-Hazzaa, 2012). Swelling 
demand for high quality animal-based proteins will place increased pressure on global 
resources which contributes to greenhouse gas emissions including requiring more water and 





 The issue surrounding food security is not only restricted to terrestrial protein sources 
as evidenced from recent changes to EU fishery policies relating to marine and oceanic 
sustainability which has seen larger volumes of commercially underutilized pelagic species 
landed (Pauly & Zeller, 2016; Manach et al., 2013).  Industry, researchers and government 
have adapted rapidly and and prioritised the task of maximising the utilization of protein 
containing marine sources (Gajanan et al, 2016;  Slizyte et al., 2016; Harnedy et al., 2018). 
Closer to land, costal sustainability of marine alga sources has similarly been emphasised 
(Rebours et al., 2014; Monagail et al., 2017). The worldwide seaweed industry produce many 
products from seaweed components either for direct or indirect human use. Macroalgae and 
microalgae are the most abundant costal ecosystems and play vital role as habitats for 
invertebrates, fish, mammals and birds (Bishop et al., 2017). The nutritional importance of 
edible seaweeds shoudl not be underestimated due to their favourable fibre, lipid, 
carbohydrate, mineral, vitamin and protein content (Norziah & Ching, 2000; Cian et al., 2015). 
Edibble macroalgae was once a staple food within the western diet, and remains as one within 
far eastern countries including China and Japan (Teas et al., 2013). The resurgence of 
European seaweeds tailored towards disease states has recently shifted with advice to avoid 
certain sources of seaweed due to potential mineral toxicity (Clarke et al., 2003; Zava & Zava, 
2011).  
 The protein content between seaweeds vary dramatically ranging from 5% to 40% of 
dry weight. The protein content of seaweeds depends particularly on species, environmental 
conditions and the season in which harvested (Cerna, 2011, 1999; Khairy & Shafay, 2013). 
Algal protein is of particular interest due to the favourable amino acid composition containing 
all essential amino acids including glycine, alanine, proline and glutamic and aspartic acids 





reported algal protein content, with some reaching 40% of dry weight (Fleurence & Dumay, 
2018). Proteins with physiological relevance may be an attractive approach using seaweeds 
as a source of ingredients with high nutritional quality.   
 As mentioned previously, the readily available access to diverse foodstuffs has its 
limitations in terms of health implications. Population rise of obesity and diabetes has 
reached epidemic proportions placing major strain on health care systems (Kim & Basu, 2016). 
Type 2 diabetes (T2D) cases are expected to rise from 340 million presently, to 640 million by 
2040 (Marín-Peñalver et al., 2016). Currently type 2 diabetes is the most common metabolic 
and endocrine disorder and now considered the global epidemic of the century (Golden et al., 
2009; Kharroubi & Darwish, 2015). Body systems maintain glycaemia within narrow 
parameters following food intake, however individuals diagnosed with T2D, hyperglycaemic, 
pancreatic dysfunction, altered insulin secretion, insulin resistance and insensitivity are 
unfortunately very common making up >5-10% of the global population (Færch et al., 2015). 
The need for modern reinvention of dietary approaches to prevent or manage obesity and 
related metabolic diseases such as T2D is very necessary. The metabolic benefit of protein in 
helping improve glycaemic regulation is well established, however the source of protein and 
quantity needed to enhance its therapeutic potential is not well established. It is however 
well recognised,, that under most conditions, protein provides an increased satiety response 
which lowers subsequent food intake than the isoenergetic ingestion of fat or carbohydrates.  
Despite this some studies report that the satiating effects of certain proteins are not evident. 
The digestion rate of protein and subsequent rate at which liberated amino acids or small 
peptides are absorbed and presented in the blood circulation will affect bioavailability. Thus 
protein digestion products may have influences upon improved insulin secretion, post-





composition of the protein does not always correlate with improvements relating to these 
pathways.  
Evidence now argues liberated peptide fragments of protein, known as protein 
hydrolysates including small molecular weight peptides (SMWPs), can promote activation of 
satiety centres via cholecystokinin and leptin production, both potent satiety-promoting 
hormones (Add reference here e.g. Caron et al., 2016). The benefits of ingesting protein 
hydrolysates are not limited to satiety, with studies displaying potent post-prandial 
insulinotropic hormone secretion including glucagon-like-peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP), which are associated with beneficial effects upon 
satiety, insulin secretion and delayed gastric emptying. The post-prandial effect of GLP-1 and 
GIP is unfortunately short-lived, due to rapid degradation of both hormones by the serine 
protease, dipeptidyl peptide 4 (DPP-4) (Deacon, 2011).  
Protein hydrolysates and their constituent peptides have reported DPP-4 inhibitory 
activity in both in vitro and in vivo experimental models (Harnedy et al, 2017). Recently 
bioactive peptide fragments identified from Palmaria palmata have displayed DPP-4 
inhibitory activity in vitro.  Proteins from casein and whey fractions of milk have similarly been 
reported to contain DPP-4 inhibitory activity in vitro. Proteins from marine collagen and fish 
contain high proline resides, may also present DPP-4 inhibitory activity (Xia et al, 2017). Work 
carried out investigating the anti-diabetic activity of fish proteins have shown some promising 
data relating to bioactivity responses within culture cells and small rodent models. Both 
salmon and blue whiting protein hydrolysates reported potent dose-dependent insulinotropic 
activity including GLP-1 secretion in vitro (Harnedy et al, 2017; Harnedy et al, 2018). 





target cells intact is problematic. Despite this, improvement in post-prandial glycaemic and 
enhanced insulinotropic responses were found following oral administration of blue whiting 
protein hydrolysates after an OGTT glucose tolerance test (Harnedy et al, 2018) There are 
several amino acids of which are known to promote insulin and GLP-1 secretion, particularly 
alanine and glutamine, which are abundant in marine proteins. their is expected that small 
bioactive peptides may be closely involved in stimulating the insulinotropic responses. 
 The screening of protein derived from algal species is not without concerns. In 
particular, the sustainability and reproducibility of the algal source including preferential 
harvesting seasons to maximise protein yield is acknowledged. With this noted, characterising 
the therapeutic effect of algal proteins targeting the treatment of T2D is nevertheless a 
worthwhile endeavour. This study aimed to explore the satiety and glycaemic effect of protein 
extracted from Palmaria palmata protein hydrolysate abundant in SMWPs within a 
Streptozotocin induced diabetic mouse model.  
Background & Aims 
The intake of seaweed has been linked to improved health in countries that habitually 
incorporate it within their diet including lower incidence of certain cancers including 
improved iodine and fibre status, however the effect of seaweed proteins on health is still 
within its infancy. Seaweeds vary in protein content, with red seaweed, Palmaria palmata, 
local to Irish and northern European shores containing the highest protein content, however 
varying from 10% to 30% (w/v) dependent on seasonality. Using a similar approach as the 
previous chapter, the aim of this work is to investigate the effect of long-term twice-daily oral 
intake of seaweed protein hydrolysates in diabetes-induced mice with focus on food intake, 





similar to the previous work carried out, a reduction of food intake will be evident, promoting 
improvements in non-fast blood glucose, fasting blood glucose levels suggesting metabolic 






























7.2 Materials and Methods 
Establishing diabetes and grouping 
Using an animal model described in 2.3.3, 10 week old (n=32) HsdOla:TO mice were 
administered several low doses of the -cell toxin Streptozotocin (40 mg/kg bodyweight x 3 
on day 1, 4 and 7 pre-grouping). Prior to treatment commencing animals were firstly 
acclimatized for 3 days (study day -3 to day -1) with twice daily oral saline (0.9% NaCl) gavage 




Glucose tolerance tests (intraperitoneal and oral)  
As described in section 2.2.3 and 2.3.4 blood samples were collected from a minor tail vein 
bleed in fasted (8 h) mice. Blood glucose was measured using a handheld glucometer (Bayer 
Contour, Leverkusen, Germany) prior (t=0) to administrating a glucose challenge (18.8 
mmol/kg/ bodyweight). Once administered (either i.p or oral), blood glucose was further 
analysed at 15, 30, 60, 90 and 120 min.  
 
Tissue excision 
On completion of all experiments mice were fasted (4 h) and sacrificed. Mice were placed 
unconscious via oral inhalation of a general anaesthetic (Isoflurane) and euthanatized via 
cervical dislocation. Tissue excision protocol explained in detail in section 2.4.6.  
 





Thawed tissue was rinsed in cold PBS before being weighed and transferred to a bijou 
containing 2 ml of ice cold acid ethanol (1.5% (v/v) HCl (12.5 M), 75% (v/v) ethanol, 23.5% 
(v/v) H20). Described in detail in section 2.4.7 and 2.4.8 
 
Assessment of pancreatic insulin and glucagon content  
Pancreatic homogenates were diluted to a range of concentrations (1:100, 1:200, 1:500 and 
1:1000) using stock RIA buffer prepared in section 2.2.2 and tested for insulin content using 
the RIA described in 2.2.3.  
 
Total pancreatic protein content  
Insulin RIA and glucagon ELISA were used to determine total pancreatic hormone content. In 
order to quantify detected hormone percentage it was compared to total pancreatic protein 
concentration from tissue homogenate described in section 2.4.7. 
Assessment of terminal plasma lipid profile  
Terminal plasma sample lipid profile was determine using an I-Lab 650 clinical chemistry 
system (Instrumentation Laboratory, Warrington, UK). The analysis consisted of assessing 
total triglycerides, total cholesterol, high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) concentration. Reagents for triglyceride analysis were obtained from 
Instrumentation Laboratory (Warrington, UK) and reagent for LDL cholesterol were obtained 







Data was expressed as mean ± SEM with values compared using one-way analysis of variance 
(ANOVA) unless otherwise stated. Data between groups were considered statistically 

































Fig 7.1 – Animal grouping post-streptozotocin (STZ) injection acclimatization  
Groups of mice were given an i.p. injection of STZ (40 mg/kg/bw) once every 3 days for 9 days and 
given a further 9 days for acclimatization. Once all STZ-injected animals had shown significant 
elevation of non-fasting blood glucose (cut-off 10 mM) they were subsequently group based upon 
non-fasting blood glucose (NFBG) and body weight. All STZ-treated mice by day 20 had displayed 
significantly elevated (p<0.001) NFBG compared to their pre-STZ injected state (Fig 7.1).  
Fig 7.2 – Effects of twice daily treatment on non-fasting blood glucose parameters 
Animals were assigned various treatments; including physiological saline only within STZ-injected 
mouse groups or a non-STZ control group. Other groups consisted of STZ-injected mice given twice 
daily treatments of either P. palmata protein hydrolysate (PPPH, 50 mg/kg/bw) or metformin (200 
mg/kg/bw) dissolved in a physiological saline carrier. Every third day NFBG was measured using a 
handheld glucometer. A significant improvement in NFBG was evident within the metformin group 
from day 9 to completion of the study at day 18 (p<0.01 – p<0.001) and similar improvements 
displayed within the PPPH group from day 9 to 18 also (p<0.01 – p<0.001) versus the STZ-saline control 
group, respectively (Fig. 7.2A). Total NFBG was analysed via area under the curve, with both treatment 
groups resulting in a significant reduction of NFBG over the study duration in the PPPH (p<0.001) and 
metformin (p<0.001) versus the STZ saline control group. The non-STZ control group had consistently 
lower NFBG than all STZ groups (Fig. 7.2).  
Fig 7.3 - Effects of twice daily treatment on non-fasting plasma insulin parameters 
Non-fasting plasma insulin concentrations were similarly analysed using RIA every third day. Mice all 
displayed significantly lower circulating plasma insulin concentrations versus the non-STZ control 
group (Fig7.3). Furthermore, the PPPH treatment group displayed elevated circulating insulin 
concentrations from day 6 through day 18 of the study (day 6 p<0.01 – day 18 p<0.001) except on day 





(p<0.05) and day 18 (p<0.001), both versus the STZ saline treated control group. Total plasma insulin 
analysed via area above the curve (AAC) similarly resulted in significantly higher plasma insulin levels 
within the PPPH (p<0.001) and metformin (p<0.001) versus the STZ saline treated control group (Fig. 
7.3B).  
Fig 7.4 - Effects of twice daily treatment on energy intake 
Food intake was assessed over the 18 day treatment period and converted into energy intake (1 g of 
food = 12.99 kJ of energy). A reduction of food intake was within the Palmaria palmata protein 
hydrolysate (PPH) group at day 15 (25% reduction, p<0.05) and day 18 (24% reduction, p<0.01) versus 
the STZ saline treated control group (Fig. 7.4). No significant change in energy intake was noted within 
the metformin group versus the STZ control group. The normal control mice which were not given STZ 
injections consumed less food than STZ saline treated mice on day 15 (30% reduction, p<0.05) and day 
18 (33% reduction, p<0.05) (Fig. 7.4). 
Fig 7.5 A - Effects of twice daily treatments on long-term glucose control analysed using glycated 
haemoglobin (HbA1c) 
Following the completion of the intervention period terminal HbA1c was analysed using the HbA1c 
analyser (A1cNow) kit. The STZ saline treated control group showed HbA1c levels of 10.5%, which was 
the significantly  reduced in the PPPH treatment group (7.2%; p<0.01) and metformin group (6.8%; 
p<0.001) (Fig. 7.5A).  The control mice which were not injected with STZ had the lowest HbA1c values 
(4.0%; p<0.001) versus the STZ saline treated group (Fig. 7.5A).  
7.5 B - Effects of twice daily treatment on fasting glucose concentration  
Blood glucose concentrations were significantly improved following an 8 h fasting period when 
compared to STZ saline treated mice.  Blood glucose was measured from tail blood via a handheld 
Bayer Countour glucometer.  Both of the STZ treatment groups resulted in improved fasting glucose, 





(p<0.05) versus the severely hyperglycaemic STZ saline treated control group ((28.7 mmol/L). Fasting 
blood glucose for the control mice not injected with STZ were within the normoglycaemic physiological 
glucose range of 5.4 mmol/L (Fig. 7.5B).  
Fig 7.6 – Effect of twice daily treatments on oral glucose tolerance responses 
Mice were fasted for 8 h and blood glucose levels analysed prior to glucose challenge (t=0 min). 
Glucose was administered orally (18.8 mM) and subsequently bloodglucose concentrations measured 
at regular intervals up until 120 min (Fig. 7.6).  Improvements in glucose tolerance were noted at each 
time point from 0 min through 120 min within both the PPPH groups (p<0.01 – p<0.001) and within 
the metformin treated group (p<0.05 – p<0.01) compared to the STZ saline treated control group. 
Total blood glucose concentration was analysed using area under the curve (AUC), again with both 
treatment groups resulting in significantly lower blood glucose concentrations (PPPH p<0.05; 
metformin p<0.01) versus the STZ saline treated control group (Fig. 7.6).  The best oral glucose 
tolerance responses was shown by the mice which had not been treated with STZ injections (p<0.001, 
Fig. 7.6). 
7.7 A – Measurement of the percentage bodyweight changes following interventions in STZ mice 
The weight of each animal was measured every 3 days. Changes in body weight percentages were 
analysed via pre- and post-treatment weight on day 0 and day 18.  A small reduction in weight was 
noted within the STZ saline control group (1.5%), however a significant reduction of 6.8% was noted 
within the STZ PPPH group (p<0.01) and 4.9% within the STZ metformin group (p<0.05) (Fig 7.7A).  In 
contrast the mice which did not received STZ injections nshowed a 10% increase (p<0.001) in 
bodyweight gain over the same 18 day study (Fig. 7.7A).  
7.7 B – Assessment of total plasma GLP-1 concentrations following interventions in STZ mice  
Following the completion of the 18 day intervention period plasma total GLP-1 was analysed using an 





of circulating GLP-1 (p<0.01) which was similar to the control mice which were not injected with STZ 
(p<0.001) Fig 7.7B. There was no significant difference in the ctotal GLP-1 plasma concentrations 
between the STZ saline treated control and the STZ metformin treatment group. (Fig 7.7 B) 
 
Fig 7.8 A – Analysis of po circulating plasma triglyceride concentrations following interventions in 
STZ treated mice  
There was no difference in triglyceride concentrations between the STZ saline treated control, the STZ 
metformin treatment group nor the mice which were not injected with STZ (Fig. 7.8A) . However in 
contrast, the STZ PPPH treatment group displayed a significant reduction in plasma triglyceride 
concentration (p<0.05) versus the STZ saline treated control group (Fig. 7.8A).  
 
Fig 7.8 B – Analysis of post-treatment circulating plasma cholesterol concentration  
There was no change in cholesterol concentrations between the STZ saline treated controls and the 
STZ metformin treatment group. However, the STZ PPPH treatment group displayed a significant 
reduction in plasma total cholesterol concentration (p<0.01) versus STZ saline treated control mice. 
The mice which were not injected with STZ also showed a reduction in total cholesterol, but this was 
less marked than the PPPH mice (p<0.05) (Fig 7.8B).  
Fig 7.9 – Analysis of total pancreatic glucagon and protein content 
Excised pancreas from each treatment group was analysed for pancreatic glucagon content via ELISA. 
Hormones were extracted in acid-ethanol using 30 mg of tissue and homogenised (See section 2.8). 
On analysis, there was no significant difference in glucagon content between any of the STZ treatment 
groups including the control mice not injected with STZ (Fig7.9A).Excised pancreas from each 





Peptides were extracted using acid-ethanol using 30 mg of tissue followed by homogenization. Results 
showed, there was a significant reduction in total pancreatic protein content within the STZ PPPH 
group (p<0.001) the STZ metformin group (p<0.01) and furthermore within the non-STZ saline control 
group (p<0.05) versus the STZ saline treated control mice (Fig. 7.9B).  
Furthermore, when the pancreatic glucagon content was expressed as a percentage of the total 
protein content extracted, the STZ injected PPPH and metformin groups, as well as the mice which 
were not injected with STZ showed a trend towards increased glucagon:total protein ratio but this 
failed to reach significance (Fig. 7.10).   
 
Fig 7.11 A– Effects of chronic treatments of STZ mice on bone mineral content (BMC) and bone 
mineral density (BMD) using DEXA 
Bone mineral content was elevated within the STZ PPPH treatment group (p<0.01) and STZ metformin 
treatment group (p<0.01) compared to the STZ saline treated control group (Fig. 7.11A). The BMC of 
the PPPH treatment group was also elevated versus the group of control mice not given STZ injections 
(p<0.05). ‘This increase was also supported by an increase in the femur BMC (P<0.05). No differences 
were found between the STZ saline treated and the normal healthy mice who did not receive the STZ 
injection (Fig. 7.11A). No changes in bone mineral density were found between any of the control or 
treatment groups (Fig. 7.11B).   
Fig 7.13 Effect of treatment of STZ mice on lean body mass (g) and body fat mass using DEXA 
No significant changes were reported within lean body mass analysis between any of the the STZ 
groups. However, the mice who did not receive STZ injections showed a significant rise in lean mass 





No significant changes were found in fat mass analysis between the STZ groups. However,  the mice 
who did not receive STZ injections showed a significant increase in body fat mass versus the STZ saline 
treated control mice (p<0.01; Fig 7.13B).  
When the % body fat was calculated this was higher for the STZ PPPH treatment group (p<0.05), the 
STZ metformin treatment group (p<0.001) and the group of control mice not given STZ injections 
(p<0.001), compared to the STZ saline treated mice (Fig. 7.14A). When the lean mass and fat mass 
values were added together there was no difference in values for STZ PPPH nor STZ metformin treated 
mice versus the STZ saline treated controls (Fig 7.14B). However, the control mice not given STZ 
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Fig 7.1. Animals were given 3 doses of STZ (40 mg/kg/bw) over a 9 ay period and monitored for (A) 
non-fasting blood glucose and (B) body weight including observation of (C) pre- and post STZ injection 
on NF-BG. Both blood glucose and weight were significantly elevated versus lean control group. 
Results are Mean±SEM for 7-8 observations per group. **p>0.01, ***p<0.001 change versus starting 
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Fig 7.2 Effects of twice-daily administration of palmaria palmata hydrolysate and metformin on 
non-fasting blood glucose in diabetes induced STZ mice (A). Parameters were measured 6 days 
prior with treatment commencing at day 0 to day 18. Twice daily treatment with palmaria 
palmata hydrolysates (50 mg/kg bw) and metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) 
NaCl) in both a STZ and non-STZ control groups. Values represent mean ± SEM for 7-8 mice.  
**p<0.01, ***p<0.001 vs STZ saline control. (B) represents Mean±SEM blood glucose area under 
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Fig 7.3. Effects of twice-daily administration of Palmaria palmata hydrolysate and metformin on non-fasting 
plasma insulin concentration in diabetes induced STZ mice (A). Parameters were measured 6 days prior to and 
during treatments commencing at day 0 to day 18. Twice daily treatment with Palmaria palmata hydrolysates 
(50 mg/kg bw) and metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl) in both a STZ and non-STZ 
control groups. Values represent mean ± SEM for 8 mice. ***p<0.001 vs STZ saline, (B) represents Mean ± 
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Fig 7.4 Effects of twice-daily administration of marine hydrolysates on energy intake in STZ treated 
mice. Food was measured every 3 days until day 18 following daily treatment with marine 
hydrolysates (50 mg/kg bw), metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). Values 
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Fig 7.5 A. Effects of twice-daily administration of PPPH and metformin on terminal glycated 
haemoglobin (HbA1c). Values represent mean ± SEM for 8 mice.  *p<0.05, **p<0.01, ***p<0.001 
versus STZ saline treated  control group.  
 
Fig 7.5 B. Effects of twice-daily administration of PPPH and metformin on fasting blood glucose. 
Mice were fasted for 12 h prior to measurement of glucose. Values represent mean ± SEM for 7-8 
mice.  *p<0.05 versus STZ saline control group.p<0.05, p<0.001 versus the non-STZ saline 
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Fig 7.6. Effects of chronic treatment with twice-daily administration of PPPH or metformin on (A) 
terminal oral glucose tolerance and (B) integrated OGTT AUC values. Parameters were measured prior 
to (t=0) and 15, 30, 60, 90 and 120 min after administration of glucose alone (18 mmol/l kg body weight; 
oral gavage). Glucose AUC values for 0-120 min post-injection. Values are expressed as mean  S.E.M. 
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Fig 7.7. Effects of twice-daily administration of PPPH or metformin on percentage weight change (A) in STZ 
mice. Weight was measured 3 days prior to and 18 days during twice daily treatment with marine 
hydrolysates (50 mg/kg bw), metformin (200 mg/kg bw) or saline vehicle (0.9% (w/v) NaCl). Values represent 
mean ± SEM for 7-8 mice.  *p<0.05, **p<0.01 versus STZ saline treated control group.  
 
Fig 7.7 B. Effects of twice-daily administration of PPPH or metformin on terminal plasma total GLP-
1 concentration. Values represent mean ± SEM for 8 mice.  **p<0.01, ***p<0.001 versus STZ saline 
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Fig 7.8 A. Effects of twice-daily administration of PPPH or metformin on terminal plasma 
triglyceride concentrations. Values represent mean ± SEM for 8 mice.  *p<0.05 versus STZ saline 
treated control group.  
 
Fig 7.8 B. Effects of twice-daily administration of PPPH or metformin on terminal plasma total 
cholesterol concentration. Values represent mean ± SEM for 7-8 mice.  Δp<0.05, ΔΔp<0.01, 
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Fig 7.9 A. Effects of twice-daily administration of PPPH or metformin on terminal pancreatic 
glucagon concentrations. Values represent mean ± SEM for 8 mice.   
 
Fig 7.9 B. Effects of twice-daily administration of PPPH or metformin on terminal pancreatic 
hormone content analysed via Bradford assay. Values represent mean ± SEM for 8 mice.  *p<0.05, 
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Fig 7.10. Effects of twice-daily administration of palmaria palmata on terminal pancreatic 
glucagon vs hormone content analysed via Bradford assay and glucagon ELISA. Values represent 
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Fig 7.11 A. Effects of twice-daily administration of PPPH or metformin on bone analysis (BMC) 
assessed by PIXImus DEXA. Graph represents total body bone mineral content (BMC g/cm2). Values 
represent mean ± SEM for 8 mice.  **p<0.01, versus STZ saline treated control group and Δp<0.05 
versus non-STZ saline control, respectively.  
 
Fig 7.11 B. Effects of twice-daily administration of palmaria palmata hydrolysate on bone mineral 
density (BMD) assessed by PIXImus DEXA. Graph represents total body bone mineral density (BMD 
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Fig 7.16. Effects of twice-daily administration of PPPH or metformin on anthropometric analysis 
(Femur ROI BMC) assessed via PIXImus DEXA. Values represent mean ± SEM for 7-8 mice.   *p<0.05, 
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Fig 7.13 A. Effects of twice-daily administration of PPPH or metformin on anthropometric analysis 
as assessed via PIXImus DEXA. Graph represents total body lean mass (g). Values represent mean 
± SEM for 7-8 mice.  *p<0.05, versus STZ saline treated control group. 
 
Fig 7.13 B. Effects of twice-daily administration of marine hydrolysates on anthropometric analysis 
assessed via PIXImus DEXA. Graph represents total body fat mass (grams) Values represent mean 






































Fig 7.19 A. Effects of twice-daily administration of marine hydrolysates on anthropometric analysis 
assessed via PIXImus DEXA. Graph represents total body fat (%) Values represent mean ± SEM for 
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Non-fasting blood glucose analysis of STZ mice during treatment interventions 
 
Insulin is required for carbohydrate, fat and protein metabolism at cellular level and to aid in achieving 
post-prandial normoglycamia (Cornier et al., 2005). In healthy individuals, the rate at which 
carbohydrate utilized within cellular respiration or stored as glycogen is significantly better than those 
subjects with type 2 diabetes (T2D) primarily due to tissue insulin resistance and diminished glucagon 
feedback leading to hyperglucagonaemia (Matsumoto et al., 1997). Hyperglycaemia and insulin 
resistance promote glucagon dependent hyperglycaemia by enhancing hepatic glucose output  
contributing to the diabetic state (Færch et al., 2016). Improvement in non-fasting blood glucose 
concentrations were noted within STZ mice given eiteher the P. palmata hydrolysate or metformin 
treatment. Both Palmaria palmata hydrolysate and metformin caused a significant reduction in NF-
BG. Improvements were noted from day 9 and throughout the study until day 18 for both PPPH 
treatment (day 9 p<0.01 to day 18 p<0.001) and metformin (day 9 p<0.01 to day 18 p<0.001)  
comparative to the saline treated STZ control group. As expected, the non-STZ mice displayed 
euglycaemic levels throughout the study. When analysed using the area under the curve (AUC) 
metformin had improved the total NF-BG compared to the hydrolysate group. In the STZ saline treated 
group NF-BG continued to rise throughout the study, suggesting that the relative reduction of insulin 
post-STZ injection was promoting sustained hyperglycaemia due to the lack of insulin present or via 
glucagon mediated pathways. Interestingly, the mechanism of which the hydrolysate improved NF-BG 
may be humoral in nature, potentially via DPP-4 inhibition seen in other studies of which improve 
pancreatic function via incretin hormone signalling, or gluconeogenic amino acids promoting glucagon 
suppression via negative feedback mechanisms (Holst et al., 2017). Small molecule glucagon receptor 
antagonists have demonstrated excellent glucose-lowering efficacy in clinical study (Mu et al., 2012). 
Ultimately however, the effect perhaps is contrived from a protective effect upon beta-cell survival, 





period would be corroborate this statement. The most potent increase in blood glucose concentration 
arises from hepatic glucose liberation of glycogen stores. Metformin has been shown to reduce 
hepatic glucose release; however, its effects are now thought to also play a key role in reducing 
glucose absorption from the gut. Studies have shown metformin-induced GLP-1 secretion, and as a 
result dual-therapy with DPP-4 inhibitors is now more common (Hundal et al., 2000; Mannucci et al., 
2001).  Indeed, metformin may well have a direct effect up plasma DPP-4 enzyme acidity as 
demonstrated by Cuthbertson et al., 2009) 
Non-fasting circulating plasma insulin during treatment administration 
Multiple low doses of streptozotocin (STZ) injection within the literature is used to cause mild to 
moderate β-cell damage via cytotoxic cellular immune response promoting hypoinsulinaemia and 
hyperglycaemia (McEvoy et al., 1984). Typically, large doses of STZ are administered to investigate 
immunological changes within the pancreas more in-line with insulin dependent diabetes (Deeds et 
al., 2011). Clinically, STZ is used as a chemotherapeutic agent in the treatment of pancreatic β-cell 
carcinomas, however it has been invaluable for the study of both insulin dependent and non-insulin 
dependent diabetes (Eleazu et al., 2013).  STZ has a chemical structure similar to glucose, allowing STZ 
to bind and enter the cell via GLUT-2 transporters (Schnedl et al., 1994). STZ at lower doses elicits an 
immune and inflammatory reactions through release of autoantigens and macrophage infiltration.  As 
well as the adverse effects upon glycaemia, STZ has other detrimental side effects including 
hepatotoxicity (Aldahmash et al., 2016). Circulating plasma insulin concentrations were established 
from six days prior to treatment and through to day 18 of twice daily treatment administration. 
Initially, non-fasting insulin concentrations were reduced by approximately 75% versus that of the 
control mice who were not given the low dose STZ injections.. The STZ saline treated control group 
maintained hypoinsulinaemic state throughout the study. Compared to the latter mice, the metformin 
treatment group had elevated plasma insulin levels at day 6 initially, and while an increasing trend 





surprisingly, the hydrolysate treatment group has shown significantly higher non-fasting plasma 
insulin concentrations from day 6 to 18, exceptions for day 12.  When assessed using insulin area 
under the curve (AUC), the P. palmata hydrolysate treatment group showed a 2-fold increase of 
plasma insulin while the metformin group had a 1.7-fold increase versus the STZ saline treated control 
group. Without intervention, all both groups of mice would thus have progressed to the severe state 
of hyperglycaemia similarly to the STZ saline treated group. Thus both treatment groups partially 
ameliorated the glycaemic decline following STZ administration. The rise in non-fasting insulin 
secretion is very likely linked to the improvement in non-fasting blood glucose, improvements in 
glucagon signalling including potentially protective effects of post-prandial GLP-1. Metformin is known 
to be an insulin sensitizer drug (Bailey, 2005) and indeed these mice do not display insulin resistance 
which could partially explain the improvement of NF-BF.  Further in depth investigations on the effect 
on pancreatic function and improvements in circulating insulin are needed. However a study within 
LPS-induced RAW264.7 macrophage cells elicited anti-inflammatory effect when treated with salmon 
protein hydrolysates (Chang-Bum et al., 2012), of which may also partly explain the improvements 
seen within this study.  
Energy intake via dietary sources during treatment analysis 
The satiety effects of proteins are well established (Westerterp-Plantenga et al., 2012); within this 
study, the hydrolysate group caused a significant reduction in dietary energy intake. The metformin 
treatment group showed a food intake reduction trend, but this was deemed non-significant. From 
day 15, onwards the non STZ treated control animals presented a significant reduction of energy 
intake versus the STZ saline treated control group and similarly the hydrolysate group reduced energy 
intake from day 15 onwards to study completion. Hyperphagia is an expected feature of the STZ 
treatment process (Hidaka et al, 2001).  The average energy intake of the P. palmata hydrolysate 
group was 22% lower during the 18 days of hydrolysate treatment. The reason for this reduction  is 
not related to the caloric source administered. Metformin is known for improvements in satiety, 





not fully understood, however it may at least be partially mediated through GLP-1 or action on DPP-4 
enzyme activity of which was discussed above.  
Post-treatment analysis of glycated haemoglobin (HbA1c) 
Following 18 days of various oral treatments, terminal HbA1c was assessed just prior to euthanization.  
HbA1c has become the gold standard measurement of long-term glycaemic control and used for 
diagnosis and prognosis of disease state in diabetes patients (Florkowski, 2013). Typically assessed at 
least 72 days apart in humans due to red blood cell recycling, the HbA1c within the study was assessed 
40 days after the first STZ injection, which included the later 18 days of treatment administration. 
Analysis had shown that untreated STZ saline control animals had an HbA1c of 10.5% indicated a very 
poorly controlled glycaemic status. Interestingly, both the hydrolysate and metformin treatment 
groups had shown a significant reduction versus STZ saline control treatment group showing values of 
7.2% for P. palmata hydrolysate and 6.7% for metformin. The mice not treated with STZ injections 
however had well controlled value of 4.05%. In relation to diabetic status, both PPPH and metformin 
groups would still be considered within the diabetic ranges. It is perhaps not surprising that HbA1c was 
not reduced further, as although NF-BG was markedly reduced, however post-treatment NF-BG levels 
were still above 15 mmol/L. A longer treatment period may have improved both NF-BG and HbA1c, 
however health concerns would likely be raised for the health of the STZ saline treated control if left 
untreated for a longer duration. Individuals with T2D who being are placed onto metformin treatment 
often show markedly improved HbA1c within 6 months including reduction of cardiovascular events 
(Svensson et al., 2017). Similarly, studies investigating high protein diets have shown an improvement 
in HbA1c over the same period, however identifying the underlying mechanisms of action by which 
macronutrient dietary patterns are affected by increasing protein intake and how this ultimately 







Terminal excise pancreatic hormone content post-treatment 
Both glycaemic and pancreatic negative feedback systems are affected throughout the progression of 
Type 2 diabetes (Wilcox, 2005). Within this study, we aimed to investigate total pancreatic hormone 
content with particular emphasis on glucagon content within the pancreas. Overall glucagon content 
may be significantly altered within the pancreas causing progressive hyperglycaemia and 
hyperglucagonemia, we aimed to assess this effect via changes in pancreatic glucagon content (Cryer, 
2012). Here, 30 mg of pancreas from each animal was assessed for hormone content using the 
modified acid-ethanol extraction protocol (Pollock et al., 1988).  On analysis of glucagon, there were 
no significant differences in glucagon content, however the STZ saline treated control and PPPH group 
has displayed a tendency for reduced glucagon. Inversely however, when total pancreatic hormone 
content was assessed post-acid ethanol extraction, treatment groups, including the non-STZ control 
group displayed a 2-fold to 3-fold reduction in hormone content versus the STZ control group. When 
comparing the total peptide content and glucagon content, a dramatic change was noted, with 10% 
of the total hormone content extracted from the STZ control group arising from glucagon content, 
whereas the hydrolysate, metformin and non-STZ groups had over double the glucagon content in 
comparison to total hormone content analysed but failed to reach significance. This would support 
the hypothesis that within uncontrolled diabetes such as the STZ control group, glucagon content 
within the pancreas may be significantly depleted due to over stimulation and relative lack of insulin 
to promote negative feedback within α-cells. The result would further suggest that improvements 
seen in regards to non-fasting blood glucose are potentially at least partially derived from correction 
or improvement of hepatic glucose release, which is reported already with metformin.  
Bone parameters and body fat and lean mass analysis after interventions in STZ mice. 
Within the literature there has been inconsistency regarding the effect of diabetes on bone mineral 
parameters. These discrepancies described within obese and T2D individuals maybe reported due to 





mass was not a concern, as the animals were lean and healthy prior to STZ induction of diabetes 
presenting weight loss due to relative lack of insulin promoting adipose utilization as a fuel source. 
Furthermore, associations between elevated insulin concentrations and elevated BMD are warranted, 
however again, this was also not a concern within the STZ groups. On analysis, there was no BMD 
changes within any of the treatment groups, including the non-STZ control group. Studies analysing 
bone mineral content (BMC) have explained that BMC may be related to bone strength and increases 
are not always accompanied with increased BMD which may be used to assess fracture risk (Curtis et 
al., 2016). Rather interestingly in humans, stress fractures risk may not be protected by increased fat 
mass (Moayeri et al., 2017). Within the present study, both the PPPH and metformin groups have 
shown significantly increased BMC compared to the STZ saline treated control group. In comparison 
to the normal mice not given STZ injections,  there was no additional effect of metformin, however 
there was within the P. palmata group. Explaining the improvements in BMC may require 
understanding peptide-chelating properties of small molecular weight peptides (SMWPs) and amino 
acids. Several studies have shown that glycine is a potent calcium chelator with SMWPs similarly 
binding calcium to the C-terminus of the peptide chain and thought to be a viable approach for 
increasing the bioavailability of calcium for treatment of osteoporosis and sarcopenia in the elderly 
(Tang & Skibsted, 2016; Sun et al., 2016; Wu et al., 2017). The calcium contained within the 
hydrolysate after protein fractioning is currently unknown, however Palmaria palmata may contain 
7% calcium based on dry weight, which might also explain the improvement in bone mineral content, 
which may show improved BMC from both peptide chelating and increased calcium absorption. 
Furthermore, when a more in depth analysis of a particular region of interest in the femur in the PPPH 
group showed enhance BMC. Each of the other groups, including the mice not injected with STZ, 
reported no changes in femur BMC.  





Lean mass and fat mass was reduced in each of the STZ injected groups. Lean mass was significantly 
higher within the mice not injected with STZ and included an increase in fat mass. As the animals 
progressed post-STZ injection, it is not surprising that body composition was altered, especially fat 
mass. The relative low levels of insulin (hypoinsuinaemia) promotes alternative utilization of adipose 
stores as a fuel source (Morigny et al., 2016) and weight loss. The analysis of circulating lipid levels 
resulted in reduced triglycerides in both STZ P. palmata hydrolysate and metformin treatment groups 
including the non-STZ saline control, however this was only seen as significant within the hydrolysate 
group.  
Conclusion 
The work carried out within has been the first reported instance of improving diabetes parameters in 
STZ treated mice using Palmaria palmata protein hydrolysates. Work performed previously 
investigating cellular activation of cells including secretion of insulin, GLP-1, GIP, including improved 
glucose uptake in adipocyte cells was useful during the screening process, but was hugely dependent 
on the hydrolysing enzymes used. The researcher firstly identified the most promising hydrolysis 
method, which was screened acutely in vitro and in vivo. Following this the chronic administration of 
the most promising bioactive candidate within diabetic induced mice has shown improvements in non-
fasting glucose, elevation of circulating insulin, lowered HbA1c and improvements in lipid profiles. The 
results presented within, could be derived partially from the reduction of dietary energy intake, 
however this alone would not explain the effect upon pancreatic glucagon, anthropometric and 
improvement in fasting blood glucose. Interestingly, this is not the first study we have conducted with 
protein hydrolysates that displayed improvements in bone mineral content (Refer to chapter 6), and 
this represents an aspect of proteomic research that warrants further investigation for improving 
calcium bioavailability. With these outcomes noted, there is still unanswered questions that need 
addressed using a biochemical, immunological and immunohistochemistry approaches. For example, 





concentration pre- and post-treatment, including leptin, ghrelin and CCK. The research aimed to 
identify cellular glucagon content within the pancreas. Changes relating to improved NF-BG would 
most likely be derived from this mechanism partly due to only modest improvement in circulating 
insulin seen within treatment groups. Establishing circulating plasma glucagon levels throughout the 
study however, would have added to the hypothesis that the hepatic improvements of metformin, 
including the peptide or amino acid signalling of the hydrolysate are very likely the key factors for the 
antidiabetic effect presented within including a protective effect of the contained peptides within the 
hydrolysate on pancreatic functionality and insulin secretory effects displayed within. The research 
has acknowledged these approaches and aims to answer these questions in time. In relation to food 
derived bioactive algal protein components and sustainability of algal sources leads to the ultimate 
conclusion that small bioactive molecules have advantageous effects upon glucose homeostasis. The 
hydrolysate deployed within were produced initially at lab scale and unfortunately upscaling this 
approach relies mainly on the availability of the algal source including the season harvested, which 
significantly affects protein content, including during the processing the loss of other nutritional 
compounds such as fibrous, lipid and vitamin based compounds. The characterisation of bioactive 
peptides, previously reported to contain DPP-4 inhibitory activity (Harnedy et al., 2015) may be the 
best approach using novel protein sources that have cultivation issues. Nevertheless, the results 
presented within have presented biological activity of novel small molecular weight peptides, that 
when taken orally improved satiety and glycaemia in a STZ diabetes induced mouse model. Ultimately, 
algal protein sources subjected to enzymatic hydrolysis may be used as a niche functional food 
ingredient with anti-diabetic properties, however further human investigations will be needed to 
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8.1 - Abstract 
Background and aims 
Boarfish (Capros aper) is a currently underutilised catch that has recently gained attention 
due to its potential as an alternate protein source. Furthermore, emerging in vitro and in 
vivo research has indicated that boarfish protein hydrolysates (BFH) may favourably impact 
on glycaemic control. This study aims to investigate the impact of consuming boarfish on 
postprandial glycaemic control in human participants. 
 
Methods 
A randomised placebo controlled crossover study was undertaken to assess the effect of 
consuming a drink containing BFH (3.5g) on glycaemic response in comparison to a control 
drink in a cohort of apparently healthy participants (n=20). Measures of satiety (ghrelin, 
leptin) and glycaemic control (glucose, insulin & glucagon-like peptide-1 (GLP-1)) were 
determined in a fasting blood sample (0 mins) and in six postprandial samples over a 180 
minute period (15, 30, 60, 90, 120, and 180 mins). The participants also provided subjective 
measures of satiety using a visual analogue scale at each of the timepoints.   
 
Results 
A paired sample T test found no significant differences between consuming the BFH and the 
control drink in any of the measured blood biomarkers at any timepoint. Consumption of 
the BFH was shown to significantly increase satiety rating by 11.1% (P=0.034) at 180 







The study noted a lack of effect of the BFH on glycaemic control which may be due to the 
comparatively low dose used in this study.  The satiety inducing effects of BFH needs to be 
further explored to determine its potential role in decreasing food intake and weight 
management.  
 
8.2 - Introduction 
The marine environment has historically made a considerable contribution to the human 
diet particularly in relation to the provision of protein and polyunsaturated fatty acids from 
fish (Beveridge et al. 2013). The existing high demand for a select range of fish species such 
as cod (Gadus genus) has led to excessive overfishing resulting in a depletion of their global 
stocks and has raised questions and challenges regarding their future sustainability 
(Srinivasan et al. 2010). This has led to the development of international strategies to 
monitor fishing of these species through the establishment of quotas and ecological 
monitoring programmes to avoid their endangerment (European Union, 2017). This had led 
to the need to increase efforts to identify alternative fish sources with a particular interest 
in the valorisation of the estimated that 20 million tons of marine captured fish and fish by-
products that are discarded ever year (Rustad et al. 2003). However, it must be noted that 
there are considerable challenges to marketing these underutilised species due to a lack of 
consumer acceptability and thus many are targeted as an inexpensive source for protein 





protein sustainability. Initially the isolation of protein from these underutilised fish species 
was for their basic nutritional properties however the development of enzyme technologies 
that can both recover and modify proteins resulting in the potential development of peptide 
hydrolysates (Kristinsson and Rasco, 2000). 
The pelagic species Capros aper commonly known as Boarfish has emerged as a potential 
candidate for protein extraction as it is plentiful and inexpensive (Egerton et al. 2017). 
Boarfish is a bycatch product of the mackerel trawl fisheries and the increased pressure 
from the European union to utilise unwanted by-catches has seen an increased quantity of 
Boarfish landing increase from 600 tonnes in 2004 to 21584 tonnes in 2008 (Common 
Fishing Regulation (no 2371/2002; Marine institute, 2008). Emerging evidence has 
suggested a role for fish derived protein hydrolysates on metabolic health (Chalamaiah et al. 
2012). This has led to increased efforts to use novel commercial protease combinations 
during boarfish extraction in an effort to isolate bioactive hydrolyses for the functional food 
market. Previous experiments carried out by this group have demonstrated that boarfish 
hydrolysates have the potential to induce insulin production in vitro as well as improve 
postprandial glycaemic control in mice which has been suggested to be due to the induction 
of incretin hormones (e.g. GLP-1) and insulin (Parthsarathy et al. 2018). Furthermore, other 
unpublished experiments from this research group has indicated that mice consumed less 
food over a controlled 3 hour feeding period. Therefore, this study aims to determine if the 
boarfish hydrolysate can have similar effects in human participants by investigating the 
effect of boarfish protein hydrolysate consumption on blood glucose, insulin response and 
incretin hormones prior to a glucose tolerance test in human participants. The secondary 
aim is to determine the effect of consuming the boarfish protein hydrolysate on markers of 





8.3 - Methods 
Recruitment 
This study was granted ethical approval by Ulster University Research Ethics Committee 
(UUREC) (REC/16/0078). Healthy participants were invited to participate in this is a double 
blinded cross over trial through email, leaflets, and posters. Participants who expressed an 
interest were screened for eligibility using the following criteria; non-smokers, non-pregnant 
or lactating, not currently suffering from any chronic illness or taking medications, aged 
between 18-65 years, BMI between 19.5-24.9 kg/m2. All criteria was self-reported, with the 
exception of BMI, height was measured to the nearest 0.1cm using a stadiometer (Marsden, 
Leicester, UK) and weight was measured to the nearest 0.1kg using a portable Seca scale 
(Seca, Brosch Direct, Peterborough, UK) and BMI was calculated. Eligible participants (n=10 
male, n=10 female) were asked to provide informed written consent. 
Protein hydrolysate 
Boarfish were caught off the coast of Ireland and supplied by Killybegs Fishermen’s 
Organisation, Killybegs, Ireland, the boarfish used in this study were by-catches. The fish 
were disembowelled, minced, and stored at -20oC in Killybegs Fisheries. The protein 
hydrolysate was created in the University of Limerick. Details of the methodology are 
outlined elsewhere (Parthsarathy et al. 2018) however in brief, the fish meat was brought to 
room temperature and combined with distilled water at a ratio of 1:1 and centrifuged 
(Ultra-Turrax® T25 Basic, IKA®, Staufen, Germany) at 24,000 RPM/min for 15 seconds, and 
repeated 4 times. A 6.8 (w/v) boarfish protein suspension was obtained by adding additional 
distilled water. The homogenous solution was raised to 50oC and the pH adjusted to 7.0. 





The solution was incubated at 50oC for 4 hours and 90oC for 20 minutes. The solution was 
double filtered (Whatman grade 1:11 µm) and freeze dried (FreeZone 18L, Labconco, MO, 
USA.  
The dose used in this intervention study was extrapolated from our previous work that 
reported murine models consuming 50 mg BFH per kg body weight significantly 
improvement glycaemic control (Parthsarathy et al. 2018). We estimated that human 
participants would weigh 70kg, and therefore the calculated dose was 3.5g of BFH. 
 
Test drink 
Due to the remaining odour and taste present in the hydrolysate, a beverage was developed 
to blind the treatment from both the participants and the researchers, this was achieved 
using a drink that contained; water, tomato, roasted pepper, chilli, and garlic. These items 
were cooked, blended, and stored at -20oC in Ulster University until consumption. 
 
Study design and intervention 
Twenty healthy human participants attended the human interventions suite in Ulster 
University on two occasions. Appointments were separated by 14 days. At the first 
appointment, participants were randomly assigned to consume either 60ml of the test drink 
with 3.5g BFH and 75g of glucose (Penlan, Kent, UK) in a 300ml solution or 60ml of the test 
drink without the BFH and 75g of glucose in a 300ml solution. At the second appointment, 






Cannulation and sample processing 
Participants were fasted overnight for 12 h on arrival. A cannula was fitted and a fasting 
blood sample taken (0 mins) followed by six postprandial blood samples (15, 30, 60, 90, 120, 
and 180 mins). Blood (10ml) was collected at each sampling point and centrifuged 
immediately, for 15 mins at 3000 g. Aliquots were stored at – 80oC until analysis. 
  
Visual analogue scale 
Participants completed a VAS whilst fasting (0 mins) and at six points postprandial (15, 30, 
60, 90, 120, 180 mins). Participants ranked their hunger on a scale of 1-10 with 1 being the 
least hungry, and 10 being the most hungry. Participants ranked their desire to consume, 
sweet, salty, and savoury food on a scale of 1-10, with 1 being no desire, and 10 being a 
strong desire, this assessed their food preference. 
 
Biochemical Analysis 
Plasma samples collected were analysed for insulin, active GLP-1, and leptin using a multi 
spot electrochemiluminescent assay (Meso Scale Diagnostics, Gaithersburg, MD, USA). Inter 
and intra assay coefficients of variance (CV) were both below 10%. Plasma glucose was 







Statistical analysis was conducted using statistical software GraphPad Prism version 5.0 
(GraphPad Software Inc., San Diego, CA, USA). Data was tested for normality using the 
Kolmogorov-Smirnov test. Variables that were not normally distributed were log 
transformed. Participant mean and area under the curve (AUC) blood glucose, insulin, GLP-1, 
ghrelin, and leptin concentrations of the BFH were compared to the control at each timepoint 
using a paired T test. Similarly, mean VAS scores were also compared between participants 
when they consumed the BFH with when they consumed the control using a paired T test. 
Data is presented as the mean ± SD. A P value of < 0.05 was considered to be significant.  
 
 
8.4 - Results 
Participant characteristics 
As shown in table 1, the mean (SD ±) age (years) of the ten males and ten females 
participants was 29.20 (±7.28), the mean (SD ±) BMI (kg/m2) of the participants at the 
treatment appointment was 19.73 (±2.12), and at the control appointment was 19.75 kg/m2 
(±2.09). 
 
Blood insulin and glucose 
As shown in figure 1, there was no significant difference in blood insulin concentrations 
between participants consuming BFH and control at any sampling point. There was no 
significant difference in the overall 0-180 min area under the curve (AUC) blood insulin 





in blood glucose concentration at any sampling point between participants consuming BFH 
and those consuming the control. There was also no difference in the overall 0-180 min area 
under the curve (AUC) blood insulin concentration between each treatment group. 
 
GLP-1 
No difference in GLP-1 concentrations were observed at any sampling point between 
participants consuming BFH and those consuming the control (figure 2). There was also no 
difference in the overall 0-180 min area under the curve (AUC) GLP-1 concentration 
between each treatment group. 
 
Hormone analysis 
Figure 3 shows there was no significant difference in leptin concentrations at any sampling 
point between participants consuming BFH and those consuming the control. There was 
also no difference in ghrelin concentrations at any sampling point between participants 
consuming BFH and those consuming the control.  
 
Satiety VAS 
Participants rated their appetite and food preference on a scale of 1-10 at each of the seven 
sampling points. A significant increase in satiety rating by 11.1% at 180 minutes (P=0.034) 
was reported following BPH consumption in comparison to the control drink. No other 






8.5 - Discussion 
This study identified that 3.5g of BFH had no effect on markers of postprandial glycaemic 
control. Blood glucose and insulin were not different when participants consumed boarfish 
protein hydrolysate compared with control. There was also no effect of BFH on ghrelin and 
leptin, however participants consuming the control reported they were significantly 
hungrier after 180 minutes compared with participants consuming the BFH.  
Protein has previously been shown to impact on glycaemic control through an array of 
mechanisms including a potential effect on gastric emptying, a stimulation of incretin 
hormone release as well as a direct effect of amino acids on beta cells following absorption 
(Gunnarsson et al. 2006, Ma et al. 2009). However, the protein source and amino acid 
composition has been suggested to influence its efficacy with leucine, alanine and 
phenylalanine amino acids identified as potent candidates (Manders et al. 2012). Whey 
protein has been shown to be more insulinotrophic than casein, gluten and cod albeit the 
study involved the consumption of 45g compared to the 3.5g used in the current study 
(Mortensen et al. 2009). The rapid absorption and appearance of amino acids in the blood 
was suggested, in part, to help explain its superiority over whey over the other protein 
sources, although it is clear that protein elicits its beneficial effects in a dose dependant 
manner (Petersen, et al. 2009; Akhavan et al. 2010). The dose selected in this study was 
extrapolated from murine experiments where it was deemed to be effective at modulating 
glycaemic control. Oral gavage of BPH (50mg/ml) in mice was shown to impact postprandial 
glycaemic response with a 22% reduction of iAUC blood glucose as well as an increased 





postprandial glycaemia due to the presence of short peptides containing leucine, isoleucine, 
arginine, alanine and phenylalanine, amino acids which have previously been shown to be 
insulinotrophic in previous studies (Manders et al. 2012). The lack of effect of BPH in the 
current study could be due to the low dose, which is supported by a study by Vikøren et al. 
(2013) where consumption of fish protein at 3g/day was shown to have no significant effect 
on glycaemic control over 4 weeks however a further 4 weeks at 6g/day was shown to 
improve glucose tolerance with a noted decrease in postprandial glucose as well as LDL 
cholesterol, and HDL:LDL. 
The secretion of GLP-1 is known to influence glycaemic control and appetite and dietary 
protein has previously been shown to stimulate the release of GLP-1. It has been proposed 
that protein components can directly stimulate the enteroendocrine L cells to secrete GLP-1, 
which can subsequently bind to G-coupled receptors in β-cells resulting in cAMP mediated 
insulin release. In vitro studies previously undertaken by this research group showed that 
BFH significantly increased GLP-1 release GLUTag cells by 30% (p<0.01) (Parthsarathy et al. 
2018), the dosage used was similar to other in vitro studies (Cudennec et al. 2012, Harnedy 
et al. 2018). The current human study did not note any impact of consuming 3.5g of BFH on 
GLP-1 response which is a considerably lower dose than the study by Ma et al. which noted 
a significant increased GLP-1 status following the consumption of 55g of whey protein (Ma 
et al. 2009).  
 
The current study found that participants consuming 3.5g BFH reported significantly less 
hunger compared to the participants consuming the control at 180 mins (-11.1%), albeit no 





that protein consumption can impact on measures of appetite (Stubbs et al. 1996, 
Johnstone et al. 1996, Poppitt et al. 1998) and has been shown to be influenced by dose 
with higher intake (30g) increasing self reported hunger in comparison to lower intake (10g) 
in the absence of any alteration to ghrelin concentrations (Lejeune et al. 2006).  
The reported appetite supressing effects of consuming a high protein meal has also been 
shown to result in an increased latency time until food consumption as well as a significantly 
decreased food intake in comparison to either a high carbohydrate or fat meal (Chapelot 
and Payen 2010). It is important to note that there is evidence to implicate no role for 
protein content or dose on appetite and it has been shown that consumption of a meal 
containing 77% protein, did not change satiety, as measured by food intake, and VAS (de 
Graaf et al. 1992) and increasing protein dose had no impact. Interestingly, this study and 
ours, both used liquid meals, which have been suggested to be less satiating than solid 
meals. The satiating effects of the BFH reported in the current study will need to be 
followed up with BFH preload food intake study and a subsequent long term intervention to 
determine if BFH can impact on weight maintainance.   
The current study investigated the impact of 3.5g of BFH on glycaemic control however it 
must be noted that whilst this dose was calculated on efficacious dose in animal models the 
opportunity to investigate higher doses comparable with other protein studies such as whey 
(55g) was limited by the considerable challenge of the sensory properties and organoleptic 
acceptability reported in product development. Therefore, the 3.5g of BFH per serving was 
deemed to avoid acceptability issues and the participants consumed the entire dose in the 





of the protein extraction and BFH manufacturing process to minimise/improve the sensory 
properties of the BFH. 
 
8.6 - Conclusion 
This study concludes that 3.5g of BFH does not affect glycaemic control. These results 
corroborate previous findings that have reported protein consumption results in a self-
reported decrease in satiety, however no change in leptin or ghrelin. Future studies should 


















Table 1: Descriptive statistics of study 
 participants (n=20) including mean (±SD) biomarkers of glycaemic 
control and appetite 
 Mean (±SD) 
Age (y) 29.20 (7.28)  
Male/Female (n) 20:20 
BMI (Kg/m2) 19.74 (2.11) 
Insulin (mg/mL) 335.74 (367.90) 
Glucose (mmol/L) 5.47 (0.44) 
GLP-1 (ng/mL) 5.27 (2.10) 
Leptin (ng/mL) 6.04 (10.09) 
Ghrelin (ug/mL) 309.88 (143.41) 
BMI; body mass index, GLP-1; glucagon like peptide-1, SD; 
standard deviation. P values are generated using an unpaired T 
test assessing the mean difference of markers following 




















Fig 1. (A) blood glucose, (B) insulin, (C) GLP-1, (D) leptin, and (E) ghrelin concentrations were 
measured in participants treated with BFH and control, at fasting, and 15, 30, 60, 90, 120, 180 mins 
postprandial. Values represent means ± standard deviation. *p<0.05 
 







Fig 2. Visual analogue scales (VAS) were completed assessing participants self reported satiety, 
participants were treated with BFH and control, VAS were completed at fasting, and 15, 30, 60, 90, 














































9.1 Future work approaches 
The work presented within displayed the bioactivity including the oral bioavailability of small 
molecular weight peptides from marine sources, with emphasis on functional food development 
targeting obesity and type 2 diabetes. The hydrolysates analysed were derived from underutilized 
protein sources, including pelagic fish (Boarfish and blue whiting), discarded processing offcuts 
(Salmon muscle and skin) and finally a native algal source (palmaria palmata). The protein source was 
initially extracted using aqueous alkaline methods described in earlier chapters, however the 
generation of the small molecular weight peptides were derived from lab based enzymatic hydrolysis 
using singular or combinations of food grade proteolytic enzymes. To date there has been a wealth of 
literature additions to this area of rapidly expanding biomolecules (Giri & Oshima, 2012; Harnedy & 
Fitzgerald, 2012; Cheung et al, 2015)  
Generated hydrolysates were first screened within cultured cells and cellular based signalling 
assays. This included identifying the hydrolysis method, which presented the most promising in vitro 
activity. Cell lines chosen, were tailored towards potential diabetes treatment, including insulin 
secreting BRIN-BD11, GLP-1 secreting GLUTag and GIP secreting STC-1 cells. Furthermore, 
transdifferentiated fibroblasts of which progress into adipocytes under experimental conditions were 
used for glucose uptake investigation in the presence and absence of insulin. It is becoming 
increasingly acknowledged that small molecules have the capacity to interact with large complex 
endogenous hormones, and as such, the research investigated protein-protein interaction of SMWPs 
and the ability to inhibit dipeptidyl-peptidase-4 (DPP-4) and α-amylase activity, both current 
treatment approaches for individuals with T2D. From here, the bioactivity was determined, including 
cellular signalling events. Protein, peptides and amino acids are only considered bioactive due to their 
cellular interaction and activation mechanics, in order to investigate this the researcher highlighted 





activation via intracellular calcium mobilization, membrane potential and cyclic AMP production 
during acute co-incubation with hydrolysates.  
One of the most challenging aspects of orally administered amide containing biomolecules is 
appreciating that molecule may not remain intact in the harsh proteolytic environment of the gastro-
intestinal tract (GI). The hydrolysates were screened for bioactivity and were further digested using 
simulated gastrointestinal digestion (SGID) and were subsequently rescreened across the bioassays 
mentioned within. The bioactivity change was compared to the primary hydrolysate fraction, 
interestingly, several hydrolysates retained or improved upon bioactivity with some exceptions which 
will be discussed later. The oral intake of proteins and their subsequent digestion is classically 
investigated at the rate of which the amino acids are elevated within circulatory transport systems 
(Uauy et al, 2016). This approach has many limitation when administering intact proteins, and even 
more so when administering small molecular weight peptides. Evidence shows that small peptides 
have the capacity to resist further digestion and enter circulation via dependent or independent 
intestinal peptide transport systems (Silk, 1974).  
The research aimed to highlight this important mechanism by firstly displaying the 
concentration of each protein hydrolysate needed to promote a biological response. The 
concentration ranges investigated needed to show a reduction in post-prandial glucose following an 
oral glucose challenge, however equally important, needed to reflect a practical protein intake 
quantity that could be potentially incorporated into a functional food or drink. Typically at lower doses 
of hydrolysates (10-25 mg/kg) resulted in no glycaemic benefit, however higher concentration ranges 
(50 – 100 mg/kg) had revealed significant improved when administered orally in mice. Using a 
combination of screening approaches, each hydrolysate had been scored on in vitro bioactivity 
including acute and delayed in vivo effect, and finally, the quantity needed for upscaling to human 
investigation was established. When considering which hydrolysate would firstly be deployed within 





which one would be carried through to human investigation. The results presented throughout, 
highlighted several other hydrolysate preparations from other biological sources that were equally 
promising, including the algal source, however due to the limited quantity available unfortunately 
forced a change to a more sustainable nitrogen source.   
Interestingly, each of the hydrolysates selected for chronic in vivo investigation had various 
effects upon acute and long-term glucose control, circulating lipids, and body mass and bone mineral 
outcomes including glycated haemoglobin improvement. Each in their own right, could have been 
selected for acute and chronic human study, with salmon skin gelatine being the obvious choice due 
to its sensory characteristics, however boarfish was selected as it was equally as promising and a 
readily available supply was available over the salmon counterpart.    
Finally, two human intervention studies were carried out, one of which is included. Firstly, 
mimicking the glucose tolerance improvement displayed with boarfish, the same study approach was 
attempted in humans using an industry generated up-scaled hydrolysate. The lab generated boarfish 
hydrolysate required 50 mg/kg bodyweight to acutely elicit a post-prandial glucose improvement. This 
was the same dose applied to the genetically obese and diabetic (ob/ob) chronic animal study, 
however administered twice daily. Upscaling this dose from mice to humans required a 3.5 g intake 
for a 70 kg human or 7 g needed if following the same dosing regimen within the long-term ob/ob 
animal study. Issues had arose due to the challenging sensory characteristics of the boarfish semi-pilot 
hydrolysate that had been generated at industry scale. The hydrolysate unfortunately required 
incorporation into a food matrix to mask the sensory characteristics of the semi-pilot scale 
hydrolysate. The researchers collaborated with a flavour technician and chef to successful mask the 
sensory characteristics however no more than 3.5 g could be incorporated into the soup-based 
foodstuff of which was a major limitation when compared to literature doses of protein needed to see 
glycaemic benefit. Potentially, the lipid oxidation of the semi-pilot scale hydrolysate increased the 





future work of which each researcher involved within the study has acknowledged, however as this 
was the first study of its kind including a unique approach to generating small molecular weight 
peptides, future study using the same approach will be much more streamlined avoiding any 
unsavoury issues.  
Until now, this has been a brief overview of the logistics deployed within a cross-border 
collaborative team, used to minimise the screening time of a large range of protein products and 
maximise publication, industry and therapeutic potential of underutilized nitrogen sources. The 
remaining of the work presented within will briefly discuss key highlights of the entirety of the work 
looking at several key factors for obesity and diabetes treatment. These include maximizing 
insulinotropic and incretin secretion, targeting protein-protein interactions, satiety based 
improvement and finally oral bioavailability of protein molecules and the hurdles that this work 
overcame that future work within this area can acknowledge. 
 
Maximising cellular secretion mechanisms of protein hydrolysates 
Tailoring hydrolysates towards obesity and diabetes was the overall aim of this work. The pancreas 
responds well to peptide-based therapeutics, which is now well established due to the rising rate of 
peptide mimetics currently used to treat diabetes (Verspohl, 2009). Pancreatic islet morphology 
consists of diverse network of cells working in harmony to maintain glycaemia. Pancreatic cells secrete 
a range of glucose dependent and independent homeostatic peptide hormones including insulin, 
glucagon, somatostatin, amylin, pancreatic polypeptide and ghrelin. Pancreatic β-cell dysfunction 
plays a critical role in the pathogenesis of both type 1 and type 2 diabetes (Gromada et al, 1998). 
Insulin produced within β-cells is a critical regulator of metabolism and is primarily glucose responsive; 
however, other nutrients such as free fatty acids, peptides and amino acids can trigger potent 
insulinotropic responses (Torres et al, 2009). More recently, approaches exploiting insulin secretion 





secretion can be more efficient and potentially safer towards lowering elevated levels of circulating 
glucose (Meloni et al, 2013). Within this work, specific β-cell receptors and their activation was not 
investigated, however acute incubation with various hydrolysate concentrations and their effect 
towards general cellular signalling events were assessed. The hydrolysates were effective upon 
stimulating several signalling mechanisms including elevated cAMP and intracellular calcium 
mobilization. This would suggest that peptide-based cellular receptors were activated via the 
hydrolysate peptides and area which has exploded looking for the next new small peptide mimetics 
for improving insulin secretion. This leads to the suggestion that these hydrolysates could have other 
signalling effects throughout bodily systems and not necessarily confined within the pancreatic islet. 
An example of improving potential bioactivity was evident initially when comparing the hydrolysates 
generated using aqueous hydrolysis to the further simulated gastrointestinal hydrolysis (SGID) aq/alk 
hydrolysate. Typically, within industry, hydrolysates are generated using aqueous alkaline solutions 
and rarely implement enzymatic hydrolysis purely due to cost restraints. The insulin secretion data of 
the aq/alk hydrolysate was only elevated above basal control at 1.25mg/ml and higher, whereas 
further hydrolysis using SGID showed significant insulin secretion at a concentration of 0.312 mg/ml, 
resulting in 4 times lower dose required to stimulate a response. We hypothesize that this is primarily 
derived from increasing the receptor activation potential, firstly by increasing the number of 
generated small peptides from the intact protein source, and secondly, due to the increasing number 
of small molecular weight peptides a further systematic effect via multiple receptors may be possible. 
This was not always the case however, especially when only one proteolytic enzyme was used in the 
initial hydrolysis step such as the hydrolysates generated using Alcalase, Promod or bromelain only. 
Interestingly, the cellular secretory activity favoured hydrolysates that were generated using 
sequential hydrolysis of more than one proteolytic enzyme. An example of this was the hydrolysates 
generated using Alcalase and Flavourzyme in combination resulting in improved bioactivity with pre- 
and post-SGID digestion. This effect is most likely derived from both enzymes cleaving different 





can improve hydrolysis outcomes and lower the required time needed to yield small molecular weight 
peptides, whereas Alcalase can be further used as a serine protease targeting specific amino acids 
within the peptide chain further digesting larger amino acids. Finally, bioactivity of the hydrolysates 
generated using one proteolytic enzyme were generally improved upon once they had been subjected 
to SGID, this again confirms that the singular application of one enzyme may not promote the degree 
of hydrolysis needed to generate enough small molecular weight peptides that are under 5000 da, 
with the overall target from our own work showing peptides ranging from 3 to 8 amino acids having 
the most potent effect towards cellular activation. Excitingly, we had confirmed this after the 
screening of all lab based hydrolysates by further screening an industry scale hydrolysate from a 
common marine nitrogen source that was generated using a 45 min aqueous only hydrolysis method. 
The protein and peptides failed to elicit any response towards satiety or insulin secretion within cells, 
mainly due to the small degree of hydrolysate yield using such a short process.  
Maximising hydrolysis effect and oral bioavailability  
As discussed, sequential hydrolysis promoted improved bioactivity across most of the nitrogen 
sources investigated within. Several hydrolysates, including boarfish and palmaria palmata were 
extremely promising at improving post-prandial glycaemia, whereas salmon based hydrolysates were 
indeed the best candidates for reducing food intake within trained animals. Each of these mechanisms 
suggest that the source of protein has specific effect after hydrolysis and that disease-targeted 
therapeutics can be optimised dependant solely on the nitrogen source.  An important factor when 
comparing the glycaemic versus satiety effect would be to first compare the amino acid profile of each 
source and determine whether there are elevation of specific amino acids within the intact protein. 
Salmon generated quatrapeptides containing glycine at the n-terminus have been shown to inhibit 
DPP-4 (Neves et al, 2017). Similarly our own work has shown quatrapeptides, pentapeptides and 
octapeptides having increased potency over larger peptides and proteins. The bioactivity of several 





within intestinal cell lines; however, rescreening hydrolysates after SGID may not be the best 
indication of oral bioactivity loss. The rationale for this comes from the length of time that the peptides 
were subjected to SGID, 4 h. The molecular mass screening of peptides would best suit the hydrolysis 
approach, aiming for hydrolysates that contain greater than 60% low molecular weight peptides may 
indeed increase oral bioavailability and bioactivity. Larger peptide fractions, greater than 5 – 10 kDa 
may not show bioactivity within the gut and certainly not within internal systems specifically due to 
rapid digestion by endogenous enzymes. Smaller peptides, 400 – 1200 da may be the ideal molecular 
weight target and one that is commonly reported within the literature. Furthermore, peptide 
fragments produce favourable inhibitory effects towards endogenous enzymes are also generally 4 – 
10 amino acids in length rather than the penultimate amino acid residue being an indicator. This is a 
major issue for industry, primarily due to aqueous hydrolysis and the time required to obtain this level 
of consistent fragmentation and secondly, if enzymes are to be deployed the cost connected with 
obtaining large enzymes quantities including the additional step of enzyme denaturing, again, 
increases the total associated with attempting to obtain consistent SMWPs. The addition of enzymes 
in the right environment does have added benefits. Under experimental conditions and screening of 
hydrolysates, industry has the potential to accurately produce the same hydrolysates throughout 
consecutive runs with the aid of computer-monitored production.  
Functional food development targeting gut hormones and enzymes 
It would foolish to assume that all small molecular weight peptides are absorbed within the intestinal 
mucosa and have biological effect within internal systems, indeed we must acknowledge that the 
primary effect seen within our studies are derived primarily from the gastrointestinal tract itself. 
Peptides are extremely advantageous for cell specificity study. This was not a study outcome however, 
with the primary aim of producing a functional food that was firstly, inexpensive and secondly, elicited 
a biological response. At times screening hydrolysates within insulin secreting pancreatic cells lines 





upon the gut or improve upon gut hormones, however the work had shown that interaction with a 
complex and vital cell, such as the β-cell was indeed possible. Prior to this however, the gut and its 
promising approach to treating obesity and diabetes had become the primary source of bioactivity for 
these biopeptides as they were administered orally. It is still considered to this day that protein within 
the gut has minor effect until they are digested into amino acid form. Interestingly, the work within 
had shown significant secretion of incretin hormones, GLP-1 and GIP, and rather than the cells which 
secrete these hormones (L- & K-cells) being classed a nutrient sensing cells, of which they do respond 
to via post-prandial nutrient intake, may also be a target for small molecule activation. It will not be 
known however until receptor signalling work is carried out using peptides identified from the 
hydrolysates. The interaction of SMWPs generated from novel sources and their interaction with 
endogenous DPP-4 has recently evolved into the rationale that this approach can and may be a target 
for improvements in diabetes outcomes. Work presented in early chapters had shown that the 
hydrolysates generated do indeed have an inhibitory effect towards this enzyme, however improving 
this inhibitory activity would only be possible again, by identifying the molecules which had the 
inhibitory effect. With this noted, these two approach mentioned are a substantial approach to 
treating diabetes via improvements in incretin secretion including inhibiting DPP-4 increasing the 
incretin effect. This work is only within its infancy; however, future work should focus primarily on the 
gut and its diverse cells that can be exploited for obesity and diabetes management. 
Nitrogen sources and hydrolysis approaches 
Investigation of hydrolysates within this project aimed at using a stratified approach deploying each 
hydrolysate within the same in vitro and in vivo models. Fortunately, we can now conclude that the 
source of protein does indeed have varied effects, some displaying activity across a broad range of 
experiments while some having increased bioactivity towards a specific outcome. For example, the 
reduction of food intake seen within animals that were administered both versions of salmon 





activity was derived using a biomarker approach. Similarly, the prolonged glycaemic improvement 
seen from boarfish hydrolysates or peptides from the algal source that inhibited DPP-4 with potent 
incretin and insulinotropic activities would warrant incorporation into a food based diet and fed to 
animals long-term to establish if the effect is sustained throughout obesity progression. This approach 
would reaffirm the bioactivity of the hydrolysates, specifically if dietary protein intake were altered 
with various quantities of protein from different biological sources. Most importantly however, is the 
hydrolysis approach to generating the hydrolysates. The molecular weight of the intact protein may 
be a factor when considering which method of hydrolysis more applicable, with proteins ranging from 
55- to 220kDa. This suggests that lower molecular weight proteins may only require a single hydrolysis 
step, whereas larger proteins may benefit from sequential hydrolysis with more than one proteolytic 
enzyme, time will tell.  
Future work considerations in brief 
From the work contained within, several areas need further investigation via animal and human 
models of diabetes and obesity 
1) Calcium chelating potential of small molecular weight peptides targeting individuals at risk 
from stress fractures 
2) Protein hydrolysates (20g+) tested within pre- and post-diabetes individuals 
3) The effect of protein hydrolysates on glucagon signalling in T1DM models 
4) The DPP4 inhibitor activity via firstly pre-loading protein hydrolysates followed by a glucose 
challenge rather than both being administered at once 
5) Helping industry to optimise hydrolysis profiles of protein via enzymatic hydrolysis rather than 
aqueous  
6) Incorporation of hydrolysates into a food matric at various percentages and given long-term 
to animals with the overall outcome targeting biomarkers of obesity and diabetes 





8) The delayed improvement of boarfish hydrolysates and use in protein pre-loading study 
Conclusion  
The work carried out over the past 3 years attempting to exploit novel and underutilized nitrogen 
sources has evolved exponentially not only within our own collaborative work but also across the 
globe. Generating novel peptides from a vast range of proteins from insects, dairy, animal, fish, 
macroalgae, microalgae, crustaceans and everything in between aiming to exploit therapeutic 
potential is now established as a viable approach to improving health; however, the nitrogen source 
is not always sustainable. This should not alter the approach however, as screening of biological 
peptides have the advantage of artificially synthetizing promising peptides that can be further 
modified to improve duration of action and avoid unwanted degradation once administered. This was 
not an approach used within this work, which aimed to reaffirm oral intake of small molecular weight 
peptides can have benefits beyond nutrition. This work was not without its limitations and issues, 
specifically sensory characteristics of marine based proteins and potentially aromatic compounds such 
as free fatty acids which made incorporation into a food matric mandatory. Furthermore, translation 
from in vivo to human study was one of the most disappointing aspects when concluding that the 
nitrogen source chosen, Boarfish, may have anti-diabetic effect. The researchers have learned a viable 
lesson that upscaling dosages from mice to humans is not as transparent as it appears. Studies 
involving protein upon biological activity routinely use greater than 10g, with some as high as 50g. 
This was not possible due to the issues mentioned; however, production of hydrolysates will consider 
this with modifications already implemented to improve upon sensory characteristics. The future work 
should focus primarily on intestinal based hormones and improve upon bioactivity by generating 
hydrolysates that contain predominately peptides within the molecular weight range of 400 – 1200 
da using proteolytic enzymes avoiding aqueous only hydrolysis completely. With this noted, aqueous 
hydrolysis is a good starting approach to initiate the breakage of peptide bonds, however the only 





thesis has reaffirmed that novel protein sources have potent cellular secretory and signalling activity 
as well as acute and chronic in vivo improvements upon obesity and diabetes markers, with exceptions 












































Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of 
incretin therapies. Drugs Aging. 2008;25(11):913-25. 
Adibi SA. The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology. 
1997 Jul;113(1):332-40. 
Adler-Nissen J. Enzymic hydrolysis of proteins for increased solubility. J. Agric. Food Chem., 1976, 24 (6), pp 
1090–1093 
Admassu H, Gasmalla MAA, Yang R, Zhao W. Bioactive Peptides Derived from Seaweed Protein and Their Health 
Benefits: Antihypertensive, Antioxidant, and Antidiabetic Properties. J Food Sci. 2018 Jan;83(1):6-16. 
Ahn CB, Cho YS, Je JY. Purification and anti-inflammatory action of tripeptide from salmon pectoral fin byproduct 
protein hydrolysate. Food Chem. 2015 Feb 1;168:151-6. 
Ahn CB, Je JY, Cho YS. Antioxidant and anti-inflammatory peptide fraction from salmon byproduct protein 
hydrolysates by peptic hydrolysis. Food Research International Volume 49, Issue 1, November 2012, Pages 92-
98. 
 
Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):517-33. 
Akhavan T, Panahi S, Anderson GH, Luhovyy BL. Application of dairy-derived ingredients in food intake and 
metabolic regulation. In: Corredig M, editor. Cambridge, UK: Woodhead Publishing Ltd; 2009. p. 212–37. 
Akhavan, T., Luhovyy, B.L., Brown, P.H., Cho, C.E. and Anderson, G.H., 2010. Effect of premeal consumption of 
whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults–
The American journal of clinical nutrition, 91(4), pp.966-975. 
Aldahmash BA, El-Nagar DM, Ibrahim KE. Attenuation of hepatotoxicity and oxidative stress in diabetes STZ-
induced type 1 by biotin in Swiss albino mice. Saudi J Biol Sci. 2016 Mar;23(2):311-7. 
Ali Adem Bahar and Dacheng Ren. Antimicrobial Peptides. Pharmaceuticals (Basel). 2013 Dec; 6(12): 1543–1575. 
Amado IR, Vázquez JA, González P, Esteban-Fernández D, Carrera M, Piñeiro C. Identification of the major ACE-
inhibitory peptides produced by enzymatic hydrolysis of a protein concentrate from cuttlefish wastewater. Mar 
Drugs. 2014 Mar 10;12(3):1390-405. 
Amelia K. Linnemann, Joshua C. Neuman, Therese J. Battiola, Jaclyn A. Wisinski, Michelle E. Kimple, and Dawn 
Belt. Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis. Mol 





American Diabetes Association.  Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010 Jan; 
33(Suppl 1): S62–S69. 
Antonaccio MJ. Angiotensin converting enzyme (ACE) inhibitors. Annu Rev Pharmacol Toxicol. 1982;22:57-87. 
Ashwell M, C. J. Meade. Obesity: Do fat cells from genetically obese mice (C57BL/6J ob/ob) have an innate 
capacity for increased fat storage?. December 1978, Volume 15, Issue 6, pp 465–470. 
Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health 
Promot. 2014; 3: 1. 
Astrup A. The satiating power of protein—a key to obesity prevention?, The American Journal of Clinical 
Nutrition, Volume 82, Issue 1, 1 July 2005, Pages 1–2, 
Augustyniak A, Bartosz G, Cipak A, et al. Natural and synthetic antioxidants: an updated overview. Free Radic 
Res. 2010 Oct;44(10):1216-62. 
Banan-Mwine Daliri E, Oh DH, and Lee BH. Bioactive Peptides. Foods. 2017 May; 6(5): 32. 
Barrett AJ, McDonald JK. Nomenclature: protease, proteinase and peptidase. Biochem J. 1986 Aug 1; 237(3):935. 
Batista. Recovery of proteins from fish waste products by alkaline extraction European Food Research and 
Technology. December 1999, Volume 210, Issue 2, pp 84–89 
Beckman LM, Beckman TR, Earthman CP. Changes in Gastrointestinal Hormones and Leptin after Roux-en-Y 
Gastric Bypass Procedure: A Review. J Am Diet Assoc. 2010 Apr; 110(4): 571–584. 
Beveridge, M.C.M., Thilsted, S.H., Phillips, M.J., Metian, M., Troell, M. and Hall, S.J., 2013. Meeting the food and 
nutrition needs of the poor: the role of fish and the opportunities and challenges emerging from the rise of 
aquaculturea. Journal of fish biology, 83(4), pp.1067-1084. 
Billyard T, McTernan P, Kumar S. Potential therapies based on antidiabetic peptides. Best Pract Res Clin 
Endocrinol Metab. 2007 Dec;21(4):641-55. 
Bilsborough S, Mann N. A review of issues of dietary protein intake in humans. Int J Sport Nutr Exerc Metab. 
2006 Apr;16(2):129-52. 
Bishop MJ, Mayer-Pinto M, Airoldi L, Firth LB, et al. Effects of ocean sprawl on ecological connectivity: impacts 





Blanca Hernández-Ledesma, María José García-Nebot, Samuel Fernández-Tomé, Lourdes Amigo, Isidra Recio. 
Dairy protein hydrolysates: Peptides for health benefits. International Dairy Journal, Volume 38, Issue 2, 2014, 
Pages 82-100. 
Bleakley S, Hayes M. Algal Proteins: Extraction, Application, and Challenges Concerning Production. Smith CJ, ed. 
Foods. 2017;6(5):33. doi:10.3390/foods6050033. 
 
Boohaker R.J, Lee MW, Vishnubhotla P, J.M. Perez, and A.R. Khaled. The Use of Therapeutic Peptides to Target 
and to Kill Cancer Cells. Curr Med Chem. 2012; 19(22): 3794–3804. 
Bramante CT, Lee CJ and Gudzune KA. Treatment of Obesity in Patients with Diabetes. Diabetes Spectrum 2017 
Nov; 30(4): 237-243. 
Breen DM, Rasmussen BA, Côté CD, Jackson VM, and Lam TKT. Nutrient-Sensing Mechanisms in the Gut as 
Therapeutic Targets for Diabetes. Diabetes. 2013 Sep; 62(9): 3005–3013. 
Brennan IM1, Luscombe-Marsh ND, Seimon RV, Otto B, Horowitz M, Wishart JM, Feinle-Bisset C. Effects of fat, 
protein, and carbohydrate and protein load on appetite, plasma cholecystokinin, peptide YY, and ghrelin, and 
energy intake in lean and obese men. Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G129-40. 
Brooks M. Hybertson, Bifeng Gao, Swapan K. Bose, Joe M. McCord. Oxidative stress in health and disease: The 
therapeutic potential of Nrf2 activation. Molecular Aspects of Medicine Volume 32, Issues 4–6, August–
December 2011, Pages 234-246 
Brown, E.M., Allsopp, P.J., Magee, P.J., Gill, C.I., Nitecki, S., Strain, C.R. and McSorley, E.M., 2014. Seaweed and 
human health. Nutrition reviews, 72(3), pp.205-216. 
Bruno BJ, Miller GD, and Lim C. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013 
Nov; 4(11): 1443–1467. 
Burgi D, Smith AJ. Capillary electrophoresis of proteins and peptides. Curr Protoc Protein Sci. 2001 May;Chapter 
10:Unit 10.9 
Cai X, Yang Q, Lin J, Fu N, Wang S. A Specific Peptide with Calcium-Binding Capacity from Defatted Schizochytrium 
sp. Protein Hydrolysates and the Molecular Properties. Molecules. 2017 Mar 29;22(4). 
Calderon JL, Zadshir A, Norris K. A survey of kidney disease and risk-factor information on the World Wide Web. 
MedGenMed. 2004;6:3. 
Campos Sala P, Susana Torrinhas R, Giannella-Neto D, Linetzky Waitzberg D. Relationship between gut hormones 





Carreiro AL, Dhillon J, Gordon S, et al. The macronutrients, appetite and energy intake. Annu Rev Nutr. 2016 Jul 
17; 36: 73–103. 
Carreiro AL, Dhillon J, Gordon S, et al. The macronutrients, appetite and energy intake. Annual review of 
nutrition. 2016;36:73-103. 
Catnach SM, Fairclough PD, Hammond SM. Intestinal absorption of peptide drugs: advances in our 
understanding and clinical implications. Gut. 1994;35(4):441-444. 
Černá M. Seaweed proteins and amino acids as nutraceuticals. Adv Food Nutr Res. 2011;64:297-312. 
 
Chae HJ, In MJ, Kim MH. Process development for the enzymatic hydrolysis of food protein: Effects of pre-
treatment and post-treatments on degree of hydrolysis and other product characteristics. Biotechnology and 
Bioprocess Engineering 
Chalamaiah, M., Hemalatha, R. and Jyothirmayi, T., 2012. Fish protein hydrolysates: proximate composition, 
amino acid composition, antioxidant activities and applications: a review. Food chemistry, 135(4), pp.3020-3038. 
Chambers L, McCrickerd K, Yeomansa MR. Optimising foods for satiety. Trends in Food Science & Technology 
Volume 41, Issue 2, February 2015, Pages 149-160. 
Champagne CM, Broyles ST, Moran LD, et al. Dietary intakes associated with successful weight loss and 
maintenance during the Weight Loss Maintenance Trial. Journal of the American Dietetic Association. 
2011;111(12):1826-1835. 
Chapelot, D. and Payen, F., 2010. Comparison of the effects of a liquid yogurt and chocolate bars on satiety: a 
multidimensional approach. British journal of nutrition, 103(5), pp.760-767. 
Chartrand D, Da Silva MS, Julien P, Rudkowska I. Influence of Amino Acids in Dairy Products on Glucose 
Homeostasis: The Clinical Evidence. Can J Diabetes. 2017 Jun;41(3):329-337. 
Chatterton DE, Nguyen DN, Bering SB, Sangild PT. Anti-inflammatory mechanisms of bioactive milk proteins in 
the intestine of newborns. Int J Biochem Cell Biol. 2013 Aug;45(8):1730-47. 
Chatterton DE, Nguyen DN, Bering SB, Sangild PT. Anti-inflammatory mechanisms of bioactive milk proteins in 
the intestine of newborns. Int J Biochem Cell Biol. 2013 Aug;45(8):1730-47. 
Chaudhury A, Duvoor C, Sena V, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes 





Cheorun Jo, Faisal Fareed Khan, Muhammad Issa Khan & Javed Iqbal. Marine bioactive peptides: Types, 
structures, and physiological functions. Food Reviews International Volume 33, 2017 
Cheung GW, Kokorovic A, Lam CK, Chari M, Lam TK. Intestinal cholecystokinin controls glucose production 
through a neuronal network. Cell Metab. 2009 Aug;10(2):99-109. 
Cheung RCF, Ng TB, Wong JH.  Marine Peptides: Bioactivities and Applications. Mar Drugs. 2015 Jul; 13(7): 
4006–4043. 
Cheung RCF, Ng TB, Wong JH. Marine Peptides: Bioactivities and Applications. Tuck KL, ed. Marine Drugs. 
2015;13(7):4006-4043. 
Cheung RCF, Ng TB, Wong JH. Marine Peptides: Bioactivities and Applications. Mar Drugs. 2015 Jul; 13(7): 4006–
4043. 
Chiu CJ, Wray LA, Beverly EA. Relationship of glucose regulation to changes in weight: a systematic review and 
guide to future research. Diabetes Metab Res Rev. 2010 Jul;26(5):323-35 
Cian RE, Drago SR, Sánchez de Medina F, Martínez-Augustin O. Proteins and Carbohydrates from Red Seaweeds: 
Evidence for Beneficial Effects on Gut Function and Microbiota. Barrow C, ed. Marine Drugs. 2015;13(8):5358-
5383. 
 
Cian RE, López-Posadas R, Drago SR, Sánchez de Medina F, Martínez-Augustin O. A Porphyra columbina 
hydrolysate upregulates IL-10 production in rat macrophages and lymphocytes through an NF-κB, and p38 and 
JNK dependent mechanism. Food Chem. 2012 Oct 15;134(4):1982-90. 
Clark CD, Bassett B, Burge MR. Effects of kelp supplementation on thyroid function in euthyroid subjects. Endocr 
Pract. 2003 Sep-Oct;9(5):363-9. 
 
Clark MJ, Slavin JL. The effect of fiber on satiety and food intake: a systematic review. J Am Coll Nutr. 
2013;32(3):200-11. 
Clemmensen C, Smajilovic S, Smith EP,  et al. Oral L-Arginine Stimulates GLP-1 Secretion to Improve Glucose 
Tolerance in Male Mice. Endocrinology, Volume 154, Issue 11, 1 November 2013, Pages 3978–3983 
Clin Pharmacokinet. 1981 Jan-Feb;6(1):1-24. Clinical implications of enzyme induction and enzyme inhibition. 
Park BK, Breckenridge AM. 





Colt E, Kälvesten J, Cook K, Khramov N, Javed F. The effect of fat on the measurement of bone mineral density 
by digital X-ray radiogrammetry (DXR-BMD). International journal of body composition research. 2010;8(2):41-
44. 
 
Conlon JM, Mechkarska M. Host-Defense Peptides with Therapeutic Potential from Skin Secretions of Frogs from 
the Family Pipidae. Pharmaceuticals (Basel). 2014 Jan; 7(1): 58–77. 
Conlon JM. Purification of naturally occurring peptides by reversed-phase HPLC. Nat Protoc. 2007;2(1):191-7. 
Cornier MA, Donahoo WT, Pereira R, et al. Insulin sensitivity determines the effectiveness of dietary 
macronutrient composition on weight loss in obese women. Obes Res. 2005 Apr;13(4):703-9. 
 
Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. 
Endocrinology. 2012 Mar;153(3):1039-48. 
 
Cudennec B, Caradec T, Catiau L, Ravallec R. Upgrading of sea by-products: potential nutraceutical applications. 
Adv Food Nutr Res. 2012;65:479-94. 
Cudennec CJ, Domenger D, Belguesmia Y, Flahaut C, Kouach M, Lesage J, Goossens JF, Dhulster P, Ravallec 
R.Simulated GI digestion of dietary protein: Release of new bioactive peptides involved in gut hormone 
secretion. Food Res Int. 2016 Nov;89(Pt 1):382-390. 
Cudennec, B., Fouchereau-Peron, M., Ferry, F., Duclos, E. and Ravallec, R., 2012. In vitro and in vivo evidence for 
a satiating effect of fish protein hydrolysate obtained from blue whiting (Micromesistius poutassou) 
muscle. Journal of functional foods, 4(1), pp.271-277. 
Curtis E, Harvey N, D’Angelo S, et al. Bone mineral content and areal density, but not bone area, predict incident 
fracture risk: a comparative study in a UK prospective cohort. Archives of osteoporosis. 2016;11(1):39. 
doi:10.1007/s11657-016-0293-0. 
 
Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Investigation of the effect of oral metformin on 
dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med. 2009 Jun;26(6):649-54. 
Da Costa JP, Cova M, Ferreira R, Vitorino R. Antimicrobial peptides: an alternative for innovative medicines? Appl 
Microbiol Biotechnol. 2015 Mar;99(5):2023-40. 
Daliri EB-M, Oh DH, Lee BH. Bioactive Peptides. Hayes M, ed. Foods. 2017;6(5):32. doi:10.3390/foods6050032. 
Daly JM, Reynolds J, Sigal RK, Shou J, Liberman MD. Effect of dietary protein and amino acids on immune 





Daniel H. Molecular and integrative physiology of intestinal peptide transport. Annu Rev Physiol. 2004;66:361-
84. 
de Graaf C, Blom WA, Smeets PA, Stafleu A, Hendriks HF. Biomarkers of satiation and satiety. Am J Clin Nutr. 
2004 Jun;79(6):946-61. 
de Graaf, C., Hulshof, T., Weststrate, J.A. and Jas, P., 1992. Short-term effects of different amounts of protein, 
fats, and carbohydrates on satiety. The American journal of clinical nutrition, 55(1), pp.33-38. 
De Leo F, Panarese S, Gallerani R, Ceci LR. Angiotensin converting enzyme (ACE) inhibitory peptides: production 
and implementation of functional food. Curr Pharm Des. 2009;15(31):3622-43. 
Deacon CF. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes. Peptides. 
2018 Feb;100:150-157. doi: 10.1016/j.peptides.2017.10.011. 
Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, et al. Single Dose Streptozotocin Induced Diabetes: 
Considerations for Study Design in Islet Transplantation Models. Lab Anim. 2011 Jul; 45(3): 131–140. 
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic 
control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 
May;28(5):1092-100. 
Del Mar Bibiloni M, Tur JA, Morandi A, Tommasi M, Tomasselli F, Maffeis C. Protein Intake as a Risk Factor of 
Overweight/Obesity in 8– to 12–Year-Old Children. Medicine. 2015 Dec; 94(52): e2408. 
Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res. 2004 Nov-
Dec;36(11-12):775-81. 
Deutz N, Wolfe RR. Is there a maximal anabolic response to protein intake with a meal? Clin Nutr. 2013 Apr; 
32(2): 309–313. 
Diana Röhrborn, Nina Wronkowitz, and Juergen Eckel. DPP4 in Diabetes. Front Immunol. 2015; 6: 386. 
Dicker D. DPP-4 Inhibitors, Impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011 May; 
34(Supplement 2): S276-S278. 
DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia 





Dong JY, Zhang ZL, Wang PY, Qin LQ. Effects of high-protein diets on body weight, glycaemic control, blood lipids 
and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. Br J Nutr. 2013 Sep 
14;110(5):781-9. 
Dong JY, Zhang ZL, Wang PY, Qin LQ. Effects of high-protein diets on body weight, glycaemic control, blood lipids 
and blood pressure in type 2 diabetes: meta-analysis of randomised controlled trials. Br J Nutr. 2013 Sep 
14;110(5):781-9. 
 
Du K, Markus E, Fecych M, Rhodes JS, Beverly JL. Satiety and memory enhancing effects of a high-protein meal 
depend on the source of protein. Nutr Neurosci. 2018 May;21(4):257-267. 
Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR. Effects of antidiabetic drugs on 
dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of 
glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. Epub 2007 May 13. 
Egerton, S., Culloty, S., Whooley, J., Stanton, C., Ross, R.P. and Handling editor: Emory Anderson, 2017. Boarfish 
(Capros aper): review of a new capture fishery and its valorization potential. ICES Journal of Marine 
Science, 74(8), pp.2059-2068. 
Eleazu CO, Eleazu KC, Chukwuma S, and Essien UN. Review of the mechanism of cell death resulting from 
streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes 
Metab Disord. 2013; 12: 60. 
 
Ennaas N, Hammami R, Gomaa A, Bédard F, Biron É, Subirade M, Beaulieu L, Fliss I. Collagencin, an antibacterial 
peptide from fish collagen: Activity, structure and interaction dynamics with membrane. Biochem Biophys Res 
Commun. 2016 Apr 29;473(2):642-7. 
Erdman JW Jr. AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare 
professionals from the Nutrition Committee of the AHA. Circulation. 2000 Nov 14; 102(20):2555-9. 
European Union, 2017 https://ec.europa.eu/fisheries/cfp/fishing_rules/tacs_en accessed on 18/05/2018 
Evans JL, Balkan B, Chuang E, et al. Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes. 
[Updated 2016 Jul 20]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South 
Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279141/ 
Ezcurra M, Reimann F, Gribble FM, Emery E. Molecular mechanisms of incretin hormone secretion. Current 





F.J.OelshlegelJr, J.R.Schroeder, M.A.Stahmann. A simple procedure for basic hydrolysis of proteins and rapid 
determination of tryptophan using a starch column. ANALYTICAL BIOCHEMISTHY 34, 331-334 (1970). 
Færch K, Johansen NB, Witte DR, Lauritzen T, Jørgensen ME, Vistisen D. Relationship between insulin resistance 
and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab. 2015 
Feb;100(2):707-16. 
 
Færch K, Vistisen D, Pacini G, et al. Insulin Resistance is accompanied by Increased Fasting Glucagon and Delayed 
Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes 2016 Aug; 
db160240. 
 
Feskens EJ, Bowles CH and Kromhout D: Inverse association between fish intake and risk of glucose intolerance 
in normoglycemic elderly men and women. Diabetes Care 14: 935-941, 1991 
Finer N. Low-calorie diets and sustained weight loss. Obes Res. 2001 Nov;9 Suppl 4:290S-294S. 
Fleurence J, Morançais M, Dumay J. 9 - Seaweed proteins. Editor(s): Rickey Y. Yada,In Woodhead Publishing 
Series in Food Science, Technology and Nutrition, Proteins in Food Processing (Second Edition), Woodhead 
Publishing, 2018, Pages 245-262, ISBN 9780081007228. 
 
Flint, A., Raben, A., Astrup, A. and Holst, J.J., 1998. Glucagon-like peptide 1 promotes satiety and suppresses 
energy intake in humans. The Journal of clinical investigation, 101(3), pp.515-520. 
Florkowski C. HbA1c as a Diagnostic Test for Diabetes Mellitus – Reviewing the Evidence. Clin Biochem Rev. 2013 
Aug; 34(2): 75–83. 
 
Foltz M, Ansems P, Schwarz J, Tasker MC, Lourbakos A, Gerhardt CC. Protein hydrolysates induce CCK release 
from enteroendocrine cells and act as partial agonists of the CCK1 receptor. J Agric Food Chem. 2008 Feb 
13;56(3):837-43. 
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015 
Jan;20(1):122-8. 
Francis S. Willard, Ana B. Bueno, 2 and Kyle W. Sloop. Small Molecule Drug Discovery at the Glucagon-Like 
Peptide-1 Receptor. Exp Diabetes Res. 2012; 2012: 709893. 
Franz MJ, Boucher JL, Evert AB. Evidence-based diabetes nutrition therapy recommendations are effective: the 





Frid, A.H., Nilsson, M., Holst, J.J. and Björck, I.M., 2005. Effect of whey on blood glucose and insulin responses 
to composite breakfast and lunch meals in type 2 diabetic subjects. The American Journal of Clinical 
Nutrition, 82(1), pp.69-75. 
Anderson. H, Woodend. D. Effect of Glycaemic Carbohydrates on Short-term Satiety and Food Intake. 2003. 
Nutrition Reviews , Vol. 61, No. 5 
Gajanan PG, Elavarasan K, Shamasundar BA. Bioactive and functional properties of protein hydrolysates from 
fish frame processing waste using plant proteases. Environ Sci Pollut Res Int. 2016 Dec;23(24):24901-24911. 
Galgani J and Ravussin E. Energy metabolism, fuel selection and body weight regulation. Int J Obes (Lond). 2008 
Dec; 32(Suppl 7): S109–S119. 
Galland-Irmouli AV, Fleurence J, Lamghari R et al. Nutritional value of proteins from edible seaweed Palmaria 
palmate (Dulse). J Nutr Biochem. 1999 Jun;10(6):353-9. 
Galland-Irmouli AV, Fleurence J, Lamghari R, Luçon M, Rouxel C, Barbaroux O, Bronowicki JP, Villaume C, Guéant 
JL. Nutritional value of proteins from edible seaweed Palmaria palmata (dulse). J Nutr Biochem. 1999 
Jun;10(6):353-9. 
Gannon, M.C., Nuttall, F.Q., Saeed, A., Jordan, K. and Hoover, H., 2003. An increase in dietary protein improves 
the blood glucose response in persons with type 2 diabetes. The American journal of clinical nutrition, 78(4), 
pp.734-741. 
García-Moreno PJ, Pérez-Gálvez R, Espejo-Carpio FJ, Ruiz-Quesada C, Pérez-Morilla AI, Martínez-Agustín O, 
Guadix A, Guadix EM. Functional, bioactive and antigenicity properties of blue whiting protein hydrolysates: 
effect of enzymatic treatment and degree of hydrolysis. J Sci Food Agric. 2017 Jan;97(1):299-308. 
Gardner ML, Illingworth KM, Kelleher J, Wood D. Intestinal absorption of the intact peptide carnosine in man, 
and comparison with intestinal permeability to lactulose. J Physiol. 1991 Aug;439:411-22. 
Gault VA, Kerr BD, Harriott P, Flatt PR. Administration of an acylated GLP-1 and GIP preparation provides added 
beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and 
obesity. Clin Sci (Lond). 2011 Aug;121(3):107-17. 
Geiser M. (2003) The wonders of whey protein. NSCA’s Performance Training Journal 2, 13-15 
Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med. 1981 Jan;70(1):105-15. 
Gibson AA., Sainsbury A. Strategies to Improve Adherence to Dietary Weight Loss Interventions in Research and 





Giri A, Ohshima T. Bioactive marine peptides: nutraceutical value and novel approaches. Adv Food Nutr Res. 
2012;65:73-105. 
Godinho, Pires C, Pedro S, Teixeira B, Mendes R, Nunes ML, Batista I. . Antioxidant Properties of Fish Protein 
Hydrolysates Prepared from Cod Protein Hydrolysate by Bacillus sp. Appl Biochem Biotechnol. 2016 
Mar;178(6):1095-112. 
Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and Incidence of Endocrine and 
Metabolic Disorders in the United States: A Comprehensive Review. The Journal of Clinical Endocrinology and 
Metabolism. 2009;94(6):1853-1878. doi:10.1210/jc.2008-2291. 
 
Goldfine A, Patti ME. Diabetes Improvement Following Roux-en-Y Gastric Bypass: Understanding Dynamic 
Changes in Insulin Secretion and Action. Diabetes 2014 May; 63(5): 1454-1456. 
Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very 
long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and 
laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017 Nov;31(11):4331-4345. 
Gonca Pasin and Kevin B Comerford. Dairy Foods and Dairy Proteins in the Management of Type 2 Diabetes: A 
Systematic Review of the Clinical Evidence. Adv Nutr. 2015 May; 6(3): 245–259. 
Graf, S., Egert, S. and Heer, M., 2011. Effects of whey protein supplements on metabolism: evidence from human 
intervention studies. Current Opinion in Clinical Nutrition & Metabolic Care, 14(6), pp.569-580. 
Gray A. Nutritional Recommendations for Individuals with Diabetes. [Updated 2015 May 31]. In: De Groot LJ, 
Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 
Available from: https://www.ncbi.nlm.nih.gov/books/NBK279012/ 
Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by 
metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006 Oct 10;547(1-
3):192-9. Epub 2006 Jul 27. 
Griffioen-Roose S, Mars M, Siebelink E, Finlayson G, Tomé D, de Graaf C. Protein status elicits compensatory 
changes in food intake and food preferences. Am J Clin Nutr. 2012 Jan;95(1):32-8. 
Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-
like peptide 1. Pflugers Arch. 1998 Apr;435(5):583-94. 






Grosso C, Valentão P, Ferreres F, Andrade PB. Alternative and Efficient Extraction Methods for Marine-Derived 
Compounds. Mar Drugs. 2015 May; 13(5): 3182–3230. 
Grosso C, Valentão P, Ferreres F, Andrade PB. Bioactive marine drugs and marine biomaterials for brain diseases. 
Mar Drugs. 2014 May 2;12(5):2539-89. 
Guillausseau, P.J., 2003. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. 
A survey in general practice. Diabetes & metabolism, 29(1), pp.79-81. 
Gundry RL, White MY, Murray MI, Kane LA, Fu Q, Brian A. Stanley, and Jennifer E. Van Eyk. Preparation of 
Proteins and Peptides for Mass Spectrometry Analysis in a Bottom-Up Proteomics Workflow. Curr Protoc Mol 
Biol. 2009 Oct; CHAPTER: Unit10.25. 
Gunnarsson, P.T., Winzell, M.S., Deacon, C.F., Larsen, M.O., Jelic, K., Carr, R.D. and Ahrén, B., 2006. Glucose-
induced incretin hormone release and inactivation are differently modulated by oral fat and protein in 
mice. Endocrinology, 147(7), pp.3173-3180. 
Gupta D, Krueger CB, Lastra G. Over-nutrition, obesity and insulin resistance in the development of β-cell 
dysfunction. Curr Diabetes Rev. 2012 Mar;8(2):76-83. 
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GP. Peptide toxicity prediction. Methods Mol 
Biol. 2015;1268:143-57. 
Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab. 2013 May-Jun; 17(3): 413–
421. 
Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab. 2013 May-Jun; 17(3): 413–
421. 
H. P. J. Bennett, D. F. Elliott, B. E. Evans, P. J. Lowry, and C. McMartin. Complete amino acid analysis of peptides 
and proteins after hydrolysis by a mixture of Sepharose-bound peptidases. Biochem J. 1972 Sep; 129(3): 695–
701. 
Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today. 2003 Jun 
15;8(12):536-44. 
Hall C, Dawson TP, J. I. Macdiarmid, R.B. Matthews & P. Smith. The impact of population growth and climate 
change on food security in Africa: looking ahead to 2050. International Journal of Agricultural Sustainability. 






Hamed, I, Özogul, F, Özogul, Y. and Regenstein, J.M., 2015. Marine bioactive compounds and their health 
benefits: a review. Comprehensive reviews in food science and food safety, 14(4), pp.446-465. 
Hans Neurath. Proteolytic enzymes, past and future. Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10962–10963, 
September 1999 
Hao Z, Münzberg H, Rezai-Zadeh K, et al. Leptin deficient ob/ob mice and diet-induced obese mice responded 
differently to Roux-en-Y bypass surgery. International journal of obesity (2005). 2015;39(5):798-805. 
Harnedy PA,  FitzGerald RJ. Bioactive peptides from marine processing waste and shellfish: A review. Journal of 
Functional Foods. Volume 4, Issue 1. 2012, Pages 6-24, ISSN 1756-4646, 
Harnedy PA, FitzGerald RJ. BIOACTIVE PROTEINS, PEPTIDES, AND AMINO ACIDS FROM MACROALGAE. J Phycol. 
2011 Apr;47(2):218-32. 
Harnedy PA, FitzGerald RJ. Cardioprotective peptides from marine sources. Curr Protein Pept Sci. 2013 
May;14(3):162-72. 
Harnedy PA, O'Keeffe MB, FitzGerald RJ. Purification and identification of dipeptidyl peptidase (DPP) IV inhibitory 
peptides from the macroalga Palmaria palmata. Food Chem. 2015 Apr 1;172:400-6. 
Harnedy PA, Parthsarathy V, M. McLaughlin CM, O'Keeffe MB,  Allsopp PJ, McSorley EM, O'Harte FPM, FitzGerald 
RJ. Atlantic salmon (Salmo salar) co-product-derived protein hydrolysates: A source of antidiabetic peptides. 
Food Research International. Volume 106, 2018, Pages 598-606. 
Harnedy PA, Parthsarathy V, M. McLaughlin CM, O'Keeffe MB,  Allsopp PJ, McSorley EM, O'Harte FPM, FitzGerald 
RJ. Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic 
properties. Journal of Functional Foods Volume 40, January 2018, Pages 137-145 
Harnedy PA, Soler-Vila A, Edwards MD, FitzGerald RJ. The effect of time and origin of harvest on the in vitro 
biological activity of Palmaria palmata protein hydrolysates. Food Research International 62 (2014) 746–752 
Harnedy, P.A., Parthsarathy, V., McLaughlin, C.M., O'Keeffe, M.B., Allsopp, P.J., McSorley, E.M., O'Harte, F.P. and 
FitzGerald, R.J., 2018. Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in 
vivo antidiabetic properties. Journal of Functional Foods, 40, pp.137-145. 
Hasler CM. Functional foods: benefits, concerns and challenges-a position paper from the American council on 
science and health.J Nutr. 2002 Dec;132(12):3772-81 





Hayes M, Tiwari BK. Bioactive Carbohydrates and Peptides in Foods: An Overview of Sources, Downstream 
Processing Steps and Associated Bioactivities. Int J Mol Sci. 2015 Sep; 16(9): 22485–22508. 
Hayes, M., Mora, L., Hussey, K. and Aluko, R.E., 2016. Boarfish protein recovery using the pH-shift process and 
generation of protein hydrolysates with ACE-I and antihypertensive bioactivities in spontaneously hypertensive 
rats. Innovative Food Science & Emerging Technologies, 37, pp.253-260. 
He HL, Chen XL, Wu H, Sun CY, Zhang YZ, Zhou BC. High throughput and rapid screening of marine protein 
hydrolysates enriched in peptides with angiotensin-I-converting enzyme inhibitory activity by capillary 
electrophoresis. Bioresour Technol. 2007 Dec;98(18):3499-505. 
Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011 
Jul;54(7):1720-5. 
Herbst R, Marciano-Cabral F, Leippe M. Antimicrobial and pore-formi ng peptides of free-living and potentially 
highly pathogenic Naegleria fowleri are released from the same precursor molecule. J Biol Chem. 2004 Jun 
18;279(25):25955-8. 
Hermansen K. Diet, blood pressure and hypertension. Br J Nutr. 2000 Mar;83 Suppl 1:S113-9. 
Hidaka S, Yoshimatsu H, Kondou S et al. Hypoleptinemia, but not hypoinsulinemia, induces hyperphagia in 
streptozotocin-induced diabetic rats. J Neurochem. 2001 May;77(4):993-1000. 
 
Hisham R. Ibrahim,a, Ahmed S. Ahmed,b and Takeshi Miyataa. Novel angiotensin-converting enzyme inhibitory 
peptides from caseins and whey proteins of goat milk. J Adv Res. 2017 Jan; 8(1): 63–71. 
Hoffman JR and Falvo MJ - Protein – Which is Best?. J Sports Sci Med. 2004 Sep; 3(3): 118–130. Published online 
2004 Sep 1. 
Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 
2009 Jan 15;297(1-2):127-36. 
Holst JJ, Wewer Albrechtsen NJ, Pedersen J & Knop P. Glucagon and Amino Acids Are Linked in a Mutual 
Feedback Cycle: The Liver–α-Cell Axis. Diabetes 2017 Feb; 66(2): 235-240. 
 
Hong P, Koza S, Bouvier ESP. Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their 





Hsieh CH, Wang TY, Hung CC, Chen MC, Hsu KC. Improvement of glycemic control in streptozotocin-induced 
diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor. Food Funct. 
2015 Jun;6(6):1887-92. 
Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 
diabetes mellitus in women. N Engl J Med. 2001 Sep 13;345(11):790-7. 
Huang S, Lin H, Deng SG. Study of Anti-Fatigue Effect in Rats of Ferrous Chelates Including Hairtail Protein 
Hydrolysates. Nutrients. 2015 Dec 1;7(12):9860-71.  
Huang SL, Jao CL, Ho KP, Hsu KC. Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking 
juice hydrolysates. Peptides. 2012 May;35(1):114-21. 
I M.E.Lacroix,E C.Y.Li-Chan. Food-derived dipeptidyl-peptidase IV inhibitors as a potential approach for glycemic 
regulation – Current knowledge and future research considerations. Trends in Food Science & Technology. 
Volume 54, August 2016, Pages 1-16 
Ialenti A, Santagada V, Caliendo G, Severino B, Fiorino F, Maffia P, Ianaro A, Morelli F, Di Micco B, Cartenì M, 
Stiuso P, Metafora V, Metafora S.Synthesis of novel anti-inflammatory peptides derived from the amino-acid 
sequence of the bioactive protein SV-IV. Eur J Biochem. 2001 Jun;268(12):3399-406. 
Ishak, N. & Sarbon, N. A Review of Protein Hydrolysates and Bioactive Peptides Deriving from Wastes Generated 
by Fish Processing. Food Bioprocess Technol (2018) 11: 2. https://doi.org/10.1007/s11947-017-1940-1 
Iwaniak A,  Minkiewicz P,  Darewicz M. Food‐Originating ACE Inhibitors, Including Antihypertensive Peptides, as 
Preventive Food Components in Blood Pressure Reduction. February 2014. Comprehensive Reviews in Food 
Science and Food Safety 13(2):114-134 
J Wiles, R Woodward, and S R Bird. Effect of pre-exercise protein ingestion upon VO2, R and perceived exertion 
during treadmill running. Br J Sports Med. 1991 Mar; 25(1): 26–30. 
J. C. Henquin, J. Rahier. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011 
Jul; 54(7): 1720–1725. 
Jakubowicz D, Froy O, Ahrén B, Boaz M, Landau Z, Bar-Dayan Y, Ganz T, Barnea M, Wainstein J. Incretin, 
insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical 
trial. Diabetologia. 2014 Sep;57(9):1807-11. 
Jakubowicz j, Froy o, Ahrén b, Boaz M, et al. Incretin, insulinotropic and glucose-lowering effects of whey protein 





Jao CL, Hung CC, Tung YS, Lin PY et al. The development of bioactive peptides from dietary proteins as a 
dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes. Biomedicine (Taipei). 2015 Sep; 5(3): 
14. 
Jeewanthi RKC, Kim MH, Na-Kyoung Lee, Yoh Chang Yoon, and Hyun-Dong Paik. Peptide Analysis and the 
Bioactivity of Whey Protein Hydrolysates from Cheese Whey with Several Enzymes. Korean J Food Sci Anim 
Resour. 2017; 37(1): 62–70. 
Jeyabalan J, Viollet B, Smitham P, Ellis SA, Zaman G, Bardin C, Goodship A, Roux JP, Pierre M, Chenu C. The anti-
diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int. 2013 
Oct;24(10):2659-70. 
Johnstone, A.M., Stubbs, R.J. and Harbron, C.G., 1996. Effect of overfeeding macronutrients on day-to-day food 
intake in man. European journal of clinical nutrition, 50(7), pp.418-430. 
Joshi S, Tough IR, Cox HM. Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa. Br J 
Pharmacol. 2013 Nov;170(5). 
K. Suresh Kumar, K. Ganesan, P. V. Subba Rao. Seasonal variation in nutritional composition of Kappaphycus 
alvarezii (Doty) Doty—an edible seaweed. J Food Sci Technol. 2015 May; 52(5): 2751–2760. 
Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994. 
Aug;43(8):1066-1084. 
Kamper AL, Strandgaard S. Long-Term Effects of High-Protein Diets on Renal Function. Annu Rev Nutr. 2017 Aug 
21;37:347-369. 
Kang KH, Qian ZJ, Ryu B, Karadeniz F, Kim D, Kim SK. Antioxidant peptides from protein hydrolysate of microalgae 
Navicula incerta and their protective effects in HepG2/CYP2E1 cells induced by ethanol. Phytother Res. 2012 
Oct;26(10):1555-63. 
Kapoor S, Rafiq A, Sharma S. Protein engineering and its applications in food industry. Crit Rev Food Sci Nutr. 
2017 Jul 24;57(11):2321-2329 
Karamanlis A, Chaikomin R, Doran S, Bellon M, Bartholomeusz FD, Wishart JM, Jones KL, Horowitz M, Rayner CK. 
Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. 
Am J Clin Nutr. 2007 Nov;86(5):1364-8. 
Katharina Simon, Georg A. Hollander, Andrew McMichael. Evolution of the immune system in humans from 





Key TJ, Appleby PN, Rosell MS. Health effects of vegetarian and vegan diets. Proc Nutr Soc. 2006 Feb;65(1):35-
41. 
Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. 
Public Health Nutrition: 2004 7(1A), 187–200 
Khairy HM, El-Shafay SM. Seasonal variations in the biochemical composition of some common seaweed species 
from the coast of Abu Qir Bay, Alexandria, Egypt. Oceanologia Volume 55, Issue 2, 20 May 2013, Pages 435-452. 
Khan A, Narangoda S, Ahren B, Holm C, Sundler F & Efendic S. Long-term leptin treatment of ob/ob mice 
improves glucose-induced insulin secretion. International Journal of Obesity volume 25, pages 816–821 (2001) 
Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World Journal of Diabetes. 
2015;6(6):850-867. doi:10.4239/wjd.v6.i6.850. 
Khosravi S, Rahimnejad S, Herault M, Fournier V, Lee CR, Dio Bui HT, Jeong JB, Lee KJ. Effects of protein 
hydrolysates supplementation in low fish meal diets on growth performance, innate immunity and disease 
resistance of red sea bream Pagrus major. Fish Shellfish Immunol. 2015 Aug;45(2):858-68. 
Kim DD, Basu A. Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-
Analysis, nd Empirical Analysis. Value in Health, Volume 19, Issue 5, 2016, Pages 602-613. 
Kim W,  Egan JM. The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. Pharmacol Rev. 2008 
Dec; 60(4): 470–512. 
Kim YS, Ahn CB, Je JY. Anti-inflammatory action of high molecular weight Mytilus edulis hydrolysates fraction in 
LPS-induced RAW264.7 macrophage via NF-κB and MAPK pathways. Food Chem. 2016 Jul 1;202:9-14. 
Kim YT, Kim SK, Jeon YJ, Park SJ. Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma 
cells by competing with intracellular α-enolase for plasminogen binding and inhibiting uPA-mediated activation 
of plasminogen. BMB Rep. 2014 Dec;47(12):691-6. 
Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in 
isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23. 
Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight 
in humans: a review. Obes Rev. 2007 Jan;8(1):21-34. 
Krajcovicova-Kudlackova M, Babinska K, Valachovicova M. Health benefits and risks of plant proteins. Bratisl Lek 
Listy. 2005;106(6-7):231-4. 
Kristinsson, H.G. and Rasco, B.A., 2000. Fish protein hydrolysates: production, biochemical, and functional 





Kuong K, Laillou A, Chea C, et al. Stability of Vitamin A, Iron and Zinc in Fortified Rice during Storage and Its 
Impact on Future National Standards and Programs—Case Study in Cambodia. Nutrients. 2016 Jan; 8(1): 51. 
Kushner RF, Doerfler B. Low-carbohydrate, high-protein diets revisited. Curr Opin Gastroenterol. 2008 
Mar;24(2):198-203. 
Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid?. Nutr Rev. 1990 Aug;48(8):297-309. 
Lassoued I, Mora L, Barkia A, Aristoy MC, Nasri M, Toldrá F. Bioactive peptides identified in thornback ray skin's 
gelatin hydrolysates by proteases from Bacillus subtilis and Bacillus amyloliquefaciens. J Proteomics. 2015 Oct 
14;128:8-17. 
Lauritano C & Ianora A. Marine Organisms with Anti-Diabetes Properties. Mar Drugs. 2016 Dec; 14(12): 220. 
Lavigne, C., Marette, A. and Jacques, H., 2000. Cod and soy proteins compared with casein improve glucose 
tolerance and insulin sensitivity in rats. American Journal of Physiology-Endocrinology And Metabolism, 278(3), 
pp.E491-E500. 
Le Manach F, Chaboud C, Copeland D, et al. European Union’s Public Fishing Access Agreements in Developing 
Countries. Hyrenbach D, ed. PLoS ONE. 2013;8(11):e79899. doi:10.1371/journal.pone.0079899. 
 
Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with 
type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47-53. 
Lee JK, Jeon JK, Kim SK, Byun HG. Characterization of bioactive peptides obtained from marine invertebrates. 
Adv Food Nutr Res. 2012;65:47-72. 
Lefranca F, Tabancab N, Kiss R. Assessing the anticancer effects associated with food products and/or 
nutraceuticals using in vitro and in vivo preclinical development-related pharmacological tests. Seminars in 
Cancer Biology, Volume 46, October 2017, Pages 14-32 
Leidy HJ, Mattes RD, Campbell WW. Effects of acute and chronic protein intake on metabolism, appetite, and 
ghrelin during weight loss. Obesity. 2007 May;15(5):1215-25. 
Leidy HJ, Racki EM. The addition of a protein-rich breakfast and its effects on acute appetite control and food 
intake in 'breakfast-skipping' adolescents. Int J Obes (Lond). 2010 Jul;34(7):1125-33. 
Lejeune, M.P, Westerterp, K.R, Adam, T.C., Luscombe-Marsh, N.D. and Westerterp-Plantenga, M.S., 2006. 





a high-protein diet and measured in a respiration chamber–. The American journal of clinical nutrition, 83(1), 
pp.89-94. 
Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in 
Adulthood. Dtsch Arztebl Int. 2009 Oct; 106(40): 641–648. 
Lepe M, Bacardí Gascón M, Jiménez Cruz A. Long-term efficacy of high-protein diets: a systematic review. Nutr 
Hosp. 2011 Nov-Dec;26(6):1256-9. 
Li M, Maddison LA, Page-McCaw P, Chen W. Overnutrition induces β-cell differentiation through prolonged 
activation of β-cells in zebrafish larvae. Am J Physiol Endocrinol Metab. 2014 Apr 1; 306(7): E799–E807. 
Li XR, Chi CF, Li L, Wang B. Purification and Identification of Antioxidant Peptides from Protein Hydrolysate of 
Scalloped Hammerhead (Sphyrna lewini) Cartilage. Mar Drugs. 2017 Mar 1;15(3). 
Li Y, Jiang H, Huang G. Protein Hydrolysates as Promoters of Non-Haem Iron Absorption. Nutrients. 2017 Jun 
15;9(6). 
Lin J, Cai X, Tang M, Wang S. Preparation and Evaluation of the Chelating Nanocomposite Fabricated with Marine 
Algae Schizochytrium sp. Protein Hydrolysate and Calcium. J Agric Food Chem. 2015 Nov 11;63(44):9704-14. 
Lindgren O, Pacini G, Tura A, Holst JJ, Deacon CF, Ahrén B. Incretin effect after oral amino acid ingestion in 
humans. J Clin Endocrinol Metab. 2015 Mar;100(3):1172-6. 
Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM. Inhibition of dipeptidyl peptidase IV 
activity by oral metformin in Type 2 diabetes. Diabet Med. 2005 May;22(5):654-7. 
Line Q. Bendtsen, Janne K. Lorenzen, Nathalie T. Bendsen, Charlotte Rasmussen, and Arne Astrup. Effect of Dairy 
Proteins on Appetite, Energy Expenditure, Body Weight, and Composition: a Review of the Evidence from 
Controlled Clinical Trials. Adv Nutr. 2013 Jul; 4(4): 418–438. 
Lobo L, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. 
Pharmacogn Rev. 2010 Jul-Dec; 4(8): 118–126. 
López-Villar E, Martos-Moreno GÁ, Chowen JA, Okada S, Kopchick JJ, Argente J.  A proteomic approach to obesity 
and type 2 diabetes. J Cell Mol Med. 2015 Jul;19(7):1455-70. 
Lordan S, Ross RP, Stanton. C Marine Bioactives as Functional Food Ingredients: Potential to Reduce the 





Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Oral Hypoglycemic Drugs: Pathophysiological Basis of 
Their Mechanism of Action. Pharmaceuticals. 2010;3(9):3005-3020. doi:10.3390/ph3093005. 
Luber G, Prudent N. Climate Change and Human Health. Transactions of the American Clinical and Climatological 
Association. 2009;120:113-117. 
 
Luc J.C. van Loon, Margriet Kruijshoop, Paul P.C.A. Menheere, Anton J.M. Wagenmakers, Wim H.M. Saris, and 
Hans A. Keizer. Amino Acid Ingestion Strongly Enhances Insulin Secretion in Patients With Long-Term Type 2 
Diabetes 
Luc Van Gaal, André Scheen. Weight Management in Type 2 Diabetes: Current and Emerging Approaches to 
Treatment. Diabetes Care 2015 Jun; 38(6): 1161-1172. 
Luca Montesi, Marwan El Ghoch, Lucia Brodosi, Simona Calugi, Giulio Marchesini, Riccardo Dalle Grave. Long-
term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes. 2016; 9: 
37–46. 
Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake and satiety. J Am Coll Nutr 
2007;26(6):704S–12S. 
Ma J, Stevens JE, Cukier K, et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones 
after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009;32:1600–1602 
Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis 
of observational studies. European Journal of Epidemiology. 2012;27(5):319-332. 
Ma, J., Stevens, J.E., Cukier, K., Maddox, A.F., Wishart, J.M., Jones, K.L., Clifton, P.M., Horowitz, M. and Rayner, 
C.K., 2009. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate 
meal in diet-controlled type 2 diabetes. Diabetes Care, 32(9), pp.1600-1602. 
Mac Monagail M, Cornish L,  Morrison L, Araújo R, Critchley AT. Sustainable harvesting of wild seaweed 
resources. European Journal of Phycology Volume 52, 2017 - Issue 4: Applied Phycology Special Issue. 
 
Manders, R.J., Koopman, R., Sluijsmans, W.E., van den Berg, R., Verbeek, K., Saris, W.H., Wagenmakers, A.J. and 
van Loon, L.J., 2006. Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces 
postprandial blood glucose excursions in Type 2 diabetic men. The Journal of nutrition, 136(5), pp.1294-1299. 
Manders, R.J., Little, J.P., Forbes, S.C. and Candow, D.G., 2012. Insulinotropic and muscle protein synthetic 






Mannucci E, Ognibene A, Cremasco F, et al. Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin 
Levels in Obese Nondiabetic Subjects. Diabetes Care 2001 Mar; 24(3): 489-494. 
 
Marathe CS, Rayner CK, Jones KL and Horowitz M. Relationships Between Gastric Emptying, Postprandial 
Glycemia, and Incretin Hormones. Diabetes Care 2013 May; 36(5): 1396-1405. 
Marine Institute, The Stockbook: Annual Review of Fish Stocks in 2008 with Management Advice for 2009, 2008 
Galway Marine Institute pg. 422 
Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, del Cañizo-Gómez JL. Update on the treatment of type 
2 diabetes mellitus. World J Diabetes. 2016 Sep 15; 7(17): 354–395.  June 1998, Volume 3, Issue 1, pp 35–39 
Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, del Cañizo-Gómez FJ. Update on the treatment of type 
2 diabetes mellitus. World Journal of Diabetes. 2016;7(17):354-395. doi:10.4239/wjd.v7.i17.354. 
 
Marlow HJ, Hayes WK, Soret S, Carter RL, Schwab ER, Sabaté J. Diet and the environment: does what you eat 
matter? Am J Clin Nutr. 2009 May;89(5):1699S-1703S. 
 
Marmonier, C., Chapelot, D. and Louis-Sylvestre, J., 2000. Effects of macronutrient content and energy density 
of snacks consumed in a satiety state on the onset of the next meal. Appetite, 34(2), pp.161-168. 
Marsha J. Daniel. Lipid Management in Patients with Type 2 Diabetes. Am Health Drug Benefits. 2011 Sep; 4(5): 
312–322. 
Marshall S. 60 years of metformin use: a glance at the past and a look to the future. Diabetologia 
Martin WF, Armstrong LE, Rodriguez NR. Dietary protein intake and renal function. Nutr Metab (Lond). 2005; 2: 
25. 
Martínez-Maqueda D , Hernández-Ledesma B, Amigo L, et al. Extraction/Fractionation Techniques for Proteins 
and Peptides and Protein Digestion. Food Microbiology and Food Safety 2, 2013 
Martins A,  Vieira H, Gaspar H, Santos S. Marketed Marine Natural Products in the Pharmaceutical and 
Cosmeceutical Industries: Tips for Success. Mar Drugs. 2014 Feb; 12(2): 1066–1101. 
Matsumoto K, Miyake S, Yano M, et al. Glucose Tolerance, Insulin Secretion, and Insulin Sensitivity in Nonobese 
and Obese Japanese Subjects. Diabetes Care 1997 Oct; 20(10): 1562-1568. 
 





Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. 
Curr Med Chem. 2009;16(23):2943-51. 
McBrayer DN, Tal-Gan Y. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus. Drug Dev 
Res. 2017 Sep;78(6):292-299. 
McCarty MF. Nutraceutical resources for diabetes prevention--an update. Med Hypotheses. 2005;64(1):151-8. 
McEvoy RC, Andersson J, Sandler S, and Hellerström H. Multiple low-dose streptozotocin-induced diabetes in 
the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta 
cell line. J Clin Invest. 1984 Sep; 74(3): 715–722. 
 
McGregor RA, Poppitt SD. Milk protein for improved metabolic health: a review of the evidence. Nutr Metab 
(Lond). 2013; 10: 46. 
Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: 
mechanism and glucose dependence. Diabetes, Obesity & Metabolism. 2013;15(1):15-27. 
Milner JA. Functional foods and health promotion. J Nutr. 1999 Jul;129(7 Suppl):1395S-7S. 
Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients 
with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Therapeutics and 
Clinical Risk Management. 2017;13:455-468. 
 
Moghaddam E, Vogt JA, Wolever TMS. The Effects of Fat and Protein on Glycemic Responses in Nondiabetic 
Humans Vary with Waist  circumference, Fasting Plasma Insulin, and Dietary Fiber Intake. J. Nutr. October 2006 
136: 2506-2511 
Moneret-Vautrin DA, Hatahet R, Kanny G. Protein hydrolysates: hypoallergenic milks and extensively hydrolyzed 
formulas. Immuno-allergic basis for their use in prevention and treatment of milk allergy. Arch Pediatr. 2001 
Dec;8(12):1348-57. 
Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016 
Jun;125:259-66. 
 
Mortensen, L.S, Hartvigsen, M.L, Brader, L.J, Astrup, A, Schrezenmeir, J, Holst, J.J., Thomsen, C, Hermansen, K. 
2009. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 






Mótyán JA, Tóth F, Tőzsér J. Research Applications of Proteolytic Enzymes in Molecular Biology. Biomolecules. 
2013 Dec; 3(4): 923–942. 
Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in Diet and Lifestyle and Long-Term Weight Gain in 
Women and Men. N Engl J Med. 2011 Jun 23; 364(25): 2392–2404. 
Mu J, Qureshi SA, Brady EJ, Muise ES et al. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, 
a novel small-molecule glucagon receptor antagonist. PLoS One. 2012;7(11):e49572. 
 
Muheem A, Shakeel F, Asadullah M et al. A review on the strategies for oral delivery of proteins and peptides 
and their clinical perspectives. Saudi Pharmaceutical Journal. Volume 24, Issue 4 2016, Pages 413-428, 
Musaiger AO, Al-Hazzaa HM. Prevalence and risk factors associated with nutrition-related noncommunicable 
diseases in the Eastern Mediterranean region. International Journal of General Medicine. 2012;5:199-217. 
doi:10.2147/IJGM.S29663. 
 
Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by 
leptin gene therapy. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14804-8. 
N D Rawlings and A J Barrett. Evolutionary families of peptidases. Biochem J. 1993 Feb 15; 290(Pt 1): 205–218. 
Na Sun, Haitao Wu, Ming Du, Yue Tang, Hongwei Liu, Yinghuan Fu, Beiwei Zhu. Food protein-derived calcium 
chelating peptides: A review. Trends in Food Science & Technology. Volume 58, 2016, Pages 140-148. 
 
Naqvi S, Naveed S, Ali Z, et al. Correlation between Glycated Hemoglobin and Triglyceride Level in Type 2 
Diabetes Mellitus. Muacevic A, Adler JR, eds. Cureus. 2017;9(6):e1347. doi:10.7759/cureus.1347. 
Nasri H, Baradaran H, Shirzad H, Rafieian-Kopaei M. New Concepts in Nutraceuticals as Alternative for 
Pharmaceuticals. Int J Prev Med. 2014 Dec; 5(12): 1487–1499. 
Nasri M. Chapter Four - Protein Hydrolysates and Biopeptides: Production, Biological Activities, and Applications 
in Foods and Health Benefits. A Review. Advances in Food and Nutrition Research Volume 81, 2017, Pages 109-
159 
Nekhai S, Bottaro DP, Woldehawariat G, Spellerberg A, Petryshyn R. A cell-permeable peptide inhibits activation 
of PKR and enhances cell proliferation. Peptides. 2000 Oct;21(10):1449-56. 
Neves AC, Harnedy PA, O'Keeffe MB, Alashi MA, Aluko RE, FitzGerald RJ. Peptide identification in a salmon gelatin 
hydrolysate with antihypertensive, dipeptidyl peptidase IV inhibitory and antioxidant activities. Food Res Int. 





Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in 
children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 
2014 Aug 30;384(9945):766-81. 
Ngo DH, Ryu B, Kim SK. Active peptides from skate (Okamejei kenojei) skin gelatin diminish angiotensin-I 
converting enzyme activity and intracellular free radical-mediated oxidation. Food Chem. 2014 Jan 15;143:246-
55. 
Nobile V, Duclos E, Michelotti A, Bizzaro G, Negro, Soisson F. Supplementation with a fish protein hydrolysate 
(Micromesistius poutassou): effects on body weight, body composition, and CCK/GLP-1 secretion. Food Nutr 
Res. 2016; 60: 10.3402/fnr.v60.29857. 
Nomura Y, Oohashi K, Watanabe M, Kasugai S. Increase in bone mineral density through oral 
administration of shark gelatin to ovariectomized rats. Nutrition. 2005 Nov-Dec;21(11-12):1120-6. 
Norziah MH, Ching CY. Nutritional composition of edible seaweed Gracilaria changgi. Food Chemistry, Volume 
68, Issue 1, January 2000, Pages 69-76. 
 
NT. Hoyle  JH. Merritt. Quality of Fish Protein Hydrolysates from Herring (Clupea harengus). Food Science 
Volume59, Issue1 January 1994 Pages 76-79 
Nuttall FQ, Mooradian AD, Gannon MC, Billington CJ, Krezowski PA: Effect of protein ingestion on the glucose 
and insulin response to a standardized oral glucose load. Diabetes Care 7:465-70, 1984. 
Oesch S, Degen L, Beglinger C. Effect of a protein preload on food intake and satiety feelings in response to 
duodenal fat perfusions in healthy male subjects. 2005, Am J Physiol Regul Integr Comp Physiol 289: R1042–
R1047 
Oh YS, Jun HS. Role of bioactive food components in diabetes prevention: effects on Beta-cell function and 
preservation. Nutr Metab Insights. 2014 Jul 6;7:51-9. 
Oseguera-Toledo ME, González de Mejía E, Reynoso-Camacho R, Cardador-Martínez A, Amaya-Llano SL. Proteins 
and bioactive peptides. Nutrafoods December 2014, Volume 13, Issue 4, pp 147–157 
Packer M, Lee WH, Yushak M, Medina N. Comparison of Captopril and Enalapril in Patients with Severe Chronic 
Heart Failure. N Engl J Med 1986; 315:847-853 
Paddon-Jones D,  Westman  E, Mattes MD et al. Protein, weight management, and satiety. The American Journal 
of Clinical Nutrition, Volume 87, Issue 5, 1 May 2008, Pages 1558S–1561S 





Pal S, Ellis V. The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. 
Br J Nutr. 2010 Oct;104(8):1241-8 
Pal, S. and Ellis, V., 2010. The acute effects of four protein meals on insulin, glucose, appetite and energy intake 
in lean men. British journal of nutrition, 104(8), pp.1241-1248. 
Pan MH, Tung YC, Yang G, Li S, Ho CT. Molecular mechanisms of the anti-obesity effect of bioactive compounds 
in tea and coffee. Food Funct. 2016 Nov 9;7(11):4481-4491. 
Pangestuti R , Kim SK. Bioactive Peptide of Marine Origin for the Prevention 
Park YM, Heden TD, Liu Y, Nyhoff LM, Thyfault JP, Leidy HJ, Kanaley JA. A high-protein breakfast induces greater 
insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with 
type 2 diabetes. J Nutr. 2015 Mar;145(3):452-8. 
Park YW, Nam MS. Bioactive Peptides in Milk and Dairy Products: A Review. Korean J Food Sci Anim Resour. 
2015; 35(6): 831–840. 
Parolini C, Vik R, Busnelli M et al. A salmon protein hydrolysate exerts lipid-independent anti-atherosclerotic 
activity in ApoE-deficient mice. PLoS One. 2014 May 19;9(5) 
Pasiakos SM, Lieberman HR, McLellan TM. Effects of protein supplements on muscle damage, soreness and 
recovery of muscle function and physical performance: a systematic review. Sports Med. 2014 May;44(5):655-
70. 
Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes. P T. 2010 
Sep; 35(9): 509–513. 
Patil P, Mandal S, Tomar SK, Anand S. Food protein-derived bioactive peptides in management of type 2 
diabetes. Eur J Nutr. 2015 Sep;54(6):863-80. 
Pauly D, Watson R, Alder J. Global trends in world fisheries: impacts on marine ecosystems and food security. 
Philos Trans R Soc Lond B Biol Sci. 2005 Jan 29; 360(1453): 5–12. 
Pauly D, Zeller D. Catch reconstructions reveal that global marine fisheries catches are higher than reported and 
declining. Nature Communications. 2016;7:10244. doi:10.1038/ncomms10244. 
 
Pesta DH, Samuel VT. A high-protein diet for reducing body fat: mechanisms and possible caveats. Nutr Metab 





Peter JM Weijs, Luc Cynober, Mark DeLegge, Georg Kreymann, Jan Wernerman, Robert R Wolfe. Proteins and 
amino acids are fundamental to optimal nutrition support in critically ill patients. Critical Care 2014, 18:591 
Petersen, B.L., Ward, L.S., Bastian, E.D., Jenkins, A.L., Campbell, J. and Vuksan, V., 2009. A whey protein 
supplement decreases post-prandial glycemia. Nutrition Journal, 8(1), p.47. 
Pham-Huy LA, He H, Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. Int J Biomed Sci. 2008 Jun; 
4(2): 89–96. 
Phillips SM, Van Loon LJ. Dietary protein for athletes: from requirements to optimum adaptation. J Sports Sci. 
2011;29 
Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014 Feb;74(2):223-
42. 
Polanco-LugoI E, Dávila-Ortiz G, Betancur-AnconaII BA, Chel-GuerreroII LA. Effects of sequential enzymatic 
hydrolysis on structural, bioactive and functional properties of Phaseolus lunatus protein isolate. Food Sci. 
Technol, Campinas, 34(3): 441-448, July-Sept. 2014 
Pollock HG, Hamilton JW, Rouse JB, Ebner KE, Rawitch AB. Isolation of Peptide Hormones from the Pancreas of 
the Bullfrog (Rana catesbeiana). THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 263, No. 20, Issue of July 15, pp. 
97469751, 19 
 
Pomerleau J  , Verdy M, Garrel DR, Nadeau M - Effect of protein intake on glycaemic control and renal function 
in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1993) 36:829-834 
Popkin BM, Kenan WR. Preventing type 2 diabetes: Changing the food industry. Best practice & research Clinical 
endocrinology & metabolism. 2016;30(3):373-383. doi:10.1016/j.beem.2016.05.001. 
 
Poppitt, S.D., McCormack, D. and Buffenstein, R., 1998. Short-term effects of macronutrient preloads on 
appetite and energy intake in lean women. Physiology & behavior, 64(3), pp.279-285. 
Post RE, Mainous AG, King DE, Simpson KN. Dietary fiber for the treatment of type 2 diabetes mellitus: a meta-
analysis. J Am Board Fam Med. 2012 Jan-Feb;25(1):16-23. 
Pouliot Y, Guy MM, Tremblay M, Gaonac'h AC, Chay Pak Ting BP, Gauthier SF, Voyer N. Isolation and 
characterization of an aggregating peptide from a tryptic hydrolysate of whey proteins. J Agric Food Chem. 2009 





Power O, Nongonierma AB, Jakeman P, FitzGerald RJ. Food protein hydrolysates as a source of dipeptidyl 
peptidase IV inhibitory peptides for the management of type 2 diabetes. Proc Nutr Soc. 2014 Feb;73(1):34-46. 
Power, O, Hallihan, A. and Jakeman, P., 2009. Human insulinotropic response to oral ingestion of native and 
hydrolysed whey protein. Amino acids, 37(2), pp.333-339. 
Power-Grant O, Nongonierma A, Jakeman P, FitzGerald RJ. Food protein hydrolysates as a source of dipeptidyl 
peptidase IV inhibitory peptides for the management of type 2 diabetes. October 2013. Proceedings of The 
Nutrition Society 73(01):1-13 
Proietti I, Frazzoli C, Mantovani A. Exploiting Nutritional Value of Staple Foods in the World’s Semi-Arid Areas: 
Risks, Benefits, Challenges and Opportunities of Sorghum. Samman S, Darnton-Hill I, eds. Healthcare. 
2015;3(2):172-193. doi:10.3390/healthcare3020172. 
 
Quinlivan EP, Gregory JF 3rd. Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr. 
2003 Jan;77(1):221-5. 
Ralph J.F. Manders, Stephan F.E. Praet, Ruth C.R. Meex, René Koopman, André L. de Roos, Anton J.M. 
Wagenmakers, Wim H.M. Saris, and Luc J.C. van Loon. Protein Hydrolysate/Leucine Co-Ingestion Reduces the 
Prevalence of Hyperglycemia in Type 2 Diabetic Patients. Diabetes Care 2006 Dec; 29(12): 2721-2722. 
Ray PD, Huang BW, and Yoshiaki Tsuji. Reactive oxygen species (ROS) homeostasis and redox regulation in 
cellular signalling. Cell Signal. 2012 May; 24(5): 981–990. 
Rebours C, Marinho-Soriano E, Zertuche-González J.A. et al. Seaweeds: an opportunity for wealth and 
sustainable livelihood for coastal communities. J Appl Phycol (2014) 26: 1939.  
 
Rebours C, Marinho-Soriano E, Zertuche-González JA, et al. Seaweeds: an opportunity for wealth and sustainable 
livelihood for coastal communities. J Appl Phycol. 2014; 26(5): 1939–1951. 
Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives. Int J 
Pharm. 2013 Jan 2;440(1):48-62. 
Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. Approaches for Enhancing Oral Bioavailability of 
Peptides and Proteins. Int J Pharm. 2013 Apr 15; 447(0): 75–93. 
Richter CK, Skulas-Ray AC, Champagne CM, and Kris-Etherton PM. Plant Protein and Animal Proteins: Do They 





Ripudaman S. Hundal, Martin Krssak, Sylvie Dufour et al. Mechanism by Which Metformin Reduces Glucose 
Production in Type 2 Diabetes. Diabetes. 2000 Dec; 49(12): 2063–2069. 
 
Rong He , Rotimi E. Aluko , Xing-Rong Ju. Evaluating Molecular Mechanism of Hypotensive Peptides Interactions 
with Renin and Angiotensin Converting Enzyme. PLoS ONE 9(3): e91051. 
Rosi A, Mena P, Pellegrini N, et al. Environmental impact of omnivorous, ovo-lacto-vegetarian, and vegan diet. 
Scientific Reports. 2017;7:6105. doi:10.1038/s41598-017-06466-8. 
 
Rui Liu, Lei Zhou, Yan Zhang, Nai-Juan Sheng, Zhi-Kang Wang, Ti-Zhi Wu, Xin-Zhi Wang, Hao Wu. Rapid 
Identification of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides from Ruditapes philippinarum Hydrolysate. 
Molecules 2017, 22, 1714. 
Rustad, T, 2003. Utilisation of marine by-products. Electronic Journal of Environmental, Agricultural and Food 
Chemistry, 2(4), pp.458-463. 
Rutherfurd SM. Methodology for determining degree of hydrolysis of proteins in Hydrolysates: a review. J AOAC 
Int. 2010 Sep-Oct;93(5):1515-22. 
Sabaté J, Sranacharoenpong K, Harwatt H, Wien M, Soret S. The Environmental Cost of Protein Food Choices--
CORRIGENDUM. Public Health Nutr. 2015 Aug;18(11):2096. 
 
Sable R, Parajuli P, Jois S. Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural 
Sources for Pharmaceutical Applications. Mar Drugs. 2017 Apr; 15(4): 124. 
Saleh L, Schrier NL Bruins MJ, Steegers EAP, van den Meiracker AH, Visser W. Effect of oral protein hydrolysate 
on glucose control in patients with gestational diabetes. Clin Nutr. 2018 Jun;37(3):878-883. 
Sampath Kumar NS, Nazeer RA, Jaiganesh R. Purification and identification of antioxidant peptides from the skin 
protein hydrolysate of two marine fishes, horse mackerel (Magalaspis cordyla) and croaker (Otolithes ruber). 
Amino Acids. 2012 May;42(5):1641-9. 
Sánchez A, Vázquez A. Bioactive peptides: A review. Food Quality and Safety, Volume 1, Issue 1, 1 March 2017, 
Pages 29–46 
Santiago-López L, Hernández-Mendoza A, Vallejo-Cordoba B, Mata-Haro V, González-Córdova AF. Food-derived 
immunomodulatory peptides. J Sci Food Agric. 2016 Aug;96(11):3631-41. 






Sarrouh B., Santos T.M., Miyoshi A., Dias R., Azevedo V. Up-to-date insight on industrial enzymes applications 
and global market. J. Bioprocess. Biotech. 2012:S4:002. 
Sato M, Oba T, Yamaguchi T, Nakano T, Kahara T, Funayama K, Kobayashi A, Nakano T. Antihypertensive effects 
of hydrolysates of wakame (Undaria pinnatifida) and their angiotensin-I-converting enzyme inhibitory activity. 
Ann Nutr Metab. 2002;46(6):259-67. 
Sayari N, Sila A, Haddar A, Balti R, Ellouz-Chaabouni S, Bougatef A. Valorisation of smooth hound (Mustelus 
mustelus) waste biomass through recovery of functional, antioxidative and antihypertensive bioactive peptides. 
Environ Sci Pollut Res Int. 2016 Jan;23(1):366-76.  
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010 
Sep;49(9):573-88. 
Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-
expressing cells. Diabetes. 1994 Nov;43(11):1326-33. 
 
Secchi G. Role of protein in cosmetics. Clin Dermatol. 2008 Jul-Aug;26(4):321-5. 
 
Senevirathne M, Kim SK. Utilization of seafood processing by-products: medicinal applications. Adv Food Nutr 
Res. 2012;65:495-512. September 2017, Volume 60, Issue 9, pp 1561–1565 
Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. 
Pharmacoeconomics. 2015 Aug;33(8):811-31. 
Shah M, Vella A. Effects of GLP-1 on appetite and weight. Reviews in endocrine & metabolic disorders. 
2014;15(3):181-187. doi:10.1007/s11154-014-9289-5. 
Shaw JT, Purdie DM, Neil HA, Levy JC, Turner RC. The relative risks of hyperglycaemia, obesity and dyslipidaemia 
in the relatives of patients with Type II diabetes mellitus. Diabetologia. 1999 Jan;42(1):24-7. 
Sheih IC, Wu TK, Fang TJ. Antioxidant properties of a new antioxidative peptide from algae protein waste 
hydrolysate in different oxidation systems. Bioresour Technol. 2009 Jul;100(13):3419-25. 
Shen Q, Guo R, Dai Z, Zhang Y. Investigation of enzymatic hydrolysis conditions on the properties of protein 
hydrolysate from fish muscle (Collichthys niveatus) and evaluation of its functional properties. J Agric Food 
Chem. 2012 May 23;60(20):5192-8. 





Sho H. History and characteristics of Okinawan longevity food. Asia Pac J Clin Nutr. 2001;10(2):159-64. 
Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997 Mar;82(2):291-5. 
Sievenpiper, J.L., Kendall, C.W.C., Esfahani, A., et al. 2009. Effect of non-oil-seed pulses on glycaemic control: a 
systematic review and meta-analysis of randomised controlled experimental trials in people with and without 
diabetes Diabetalogia. 52. 
Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. White Physical Activity/Exercise and Type 2 
Diabetes. Diabetes Care Jun 2006, 29 (6) 1433-1438. 
Silk DB. Progress report. Peptide absorption in man. Gut. 1974;15(6):494-501. 
Silver DL, Wang N, Tall AR. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, 
degradation, and selective lipid uptake. J Clin Invest. 2000 Jan;105(2):151-9. 
Simpson AK, Ward PS, Wong KY, Collord GJ, Habib AM, Reimann F, Gribble FM. Cyclic AMP triggers glucagon-like 
peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia. 2007 Oct;50(10):2181-9. 
Slavin J and Green G. Dietary fibre and satiety. Journal compilation © 2007 British Nutrition Foundation Nutrition 
Bulletin, 32 (suppl 1), 32–42 
Slizyte R, Rommi K, Mozuraityte R, Eck P, Five K, Rustad T. Bioactivities of fish protein hydrolysates from defatted 
salmon backbones. Biotechnology Reports. 2016;11:99-109. 
 
Smart CEM, Evans M, O’Connell S, et al. Both Dietary Protein and Fat Increase Postprandial Glucose Excursions 
in Children With Type 1 Diabetes, and the Effect Is Additive. Diabetes Care 2013 Dec; 36(12): 3897-3902 
Sranacharoenpong K, Soret S, Harwatt H, Wien M, Sabaté J. The environmental cost of protein food choices. 
Public Health Nutr. 2015 Aug;18(11):2067-73. 
 
Srinivasan, U.T., Cheung, W.W., Watson, R. and Sumaila, U.R., 2010. Food security implications of global marine 
catch losses due to overfishing. Journal of Bioeconomics, 12(3), pp.183-200. 
Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C. Orally administered glucagon-like 
peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin 
Pharmacol Ther. 2009 Dec;86(6):644-50. 
Stubbs, R.J., Johnstone, A.M. and Harbron, C.G., 1996. Breakfasts high in protein, fat or carbohydrate: effect on 





Suarez-Jimenez GM, Burgos-Hernandez A, Ezquerra-Brauer JM. Bioactive Peptides and Depsipeptides with 
Anticancer Potential: Sources from Marine Animals. Mar Drugs. 2012 May; 10(5): 963–986. 
Svensson E, Baggesen LM, Johnsen SP, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Thomsen RW. Early Glycemic 
Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based 
Cohort Study of 24,752 Metformin Initiators. Diabetes Care. 2017 Jun;40(6):800-807. 
 
Swarbrick MM, Stanhope KL, Austrheim-Smith IT, Van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal 
changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008 
Oct;51(10):1901-11. 
Sylvia H. Ley, Osama Hamdy, V. Mohan, Frank B. Hu. Prevention and Management of Type 2 Diabetes: Dietary 
Components and Nutritional Strategies. Lancet. 2014 Jun 7; 383(9933): 1999–2007. 
Sylvia H. Ley, Osama Hamdy, V. Mohan, Frank B. Hu. Prevention and Management of Type 2 Diabetes: Dietary 
Components and Nutritional Strategies. Lancet. 2014 Jun 7; 383(9933): 1999–2007. 
Tang N, Skibsted LH. Calcium Binding to Amino Acids and Small Glycine Peptides in Aqueous Solution: Toward 
Peptide Design for Better Calcium Bioavailability. J Agric Food Chem. 2016 Jun 1;64(21):4376-89. 
Teas J, Vena S, Cone DL, Irhimeh M. The consumption of seaweed as a protective factor in the etiology of breast 
cancer: proof of principle. Journal of Applied Phycology. 2013;25(3):771-779. 
 
The InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-
InterAct Study and a meta-analysis of prospective studies. Diabetologia. 2015;58(7):1394-1408. 
doi:10.1007/s00125-015-3585-9. 
Thorens B. Glucagon-like peptide-1 and control of insulin secretion. Diabete Metab. 1995 Dec;21(5):311-8. 
Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res 
Clin Endocrinol Metab. 2009 Aug;23(4):479-86. 
Thuy NT, Ha NC. Effect of replacing marine fish meal with catfish (Pangasius hypophthalmus) by-product protein 
hydrolyzate on the growth performance and diarrhoea incidence in weaned piglets. Trop Anim Health Prod. 
2016 Oct;48(7):1435-42. 
Tian S, Xu Q, Jiang R, Han T, Sun C, Na L. Dietary Protein Consumption and the Risk of Type 2 Diabetes: A 





Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med. 2007 Mar;24(3):223-
32. 
Tolhurst G, Zheng Y, Parker HE, Habib AM, Reimann F, Gribble FM. Glutamine Triggers and Potentiates Glucagon-
Like Peptide-1 Secretion by Raising Cytosolic Ca2+ and cAMP. Endocrinology. 2011 Feb; 152(2): 405–413. 
Torres N, Noriega L, Tovar AR. Nutrient modulation of insulin secretion. Vitam Horm. 2009;80:217-44. 
Tsugita A, Scheffler JJ. A rapid method for acid hydrolysis of protein with a mixture of trifluoroacetic acid and 
hydrochloric acid. Eur J Biochem. 1982 Jun;124(3):585-8. 
Tulipano G, Sibilia V, Caroli AM, Cocchi D. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl 
peptidase-4) inhibitors. Peptides. 2011 Apr;32(4):835-8. 
Uauy R, Suri DJ, Ghosh S, Kurpad A, Rosenberg IH. Low Circulating Amino Acids and Protein Quality: An 
Interesting Piece in the Puzzle of Early Childhood Stunting. EBioMedicine. 2016;8:28-29. 
Udenigwe, C.C. and Aluko, R.E., 2012. Food protein‐derived bioactive peptides: production, processing, and 
potential health benefits. Journal of Food Science, 77(1). 
UN World population prospects: The 2017 revision, key findings and advance tables (2017) (Vol. Working Paper 
No. ESA/P/WP/248). 
Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO 
Consultation. Geneva: World Health Organization; 2011. 2, Glycated haemoglobin (HbA1c) for the diagnosis of 
diabetes. Available from: https://www.ncbi.nlm.nih.gov/books/NBK304271/ 
Uttara B, V. Singh AV, Zamboni P & Mahajan RT. Oxidative Stress and Neurodegenerative Diseases: A Review of 
Upstream and Downstream Antioxidant Therapeutic Options. Curr Neuropharmacol. 2009 Mar; 7(1): 65–74. 
van de Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase Inhibitors for Patients With Type 2 Diabetes. 
Diabetes Care Jan 2005, 28 (1) 154-163. 
Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vascular Health and Risk 
Management. 2008;4(6):1189-1195. 
van der Klaauw A,   Keogh JM,  Henning  E, et al. High protein intake stimulates postprandial GLP1 and PYY 





Veldhorst, M.A., Nieuwenhuizen, A.G., Hochstenbach-Waelen, A., Westerterp, K.R., Engelen, M.P., Brummer, 
R.J.M., Deutz, N.E. and Westerterp-Plantenga, M.S., 2009. Effects of complete whey-protein breakfasts versus 
whey without GMP-breakfasts on energy intake and satiety. Appetite, 52(2), pp.388-395. 
Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 
receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. 
Vik R, Tillander V, Skorve J, Vihervaara T, Ekroos K, Alexson SE, Berge RK, Bjørndal B. Three differently generated 
salmon protein hydrolysates reveal opposite effects on hepatic lipid metabolism in mice fed a high-fat diet. Food 
Chemistry Volume 183, 15 September 2015, Pages 101-110 
Vikøren, L.A., Nygård, O.K., Lied, E., Rostrup, E. and Gudbrandsen, O.A., 2013. A randomised study on the effects 
of fish protein supplement on glucose tolerance, lipids and body composition in overweight adults. British 
Journal of Nutrition, 109(4), pp.648-657. 
Vo TS, Ngo DH, Kang KH, Park SJ, Kim SK. The role of peptides derived from Spirulina maxima in downregulation 
of FcεRI-mediated allergic responses. Mol Nutr Food Res. 2014 Nov;58(11):2226-34. 
Wada K, Nakamura K, Tamai Y, et al. Seaweed intake and blood pressure levels in healthy pre-school Japanese 
children. Nutr J. 2011; 10: 83. 
Wallace TC, Frankenfeld CL. Dietary Protein Intake above the Current RDA and Bone Health: A Systematic Review 
and Meta-Analysis. Journal of American College of Nutrition. Volume 36, 2017 - Issue 6 Pages 481-496 
Walther B, Sieber R. Bioactive proteins and peptides in foods. Int J Vitam Nutr Res. 2011 Mar;81(2-3):181-92. 
Wang X, Yu H, Xing R, Li P. Characterization, Preparation, and Purification of Marine Bioactive Peptides. Biomed 
Res Int. 2017; 2017:9746720. 
Wang X, Yu H, Xing R, Li P. Characterization, Preparation, and Purification of Marine Bioactive Peptides. Volume 
2017, Article ID 9746720, 16 pages 
 
 Tavano OL. Protein hydrolysis using proteases: An important tool for food biotechnology. Journal of Molecular 
Catalysis B: Enzymatic 90 (2013) 1–11 
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity 





Wang, T.Y, Hsieh, C.H, Hung, C.C, Jao, C.L, Chen, M.C, Hsu, K.C. Fish skin gelatin hydrolysates as dipeptidyl 
peptidase IV inhibitors and glucagon-like peptide-1 stimulators improve glycaemic control in diabetic rats: A 
comparison between warm- and cold-water fish. J. Func. Foods 2015, 18, 330–340. 
Webb KE. Intestinal absorption of protein hydrolysis products: a review. J Anim Sci. 1990 Sep;68(9):3011-22. 
Weinstock MT, Francis JN, Redman JS, Kay MJ. Protease-Resistant Peptide Design – Empowering Nature's Fragile 
Warriors Against HIV. Biopolymers. 2012; 98(5): 431–442. 
Westerterp-Plantenga MS, Lemmens SG, Westerterp KR. Dietary protein - its role in satiety, energetics, weight 
loss and health. Br J Nutr. 2012 Aug;108 Suppl 2:S105-12. 
Weykamp C. HbA1c: A Review of Analytical and Clinical Aspects. Ann Lab Med. 2013 Nov; 33(6): 393–400. 
Wilcox G. Insulin and Insulin Resistance. Clinical Biochemist Reviews. 2005;26(2):19-39. 
Wolfe RR. Protein supplements and exercise. Am J Clin Nutr. 2000 Aug;72(2 Suppl):551S-7S. 
Wu R, Chen L, Liu D, Huang J, Zhang J, Xiao X, Lei M, Chen Y, He H. Preparation of Antioxidant Peptides from 
Salmon Byproducts with Bacterial Extracellular Proteases. Mar Drugs. 2017 Jan 11;15(1). 
Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, Horowitz M, Jones KL, Rayner CK. A Protein Preload 
Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. Diabetes Care. 2016 Apr;39(4):511-
7. 
Wu W, Li B, Hou H, Zhang H, Zhao X. Isolation and identification of calcium-chelating peptides from Pacific cod 
skin gelatin and their binding properties with calcium. Food Funct. 2017 Dec 13;8(12):4441-4448. 
 
Xia EQ, Zhu SS, He MJ, Luo F, Fu CZ, and Zou TB. Marine Peptides as Potential Agents for the Management of 
Type 2 Diabetes Mellitus—A Prospect. Mar Drugs. 2017 Apr; 15(4): 88. 
Xie CL, Kim JS, Ha JM, Choung SY, Choi YJ. Angiotensin I-converting enzyme inhibitor derived from cross-linked 
oyster protein. Biomed Res Int. 2014;2014:379234. 
Xing H, Tong M, Jiang N, Zhang X, Hu H, Pan H, Li D. Antitumor bioactive peptides isolated from marine organisms. 
2017 Clin Exp Pharmacol Physiol. Jul 4. 
Yamada KM. Fibronectin peptides in cell migration and wound repair. J Clin Invest. 2000 Jun;105(11):1507-9. 
Yang HY, Yang SC, Chen JR, Tzeng YH, Han BC. Soyabean protein hydrolysate prevents the development of 





Yang JI, Tang JY, Liu YS, Wang HR, Lee SY, Yen CY, Chang HW. Roe Protein Hydrolysates of Giant Grouper 
(Epinephelus lanceolatus) Inhibit Cell Proliferation of Oral Cancer Cells Involving Apoptosis and Oxidative Stress. 
Biomed Res Int. 2016 ;2016:8305073. 
Yoon MS. The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism. Nutrients. 
2016 Jul; 8(7): 405. 
Young VR, Pellett PL. Plant proteins in relation to human protein and amino acid nutrition. Am J Clin Nutr. 1994 
May;59(5 Suppl):1203S-1212S. 
Zava TT, Zava DT. Assessment of Japanese iodine intake based on seaweed consumption in Japan: A literature-
based analysis. Thyroid Research. 2011;4:14. doi:10.1186/1756-6614-4-14. 
 
Zhan KX, Jiao WH, Yang F, Li J, Wang SP, Li YS, Han BN, Lin HW. Reniochalistatins A-E, cyclic peptides from the 
marine sponge Reniochalina stalagmitis. J Nat Prod. 2014 Dec 26;77(12):2678-84. 
Zhang BB1, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol. 2000 
Aug;4(4):461-7. 
Zhao L, Huang S, Cai X, Hong J, Wang S. A specific peptide with calcium chelating capacity isolated from whey 
protein hydrolysate. Journal of Functional Foods, Volume 10, 2014, Pages 46-53. 
Zhao YQ, Zeng L, Yang ZS, Huang FF, Ding GF, Wang B. Anti-Fatigue Effect by Peptide Fraction from Protein 
Hydrolysate of Croceine Croaker (Pseudosciaena crocea) Swim Bladder through Inhibiting the Oxidative 
Reactions including DNA Damage. Mar Drugs. 2016 Dec 13;14(12). 
Zheng W, Lee SA. Well-done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk. Nutr Cancer. 2009; 
61(4): 437–446. 
Zhengyu Liu. and Joel F. Habener1. Alpha Cells Beget Beta Cells. Cell 138, August 7, 2009 
Zhu C, Zhang W, Liu J, Mu B, Zhang F, Lai N, Zhou J, Xu A, Li Y. Marine collagen peptides reduce endothelial cell 
injury in diabetic rats by inhibiting apoptosis and the expression of coupling factor 6 and microparticles. Mol 
Med Rep. 2017 Jul 21. 
Zhu C, Zhang W, Mu B4, Zhang F, Lai N, Zhou J, Xu A, Liu J, Li Y. Effects of marine collagen peptides on glucose 
metabolism and insulin resistance in type 2 diabetic rats. J Food Sci Technol. 2017 Jul;54(8):2260-2269 
Zhu C.F., Peng H.B., Liu G.Q., Zhang F., Li Y. Beneficial effects of oligopeptides from marine salmon skin in a rat 





Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y. Treatment with marine collagen peptides modulates glucose and 
lipid metabolism in Chinese patients with type 2 diabetes mellitus. Appl Physiol Nutr Metab. 2010 Dec;35(6):797-
804. 
Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y. Treatment with marine collagen peptides modulates glucose and 
lipid metabolism in Chinese patients with type 2 diabetes mellitus. Appl Physiol Nutr Metab. 2010 
Dec;35(6):797-804. 
Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y, Li Y. Treatment with marine collagen peptides mod ulates glucose 
and lipid metabolism in Chinese patients with type 2 diabetes mellitus. Appl Physiol Nutr Metab. 2010 
Dec;35(6):797-804 
Zhu CF, Peng HB, Liu GQ, Zhang F, Li Y. Beneficial effects of oligopeptides from marine salmon skin in a rat model 
of Zied Khiari  Maurice Ndagijimana  Mirko Betti. Low molecular weight bioactive peptides derived from the 
enzymatic hydrolysis of collagen after isoelectric solubilization/precipitation process of turkey by-products. 
Poultry Science, Volume 93, Issue 9, 1 September 2014, Pages 2347–2362, type 2 diabetes. Nutrition. 2010 
Oct;26(10):1014-20. 
Zietek T, Daniel H. Intestinal nutrient sensing and blood glucose control. Curr Opin Clin Nutr Metab Care. 2015 
Jul;18(4):381-8. 
Zumwalt RW, Absheer JS, Kaiser FE, Gehrke CW. Acid hydrolysis of proteins for chromatographic analysis of 
amino acids. J Assoc Off Anal Chem. 1987 Jan-Feb;70(1):147-51. 
Zyromski MJ. Obesity-Related Effects on Pancreatic Disease. Version 1.0, June 27, 2015 
FIN 
